
<html lang="en"     class="pb-page"  data-request-id="c8b7c270-cf78-46aa-9e06-5b9320478b5f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/acs.jmedchem.0c00620;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-22"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders" /></meta><meta name="dc.Creator" content="Chiara  Borsari" /></meta><meta name="dc.Creator" content="Erhan  Keles" /></meta><meta name="dc.Creator" content="Denise  Rageot" /></meta><meta name="dc.Creator" content="Andrea  Treyer" /></meta><meta name="dc.Creator" content="Thomas  Bohnacker" /></meta><meta name="dc.Creator" content="Lukas  Bissegger" /></meta><meta name="dc.Creator" content="Martina  De Pascale" /></meta><meta name="dc.Creator" content="Anna  Melone" /></meta><meta name="dc.Creator" content="Rohitha  Sriramaratnam" /></meta><meta name="dc.Creator" content="Florent  Beaufils" /></meta><meta name="dc.Creator" content="Matthias  Hamburger" /></meta><meta name="dc.Creator" content="Paul  Hebeisen" /></meta><meta name="dc.Creator" content="Wolfgang  Löscher" /></meta><meta name="dc.Creator" content="Doriano  Fabbro" /></meta><meta name="dc.Creator" content="Petra  Hillmann" /></meta><meta name="dc.Creator" content="Matthias P.  Wymann" /></meta><meta name="dc.Description" content="The mechanistic target of rapamycin (mTOR) pathway is hyperactivated in cancer and neurological disorders. Rapalogs and mTOR kinase inhibitors (TORKi) have recently been applied to alleviate epilep..." /></meta><meta name="Description" content="The mechanistic target of rapamycin (mTOR) pathway is hyperactivated in cancer and neurological disorders. Rapalogs and mTOR kinase inhibitors (TORKi) have recently been applied to alleviate epilep..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 9, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00620" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2020 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00620" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00620" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00620" /></link>
        
    
    

<title>4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00620" /></meta><meta property="og:title" content="4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0014.jpeg" /></meta><meta property="og:description" content="The mechanistic target of rapamycin (mTOR) pathway is hyperactivated in cancer and neurological disorders. Rapalogs and mTOR kinase inhibitors (TORKi) have recently been applied to alleviate epileptic seizures in tuberous sclerosis complex (TSC). Herein, we describe a pharmacophore exploration to identify a highly potent, selective, brain penetrant TORKi. An extensive investigation of the morpholine ring engaging the mTOR solvent exposed region led to the discovery of PQR626 (8). 8 displayed excellent brain penetration and was well-tolerated in mice. In mice with a conditionally inactivated Tsc1 gene in glia, 8 significantly reduced the loss of Tsc1-induced mortality at 50 mg/kg p.o. twice a day. 8 overcomes the metabolic liabilities of PQR620 (52), the first-in-class brain penetrant TORKi showing efficacy in a TSC mouse model. The improved stability in human hepatocytes, excellent brain penetration, and efficacy in Tsc1GFAPCKO mice qualify 8 as a potential therapeutic candidate for the treatment of neurological disorders." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00620"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00620">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00620&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00620&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00620&amp;href=/doi/10.1021/acs.jmedchem.0c00620" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 22</span><span class="cit-fg-pageRange">, 13595-13617</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/22" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c01170" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00901" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Chiara Borsari</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chiara Borsari</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chiara++Borsari">Chiara Borsari</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4688-8362" title="Orcid link">http://orcid.org/0000-0002-4688-8362</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Erhan Keles</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Erhan Keles</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Erhan++Keles">Erhan Keles</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Denise Rageot</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Denise Rageot</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Denise++Rageot">Denise Rageot</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andrea Treyer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andrea Treyer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Biology, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Treyer">Andrea Treyer</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4533-7761" title="Orcid link">http://orcid.org/0000-0002-4533-7761</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Thomas Bohnacker</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Thomas Bohnacker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Thomas++Bohnacker">Thomas Bohnacker</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lukas Bissegger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lukas Bissegger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lukas++Bissegger">Lukas Bissegger</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martina De Pascale</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martina De Pascale</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martina++De+Pascale">Martina De Pascale</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Anna Melone</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Anna Melone</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Melone">Anna Melone</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rohitha Sriramaratnam</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rohitha Sriramaratnam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rohitha++Sriramaratnam">Rohitha Sriramaratnam</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Florent Beaufils</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Florent Beaufils</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PIQUR Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Florent++Beaufils">Florent Beaufils</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthias Hamburger</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthias Hamburger</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical Biology, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthias++Hamburger">Matthias Hamburger</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9331-273X" title="Orcid link">http://orcid.org/0000-0001-9331-273X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul Hebeisen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul Hebeisen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PIQUR Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul++Hebeisen">Paul Hebeisen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wolfgang Löscher</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wolfgang Löscher</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine, 30559 Hannover, Germany</div><div class="loa-info-affiliations-info">Center for Systems Neuroscience, University of Veterinary Medicine, 30559 Hannover, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wolfgang++L%C3%B6scher">Wolfgang Löscher</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Doriano Fabbro</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Doriano Fabbro</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PIQUR Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Doriano++Fabbro">Doriano Fabbro</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Petra Hillmann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Petra Hillmann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">PIQUR Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Petra++Hillmann">Petra Hillmann</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Matthias P. Wymann</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthias P. Wymann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#e18c80959589888092cf96988c808f8fa1948f88838092cf8289"><span class="__cf_email__" data-cfemail="d8b5b9acacb0b1b9abf6afa1b5b9b6b698adb6b1bab9abf6bbb0">[email protected]</span></a>. Phone: +41 61 207 5046. Fax: +41 61 207 3566.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthias+P.++Wymann">Matthias P. Wymann</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3349-4281" title="Orcid link">http://orcid.org/0000-0003-3349-4281</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00620&amp;href=/doi/10.1021%2Facs.jmedchem.0c00620" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 22</span><span class="cit-pageRange">, 13595–13617</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 9, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 April 2020</li><li><span class="item_label"><b>Published</b> online</span>9 November 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 25 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00620" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00620</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice/index.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a><span class="article_header-cc-by-nc text">with CC-BY-NC-ND<a href="/page/policy/authorchoice_ccbyncnd_termsofuse.html" title="License">license</a></span></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00620"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2044</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">8</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00620" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;4-(Difluoromethyl)-5-(4-((3R,5S)-3,5-dimethylmorpholino)-6-((R)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626), a Potent, Orally Available, and Brain-Penetrant mTOR Inhibitor for the Treatment of Neurological Disorders&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Chiara&quot;,&quot;last_name&quot;:&quot;Borsari&quot;},{&quot;first_name&quot;:&quot;Erhan&quot;,&quot;last_name&quot;:&quot;Keles&quot;},{&quot;first_name&quot;:&quot;Denise&quot;,&quot;last_name&quot;:&quot;Rageot&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Treyer&quot;},{&quot;first_name&quot;:&quot;Thomas&quot;,&quot;last_name&quot;:&quot;Bohnacker&quot;},{&quot;first_name&quot;:&quot;Lukas&quot;,&quot;last_name&quot;:&quot;Bissegger&quot;},{&quot;first_name&quot;:&quot;Martina&quot;,&quot;last_name&quot;:&quot;De Pascale&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Melone&quot;},{&quot;first_name&quot;:&quot;Rohitha&quot;,&quot;last_name&quot;:&quot;Sriramaratnam&quot;},{&quot;first_name&quot;:&quot;Florent&quot;,&quot;last_name&quot;:&quot;Beaufils&quot;},{&quot;first_name&quot;:&quot;Matthias&quot;,&quot;last_name&quot;:&quot;Hamburger&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;Hebeisen&quot;},{&quot;first_name&quot;:&quot;Wolfgang&quot;,&quot;last_name&quot;:&quot;Löscher&quot;},{&quot;first_name&quot;:&quot;Doriano&quot;,&quot;last_name&quot;:&quot;Fabbro&quot;},{&quot;first_name&quot;:&quot;Petra&quot;,&quot;last_name&quot;:&quot;Hillmann&quot;},{&quot;first_name&quot;:&quot;Matthias&quot;,&quot;last_name&quot;:&quot;P. Wymann&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;22&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;13595-13617&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00620&quot;},&quot;abstract&quot;:&quot;The mechanistic target of rapamycin (mTOR) pathway is hyperactivated in cancer and neurological disorders. Rapalogs and mTOR kinase inhibitors (TORKi) have recently been applied to alleviate epileptic seizures in tuberous sclerosis complex (TSC). Herein, we describe a pharmacophore exploration to identify a highly potent, selective, brain penetrant TORKi. An extensive investigation of the morpholine ring engaging the mTOR solvent exposed region led to the discovery of PQR626 (8). 8 displayed excellent brain penetration and was well-tolerated in mice. In mice with a conditionally inactivated Tsc1 gene in glia, 8 significantly reduced the loss of Tsc1-induced mortality at 50 mg/kg p.o. twice a day. 8 overcomes the metabolic liabilities of PQR620 (52), the first-in-class brain penetrant TORKi showing efficacy in a TSC mouse model. The improved stability in human hepatocytes, excellent brain penetration, and efficacy in Tsc1GFAPCKO mice qualify 8 as a potential therapeutic candidate for the treatment of neurologi&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00620&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00620" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00620&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00620" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00620&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00620" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00620&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00620&amp;href=/doi/10.1021/acs.jmedchem.0c00620" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00620" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00620" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00620%26sid%3Dliteratum%253Aachs%26pmid%3D33166139%26genre%3Darticle%26aulast%3DBorsari%26date%3D2020%26atitle%3D4-%2528Difluoromethyl%2529-5-%25284-%2528%25283R%252C5S%2529-3%252C5-dimethylmorpholino%2529-6-%2528%2528R%2529-3-methylmorpholino%2529-1%252C3%252C5-triazin-2-yl%2529pyridin-2-amine%2B%2528PQR626%2529%252C%2Ba%2BPotent%252C%2BOrally%2BAvailable%252C%2Band%2BBrain-Penetrant%2BmTOR%2BInhibitor%2Bfor%2Bthe%2BTreatment%2Bof%2BNeurological%2BDisorders%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D22%26spage%3D13595%26epage%3D13617%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (11)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/22" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/jmcmar.2020.63.issue-22/20201125/jmcmar.2020.63.issue-22.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The mechanistic target of rapamycin (mTOR) pathway is hyperactivated in cancer and neurological disorders. Rapalogs and mTOR kinase inhibitors (TORKi) have recently been applied to alleviate epileptic seizures in tuberous sclerosis complex (TSC). Herein, we describe a pharmacophore exploration to identify a highly potent, selective, brain penetrant TORKi. An extensive investigation of the morpholine ring engaging the mTOR solvent exposed region led to the discovery of PQR626 (<b>8</b>). <b>8</b> displayed excellent brain penetration and was well-tolerated in mice. In mice with a conditionally inactivated <i>Tsc1</i> gene in glia, <b>8</b> significantly reduced the loss of <i>Tsc1</i>-induced mortality at 50 mg/kg p.o. twice a day. <b>8</b> overcomes the metabolic liabilities of PQR620 (<b>52</b>), the first-in-class brain penetrant TORKi showing efficacy in a TSC mouse model. The improved stability in human hepatocytes, excellent brain penetration, and efficacy in <i>Tsc1</i><sup>GFAP</sup>CKO mice qualify <b>8</b> as a potential therapeutic candidate for the treatment of neurological disorders.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77632" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77632" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The mechanistic target of rapamycin (mTOR) is activated downstream of phosphoinositide 3-kinase (PI3K). The mTOR kinase is a part of two functionally distinct multiprotein complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> TORC1 monitors the availability of cellular energy, oxygen and amino acids, surface receptor ligation, and stress levels. Cell surface receptor-mediated activation of PI3K triggers PtdIns(3,4,5)<i>P</i><sub>3</sub> production, which is recognized by the pleckstrin homology domains in protein kinase B (PKB/Akt), phosphoinositide-dependent protein kinase 1 (PDK1), and the TORC2 component SIN1. Thr308 is phosphorylated by PDK1 and at Ser473 in the hydrophobic motif by mTORC2.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> TORC1 regulates lipid and protein synthesis through phosphorylation of S6 kinase (S6K), resulting in phosphorylation of the downstream effector ribosomal protein S6.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Moreover, TORC1 modulates lysosome function and inhibits autophagy. TORC2 controls cytoskeletal rearrangements, cell cycle progression, and survival.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> A critical negative regulator of TORC1 is the suppressor protein tuberous sclerosis complex (TSC), composed of hamartin (TSC1) and tuberin (tuberous sclerosis 2, TSC2). PKB/Akt regulates TSC <i>via</i> phosphorylation of tuberin on multiple sites. Phosphorylation of TSC2 blocks its GTPase-activating function, resulting in active Ras homolog enriched in brain and TORC1.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a></div><div class="NLM_p">The mTOR pathway is dysregulated in many diseases such as neurological disorders, cancer, and type 2 diabetes.<a onclick="showRef(event, 'ref4 ref8'); return false;" href="javascript:void(0);" class="ref ref4 ref8">(4,8)</a> In central nervous system (CNS) disorders, mTOR is supposed to be implicated in Parkinson’s, Alzheimer’s, and Huntington’s disease, epilepsy, stroke, and trauma.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> TSC loss of function triggers hyperactivation of TORC1, causing hyperplastic lesions in multiple organs. In ∼90% of TSC patients, epilepsy, behavioral problems, and cognitive impairment dominate the patient’s morbidity, which have made mTOR kinase a target for TSC treatment in the CNS.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a></div><div class="NLM_p">Rapamycin (<b>55</b>) and its derivatives (dubbed rapalogs; <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) are allosteric inhibitors of TORC1 and form <i>via</i> the FKBP-rapamycin binding domain (FRB domain) of TORC1 a stable complex with FK506 binding protein 12 (FKBP12) bound to rapamycin.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Chronic exposure to rapalogs has been proposed to disrupt mTORC2 after long exposure.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> The beneficial effects of <b>55</b> or rapalogs alleviating epileptic seizures caused by loss-of-function in mTOR signaling have been recently explored. Sirolimus (<b>55</b>) and everolimus (<b>56</b>, RAD001) significantly decreased seizures in mice with tissue-specific inactivation of the <i>Tsc1</i> gene primarily in glia (<i>Tsc1</i><sup>GFAP</sup>CKO mice) and prolonged their survival.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> Moreover, rapalogs displayed efficacy in reducing frequency of seizures and TSC-associated solid tumor size in TSC patients, leading to the approval of <b>56</b> for the treatment of TSC-associated seizures in 2018.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> The ability of mTOR inhibitors to induce autophagy and to reduce detrimental protein aggregates in neurons may be exploited for the treatment of other neurological disorders including Huntington’s,<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Alzheimer’s,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and Parkinson’s diseases.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> However, TORC1 inhibition by rapalogs is not efficient in all TSC patients, and significant adverse side effects due to immune suppression often demand the termination of further treatment.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> The adverse side effects are pronounced because rapalogs have a limited ability to penetrate the blood–brain barrier (BBB). Only when high plasma levels are reached, mTOR in the brain can be efficiently inhibited.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Chemical structures of selected TORKi, including <b>49</b>,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a><b>50</b>,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a><b>51</b>,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a><b>52</b>,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a><b>53</b>,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and a thiazolopyrimidine derivative (<b>54</b>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> (B) Chemical structures of <b>55</b> and rapalogs (<i>e.g.</i>, <b>56</b>), which function as allosteric inhibitors of TORC1, forming a TORC1-rapalog-FKBP12 complex.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">For these reasons, the identification of mTOR inhibitors with optimized brain permeability is an ongoing challenge for the treatment of CNS disorders.</div><div class="NLM_p">mTOR kinase inhibitors (TORKi) that bind to the ATP-pocket inhibit mTOR kinase and thus target the function of both mTORC1 and mTORC2. mTOR-selective inhibitors covering different chemical spaces have been discovered, including CC-223 (<b>49</b>),<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> sapanisertib/INK128<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> (<b>50</b>), and vistusertib/AZD2014<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (<b>51</b>; <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), and have been explored to treat a variety of human cancers.</div><div class="NLM_p">We have recently disclosed PQR620 (<b>52</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), a brain penetrable inhibitor of mTOR kinase with excellent selectivity.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Compound <b>52</b>, bearing two ethylene bridged morpholines, is the first-in-class selective catalytic mTOR inhibitor able to cross the BBB. It has been identified through chemical modifications of PQR309 (<b>57</b>, bimiralisib; see the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a> for chemical structure),<a onclick="showRef(event, 'ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31 ref32">(29−32)</a> a pan-PI3K inhibitor with moderate mTOR affinity, currently evaluated in Phase II trials of solid tumors and lymphomas.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In 2020, Novartis has proposed a novel brain-penetrant TORKi bearing a thiazolopyrimidine scaffold (<b>54</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Very recently, we have explored a novel chemical space and disclosed a tricyclic pyrimido-pyrrolo-oxazine, PQR617 (<b>53</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>), showing selectivity for mTOR over class I PI3Ks of ∼450-fold. However, this compound showed only minimal brain penetration,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> preventing application in the treatment of CNS disorders.</div><div class="NLM_p last">Because the ethylene bridge on the two morpholines in <b>52</b> has been identified as a primary site of metabolism in human liver microsomes<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> and human hepatocytes, <b>52</b> has been characterized as an optimal proof-of-concept molecule for rodent models<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> but is expected to have a short half-life in human patients. Pharmacokinetic studies of <b>52</b> in male cynomolgous monkeys showed a rapid compound degradation (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Figure S1</a>). The metabolic reactions occurred mainly by oxidation of <b>52</b> at the bridged morpholines, while the triazine core and the 4-(difluoromethyl)pyridin-2-amine did not show metabolic sensitivity (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Figure S2</a>). We therefore focused on the modification of both morpholines of <b>52</b> and on the development of a follow-up compound for <b>52</b> with improved metabolic stability in humans. We built up a broad structure–activity relationship (SAR) study to develop novel, brain-penetrable, and orally bioavailable mTORC1/2 inhibitors. Evaluation of metabolic stability and pharmacokinetic properties pinpointed PQR626 (<b>8</b>) as a promising candidate for CNS indications.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27272" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27272" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Chemistry</h3><div class="NLM_p">The library of triazine compounds was synthesized as depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. (<i>R</i>)-4-(4-Chloro-6-morpholino-1,3,5-triazin-2-yl)-3-methylmorpholine (<b>24</b>) was prepared from 2,4-dichloro-6-(morpholin-4-yl)-1,3,5-triazine (<b>23</b>), and later compound <b>1</b> was generated from intermediate <b>24</b> and boronate <b>48</b> (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> for the chemical structure) using a Suzuki cross-coupling (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>A). The first step in the synthesis of compound <b>2</b> involved the di-substitution of cyanuric chloride with the same morpholine moiety (M<sub>1</sub>, (<i>R</i>)-3-methylmorpholine) to generate intermediate <b>25</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>B). All other final compounds were synthesized starting from cyanuric chloride by following substitution with two different morpholine derivatives: first (<i>R</i>)-3-methylmorpholine was introduced (76% yield), followed by substituted morpholine M<sub><i>n</i></sub> (M<sub>2</sub>–M<sub>6</sub> and M<sub>8</sub>–M<sub>21</sub>, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>C). Influenced by the first morpholine derivative introduced, the second nucleophilic substitution yielded the desired intermediates with moderate to excellent yields (48–99%). As depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>C, the synthesis of intermediate <b>32</b> was optimized introducing first the highest sterically hindered morpholine [(3<i>S</i>,5<i>R</i>)-3,5-dimethylmorpholine, 62% yield], followed by (<i>R</i>)-3-methylmorpholine (87% yield). The last synthetic step involved the displacement of the chlorine of intermediates (<b>24</b>, <b>25</b>, <b>27–46</b>) by the heteroaryl moiety using a palladium-catalyzed Suzuki cross-coupling with boronate <b>48</b>. Yields for final compounds (<b>1–22</b>) were moderate to excellent (36–97%).</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. (A–C) Synthesis of the Compound Library (<b>1–22</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) morpholine, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), EtOH, 0 °C → rt, o/n as reported in the literature;<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (ii) (1) boronate <b>48</b>, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 2–16 h; (2) HCl, H<sub>2</sub>O, 60 °C, 3–16 h; (iii) morpholine derivative (M<sub>n</sub>–H), DIPEA, DCM, 0 °C → rt, o/n as reported in the literature;<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (iv) morpholine derivative (M<sub>n</sub>–H), DCM, −50 °C, 2 h; (v) M<sub>n</sub>–H, DIPEA, DCM, 0 °C → rt, o/n (for <b>27–29</b>, <b>32</b>, <b>34–46</b>); (vi) M<sub>n</sub>–H, DIPEA, THF, 0 °C → rt → 70 °C, o/n (for <b>30</b> and <b>31</b>); (vii) see (i) for intermediate <b>33</b>. *Compound <b>3</b> is reported in ref <a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a>.</p></p></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Combining Pharmacophore Features</h3><div class="NLM_p last">The triazine core of <b>52</b> was selected as the primary building block, and chemical features of <b>52</b> and <b>53</b> inspired scaffold explorations. The 4-(difluoromethyl)pyridin-2-amine was chosen as a heteroaromatic ring because it was found to be an essential feature for mTOR affinity. As previously suggested, the CHF<sub>2</sub>-moiety potentially (i) interacts with a nitrogen atom of the triazine core or (ii) with Glu2190 in mTOR, leading to highly potent compounds <i>in vitro</i> and in cells.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> In addition, the pyridine ring displayed a higher mTOR potency compared to the pyrimidine moiety.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The (<i>R</i>)-3-methylmorpholine represented the third pharmacophoric feature in our drug design process. This substituted morpholine provided selectivity for mTOR over the closely related PI3K family, as highlighted by the development of <b>53</b> and <b>54</b> (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Assessment of Cellular Efficacy and PI3K/mTOR Affinity</h3><div class="NLM_p">To identify novel brain penetrant TORKi with optimized metabolic stability, we focused our SAR study on the exploration of substituted morpholines. With the exception of <b>1</b>, which bears one unsubstituted morpholine, we synthesized a library of compounds bearing differently substituted morpholines (M<sub>n</sub> substituents, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>), namely, 3-methylmorpholine [M<sub>1</sub>: (<i>R</i>) and M<sub>2</sub>: (<i>S</i>)], 3,3-dimethylmorpholine (M<sub>3</sub>), 8-oxa-5-azaspiro[3.5]nonane (M<sub>4</sub>), 3,5-dimethylmorpholine [M<sub>5</sub>: (3<i>R</i>,5<i>R</i>); M<sub>6</sub>: (3<i>S</i>,5<i>S</i>); M<sub>7</sub>: (3<i>S</i>,5<i>R</i>)], (2<i>R</i>,6<i>S</i>)-2,6-dimethylmorpholine (M<sub>8</sub>), 3-ethylmorpholine [M<sub>9</sub>: (<i>R</i>) and M<sub>10</sub>: (<i>S</i>)], morpholin-3-ylmethanol [M<sub>11</sub>: (<i>R</i>) and M<sub>12</sub>: (<i>S</i>)], (<i>R</i>)-3-(methoxymethyl)morpholine (M<sub>13</sub>), 3-oxa-6-azabicyclo[3.1.1]heptane (M<sub>14</sub>), 6-oxa-3-azabicyclo[3.1.1]heptane (M<sub>15</sub>), 2-oxa-5-azabicyclo[2.2.1]heptane [M<sub>16</sub>: (1<i>R</i>,4<i>R</i>) and M<sub>17</sub>: (1<i>S</i>,4<i>S</i>)], 3-oxa-8-azabicyclo[3.2.1]octane (M<sub>18</sub>), 8-oxa-3-azabicyclo[3.2.1]octane (M<sub>19</sub>), 2-oxa-6-azaspiro[3.3]heptane (M<sub>20</sub>), and 1,4-oxazepane (M<sub>21</sub>). The compounds were tested for <i>in vitro</i> binding to the catalytic subunit of mTOR and PI3Kα (p110α) and for inhibition of PI3K/mTOR pathway in A2058 cells [phosphorylation of S6 and protein kinase B (PKB/Akt) on Ser473 to detect mTORC1 and mTORC2 activity, respectively]. Whereas <b>1</b> bearing an unsubstituted morpholine showed a selectivity for mTOR versus PI3Kα of 2.5-fold, increasing the steric demand of the morpholine substituents significantly enhanced the compounds’ selectivity (see compounds <b>2</b>, <b>4–9</b>, <b>12–14</b>; <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Sterically hindered morpholines had previously been reported to enhance the selectivity for mTOR over PI3K.<a onclick="showRef(event, 'ref26 ref27 ref36'); return false;" href="javascript:void(0);" class="ref ref26 ref27 ref36">(26,27,36)</a> The presence of a bridged morpholine resulted in a decrease in mTOR affinity, with the exception of 3-oxa-8-azabicyclo[3.2.1]octane (M<sub>18</sub>) and 8-oxa-3-azabicyclo[3.2.1]octane (M<sub>19</sub>) that led to a significant activity toward mTOR (<i>K</i><sub>i</sub> for <b>19</b> and <b>20</b> = 13 and 24 nM, respectively). Ring-enlargement from a morpholine to a 1,4-oxazepane maintained strong mTOR affinity (<i>K</i><sub>i</sub> for <b>1</b> and <b>22</b> = 8 and 15 nM, respectively). Compounds <b>4</b> and <b>8</b> showed a high potency for mTOR kinase [<i>K</i><sub>i</sub><b>4</b> = 4.7 nM; <b>8</b> = 3.6 nM] together with a 100-/80-fold selectivity for mTOR over PI3Kα. Sterically hindered morpholines caused a decrease in cellular activity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), with the exception of M<sub>3</sub> (3,3-dimethylmorpholine) and M<sub>7</sub> [(3<i>S</i>,5<i>R</i>)-3,5-dimethylmorpholine]. Bridged-morpholine derivatives (<b>15–20</b>) had poor cellular activity, apart from <b>19</b> bearing a 3-oxa-8-azabicyclo[3.2.1]octane (M<sub>18</sub>, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>) and showing moderate potency in cells (IC<sub>50</sub> for pPKB/Akt = 157 nM and for pS6 = 282 nM). The 3-oxa-8-azabicyclo[3.2.1]octane is also present in the lead compound <b>52</b>. Compounds <b>4</b> and <b>8</b> displayed the best cellular activity (IC<sub>50</sub> for pPKB/Akt = 191 and 96 nM, and for pS6 = 61 and 71 nM, respectively) and were selected for additional studies.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Investigation on the Exploration of Substituted Morpholines</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0013.gif" alt="" id="gr11" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0012.gif" alt="" id="GRAPHIC-d7e1145-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Phosphorylation of PKB (Ser473) and S6 (Ser235/236) were measured in A2058 cells treated with inhibitors. Subsequent detection of phosphoproteins was done using in-cell western assays. IC<sub>50</sub>s were measured using a 7- or 11-point 1:2 serial dilution and each concentration was measured in independent triplicate (7-point dilution) or independent duplicate (11-point dilution) experiments. Data are reported as mean ± SD. Log IC<sub>50</sub>s are reported in Table S1 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">The <i>in vitro</i> binding of the compounds to the ATP-binding site of p110α and mTOR was evaluated with a commercially available time-resolved Förster resonance energy transfer (TR-FRET) displacement assay. IC<sub>50</sub>s were measured using a 10-point 1:4 serial dilution and each concentration was performed in independent duplicate experiments. Data are reported as mean ± SD. IC<sub>50</sub>s and log IC<sub>50</sub>s are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Table S1</a>.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Marvin/JChem 20.9 was used to calculate logP (partition coefficient) and PSA (polar surface area) values, ChemAxon (<a href="https://www.chemaxon.com" class="extLink">https://www.chemaxon.com</a>).</p></div></div><div></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Clarification of Inhibitor–Protein Interactions</h3><div class="NLM_p">Because the presence of a sterically hindered morpholine increased the mTOR selectivity over PI3K, computational modeling studies for compounds <b>8</b> and <b>4</b> were performed. To explain the compounds’ different affinity for mTOR and PI3Kα, we investigated the inhibitors’ interactions with the ATP-binding site of the respective kinase. As previously described for <b>52</b>,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a><b>53</b>,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and other morpholino-substituted PI3K inhibitors,<a onclick="showRef(event, 'ref29 ref30 ref32 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref32 ref37 ref38">(29,30,32,37,38)</a> a pivotal interaction for mTOR and PI3K binding is the H-bond formation between the backbone amide of Val2240 in the hinge region of mTOR or of the Val851 in PI3Kα with the oxygen atom of the morpholine moiety. The (<i>R</i>)-3-methylmorpholine is well accommodated in the hinge region of mTOR, providing selectivity for mTOR kinase over the structurally related PI3Ks.<a onclick="showRef(event, 'ref27 ref28 ref39'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref39">(27,28,39)</a> We used the X-ray structure of PI103 in mTOR (see ref <a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a>; PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>, 3.6 Å resolution) and replaced PI103 with compound <b>8</b>. After energy minimization, the resulting mTOR-<b>8</b> complex preserved crucial interactions including the hydrogen bonds between Asp2195/Glu2190 and the 2-aminopyridine and between the oxygen atom of the (<i>R</i>)-3-methylmorpholine and the Val2240 backbone amide (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). The (3<i>S</i>,5<i>R</i>)-3,5-dimethylmorpholine points toward the solvent exposed region, and hydrophobic interactions between one of the two methyl groups and Met2345 could further stabilize the mTOR-<b>8</b> complex (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A). The interaction with Met2345 has been described to play a pivotal role in inhibitor binding stabilization also for the tricyclic pyrimido-pyrrolo-oxazine scaffold.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Because of the high sequence homology of the ATP-binding pocket of mTOR and class I PI3Ks, we can assume a similar binding mode for PI3K isoforms. Analogous computational modeling analysis was carried out starting from the X-ray structure of PI3Kα in complex with the structurally similar triazine derivative PQR530 (see ref <a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a>; PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OAC">6OAC</a>, 3.15 Å resolution). After ligand energy minimization, the oxygen atom of the (<i>R</i>)-3-methylmorpholine established a H-bond with the backbone amide of Val851 in PI3Kα, while the NH<sub>2</sub> group of the 4-(difluoromethyl)pyridin-2-amine forms H-bonds with Asp810/Asp933. Two opposing conformations are possible for the binding of (3<i>S</i>,5<i>R</i>)-3,5-dimethylmorpholine to the solvent exposed region: with the methyl groups pointing toward (i) Met2345 in mTOR (Met922 in PI3Kα) or (ii) Ile2163 in mTOR (Met772 in PI3Kα). In mTOR, both conformations are well accommodated (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). On the contrary, only one conformation can bind to PI3Kα because of a clash with Met772 in the “methyl-down” conformation (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). A superimposition of mTOR and PI3Kα ATP-binding pockets highlighted the inability of highly sterically hindered substituents to bind in the solvent exposed region of PI3Kα because of the different orientation between Met772 (PI3Kα) and Ile2163 (mTOR; <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D). Computational modeling studies were also performed for compound <b>4</b> and, similarly, both morpholine conformations bond with mTOR’s solvent exposed region, while just the “methyl-right” conformation was accommodated in the ATP-binding site of PI3Kα (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>E).</div><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Docking of <b>8</b> (light blue) to mTOR (gray) starting from PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>. H-bonds are represented as dashed black lines. The backbone amide (Val2240) essential for binding is shown in a ball-and-stick representation. (B) Sphere representation of mTOR-<b>8</b> complex and (C) of PI3Kα-<b>8</b> complex. Ile2163 (mTOR) is depicted as dark gray while Met772 (PI3Kα) in magenta. Both conformations (“methyl-up” in light blue and “methyl-down” in orange) are displayed. Docking of <b>8</b> (light blue) to PI3Kα (pink) was performed starting from PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OAC">6OAC</a>. (D) Superimposition of mTOR-<b>8</b> and PI3Kα-<b>8</b> complex; mTOR (gray) and PI3Kα (pink). (E) Superimposition of mTOR-<b>4</b> and PI3Kα-<b>4</b> complexes; mTOR (gray) and PI3Kα (pink). Both conformations (“methyl-right” in green and “methyl-left” in yellow) are displayed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Profiling of Enzymatic Activity, Selectivity, and <i>In Vitro</i> ADME</h3><div class="NLM_p">Due to their significant potency in cells, low nanomolar affinity, and high selectivity for mTOR, compounds <b>4</b> and <b>8</b> were characterized on the DiscoverX KINOMEScan platform. KdELECT assays (DiscoverX) confirmed the excellent affinity of <b>4</b> and <b>8</b> for mTOR kinase, with compound <b>8</b> showing a selectivity >150-fold for mTOR compared to class I PI3K isoforms (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The determined selectivity of <b>8</b> for mTOR kinase over class I PI3K isoforms exceeded those of previously published molecules such as CC223<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> (<b>49</b>, ∼80×) and INK128 (<b>50</b>, ∼40×) and was in the range of AZD2014 (<b>51</b>, ∼230×; <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Both compounds (<b>4</b> and <b>8</b>) displayed a low nanomolar affinity for the class III PI3K Vps34 (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Although many pharmaceutical companies have curtailed their drug discovery programs on Vps34 inhibitors,<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Vps34 has been identified as a promising therapeutic target for combination strategies in cancer treatment because of its pivotal role in autophagy.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Lipid Kinase and mTOR Binding Constants of <b>4</b>, <b>8</b>, and Reference Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="7" align="center" char="±">inhibitor binding constants<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a><i>K</i><sub>d</sub>, [nM], ±SD</th><th class="rowsep1 colsep0" align="center">*most sensitive PI3K/mTOR</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase →</th><th class="colsep0 rowsep0" align="center" char="±">mTOR</th><th class="colsep0 rowsep0" align="center" char="±">PI3Kα</th><th class="colsep0 rowsep0" align="center" char="±">PI3Kβ</th><th class="colsep0 rowsep0" align="center" char="±">PI3Kδ</th><th class="colsep0 rowsep0" align="center" char="±">PI3Kγ</th><th class="colsep0 rowsep0" align="center">PI4Kβ</th><th class="colsep0 rowsep0" align="center" char="±">VPS34</th><th class="colsep0 rowsep0" align="center">fold selectivity (class I PI3K isoforms)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="char" char="±">0.88 ± 0.17</td><td class="colsep0 rowsep0" align="char" char="±"><b>81</b> ± 27</td><td class="colsep0 rowsep0" align="char" char="±">1350 ± 71</td><td class="colsep0 rowsep0" align="char" char="±">2450 ± 354</td><td class="colsep0 rowsep0" align="char" char="±">595 ± 106</td><td class="colsep0 rowsep0" align="left">>30 000</td><td class="colsep0 rowsep0" align="char" char="±">28 ± 1.4</td><td class="colsep0 rowsep0" align="left">90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PQR626 (<b>8</b>)</td><td class="colsep0 rowsep0" align="char" char="±">0.67 ± 0.09</td><td class="colsep0 rowsep0" align="char" char="±"><b>110</b> ± 14</td><td class="colsep0 rowsep0" align="char" char="±">1450 ± 71</td><td class="colsep0 rowsep0" align="char" char="±">3500 ± 424</td><td class="colsep0 rowsep0" align="char" char="±">1350 ± 71</td><td class="colsep0 rowsep0" align="left">>30 000</td><td class="colsep0 rowsep0" align="char" char="±">65 ± 3.5</td><td class="colsep0 rowsep0" align="left">164</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CC223 (<b>49</b>)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">28 ± 11</td><td class="colsep0 rowsep0" align="char" char="±"><b>2300</b> ± 141</td><td class="colsep0 rowsep0" align="char" char="±">18,500 ± 6364</td><td class="colsep0 rowsep0" align="char" char="±">6200 ± 0</td><td class="colsep0 rowsep0" align="char" char="±">7150 ± 919</td><td class="colsep0 rowsep0" align="left">39 ± 10</td><td class="colsep0 rowsep0" align="char" char="±">2500 ± 354</td><td class="colsep0 rowsep0" align="left">>80×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">INK128 (<b>50</b>)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">0.092 ± 0.007</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 3.5</td><td class="colsep0 rowsep0" align="char" char="±">81 ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">30 ± 13</td><td class="colsep0 rowsep0" align="char" char="±"><b>3.7</b> ± 0.28</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="char" char="±">8200 ± 707</td><td class="colsep0 rowsep0" align="left">>40×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AZD2014 (<b>51</b>)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">0.14 ± 0.02</td><td class="colsep0 rowsep0" align="char" char="±"><b>33</b> ± 1.4</td><td class="colsep0 rowsep0" align="char" char="±">3300 ± 282</td><td class="colsep0 rowsep0" align="char" char="±">1500 ± 283</td><td class="colsep0 rowsep0" align="char" char="±">8400 ± 707</td><td class="colsep0 rowsep0" align="left">>30 000</td><td class="colsep0 rowsep0" align="char" char="±">23 000 ± 3535</td><td class="colsep0 rowsep0" align="left">>230×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PQR620 (<b>52</b>)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">0.27 ± 0.16</td><td class="colsep0 rowsep0" align="char" char="±"><b>980</b> ± 14</td><td class="colsep0 rowsep0" align="char" char="±">22 000 ± 2828</td><td class="colsep0 rowsep0" align="char" char="±">23 000 ± 2828</td><td class="colsep0 rowsep0" align="char" char="±">18 000 ± 707</td><td class="colsep0 rowsep0" align="left">>30 000</td><td class="colsep0 rowsep0" align="char" char="±">1400 ± 0</td><td class="colsep0 rowsep0" align="left">>3700×</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PQR617 (<b>53</b>)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="±">3.5 ± 0.49</td><td class="colsep0 rowsep0" align="char" char="±"><b>1600</b> ± 0</td><td class="colsep0 rowsep0" align="char" char="±">7450 ± 495</td><td class="colsep0 rowsep0" align="char" char="±">12 000 ± 0</td><td class="colsep0 rowsep0" align="char" char="±">11 000 ± 1414</td><td class="colsep0 rowsep0" align="left">>30 000</td><td class="colsep0 rowsep0" align="char" char="±">3250 ± 495</td><td class="colsep0 rowsep0" align="left">457</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Dissociation constants (<i>K</i><sub>d</sub>) were assessed with ScanMax technology from DiscoveRx (11 point threefold serial dilutions of the listed compounds). Experiments were performed using an automated and standardized <i>in vitro</i> assay at DiscoverX (San Diego, USA) as technical duplicates, and <i>K</i><sub>d</sub> was calculated from dose–response curves (fitting with Hill equation). <i>K</i><sub>d</sub> is shown as mean ± SD.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Values for compounds <b>49</b>, <b>50</b>, <b>51</b>, <b>52</b>, and <b>53</b> are from ref <a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>. n.d. = not determined. *Ratio of <i>K</i><sub>d</sub> of most sensitive class I PI3K isoform (indicated in bold type) over <i>K</i><sub>d</sub> for mTOR.</p></div></div></div><div class="NLM_p last">These data qualify <b>8</b> as a highly potent mTOR inhibitor with low to moderate activity for PI3Kα. Moreover, the selectivity of compound <b>8</b> for mTOR over a wide range of proteins (>400) and lipid kinases was demonstrated in a DiscoverX scanMAX kinase assay panel. Compound <b>8</b> displayed negligible binding to protein kinases at a concentration of 10 μM (Figure S3 and Table S3 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a>). It obtained excellent selectivity scores<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> of <i>S</i>(35) = 0.04 and <i>S</i>(10) = 0.017 (corresponding to 16 and 4 hits, respectively—<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Table S2</a>), compared to <b>50</b> which recorded 0.29 and 0.14 (corresponding to 118 and 55 hits, respectively—<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Table S2</a>). In order to assess off-target effects, compound <b>8</b> was tested at a 10 μM concentration in a Cerep safety pharmacology panel. No off-target interactions of <b>8</b> with the cell surface and nuclear receptors, transporters, and ion channels including hERG (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Table S4</a>) were identified. Enzyme activities such as phosphodiesterases, kinases, and proteases were also unaffected by compound <b>8</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Table S5</a>).</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Metabolic Stability and CYP450 Reactive Phenotyping</h3><div class="NLM_p">To assess its metabolic stability in comparison with <b>52</b>, compound <b>8</b> was incubated with hepatocytes from mice (CD-1), rats (Sprague-Dawley), dogs (Beagle), and humans. The hepatocytes stability is strongly predictive of <i>in vivo</i> clearance across species, as previously demonstrated with <b>57</b>.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Compound <b>8</b> showed a moderate stability with mouse, rat, and human hepatocytes, with 48.4, 42.3, and 44.0% compound remaining after 3 h of incubation. A moderate-to-high stability was observed with dog hepatocytes (75.6%; <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Table S6</a> and <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). <b>52</b> presented a high stability in mouse, rat, and dog hepatocytes (>59.9% remaining compound; see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Table S7</a>), characterizing it as an excellent TORKi to explore rodent models. Compound <b>52</b>’s limited stability in human hepatocytes (27.8% remaining compound after 3 h; <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Table S7</a>) designates <b>52</b> as a candidate for topical applications, which is also supported by its lipophilic properties. <b>8</b> achieved a 52% increase in stability in human hepatocytes with respect to <b>52</b> (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>), providing substantial advantages for the development of novel agents targeting CNS disorders.</div><figure id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Stability of <b>8</b> at 5 μM in primary hepatocyte cultures from mice, rats, dogs, and humans (<i>n</i> = 2; mean ± SEM; error bars are not shown when smaller than symbols). Values are tabulated in Table S6 of the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a>. (B,C) Pie chart displaying the % of remaining (B) compound <b>8</b> (blue) and (C) compound <b>4</b> (blue) after 60 min of incubation with the indicated human recombinant CYP isoenzymes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Stability of Compound PQR626 (<b>8</b>) and PQR620 (<b>52</b>) in Hepatocyte Cultures</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="2" align="center">cpd./species</th><th class="rowsep1 colsep0" align="center" char="±">mouse</th><th class="rowsep1 colsep0" align="center" char="±">rat</th><th class="rowsep1 colsep0" align="center" char="±">dog</th><th class="rowsep1 colsep0" align="center" char="±">human</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PQR626 (<b>8</b>)</td><td class="colsep0 rowsep0" align="left"><a class="ref internalNav" href="#t3fn1" aria-label="a">a</a>CL<sub>int</sub></td><td class="colsep0 rowsep0" align="char" char="±">4.3 ± 0.33</td><td class="colsep0 rowsep0" align="char" char="±">5.3 ± 0.19</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.20</td><td class="colsep0 rowsep0" align="char" char="±">5.3 ± 0.26</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> [min]</td><td class="colsep0 rowsep0" align="char" char="±">201 ± 16</td><td class="colsep0 rowsep0" align="char" char="±">162 ± 5.7</td><td class="colsep0 rowsep0" align="char" char="±">490 ± 57</td><td class="colsep0 rowsep0" align="char" char="±">164 ± 8.22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PQR620 (<b>52</b>)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">CL<sub>int</sub></td><td class="colsep0 rowsep0" align="char" char="±">2.7 ± 1.2</td><td class="colsep0 rowsep0" align="char" char="±">1.8 ± 0.35</td><td class="colsep0 rowsep0" align="char" char="±">1.6 ± 0.21</td><td class="colsep0 rowsep0" align="char" char="±">8.0 ± 0.18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> [min]</td><td class="colsep0 rowsep0" align="char" char="±">324 ± 177</td><td class="colsep0 rowsep0" align="char" char="±">468 ± 92</td><td class="colsep0 rowsep0" align="char" char="±">525 ± 70</td><td class="colsep0 rowsep0" align="char" char="±">108 ± 2.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">7-EC<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">CL<sub>int</sub></td><td class="colsep0 rowsep0" align="char" char="±">42 ± 0.47</td><td class="colsep0 rowsep0" align="char" char="±">16 ± 0.18</td><td class="colsep0 rowsep0" align="char" char="±">60 ± 2.1</td><td class="colsep0 rowsep0" align="char" char="±">27 ± 0.09</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> [min]</td><td class="colsep0 rowsep0" align="char" char="±">21 ± 0.23</td><td class="colsep0 rowsep0" align="char" char="±">55 ± 0.62</td><td class="colsep0 rowsep0" align="char" char="±">14 ± 0.50</td><td class="colsep0 rowsep0" align="char" char="±">31 ± 0.10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">CL<sub>int</sub> [μL/min/10<sup>6</sup> cells]; <i>t</i><sub>1/2</sub>, [min].</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Assay reference compound: 7-EC, 7-ethoxycoumarin. Results are shown as mean ± SEM (<i>n</i> = 2). Raw data are reported in Table S6 of the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">The data for <b>52</b> are reprinted from ref <a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>.</p></div></div></div><div class="NLM_p last">Both <b>8</b> and compound <b>4</b>, bearing a 3,3-dimethylmorpholine, were characterized with respect to their CYP1A-related metabolism, after incubation with individual human recombinant CYP isoenzymes CYP1A1 and CYP1A2. CYP1A1 is implicated in the metabolism of structurally similar molecules and the high interindividual expression of this isoenzyme hampers the establishment of a therapeutic dose. Compound <b>8</b> was moderately stable with CYP1A1 as indicated by 45.1% remaining compound after 60 min of incubation (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B), while compound <b>4</b> was extensively depleted, resulting in <2% remaining compound after 60 min (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C). Both compounds were not substrates of CYP1A2. Because the (<i>R</i>)-3-methylmorpholine has been suggested to protect the compounds from extensive CYP1A1 metabolism,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> the susceptibility of <b>4</b> to the CYP1A1 metabolism is related to the 3,3-dimethylmorpholine.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> <i>In Vitro</i> Permeability and hMDR1 Affinity</h3><div class="NLM_p">To determine the potential for BBB penetration, compound <b>8</b> and three other molecules with high potency in biochemical and cellular assays (<b>1</b>, <b>3</b>, <b>4</b>; <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) were tested in an <i>in vitro</i> TransWell assay using CRISPR–Cas9-generated Madin–Darby canine kidney II (MDCK) cell lines with deleted canine MDR1 (MDCK<sup>cMDR1-ko</sup>) and one line stably expressing human MDR1 (MDCK-hMDR1<sup>cMDR1-ko</sup>).<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> MDCK cells differentiate to form tight junctions and monolayers that mimic the BBB. The MDCK-hMDR1 permeability assay is able to identify compounds which are multidrug resistance protein 1 (MDR1 or P-glycoprotein, P-gp) substrates and distinguish between potential CNS and non-CNS drugs. The apparent permeability (<i>P</i><sub>app</sub>) and efflux ratio (ER) across cell monolayers was assessed in MDCK-hMDR1<sup>cMDR1-ko</sup>.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> The ER was compared against the MDCK<sup>cMDR1-ko</sup> control cells. Compound <b>53</b> is known to have limited uptake into the brain<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and displayed significantly different ER between the MDCK-hMDR1<sup>cMDR1-ko</sup> and the MDCK<sup>cMDR1-ko</sup> cells (<i>p</i>-value using an unpaired <i>t</i>-test: 0.000031, <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). Thus, <b>53</b> was classified as a hMDR1 substrate. Compound <b>52</b> and <b>57</b>, known for having good brain penetration <i>in vivo</i>,<a onclick="showRef(event, 'ref26 ref30'); return false;" href="javascript:void(0);" class="ref ref26 ref30">(26,30)</a> did not show significant differences between the ER in both cell lines (<i>p</i>-value > 0.05), and an ER close to 1 indicated that these compounds are not likely to be dependent on active transport. Similarly, none of novel tested compounds—<b>1</b>, <b>3</b>, <b>4</b>, and <b>8</b>—was classified as a hMDR1 substrate. <b>4</b> showed a nonsignificant trend toward hMDR1 affinity with an ER of 1.5 in MDCK-hMDR1<sup>cMDR1-ko</sup> cells (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). Compound <b>8</b> was no hMDR1 substrate and had a <i>P</i><sub>app</sub> comparable to those of the brain penetrating compounds <b>52</b> and <b>57</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B), supporting the assessment of its BBB permeability using <i>in vivo</i> models.</div><figure id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) ER in MDCK-hMDR1<sup>cMDR1-ko</sup> and MDCK<sup>cMDR1-ko</sup> cells. The dotted line shows ER = 1, indicative of equal apparent permeability across the cell monolayer in both directions. High ER in MDCK-hMDR1<sup>cMDR1-ko</sup> cells indicates hMDR1 affinity of the compound. Citalopram, a hMDR1 substrate,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> has been used as positive control. <b>57</b> and <b>52</b> are known to have a good BBB penetration <i>in vivo</i>, while <b>53</b> has a limited BBB penetration <i>in vivo</i>. (B) Apparent permeability (<i>P</i><sub>app</sub>) in direction from apical to basolateral compartment across MDCK-hMDR1<sup>cMDR1-ko</sup> monolayers seeded on TransWell plates. Results are shown as mean ± SD (<i>n</i> > 3), *<i>p</i>-value < 0.05 (unpaired <i>t</i>-test, GraphPad Prism 8.0.2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Pharmacological Parameters</h3><div class="NLM_p">To evaluate the <i>in vivo</i> BBB permeability and oral availability, PK parameters of <b>8</b> were determined in male Sprague Dawley rats. <b>8</b> was administered orally (5 mg/kg p.o.) and plasma and brain concentrations were assessed after the application of a single dose (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). After 30 min, the maximal concentration (<i>C</i><sub>max</sub>) of <b>8</b> was achieved both in plasma and brain. The total exposure AUC<sub>0–8</sub> for compound <b>8</b> was in plasma 2429 ng h/mL and in brain 3689 ng h/g after 8 h. The conformationally restricted compound <b>53</b> was administered at the same dose and reached an AUC<sub>0–8</sub> of >5500 ng h/mL in plasma, but only of <110 ng h/g in brain (∼1:55 brain/plasma ratio).<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> While the brain uptake of <b>53</b> was minimal, compound <b>8</b> showed excellent brain exposure (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). Compound <b>8</b> had a brain/plasma ratio of ∼1.5:1 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B).</div><figure id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharmacokinetics and pharmacodynamics in male Sprague Dawley rats. (A) Plasma (square) and brain (circle) levels of <b>8</b> and <b>53</b> after p.o. dosing at 5 mg/kg. (B) Calculation of brain/plasma ratio over time using the values reported in (A). (C) Insulin and (D) glucose plasma levels after oral administration of <b>8</b> in male Sprague Dawley rats (<i>n</i> = 3; mean ± SEM; error bars not shown when < symbols). Exact values can be found in Tables S8–S13 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">PI3Kα inhibitors are known to trigger a rapid increase in insulin and glucose plasma levels.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> We have previously reported on <b>57</b>,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> PQR530,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> and PQR514,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> which are potent pan-PI3K inhibitors, and insulin and glucose peaks were reliable markers for on-target action. <b>8</b> did not cause a rise of insulin and glucose concentration as compared to the vehicle, highlighting the selective inhibition of mTOR kinase (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C,D). These results match the observations published for the selective and brain penetrant mTOR inhibitor <b>52</b>.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Comparative PK Studies: PQR626 versus Everolimus and AZD2014</h3><div class="NLM_p">As <b>56</b> (see <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> for chemical structure) has been approved for the treatment of TSC-associated seizures, the pharmacokinetic parameters of <b>8</b> were first assessed in comparison with those of <b>56</b>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Compound <b>8</b> was orally administered (p.o.) to female C57BL/6J mice at 10 mg/kg, either as single dose or once a day for 4 consecutive days (qd4), while <b>56</b> was dosed at 10 mg/kg p.o. qd4. The plasma and brain concentrations of the compounds were monitored. The dose of compound <b>8</b> was doubled with respect to the experiments carried out in male Sprague Dawley rats (see <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) aiming to achieve higher <i>C</i><sub>max</sub>. The PK parameters for <b>8</b> were assessed both in mice and rats because significant species differences were observed with other compounds previously investigated.<a onclick="showRef(event, 'ref30 ref47'); return false;" href="javascript:void(0);" class="ref ref30 ref47">(30,47)</a> In mice dosed at 10 mg/kg, compound <b>8</b> reached a <i>C</i><sub>max</sub> of 1096 and 947 ng/mL in plasma and of 1425 and 1317 ng/g in brain, after either single or qd4 applications, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Applications of <b>56</b> once a day for 4 consecutive days at 10 mg/kg led to a <i>C</i><sub>max</sub> of 3941 ng/mL in plasma and of only 43 ng/g in brain (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Concentrations of <b>8</b> were higher in the brain than in the plasma (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A,B), highlighting the ability of compound <b>8</b> to reach the brain and confirming the results obtained in rats. PQR626 (<b>8</b>) showed a ∼1.4:1 distribution between brain and plasma, whereas the brain permeability of <b>56</b> was negligible (brain/plasma ratio ∼1:92, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C).</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Pharmacokinetic study in female C57BL/6J mice. (A–C) <b>8</b> was administered at 10 mg/kg in 20% Captisol p.o. either as single dose or administered once a day for 4 consecutive days and the blood sampling performed after the last treatment on day 4 (qd4). <b>56</b> was administered at 10 mg/kg in 8% ethanol, 10% PEG 400, and 10% Tween 80 p.o. qd4. (A) Plasma and (B) brain levels of compounds <b>8</b> and <b>56</b>. (C) Calculation of brain/plasma ratio over time using the values reported in (A,B). Values are reported in Tables S14–S19 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a>. (D–F) <b>8</b> and <b>51</b> were administered p.o. as a single dose of 25 mg/kg. <b>56</b> was administered at 10 mg/kg p.o. single dose. (D) Plasma and (E) brain levels of compounds <b>8</b>, <b>51</b>, and <b>56</b>. (C) Brain/plasma ratio over time calculated from the values reported in (D,E). Values are depicted in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Tables S20–S25</a>. All values: mean ± SEM. Error bars not shown are smaller than the symbols.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. PK Parameters after Oral Application in Female C57BL/6J Mice<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">plasma</th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">brain</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">test Item</th><th class="colsep0 rowsep0" align="center" char=".">PQR626 (<b>8</b>)</th><th class="colsep0 rowsep0" align="center">PQR626 (<b>8</b>)</th><th class="colsep0 rowsep0" align="center">everolimus (<b>56</b>)</th><th class="colsep0 rowsep0" align="center" char=".">PQR626 (<b>8</b>)</th><th class="colsep0 rowsep0" align="center">PQR626 (<b>8</b>)</th><th class="colsep0 rowsep0" align="center">everolimus (<b>56</b>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p.o. dosage[mg/kg]</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">10 qd4</td><td class="colsep0 rowsep0" align="left">10 qd4</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="left">10 qd4</td><td class="colsep0 rowsep0" align="left">10 qd4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> [ng/mL]</td><td class="colsep0 rowsep0" align="char" char=".">1096</td><td class="colsep0 rowsep0" align="left">947</td><td class="colsep0 rowsep0" align="left">3941</td><td class="colsep0 rowsep0" align="char" char=".">1425</td><td class="colsep0 rowsep0" align="left">1317</td><td class="colsep0 rowsep0" align="left">43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> [h]</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">2.0</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">0.5</td><td class="colsep0 rowsep0" align="left">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> [h]</td><td class="colsep0 rowsep0" align="char" char=".">3.0</td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">5.7</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="left">2.3</td><td class="colsep0 rowsep0" align="left">15.8*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–8h</sub> [h·ng/mL]</td><td class="colsep0 rowsep0" align="char" char=".">2936</td><td class="colsep0 rowsep0" align="left">2371</td><td class="colsep0 rowsep0" align="left">42,267</td><td class="colsep0 rowsep0" align="char" char=".">4653</td><td class="colsep0 rowsep0" align="left">3048</td><td class="colsep0 rowsep0" align="left">640</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl [mL/h/kg]</td><td class="colsep0 rowsep0" align="char" char=".">3397</td><td class="colsep0 rowsep0" align="left">3892</td><td class="colsep0 rowsep0" align="left">225</td><td class="colsep0 rowsep0" align="char" char=".">2144</td><td class="colsep0 rowsep0" align="left">3012</td><td class="colsep0 rowsep0" align="left">10,265*</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">p.o.: per os; <i>C</i><sub>max</sub>: maximal concentration, <i>T</i><sub>max</sub>: time of maximal concentration in hours (derived from minimally 3 time points); <i>t</i><sub>1/2</sub>: half-life elimination in hours; AUC: area under the curve, Cl: clearance; (<i>n</i> = 3, mean for each time-point); qd4: compound was administered once a day for 4 consecutive days and the blood sampling was performed after the last treatment on day 4. *values obtained considering only 2 time points following <i>T</i><sub>max</sub> have to be regarded as a rough estimation.</p></div></div></div><div class="NLM_p">To confirm the favorable brain distribution of <b>8</b> with respect to the currently available drugs and clinical candidates, a study including <b>8</b>, <b>56</b>, and <b>51</b> (see <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a> for chemical structures) was carried out (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. PK Parameters after Oral Application in Female C57BL/6J Mice<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">plasma</th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">brain</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">test item</th><th class="colsep0 rowsep0" align="center" char=".">PQR626 (<b>8</b>)</th><th class="colsep0 rowsep0" align="center" char=".">everolimus (<b>56</b>)</th><th class="colsep0 rowsep0" align="center" char=".">AZD2014 (<b>51</b>)</th><th class="colsep0 rowsep0" align="center" char=".">PQR626 (<b>8</b>)</th><th class="colsep0 rowsep0" align="center">everolimus (<b>56</b>)</th><th class="colsep0 rowsep0" align="center" char=".">AZD2014 (<b>51</b>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">p.o. dosage [mg/kg]</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">10</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="char" char=".">25</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="char" char=".">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> [ng/mL]</td><td class="colsep0 rowsep0" align="char" char=".">1833</td><td class="colsep0 rowsep0" align="char" char=".">3464</td><td class="colsep0 rowsep0" align="char" char=".">7189</td><td class="colsep0 rowsep0" align="char" char=".">3345</td><td class="colsep0 rowsep0" align="left">57</td><td class="colsep0 rowsep0" align="char" char=".">286</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> [h]</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td><td class="colsep0 rowsep0" align="left">24.0</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>t</i><sub>1/2</sub> [h]</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="char" char=".">6.5</td><td class="colsep0 rowsep0" align="char" char=".">7.5</td><td class="colsep0 rowsep0" align="char" char=".">2.4</td><td class="colsep0 rowsep0" align="left">NC</td><td class="colsep0 rowsep0" align="char" char=".">8.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>0–8h</sub> [h·ng/mL]</td><td class="colsep0 rowsep0" align="char" char=".">10,295</td><td class="colsep0 rowsep0" align="char" char=".">33,636</td><td class="colsep0 rowsep0" align="char" char=".">33,706</td><td class="colsep0 rowsep0" align="char" char=".">17,103</td><td class="colsep0 rowsep0" align="left">804</td><td class="colsep0 rowsep0" align="char" char=".">1338</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl [mL/h/kg]</td><td class="colsep0 rowsep0" align="char" char=".">2427</td><td class="colsep0 rowsep0" align="char" char=".">276</td><td class="colsep0 rowsep0" align="char" char=".">660</td><td class="colsep0 rowsep0" align="char" char=".">1460</td><td class="colsep0 rowsep0" align="left">NC</td><td class="colsep0 rowsep0" align="char" char=".">15,722</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">p.o.: per os; <i>C</i><sub>max</sub>: maximal concentration, <i>T</i><sub>max</sub>: time of maximal concentration in hours; <i>t</i><sub>1/2</sub>: half-life elimination in hours; AUC: area under the curve, Cl: clearance; (<i>n</i> = 3, mean for each time-point). NC = not calculated.</p></div></div></div><div class="NLM_p">Dosed at 25 mg/kg in mice, compound <b>8</b> reached a <i>C</i><sub>max</sub> of 1833 ng/mL and 3345 ng/g in plasma and brain, respectively. On the contrary, both <b>56</b> and <b>51</b> reached a higher concentration in plasma than in the brain (<i>C</i><sub>max</sub> in plasma = 3464 and 7189 ng/mL; <i>C</i><sub>max</sub> in brain = 57 and 286 ng/g; <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>D). Administered at the same dose, compound <b>8</b> yielded a <i>C</i><sub>max</sub> in brain ∼12-fold higher than that of <b>51</b> (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>E). <b>51</b> showed a higher brain/plasma ratio with respect to <b>56</b> [∼1:25 (<b>51</b>) and ∼1:61 (<b>56</b>), <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>F]. However, the brain-to-plasma ratio is significantly improved for <b>8</b> (∼1.8:1, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>F).</div><div class="NLM_p">Compared to PQR514,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> a potent pan-PI3K inhibitor, <b>8</b> did not lead to an increase in insulin and glucose plasma levels at a concentration >2-fold higher than that of PQR514 (10 <i>vs</i> 25 mg/kg). <b>56</b> and <b>51</b> also did not trigger an increase in insulin and glucose plasma concentrations (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>A,B). Moreover, metabolic side effects were not present at the same dose at which <b>8</b> led to a significant decrease in brain pS6 and pS473 PKB (see next section).</div><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Insulin and (B) glucose plasma levels after oral administration of <b>8</b> (25 mg/kg), <b>56</b> (10 mg/kg), and <b>51</b> (25 mg/kg) in female C57BL/6J mice and of PQR514 (10 mg/kg)<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> in male C57BL/6J mice. All values: mean ± SEM. Error bars are not shown when smaller than the symbols. Values are reported in Tables S26–S31 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Pharmacodynamic Evaluation of <b>8</b> in the Brain</h3><div class="NLM_p">The effects of inhibiting the mTOR pathway in the brain using <b>8</b> were investigated in C57BL/6J mice after oral administration at 25 mg/kg and compared with <b>56</b> dosed at 10 mg/kg. While <b>56</b> is an allosteric inhibitor of TORC1, <b>8</b> targets the ATP-binding site and inhibits both mTORC1 and mTORC2. Thus, <b>8</b> was expected to impact both pS6<sup>(Ser235/236)</sup> and pPKB<sup>(Ser473)</sup> levels, which, respectively, reflect the activity of mTORC1 and mTORC2 complexes. At 10 mg/kg [same dose as investigated in the vivo efficacy model], <b>56</b> did not show a decrease in pS6 levels (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). On the contrary, a single administration of compound <b>8</b> at 25 mg/kg led to an effective reduction of levels of pS6 30 min after drug dosing in murine cortex (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A,C). Similarly, <b>8</b> significantly reduced the phosphorylation of S473 PKB 30 min after dosing (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B,C). The pharmacodynamic effect of <b>8</b> in the brain was strongly correlated with the brain levels of the compound (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>D). In a time-course experiment, we observed a significant decrease in brain pS6 and pPKB at 0.5–2 h after dosing, while pS6 and pPKB levels returned to pretreated levels after 8 h (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Figure S4</a>).</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibition of mTOR signaling in murine brain cortex by PQR626 (<b>8</b>) and everolimus (<b>56</b>). (A–C) Brain cortex was collected from female C57BL/6J mice or from mice treated with <b>8</b> (25 mg/kg, p.o.) or <b>56</b> (10 mg/kg, p.o.) for 30 min. Cortex was lysed and equal amount proteins subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting, followed by the detection of pPKB, pS6, phosphorylated MAP kinases, total PKB, or α-tubulin using specific primary antibodies and respective HRP-coupled secondary antibodies and enhanced chemiluminescence. (A,B) Quantification of (A) pS6 and (B) pPKB levels in compound-treated murine cortex given as % of control cortex. For details, see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> [<i>n</i> = 3, mean ± SEM, *<i>p</i>-value < 0.05. <i>p</i>-value using an unpaired <i>t</i>-test <i>vs</i> control: compound <b>8</b>: 0.0125 (pS6); 0.0044 (pPKB)]. (C) Western blot images used for quantification of (A,B). (D) Time-course of inhibition of mTOR signaling in murine brain cortex by <b>8</b>. Brain cortex was collected from <b>8</b> (25 mg/kg, p.o.) treated female C57BL/6J mice at indicated time-points in [h] and from control mice. Western blot images are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Figure S4</a>. Phosphorylated proteins and α-tubulin levels were quantified using ImageJ, and phospho-protein/tubulin levels are presented as % of control cortex (left <i>y</i>-axis) as a function of time [<i>n</i> = 9 for control animals, <i>n</i> = 3 for each timepoint of <b>8</b> treatment, mean ± SEM]. Right <i>y</i>-axis: brain concentration of <b>8</b> in ng/mL from the same mice (<i>n</i> = 3, mean ± SEM for each time point).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Evaluation of <i>In Vivo</i> Efficacy</h3><div class="NLM_p"><i>In vivo</i> toxicokinetic studies were performed in nontumor-bearing BALB/c nude female mice to establish the maximum tolerated dose (MTD). Compound <b>8</b> was tested at 100 (group 2), 150 (group 3), and 200 mg/kg (group 4) and compared with vehicle (group 1). Animals were evaluated for 7 days after 2 weeks of once a day (qd) dosing schedule. The body weight changes are shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A. No adverse effect on body weight was observed in groups 2 and 3. Compound <b>8</b> had a tolerability in mice at 100 and 150 mg/kg comparable to that of <b>52</b> (MTD ∼150 mg/kg). Efficacy studies were performed using mice with conditional inactivation of the <i>Tsc1</i> gene primarily in glia (<i>Tsc1</i><sup>GFAP</sup>CKO mice), which develop glial proliferation and postnatal epilepsy and show a highly increased mortality. TSC-induced epilepsy originates in the CNS, and compounds must therefore target mTOR behind the BBB.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Alterations in BBB permeability are associated with mTOR-mediated inflammation in TSC epileptogenesis.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Increased permeability is not always associated with enhanced drug penetration into the brain because an increase in efflux carrier expression (i.g. P-gp) has been observed as the mechanism to protect the brain from toxins.<a onclick="showRef(event, 'ref49 ref50'); return false;" href="javascript:void(0);" class="ref ref49 ref50">(49,50)</a> While <b>55</b> is known to be a P-gp substrate,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a><b>8</b> was not affected by P-gp-mediated efflux (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), highlighting its potential advantage in the treatment of TSC-associated seizures. <b>55</b> decreased seizures and prolonged survival in <i>Tsc1</i><sup>GFAP</sup>CKO mice.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Everolimus (<b>56</b>) is currently available under the trend name Afinitor Disperz for the treatment of TSC-associated seizures.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> However, the limited BBB penetration of <b>56</b> leads to the need of a very high dose causing serious systemic side effects (immunosuppression). Moreover, <b>56</b> forms quasi-irreversible complexes with TORC1 (FRB–Rapalog–FKBP12 complexes) that act as a sink for the drug. A brain-penetrant, reversible mTOR inhibitor is expected to have a lower systemic impact on immune responses.</div><figure id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Body weight changes in BALB/c nude female mice to assess MTD. Group 1: vehicle (20% Captisol in water) once a day (qd) × 14 from day 1 p.o. (<i>n</i> = 1). Group 2: compound <b>8</b> at 100 mg/kg qd × 14 from day 1 p.o. (<i>n</i> = 3). Group 3: compound <b>8</b> at 150 mg/kg qd × 14 from day 8 p.o. (<i>n</i> = 3). Group 4: compound <b>8</b> at 200 mg/kg qd × 14 from day 15 p.o. (<i>n</i> = 3). Raw data are depicted in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Table S32</a>. (B). Body weight of <i>Tsc1</i><sup>GFAP</sup>CKO mice as a function of treatments. Data are shown as mean ± SEM. Raw data are depicted in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Table S33</a>. (C) Effects of treatments on the survival rate of <i>Tsc1</i><sup>GFAP</sup>CKO mice. All treatments started at P21, with the exception of <b>52</b> (50 mg/kg p.o. qd) which started on P27. Compound <b>56</b> at 10 mg/kg, <i>n</i> = 12; compound <b>52</b> at 100 and 50 mg/kg, <i>n</i> = 12 and 8, respectively; compound <b>8</b> at 50 bid, 50, 25, and 10 mg/kg, <i>n</i> = 7, 10, 10, and 10, respectively. Mid-study (day P45) brain and plasma collection: four additional animals per group were dosed and sacrificed on day P45. Data are presented as percent surviving at each time point. Survival was determined from the start of the study (P21) to the day the animal was found dead or until P90 (<i>i.e.</i>, animals were censored at P90). A χ<sup>2</sup> survival analysis was performed in JMP Statistical Software (a division of SAS) with treatment as a factor. The statistical report for survival analysis: Table S34 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a>. *<i>p</i>-value < 0.05. <i>p</i>-values using the log-rank test <i>vs</i> vehicle—compound <b>52</b> at 50 and 100 mg/kg: <i>p</i>-value 0.1336 and 0.0093, respectively; compound <b>8</b> at 10, 25, 50, and 50 bid mg/kg: <i>p</i>-value 0.6530, 0.4502, 0.4489, and 0.0469, respectively. <sup>$</sup><i>p</i>-value < 0.05. <i>p</i>-values using the log–rank test <i>vs</i> everolimus (<b>56</b>)—compound <b>52</b> at 50 and 100 mg/kg: <i>p</i>-value 0.0228 and 0.1483, respectively; compound <b>8</b> at 10, 25, 50, and 50 bid mg/kg: 0.0002, 0.0016, 0.0016, and 0.0542, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In a dose-range finding study, the efficacy of compound <b>8</b> (10, 25, and 50 mg/kg) on survival in <i>Tsc1</i><sup>GFAP</sup>CKO mice was assessed and compared to vehicle and treatment with <b>56</b> (10 mg/kg) and <b>52</b> (50 and 100 mg/kg). Significant changes in body weight were not observed across all compounds and doses ≤150 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B). Compounds <b>8</b> and <b>52</b> showed a positive dose–response effect on survival. Both compounds <b>8</b> at 50 mg/kg, bid (twice a day) and <b>52</b> at 100 mg/kg significantly decreased mortality as compared to vehicle control mortality data (<i>p</i>-values using the log-rank test: 0.0469 and 0.0093, respectively). <b>56</b> at 10 mg/kg prevented mortality in <i>Tsc1</i><sup>GFAP</sup>CKO mice. Compounds <b>8</b> at 50 mg/kg bid and <b>52</b> at 100 mg/kg were not statistically different from <b>56</b>, suggesting noninferiority under these study conditions (<i>p</i>-values using the log-rank test: 0.0542 and 0.1483, respectively; <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>C and Table S34 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a>). The effectiveness of <b>8</b> administered twice a day at 50 mg/kg is highly encouraging. <b>52</b> at 100 mg/kg had been previously exploited as a proof-of-concept compound to prove the ability of mTOR inhibitors in eliminating seizures in <i>Tsc1</i><sup>GFAP</sup>CKO mice. The almost complete elimination of seizures by <b>52</b> proved that ATP-competitive mTOR inhibitors are able to counteract TSC-dependent overactivation of the mTOR pathway<a onclick="showRef(event, 'ref26 ref53'); return false;" href="javascript:void(0);" class="ref ref26 ref53">(26,53)</a> and supports the further investigation of the novel, metabolically optimized TORKi <b>8</b> for TSC treatment.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47346" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47346" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Recently, epileptic seizures in TSC-patients have been shown to be reduced by treatment with everolimus. A limited clinical success has, however, been reported. The discovery of novel, brain-penetrant, and highly selective mTOR inhibitors could prevent epilepsy, improve treatment, and mitigate comorbidities. Previously, we had discovered PQR620 (<b>52</b>), a first-in-class brain-penetrant ATP-competitive TORKi able to attenuate seizures in a TSC mouse model.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">The ethylene-bridged morpholines of <b>52</b> have been replaced in PQR626 (<b>8</b>) because they were found to be the primary site of metabolism in human liver microsomes,<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> human hepatocytes, and Cynomolgus monkeys (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Figures S1 and S2</a>). Compound <b>8</b> achieves a >50% increase in stability in human hepatocytes as compared to <b>52</b>, favoring <b>8</b> as a candidate for further development in neurologic treatment in humans, as metabolically stability of TORKi is a pivotal requirement for long-term inhibition of the mTOR pathway in diseases such as TSC.</div><div class="NLM_p last">Moreover, compound <b>8</b> showed a high stability toward degradation by CYP1A1 as compared to <b>4</b>, which was extensively metabolized. The proven stability of <b>8</b> against the CYP1A1 isoenzyme is an asset in drug development, as CYP1A1 is highly variable in individual patients: liver and extrahepatic expression of this enzyme can be induced by many substrates, leading to a significant variation in pharmacokinetics of drugs metabolized by CYP1A1. Compound <b>8</b> has been discovered through an extensive triazine-scaffold exploration focused on the morpholine moiety pointing toward the solvent exposed region of the ATP-binding site. <b>8</b> is a potent, selective mTORC1/2 inhibitor and showed a good exposure both in plasma and brain after oral dosing. The lack of metabolic side effects in rats and mice, such as hyperglycemia and hyperinsulinemia, suggests its potential application in the treatment of chronic diseases. Compound <b>8</b> at 50 mg/kg twice a day significantly reduced the loss of <i>Tsc1</i>-induced mortality as compared to vehicle. The effectiveness of <b>8</b> in a <i>Tsc1</i><sup>GFAP</sup>CKO mouse model, its excellent brain penetration, optimized stability in human hepatocytes, and CYP profile are highly encouraging and suggest further preclinical and clinical investigations of the compound for the treatment of CNS disorders.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78347" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78347" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Information</h3><div class="NLM_p last">Reagents were purchased at the highest commercial quality from Acros, Combi-blocks, Sigma-Aldrich, or Fluorochem and used without further purification. Solvents were purchased from Acros Organics in AcroSeal bottles over molecular sieves. Cross-coupling reactions were performed under a nitrogen atmosphere using anhydrous solvents, and glassware was oven-dried prior to use. Thin-layer chromatography (TLC) plates were purchased from Merck KGaA (Polygram SIL/UV254, 0.2 mm silica with fluorescence indicator), and UV light (254 nm) was used to visualize the compounds. Column chromatographic purifications were performed on the Merck KGaA silica gel (pore size 60 Å, 230–400 mesh particle size). Alternatively, flash chromatography was performed with Isco CombiFlash Companion systems using prepacked silica gel columns (40–60 μm particle size RediSep). <sup>1</sup>H, <sup>19</sup>F, and <sup>13</sup>C NMR spectra were recorded on a Bruker AVANCE 400 spectrometer. NMR spectra were obtained in deuterated solvents, such as CDCl<sub>3</sub>, (CD<sub>3</sub>)<sub>2</sub>SO, or CD<sub>3</sub>OD. The chemical shifts (δ values) are reported in parts-per-million and corrected to the signal of the deuterated solvents [7.26 ppm (<sup>1</sup>H NMR) and 77.16 ppm (<sup>13</sup>C NMR) for CDCl<sub>3</sub>; 2.50 ppm (<sup>1</sup>H NMR) and 39.52 ppm (<sup>13</sup>C NMR) for (CD<sub>3</sub>)<sub>2</sub>SO; and 3.31 ppm (<sup>1</sup>H NMR) and 49.00 ppm (<sup>13</sup>C NMR) for CD<sub>3</sub>OD]. <sup>19</sup>F NMR spectra are calibrated relative to CFCl<sub>3</sub> (δ = 0 ppm) as the external standard. Peak multiplicities are reported as: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), td (triplet of doublets), q (quartet), m (multiplet), br (broadened). Coupling constants are reported in Hertz (Hz). High-resolution mass spectra (HRMS) were recorded on a Bruker maxis 4G, high-resolution ESI-QTOF. Analyses were performed in positive ion mode, and MeOH +0.1% formic acid was used as the solvent. Sodium formate was used as the calibration standard. MALDI-ToF mass spectra were obtained on a Voyager-De Pro measured in <i>m</i>/<i>z</i>. The purity of final compounds was assessed by high-performance liquid chromatography (HPLC) analyses on an Ultimate 3000SD System from Thermo Fisher with a LPG-3400SD pump system, ACC-3000 autosampler and column oven, and DAD-3000 diode array detector. An Acclaim-120 C18 reversed-phase column from Thermo Fisher was used as the stationary phase. Gradient elution (5:95 for 0.2 min, 5:95 → 100:0 over 10 min, 100:0 for 3 min) of the mobile phase consisting of CH<sub>3</sub>CN/MeOH/H<sub>2</sub>O<sub>(10:90)</sub> was used at a flow rate of 0.5 mL/min at 40 °C. The purity of all final compounds was >95%. Melting points were determined with a Stuart SMP20 apparatus.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> General Procedure 1</h3><div class="NLM_p last">Under a nitrogen atmosphere, boronate <b>48</b> (1.0–1.3 equiv) was charged in a flask and dissolved in dioxane (approx. 1 mL/0.15 mmol). The respective chlorotriazine derivative (<b>24</b>, <b>25</b>, <b>27–46</b>, 1.0 equiv), K<sub>3</sub>PO<sub>4</sub> (2 equiv), and chloro(2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]-palladium(II) (XPhos Pd G2, 0.05 equiv) and degassed distilled H<sub>2</sub>O (H<sub>2</sub>O/dioxane 1:2) were added. The reaction mixture was placed in a preheated oil bath at 95 °C and stirred at this temperature for 2–16 h. After completion of the reaction monitored by TLC, a 3 M aqueous HCl solution (10 equiv) was added and the mixture was stirred at 60 °C for 3–16 h. A 2 M aqueous NaOH solution was added until pH 9–10. The aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on a silica gel.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> General Procedure 2</h3><div class="NLM_p last">To a solution of the respective morpholine (free base or hydrochloride, 1.05 equiv) and DIPEA (2.1 equiv) in DCM (approx. 1 mL/0.15 mmol) at 0 °C, (<i>R</i>)-4-(4,6-dichloro-1,3,5-triazin-2-yl)-3-methylmorpholine (<b>26</b>, 1.0 equiv) was added dropwise. After completion of the addition, the reaction mixture was stirred at r.t. overnight. After completion of the reaction monitored by TLC, the reaction mixture was washed with NaHSO<sub>4</sub> (2×). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on a silica gel.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Procedure 3</h3><div class="NLM_p last">To a solution of the respective morpholine (free base, 1.05 equiv) and DIPEA (2.1 equiv) in THF (approx. 1 mL/0.15 mmol) at 0 °C, (<i>R</i>)-4-(4,6-dichloro-1,3,5-triazin-2-yl)-3-methylmorpholine (<b>26</b>, 1.0 equiv) was added dropwise. After completion of the addition, the reaction mixture was stirred at 70 °C overnight. After completion of the reaction monitored by TLC, the reaction mixture was washed with NaHSO<sub>4</sub> (2×). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on a silica gel.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure 4</h3><div class="NLM_p">To a solution of the respective morpholine (free base, 1.05 equiv) and DIPEA (2.1 equiv) in EtOH (approx. 1 mL/0.15 mmol) at 0 °C, (<i>R</i>)-4-(4,6-dichloro-1,3,5-triazin-2-yl)-3-methylmorpholine (<b>26</b>, 1.0 equiv) was added dropwise. After completion of the addition, the reaction mixture was stirred at r.t. overnight. After completion of the reaction monitored by TLC, the reaction mixture was washed with NaHSO<sub>4</sub> (2×). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub> and filtered, and the solvent was evaporated under reduced pressure. The crude product was purified by column chromatography on a silica gel.</div><div class="NLM_p">(<i>R</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (<b>1</b>) was prepared according to general procedure 1 from intermediate <b>24</b> (250 mg, 0.83 mmol, 1.0 equiv) and boronate <b>48</b> (298 mg, 0.92 mmol, 1.1 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 3:1) gave compound <b>1</b> as a colorless solid (248 mg, 0.61 mmol, 73%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.03 (s, 1H), 7.68 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.3 Hz, 1H), 6.84 (s, 1H), 4.91 (br s, 2H), 4.78–4.70 (m, 1H), 4.45–4.37 (m, 1H), 3.98 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.7 Hz, 1H), 3.89–3.80 (m, 4H), 3.79–3.72 (m, 5H), 3.68 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.3 Hz, 1H), 3.53 (ddd, <i>J</i><sub>H,H</sub> = 12.4, 11.4, 3.0 Hz, 1H), 3.28 (td, <i>J</i><sub>H,H</sub> = 13.0, 3.9 Hz, 1H), 1.32 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −115.99 (s, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.24 (s, 1C), 164.72 (s, 1C), 164.34 (s, 1C), 160.22 (s, 1C), 152.30 (s, 1C), 143.49 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.2 Hz, 1C), 121.34 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.8 Hz, 1C), 111.35 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.6 Hz, 1C), 104.00 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.9 Hz, 1C), 71.04 (s, 1C), 66.99 (s, 1C), 66.77 (s, 1C), 46.40 (s, 1C), 43.62 (s, 1C), 38.55 (s, 1C), 30.93 (s, 1C), 26.90 (s, 1C), 14.26 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>18</sub>H<sub>24</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 408.1954; found, 408.1958. HPLC: <i>t</i><sub>R</sub> = 7.81 min (>99.9% purity). mp 189.8 °C (dec).</div><div class="NLM_p">5-(4,6-Bis((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-4-(difluoromethyl)pyridin-2-amine (<b>2</b>) was prepared according to general procedure 1 from intermediate <b>25</b> (250 mg, 0.80 mmol, 1.0 equiv) and boronate <b>48</b> (285 mg, 0.88 mmol, 1.1 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 3:1) gave compound <b>2</b> as a colorless solid (327 mg, 0.78 mmol, 97%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.04 (s, 1H), 7.70 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.4 Hz, 1H), 6.83 (s, 1H), 5.01 (br s, 2H), 4.78–4.71 (m, 2H), 4.41 (d, <i>J</i><sub>H,H</sub> = 13.7 Hz, 2H), 3.98 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.7 Hz, 2H), 3.78 (d, <i>J</i><sub>H,H</sub> = 11.4 Hz, 2H), 3.68 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.3 Hz, 2H), 3.53 (td, <i>J</i><sub>H,H</sub> = 11.7, 3.0 Hz, 2H), 3.27 (td, <i>J</i><sub>H,H</sub> = 13.0, 3.9 Hz, 2H), 1.33 (d, <i>J</i><sub>H,H</sub> = 6.9 Hz, 6H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −115.98 (s, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.20 (s, 1C), 164.37 (s, 1C), 160.14 (s, 1C), 152.33 (s, 1C), 149.13 (s, 1C), 143.52 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.1 Hz, 1C), 121.46 (s, 1C), 111.36 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.7 Hz, 1C), 103.98 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.8 Hz, 1C), 71.07 (s, 2C), 67.01 (s, 2C), 46.39 (s, 2C), 38.53 (s, 2C), 14.26 (s, 2C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>26</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 422.2111; found, 422.21117. HPLC: <i>t</i><sub>R</sub> = 8.34 min (>99.9% purity). mp 147.3 °C (dec).</div><div class="NLM_p">4-(Difluoromethyl)-5-(4-((<i>R</i>)-3-methylmorpholino)-6-((<i>S</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (<b>3</b>). Compound <b>3</b> was prepared according to the literature.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> mp 214.0 °C.</div><div class="NLM_p">(<i>R</i>)-4-(Difluoromethyl)-5-(4-(3,3-dimethylmorpholino)-6-(3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (<b>4</b>) was prepared according to general procedure 1 from intermediate <b>28</b> (189 mg, 0.58 mmol, 1.0 equiv) and boronate <b>48</b> (188 mg, 0.58 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>4</b> as a colorless solid (178 mg, 0.41 mmol, 71%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.02 (s, 1H), 7.68 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.3 Hz, 1H), 6.84 (s, 1H), 4.94 (br s, 2H), 4.71–4.64 (m, 1H), 4.39–4.32 (m, 1H), 3.99 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.8 Hz, 1H), 3.94–3.87 (d, <i>J</i><sub>H,H</sub> = 3.2 Hz, 4H), 3.79 (dt, <i>J</i><sub>H,H</sub> = 11.4, 1.0 Hz, 1H), 3.69 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.2 Hz, 1H), 3.54 (ddd, <i>J</i><sub>H,H</sub> = 12.3, 11.4, 3.0 Hz, 1H), 3.49 (s, 2H), 3.29 (ddd, <i>J</i><sub>H,H</sub> = 13.7, 12.4, 3.8 Hz, 1H), 1.56 (d, <i>J</i><sub>H,H</sub> = 2.6 Hz, 6H), 1.33 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −116.11 (s, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 168.65 (s, 1C), 166.78 (s, 1C), 164.00 (s, 1C), 160.02 (s, 1C), 152.29 (s, 1C), 143.46 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.1 Hz, 1C), 121.68 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.9 Hz, 1C), 111.31 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.6 Hz, 1C), 103.98 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.9 Hz, 1C), 76.68 (s, 1C), 71.05 (s, 1C), 66.98 (s, 1C), 66.96 (s, 1C), 55.42 (s, 1C), 46.61 (s, 1C), 41.19 (s, 1C), 38.76 (s, 1C), 23.05 (s, 2C), 14.26 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>28</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 436.2267; found, 436.2272. HPLC: <i>t</i><sub>R</sub> = 8.77 min (98.7% purity). mp 152.4 °C.</div><div class="NLM_p">(<i>R</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-(8-oxa-5-azaspiro[3.5]nonan-5-yl)-1,3,5-triazin-2-yl)pyridin-2-amine (<b>5</b>) was prepared according to general procedure 1 from intermediate <b>29</b> (249 mg, 0.73 mmol, 1.0 equiv) and boronate <b>48</b> (239 mg, 0.73 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>5</b> as a colorless solid (163 mg, 0.36 mmol, 50%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.99 (s, 1H), 7.67 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.3 Hz, 1H), 6.83 (s, 1H), 5.00 (br s, 2H), 4.75–4.56 (m, 1H), 4.40–4.25 (m, 1H), 3.97 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.7 Hz, 1H), 3.91–3.88 (m, 2H), 3.80–3.74 (m, 3H), 3.68 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.2 Hz, 1H), 3.59 (t, <i>J</i><sub>H,H</sub> = 4.7 Hz, 2H), 3.53 (td, <i>J</i><sub>H,H</sub> = 11.9, 3.0 Hz, 2H), 2.61–2.52 (m, 2H), 2.40–2.32 (m, 2H), 1.85–1.77 (m, 1H), 1.71 (tdd, <i>J</i><sub>H,H</sub> = 10.8, 8.2, 2.5 Hz, 1H), 1.31 (d, <i>J</i><sub>H,H</sub> = 6.9 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −115.31–(−116.65) (m, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.12 (s, 1C), 164.27 (s, 1C), 160.12 (s, 1C), 152.32 (s, 1C), 149.13 (s, 1C), 143.47 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.2 Hz, 1C), 121.45 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.9 Hz, 1C), 111.31 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.6 Hz, 1C), 103.97 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.9 Hz, 1C), 71.03 (s, 1C), 70.73 (s, 1C), 66.96 (s, 1C), 66.14 (s, 1C), 60.59 (s, 1C), 46.50 (s, 1C), 43.43 (s, 1C), 38.66 (s, 1C), 31.26 (s, 1C), 31.18 (s, 1C), 14.97 (s, 1C), 14.25 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>21</sub>H<sub>28</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 448.2267; found, 448.2273. HPLC: <i>t</i><sub>R</sub> = 9.00 min (99.6% purity). mp 87.6 °C.</div><div class="NLM_p">4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>R</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (<b>6</b>) was prepared according to general procedure 1 from intermediate <b>30</b> (267 mg, 0.82 mmol, 1.0 equiv) and boronate <b>48</b> (265 mg, 0.82 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>6</b> as a colorless solid (253 mg, 0.58 mmol, 71%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.08 (s, 1H), 7.78 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.4 Hz, 1H), 6.84 (s, 1H), 5.03 (br s, 2H), 4.77–4.70 (m, 1H), 4.45–4.36 (m, 3H), 4.25 (dd, <i>J</i><sub>H,H</sub> = 11.2, 3.4 Hz, 2H), 3.98 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.7 Hz, 1H), 3.80–3.74 (m, 3H), 3.68 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.2 Hz, 1H), 3.54 (td, <i>J</i><sub>H,H</sub> = 12.0, 3.0 Hz, 1H), 3.27 (td, <i>J</i><sub>H,H</sub> = 12.8, 3.8 Hz, 1H), 1.46 (d, <i>J</i><sub>H,H</sub> = 6.7 Hz, 6H), 1.34 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −115.28–(−118.15) (m, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 168.92 (s, 1C), 164.16 (s, 1C), 163.97 (s, 1C), 160.14 (s, 1C), 152.42 (s, 1C), 143.57 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.1 Hz, 1C), 121.42 (s, 1C), 111.37 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.6 Hz, 1C), 103.95 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.0 Hz, 1C), 71.11 (s, 1C), 67.68 (s, 2C), 67.02 (s, 1C), 47.95 (s, 2C), 46.42 (s, 1C), 38.47 (s, 1C), 19.66 (s, 2C), 14.26 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>28</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 436.2267; found, 436.2273. HPLC: <i>t</i><sub>R</sub> = 8.73 min (99.4% purity). mp 102.2 °C.</div><div class="NLM_p">4-(Difluoromethyl)-5-(4-((3<i>S</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (<b>7</b>) was prepared according to general procedure 1 from intermediate <b>31</b> (244 mg, 0.75 mmol, 1.0 equiv) and boronate <b>48</b> (243 mg, 0.75 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>7</b> as a colorless solid (213 mg, 0.49 mmol, 65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.09 (s, 1H), 7.78 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.4 Hz, 1H), 6.84 (s, 1H), 5.02 (br s, 2H), 4.77–4.70 (m, 1H), 4.44–4.36 (m, 3H), 4.25 (dd, <i>J</i><sub>H,H</sub> = 11.2, 3.4 Hz, 2H), 3.99 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.7 Hz, 1H), 3.80–3.74 (m, 3H), 3.69 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.3 Hz, 1H), 3.57–3.48 (m, 1H), 3.29 (td, <i>J</i><sub>H,H</sub> = 13.0, 3.8 Hz, 1H), 1.45 (d, <i>J</i><sub>H,H</sub> = 6.7 Hz, 6H), 1.33 (d, <i>J</i><sub>H,H</sub> = 6.9 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −116.24–(−116.51) (m, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 168.91 (s, 1C), 164.19 (s, 1C), 163.99 (s, 1C), 160.15 (s, 1C), 152.45 (s, 1C), 143.58 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.1 Hz, 1C), 121.40 (s, 1C), 111.36 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.6 Hz, 1C), 103.94 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.0 Hz, 1C), 71.05 (s, 1C), 67.68 (s, 2C), 67.03 (s, 1C), 47.94 (s, 2C), 38.57 (s, 1C), 26.91 (s, 1C), 19.64 (s, 2C), 14.31 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>28</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 436.2267; found, 436.2271. HPLC: <i>t</i><sub>R</sub> = 8.89 min (97.5% purity). mp 168.7 °C.</div><div class="NLM_p">4-(Difluoromethyl)-5-(4-((3<i>R</i>,5<i>S</i>)-3,5-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (PQR626, <b>8</b>) was prepared according to general procedure 1 from intermediate <b>32</b> (149 mg, 0.46 mmol, 1.0 equiv) and boronate <b>48</b> (148 mg, 0.46 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>8</b> as a colorless solid (149 mg, 0.34 mmol, 74%; mp 100 °C). To generate the HCl salt, compound <b>8</b> was dissolved in <i>tert</i>-butyl methyl ether (30 equiv) and a 5 N solution of HCl in isopropanol (1.5 equiv) was added dropwise. The suspension was stirred at r.t. for 1 h. The solid was collected <i>via</i> Buchner filtration and dried in high vacuum. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.01 (br s, 2H), 8.82 (s, 1H), 7.83 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 54.3 Hz, 1H), 7.41 (s, 1H), 4.75–4.58 (m, 1H), 4.56–4.44 (m, 2H), 4.39–4.27 (m, 1H), 3.92 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.6 Hz, 1H), 3.76 (d, <i>J</i><sub>H,H</sub> = 11.5 Hz, 2H), 3.71 (d, <i>J</i><sub>H,H</sub> = 11.4 Hz, 1H), 3.59–3.51 (m, 3H), 3.44–3.36 (m, 1H), 3.18 (td, <i>J</i><sub>H,H</sub> = 13.2, 3.8 Hz, 1H), 1.27 (d, <i>J</i><sub>H,H</sub> = 6.9 Hz, 6H), 1.22 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, DMSO-<i>d</i><sub>6</sub>): δ −116.14–(−119.51) (m, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 167.00 (s, 1C), 164.01 (s, 1C), 163.63 (s, 1C), 155.53 (s, 1C), 146.95 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.0 Hz, 1C), 140.68 (s, 1C), 120.00 (s, 1C), 111.15 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 239.3 Hz, 1C), 110.80 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 9.7 Hz, 1C), 70.89 (s, 1C), 70.61 (s, 1C), 66.81 (s, 1C), 66.56 (s, 1C), 49.17 (s, 1C), 46.42 (s, 1C), 45.75 (s, 1C), 38.70 (s, 1C), 27.25 (s, 1C), 19.19 (s, 1C), 14.52 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>28</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 436.2267; found, 436.2274. HPLC: <i>t</i><sub>R</sub> = 8.96 min (>99.9% purity). mp 192.2 °C.</div><div class="NLM_p">4-(Difluoromethyl)-5-(4-((2<i>S</i>,6<i>R</i>)-2,6-dimethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (<b>9</b>) was prepared according to general procedure 1 from intermediate <b>33</b> (150 mg, 0.46 mmol, 1.0 equiv) and boronate <b>48</b> (149 mg, 0.46 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>9</b> as a colorless solid (142 mg, 0.33 mmol, 71%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.03 (s, 1H), 7.67 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.3 Hz, 1H), 6.84 (s, 1H), 4.98 (br s, 2H), 4.78–4.49 (m, 3H), 4.40 (d, <i>J</i><sub>H,H</sub> = 13.6 Hz, 1H), 3.99 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.7 Hz, 1H), 3.78 (d, <i>J</i><sub>H,H</sub> = 11.2 Hz, 1H), 3.68 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.3 Hz, 1H), 3.62 (dddd, <i>J</i><sub>H,H</sub> = 10.6, 6.3, 2.6, 1.7 Hz, 1H), 3.65–3.58 (m, 2H), 3.28 (td, <i>J</i><sub>H,H</sub> = 12.7, 3.8 Hz, 1H), 2.60 (t, <i>J</i><sub>H,H</sub> = 11.5 Hz, 2H), 1.33 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H), 1.26 (d, <i>J</i><sub>H,H</sub> = 6.2 Hz, 6H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −115.97–(−116.64) (m, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.18 (s, 1C), 164.38 (s, 2C), 160.13 (s, 1C), 152.30 (s, 1C), 143.51 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.2 Hz, 1C), 121.51 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.9 Hz, 1C), 111.34 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.6 Hz, 1C), 103.99 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.8 Hz, 1C), 71.74 (br s, 2C), 71.07 (s, 1C), 67.01 (s, 1C), 48.69 (br s, 2C), 46.41 (s, 1C), 38.57 (s, 1C), 18.90 (s, 1C), 14.27 (s, 1C), 14.20 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>28</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 436.2267; found, 436.2273. HPLC: <i>t</i><sub>R</sub> = 8.79 min (>99.9% purity). mp 106.4 °C.</div><div class="NLM_p">4-(Difluoromethyl)-5-(4-((<i>S</i>)-3-ethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (<b>10</b>) was prepared according to general procedure 1 from intermediate <b>34</b> (309 mg, 0.95 mmol, 1.0 equiv) and boronate <b>48</b> (307 mg, 0.95 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>10</b> as a colorless solid (192 mg, 0.44 mmol, 47%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.04 (s, 1H), 7.70 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.3 Hz, 1H), 6.83 (s, 1H), 5.00 (br s, 2H), 4.78–4.68 (m, 1H), 4.59–4.34 (m, 3H), 4.01–3.87 (m, 3H), 3.78 (d, <i>J</i><sub>H,H</sub> = 11.4 Hz, 1H), 3.69 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.3 Hz, 1H), 3.61 (dd, <i>J</i><sub>H,H</sub> = 11.6, 3.2 Hz, 1H), 3.56–3.48 (m, 2H), 3.32–3.18 (m, 2H), 1.88–1.77 (m, 2H), 1.32 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H), 0.94 (t, <i>J</i><sub>H,H</sub> = 7.5 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −116.26 (s, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.13 (s, 1C), 164.68 (s, 1C), 164.36 (s, 1C), 160.14 (s, 1C), 152.34 (s, 1C), 143.53 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.1 Hz, 1C), 121.49 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 5.0 Hz, 1C), 111.33 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.6 Hz, 1C), 103.97 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.8 Hz, 1C), 71.06 (s, 1C), 68.44 (br s, 1C), 67.00 (s, 1C), 52.09 (br s, 1C), 46.38 (s, 1C), 38.91 (br s, 1C), 38.57 (s, 1C), 24.87 (s, 1C), 21.53 (s, 1C), 14.23 (s, 1C), 10.86 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>28</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 436.2267; found, 436.2271. HPLC: <i>t</i><sub>R</sub> = 8.82 min (>99.9% purity). mp 101.3 °C.</div><div class="NLM_p">4-(Difluoromethyl)-5-(4-((<i>S</i>)-3-ethylmorpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (<b>11</b>) was prepared according to general procedure 1 from intermediate <b>35</b> (345 mg, 1.06 mmol, 1.0 equiv) and boronate <b>48</b> (343 mg, 1.06 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>11</b> as a colorless solid (241 mg, 0.55 mmol, 52%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.04 (s, 1H), 7.70 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.3 Hz, 1H), 6.83 (s, 1H), 5.05 (br s, 2H), 4.80–4.67 (m, 1H), 4.61–4.36 (m, 3H), 3.96 (ddd, <i>J</i><sub>H,H</sub> = 14.5, 11.4, 3.6 Hz, 2H), 3.90 (d, <i>J</i><sub>H,H</sub> = 11.6 Hz, 1H), 3.78 (d, <i>J</i><sub>H,H</sub> = 11.4 Hz, 1H), 3.69 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.3 Hz, 1H), 3.61 (dd, <i>J</i><sub>H,H</sub> = 11.6, 3.2 Hz, 1H), 3.53 (ddt, <i>J</i><sub>H,H</sub> = 15.2, 12.2, 3.2 Hz, 2H), 3.32–3.19 (m, 2H), 1.93–1.76 (m, 2H), 1.32 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H), 0.94 (t, <i>J</i><sub>H,H</sub> = 7.4 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −116.25 (s, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.14 (s, 1C), 164.68 (s, 1C), 164.36 (s, 1C), 160.19 (s, 1C), 152.33 (s, 1C), 143.52 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.2 Hz, 1C), 121.44 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.9 Hz, 1C), 111.34 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.5 Hz, 1C), 103.98 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.8 Hz, 1C), 71.06 (s, 1C), 68.45 (br s, 1C), 67.00 (s, 1C), 52.09 (s, 1C), 46.38 (s, 1C), 38.91 (s, 1C), 38.58 (s, 1C), 24.87 (s, 1C), 21.53 (s, 1C), 14.23 (s, 1C), 10.87 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>28</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 436.2267; found, 436.2275. HPLC: <i>t</i><sub>R</sub> = 8.69 min (99.7% purity). mp 93.5 °C.</div><div class="NLM_p">((<i>R</i>)-4-(4-(6-Amino-4-(difluoromethyl)pyridin-3-yl)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)morpholin-3-yl)methanol (<b>12</b>) was prepared according to general procedure 1 from intermediate <b>36</b> (170 mg, 0.52 mmol, 1.0 equiv) and boronate <b>48</b> (168 mg, 0.52 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>12</b> as a colorless solid (105 mg, 0.24 mmol, 44%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.02 (s, 1H), 7.66 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.1 Hz, 1H), 6.83 (s, 1H), 4.96 (br s, 2H), 4.79–4.66 (m, 2H), 4.59–4.32 (m, 2H), 4.07 (d, <i>J</i><sub>H,H</sub> = 11.9 Hz, 1H), 4.03–3.92 (m, 4H), 3.77 (d, <i>J</i><sub>H,H</sub> = 11.4 Hz, 1H), 3.70–3.62 (m, <i>J</i><sub>H,H</sub> = 11.9, 6.2, 3.4 Hz, 2H), 3.60–3.48 (m, 2H), 3.35–3.24 (m, 2H), 2.57 (br s, 1H), 1.32 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −114.79–(−118.05) (s, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.21 (s, 1C), 165.47 (s, 1C), 164.20 (s, 1C), 160.16 (s, 1C), 152.33 (s, 1C), 143.54 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.1 Hz, 1C), 121.18 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.9 Hz, 1C), 111.33 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.6 Hz, 1C), 104.08 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.1 Hz, 1C), 71.04 (s, 1C), 66.93–66.88 (m, 1C), 66.68 (s, 1C), 60.96 (s, 1C), 51.87 (s, 1C), 46.52 (s, 1C), 39.56 (s, 1C), 38.60 (s, 1C), 30.94 (s, 1C), 14.34 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>26</sub>F<sub>2</sub>N<sub>7</sub>O<sub>3</sub>, 438.2060; found, 438.2066. HPLC: <i>t</i><sub>R</sub> = 6.72 min (97.7% purity). mp 118.9 °C.</div><div class="NLM_p">((<i>S</i>)-4-(4-(6-Amino-4-(difluoromethyl)pyridin-3-yl)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)morpholin-3-yl)methanol (<b>13</b>) was prepared according to general procedure 1 from intermediate <b>37</b> (253 mg, 0.77 mmol, 1.0 equiv) and boronate <b>48</b> (250 mg, 0.77 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>13</b> as a colorless solid (162 mg, 0.37 mmol, 48%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.00 (s, 1H), 7.66 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.2 Hz, 1H), 6.81 (s, 1H), 5.13 (br s, 2H), 4.77–4.68 (m, 2H), 4.57–4.34 (m, 2H), 4.10 (d, <i>J</i><sub>H,H</sub> = 12.5 Hz, 1H), 4.01–3.92 (m, 4H), 3.76 (d, <i>J</i><sub>H,H</sub> = 11.4 Hz, 1H), 3.69–3.62 (m, 2H), 3.60–3.48 (m, 2H), 3.34–3.22 (m, 2H), 3.05 (br s, 1H), 1.32 (d, <i>J</i><sub>H,H</sub> = 6.9 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −113.80–(−117.87) (s, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.20 (s, 1C), 165.37 (s, 1C), 164.22 (s, 1C), 160.27 (s, 1C), 152.22 (s, 1C), 143.53 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.1 Hz, 1C), 121.04 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.8 Hz, 1C), 111.34 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.7 Hz, 1C), 104.15 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.0 Hz, 1C), 70.98 (s, 1C), 66.95–66.85 (m, 1C), 66.53(s, 1C), 60.43 (s, 1C), 51.85 (s, 1C), 46.47 (s, 1C), 39.58 (s, 1C), 38.61 (s, 1C), 21.05 (s, 1C), 14.30 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>26</sub>F<sub>2</sub>N<sub>7</sub>O<sub>3</sub>, 438.2060; found, 438.2068. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 5.66 min (98.1% purity). mp 100.5 °C.</div><div class="NLM_p">4-(Difluoromethyl)-5-(4-((<i>R</i>)-3-(methoxymethyl)morpholino)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)pyridin-2-amine (<b>14</b>) was prepared according to general procedure 1 from intermediate <b>38</b> (309 mg, 0.90 mmol, 1.0 equiv) and boronate <b>48</b> (293 mg, 0.90 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>14</b> as a colorless solid (275 mg, 0.61 mmol, 68%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.03 (s, 1H), 7.71 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.1 Hz, 1H), 6.83 (s, 1H), 4.93 (br s, 2H), 4.81–4.69 (m, 2H), 4.56–4.36 (m, 2H), 4.13–4.08 (m, 1H), 4.00–3.94 (m, 2H), 3.80–3.73 (m, 2H), 3.67 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.2 Hz, 1H), 3.62–3.49 (m, 4H), 3.40 (s, 3H), 3.31–3.14 (m, 2H), 1.33 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −115.36–(−118.20) (m, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.28 (s, 1C), 164.76 (s, 1C), 164.36 (s, 1C), 160.11 (s, 1C), 152.35 (s, 1C), 144.77 (s, 1C), 121.44 (s, 1C), 111.40 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.7 Hz, 1C), 103.98 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.0 Hz, 1C), 71.06 (s, 1C), 68.75–68.11 (m, 1C), 66.99 (s, 1C), 66.75 (s, 1C), 66.44–66.08 (m, 1C), 59.06 (s, 1C), 49.76–49.25 (m, 1C), 46.44 (s, 1C), 39.99–39.51 (m, 1C), 38.56 (s, 1C), 14.30 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>28</sub>F<sub>2</sub>N<sub>7</sub>O<sub>3</sub>, 452.2216; found, 452.2222. HPLC: <i>t</i><sub>R</sub> = 7.91 min (97.2% purity). mp 101.4 °C.</div><div class="NLM_p">5-(4-(3-Oxa-6-azabicyclo[3.1.1]heptan-6-yl)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-4-(difluoromethyl)pyridin-2-amine (<b>15</b>) was prepared according to general procedure 1 from intermediate <b>39</b> (228 mg, 0.73 mmol, 1.0 equiv) and boronate <b>48</b> (238 mg, 0.73 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>15</b> as a colorless solid (159 mg, 0.38 mmol, 52%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.06 (s, 1H), 7.74 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.4 Hz, 1H), 6.82 (s, 1H), 5.06 (br s, 2H), 4.77–4.68 (m, 1H), 4.50–4.30 (m, 5H), 4.00–3.94 (m, 1H), 3.84–3.74 (m, 3H), 3.67 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.3 Hz, 1H), 3.52 (td, <i>J</i><sub>H,H</sub> = 11.9, 3.0 Hz, 1H), 3.32–3.21 (m, 1H), 2.76 (q, <i>J</i><sub>H,H</sub> = 6.8 Hz, 1H), 1.94 (d, <i>J</i><sub>H,H</sub> = 8.2 Hz, 1H), 1.32 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −115.05–(−118.48) (m, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.30 (s, 1C), 166.12 (s, 1C), 164.18 (s, 1C), 160.28 (s, 1C), 152.40 (s, 1C), 143.67 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.1 Hz, 1C), 120.89 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.8 Hz, 1C), 111.31 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.7 Hz, 1C), 104.02 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.1 Hz, 1C), 71.01 (s, 1C), 66.96 (s, 1C), 65.78 (s, 1C), 65.21 (s, 1C), 61.85 (s, 1C), 61.47 (s, 1C), 46.31 (s, 1C), 38.47 (s, 1C), 27.76 (s, 1C), 14.34 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>24</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 420.1954; found, 420.1962. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 6.26 min (98.2% purity). mp 186.2 °C.</div><div class="NLM_p">5-(4-(6-Oxa-3-azabicyclo[3.1.1]heptan-3-yl)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-4-(difluoromethyl)pyridin-2-amine (<b>16</b>) was prepared according to general procedure 1 from intermediate <b>40</b> (230 mg, 0.74 mmol, 1.0 equiv) and boronate <b>48</b> (240 mg, 0.74 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>16</b> as a colorless solid (113 mg, 0.27 mmol, 36%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.11 (s, 1H), 7.82 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.4 Hz, 1H), 6.84 (s, 1H), 4.98 (br s, 2H), 4.83–4.69 (m, 3H), 4.46 (d, <i>J</i><sub>H,H</sub> = 13.7 Hz, 1H), 4.05 (d, <i>J</i><sub>H,H</sub> = 13.3 Hz, 1H), 4.01–3.93 (m, 2H), 3.87 (dt, <i>J</i><sub>H,H</sub> = 13.2, 2.9 Hz, 1H), 3.82–3.75 (m, 2H), 3.69 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.3 Hz, 1H), 3.54 (tt, <i>J</i><sub>H,H</sub> = 12.0, 3.2 Hz, 1H), 3.34–3.24 (m, 2H), 1.93 (dd, <i>J</i><sub>H,H</sub> = 8.9, 4.7 Hz, 1H), 1.34 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −115.62–(−116.97) (m, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 168.84 (s, 1C), 165.35 (s, 1C), 164.11–164.09 (m, 1C), 160.14 (s, 1C), 152.42 (s, 1C), 143.67 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.1 Hz, 1C), 121.38 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.8 Hz, 1C), 111.41 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.6 Hz, 1C), 103.99 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.1 Hz, 1C), 78.14 (s, 1C), 77.98 (s, 1C), 71.09 (s, 1C), 67.04 (s, 1C), 48.65 (s, 1C), 48.59 (s, 1C), 46.39 (s, 1C), 38.53 (s, 1C), 32.30–32.28 (m, 1C), 14.25 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>24</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 420.1954; found, 420.1956. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 6.17 min (98.9% purity). mp 205.3 °C.</div><div class="NLM_p">5-(4-((1<i>R</i>,4<i>R</i>)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-4-(difluoromethyl)pyridin-2-amine (<b>17</b>) was prepared according to general procedure 1 from intermediate <b>41</b> (257 mg, 0.83 mmol, 1.0 equiv) and boronate <b>48</b> (209 mg, 0.83 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>17</b> as a colorless solid (182 mg, 0.43 mmol, 52%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.07/9.04 (2 × s, 1H), 7.76 (2 × t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.4 Hz, 1H), 6.83 (s, 1H), 5.10–5.00 (m, 1H), 4.98 (br s, 2H), 4.80–4.73 (m, 1H), 4.72–4.67 (m, 1H), 4.43 (d, <i>J</i><sub>H,H</sub> = 12.2 Hz, 1H), 3.97 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.6 Hz, 1H), 3.92–3.86 (m, 2H), 3.77 (d, <i>J</i><sub>H,H</sub> = 11.5 Hz, 1H), 3.71–3.48 (m, 4H), 3.31–3.22 (m, 1H), 1.99–1.90 (m, 2H), 1.33 (2 × d, <i>J</i><sub>H,H</sub> = 6.9 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −116.10–(−116.89) (m, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.25/168.83 (2 × s, 1C), 164.29/164.06 (2 × s, 1C), 163.37/163.30 (2 × s, 1C), 160.20/160.16 (2 × s, 1C), 152.36/152.28 (2 × s, 1C), 143.94–143.31 (m, 1C), 121.39–121.16 (2 × s, 1C), 111.38 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.6 Hz, 1C), 104.00 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.0 Hz, 1C), 76.42/76.34 (2 × s, 1C), 74.06/73.80 (2 × s, 1C), 71.07 (s, 1C), 67.02 (s, 1C), 56.63/56.26 (2 × s, 1C), 55.06/54.98 (2 × s, 1C), 46.33 (s, 1C), 38.47 (s, 1C), 36.67/36.47 (2 × s, 1C), 14.28 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>24</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 420.1954; found, 420.1960. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 6.13 min (99.0% purity). mp 122.1 °C.</div><div class="NLM_p">5-(4-((1<i>S</i>,4<i>S</i>)-2-Oxa-5-azabicyclo[2.2.1]heptan-5-yl)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-4-(difluoromethyl)pyridin-2-amine (<b>18</b>) was prepared according to general procedure 1 from intermediate <b>42</b> (217 mg, 0.70 mmol, 1.0 equiv) and boronate <b>48</b> (227 mg, 0.70 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>18</b> as a colorless solid (129 mg, 0.31 mmol, 44%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.06/9.04 (2 × s, 1H), 7.76 (2 × t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.4 Hz, 1H), 6.83 (2 × s, 1H), 5.10–5.02 (m, 3H), 4.78–4.69 (m, 1H), 4.70 (d, <i>J</i><sub>H,H</sub> = 5.5 Hz, 1H), 4.42 (d, <i>J</i><sub>H,H</sub> = 13.4 Hz, 1H), 3.97 (dt, <i>J</i><sub>H,H</sub> = 11.4, 3.8 Hz, 1H), 3.89–3.86 (m, 2H), 3.77 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.1 Hz, 1H), 3.71–3.48 (m, 4H), 3.27 (td, <i>J</i><sub>H,H</sub> = 13.0, 3.8 Hz, 1H), 2.00–1.89 (m, 2H), 1.32 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −115.72–(−116.88) (m, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.22/168.83 (2 × s, 1C), 164.30/164.04 (2 × s, 1C), 163.40/163.25 (2 × s, 1C), 160.16/160.14 (2 × s, 1C), 152.36/152.29 (2 × s, 1C), 143.54 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.1 Hz, 1C), 121.40 (s, 1C), 111.38 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.6 Hz, 1C), 104.01 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.0 Hz, 1C), 76.43/76.34 (s × 2, 1C), 74.05/73.86 (s × 2, 1C), 71.08 (s, 1C), 67.02 (s, 1C), 56.65/56.22 (2 × s, 1C), 55.01 (s, 1C), 46.30 (s, 1C), 38.52/38.47 (2 × s, 1C), 36.68/36.49 (2 × s, 1C), 14.26 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>24</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 420.1954; found, 420.1960. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 6.12 min (95.5% purity). mp 115.2 °C.</div><div class="NLM_p">5-(4-(3-Oxa-8-azabicyclo[3.2.1]octan-8-yl)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-4-(difluoromethyl)pyridin-2-amine (<b>19</b>) was prepared according to general procedure 1 from intermediate <b>43</b> (200 mg, 0.61 mmol, 1.0 equiv) and boronate <b>48</b> (259 mg, 0.80 mmol, 1.3 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>19</b> as a colorless solid (187 mg, 0.43 mmol, 71%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.00 (s, 1H), 7.71 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.4 Hz, 1H), 6.83 (s, 1H), 5.29 (br s, 2H), 4.77–4.63 (m, 3H), 4.41 (d, <i>J</i><sub>H,H</sub> = 13.7 Hz, 1H), 3.97 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.7 Hz, 1H), 3.81–3.75 (m, 3H), 3.70–3.62 (m, 3H), 3.53 (td, <i>J</i><sub>H,H</sub> = 11.9, 3.0 Hz, 1H), 3.27 (td, <i>J</i><sub>H,H</sub> = 13.0, 3.8 Hz, 1H), 2.11–1.97 (m, 4H), 1.32 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −115.57–(−116.57) (m, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 176.21 (s, 1C), 169.34 (s, 1C), 164.48 (s, 1C), 160.16 (s, 1C), 151.68 (s, 1C), 143.80 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.1 Hz, 1C), 121.22 (s, 1C), 111.31 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.8 Hz, 1C), 104.40 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.1 Hz, 1C), 71.91–71.84 (m, 1C), 71.57 (br s, 1C), 71.07 (s, 1C), 67.01 (s, 1C), 54.93 (br s, 1C), 54.55–54.48 (m, 1C), 46.34 (s, 1C), 38.52 (s, 1C), 26.97 (br s, 1C), 26.83 (br s, 1C), 14.27 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>26</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 434.2111; found, 434.2111. HPLC: <i>t</i><sub>R</sub> = 8.29 min (98.6% purity). mp 106.1 °C.</div><div class="NLM_p">5-(4-(8-Oxa-3-azabicyclo[3.2.1]octan-3-yl)-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-4-(difluoromethyl)pyridin-2-amine (<b>20</b>) was prepared according to general procedure 1 from intermediate <b>44</b> (200 mg, 0.61 mmol, 1.0 equiv) and boronate <b>48</b> (259 mg, 0.80 mmol, 1.3 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>20</b> as a colorless solid (172 mg, 0.40 mmol, 65%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.00 (s, 1H), 7.70 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.3 Hz, 1H), 6.83 (s, 1H), 5.18 (br s, 2H), 4.77–4.68 (m, 1H), 4.48–4.27 (m, 5H), 3.97 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.7 Hz, 1H), 3.77 (d, <i>J</i><sub>H,H</sub> = 11.4 Hz, 1H), 3.68 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.2 Hz, 1H), 3.53 (ddd, <i>J</i><sub>H,H</sub> = 12.3, 11.4, 3.0 Hz, 1H), 3.31–3.14 (m, 3H), 1.95 (dd, <i>J</i><sub>H,H</sub> = 7.8, 3.8 Hz, 2H), 1.81–1.73 (m, 2H), 1.32 (d, <i>J</i> = 6.8 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −115.52–(−117.61) (m, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 168.90 (s, 1C), 165.73 (s, 1C), 164.20 (s, 1C), 160.11 (s, 1C), 151.86 (s, 1C), 143.72 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.1 Hz, 1C), 121.36 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.7 Hz, 1C), 111.30 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.8 Hz, 1C), 104.28 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.1 Hz, 1C), 73.89 (br s, 2C), 71.07 (s, 1C), 67.00 (s, 1C), 49.32 (s, 1C), 49.08 (s, 1C), 46.38 (s, 1C), 38.54 (s, 1C), 27.70 (s, 1C), 21.54 (s, 1C), 14.20 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>20</sub>H<sub>26</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 434.2111; found, 434.2118. HPLC: <i>t</i><sub>R</sub> = 8.14 min (96.2% purity). mp 124.0 °C.</div><div class="NLM_p">(<i>R</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-(2-oxa-6-azaspiro[3.3]heptan-6-yl)-1,3,5-triazin-2-yl)pyridin-2-amine (<b>21</b>) was prepared according to general procedure 1 from intermediate <b>45</b> (212 mg, 0.68 mmol, 1.0 equiv) and boronate <b>48</b> (222 mg, 0.68 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>21</b> as a colorless solid (151 mg, 0.36 mmol, 53%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.04 (s, 1H), 7.78 (t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.4 Hz, 1H), 6.82 (s, 1H), 5.04 (br s, 2H), 4.84 (s, 4H), 4.79–4.72 (m, 1H), 4.44–4.38 (m, 1H), 4.29 (s, 4H), 3.97 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.7 Hz, 1H), 3.76 (d, <i>J</i><sub>H,H</sub> = 11.4 Hz, 1H), 3.66 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.2 Hz, 1H), 3.51 (td, <i>J</i><sub>H,H</sub> = 11.7, 3.0 Hz, 1H), 3.25 (td, <i>J</i><sub>H,H</sub> = 13.0, 3.8 Hz, 1H), 1.31 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −113.75–(−116.94) (m, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.13 (s, 1C), 165.33 (s, 1C), 164.08 (s, 1C), 160.26 (s, 1C), 152.33 (s, 1C), 143.69 (t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.1 Hz, 1C), 120.96 (s, 1C), 111.38 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.7 Hz, 1C), 104.02 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 8.1 Hz, 1C), 81.05 (s, 2C), 71.02 (s, 1C), 66.98 (s, 1C), 58.89 (s, 2C), 46.29 (s, 1C), 38.81 (s, 1C), 38.46 (s, 1C), 14.27 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>24</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 420.1954; found, 420.1957. HPLC (ACN with 0.1% TFA): <i>t</i><sub>R</sub> = 5.89 min (97.8% purity). mp 174.9 °C.</div><div class="NLM_p">(<i>R</i>)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-(1,4-oxazepan-4-yl)-1,3,5-triazin-2-yl)pyridin-2-amine (<b>22</b>) was prepared according to general procedure 1 from intermediate <b>46</b> (252 mg, 0.81 mmol, 1.0 equiv) and boronate <b>48</b> (262 mg, 0.81 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>22</b> as a colorless solid (145 mg, 0.34 mmol, 43%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 9.08/9.05 (2 × s, 1H), 7.76/7.70 (2 × t, <sup>1</sup><i>J</i><sub>H,F</sub> = 55.4 Hz, 1H), 6.83 (s, 1H), 4.99 (br s, 2H), 4.78–4.69 (m, 1H), 4.45–4.36 (m, 1H), 4.01–3.66 (m, 11H), 3.58–3.49 (m, 1H), 3.32–3.22 (m, 1H), 2.04–1.96 (m, 2H), 1.32 (d, <i>J</i><sub>H,H</sub> = 6.1 Hz, 3H). <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>): δ −115.59–(−117.25) (m, 2F). <sup>13</sup>C{<sup>1</sup>H} NMR (101 MHz, CDCl<sub>3</sub>): δ 169.11/168.99 (2 × s, 1C), 164.63 (s, 1C), 164.43/164.32 (2 × s, 1C), 160.11 (s, 1C), 152.39/152.34 (2 × s, 1C), 143.58/143.52 (2 × t, <sup>2</sup><i>J</i><sub>C,F</sub> = 22.2 Hz, 1C), 121.51 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 4.8 Hz, 1C), 111.39 (t, <sup>1</sup><i>J</i><sub>C,F</sub> = 238.8 Hz, 1C), 103.94 (t, <sup>3</sup><i>J</i><sub>C,F</sub> = 7.9 Hz, 1C), 71.08 (s, 1C), 70.90 (s, 1C), 70.14–70.06 (m, 1C), 67.02 (s, 1C), 49.51/49.21 (2 × s, 1C), 46.35 (s, 1C), 45.27/45.25 (2 × s, 1C), 38.52 (s, 1C), 29.54/28.93 (2 × s, 1C), 14.22 (s, 1C). HRMS (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>19</sub>H<sub>26</sub>F<sub>2</sub>N<sub>7</sub>O<sub>2</sub>, 422.2111; found, 422.2117. HPLC: <i>t</i><sub>R</sub> = 8.06 min (99.2% purity). mp 157.5 °C.</div><div class="NLM_p">4-(4,6-Dichloro-1,3,5-triazin-2-yl)morpholine (<b>23</b>). Compound <b>23</b> was prepared according to the literature.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div><div class="NLM_p">(<i>R</i>)-4-(4-Chloro-6-morpholino-1,3,5-triazin-2-yl)-3-methylmorpholine (<b>24</b>). Compound <b>24</b> was prepared according to the literature.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">(3<i>R</i>,3′<i>R</i>)-4,4′-(6-Chloro-1,3,5-triazine-2,4-diyl)bis(3-methylmorpholine) (<b>25</b>). Compound <b>25</b> was prepared according to the literature.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><div class="NLM_p">(<i>R</i>)-4-(4,6-Dichloro-1,3,5-triazin-2-yl)-3-methylmorpholine (<b>26</b>). Compound <b>26</b> was prepared according to the literature.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p">(<i>S</i>)-4-(4-Chloro-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-3-methylmorpholine (27). Compound <b>27</b> was prepared according to the literature.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a></div><div class="NLM_p">(<i>R</i>)-4-(4-Chloro-6-(3-methylmorpholino)-1,3,5-triazin-2-yl)-3,3-dimethylmorpholine (<b>28</b>). Compound <b>28</b> was prepared according to general procedure 2 from 3,3-dimethylmorpholine hydrochloride (192 mg, 1.27 mmol, 1.05 equiv) and compound <b>26</b> (300 mg, 1.20 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>28</b> as a colorless solid (189 mg, 0.58 mmol, 48%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.53–4.45 (m, 1H), 4.15 (dd, <i>J</i><sub>H,H</sub> = 13.8, 2.7 Hz, 1H), 3.93–3.86 (m, 1H), 3.80–3.73 (m, 4H), 3.73–3.65 (m, 1H), 3.57–3.52 (m, 1H), 3.46–3.42 (m, 2H), 3.44–3.34 (m, 1H), 3.23–3.13 (m, 1H), 1.44 (s, 6H), 1.21 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). MALDI-MS: <i>m</i>/<i>z</i> 328.896 [M + H]<sup>+</sup>.</div><div class="NLM_p">(<i>R</i>)-5-(4-Chloro-6-(3-methylmorpholino)-1,3,5-triazin-2-yl)-8-oxa-5-azaspiro[3.5]nonane (29). Compound <b>29</b> was prepared according to general procedure 2 from 8-oxa-5-azaspiro[3.5]nonane (161 mg, 1.27 mmol, 1.05 equiv) and compound <b>26</b> (300 mg, 1.20 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>29</b> as a colorless solid (249 mg, 0.73 mmol, 61%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.454–4.35 (m, 1H), 4.17–4.07 (m, 1H), 3.87 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.7 Hz, 1H), 3.73–3.61 (m, 5H), 3.56–3.45 (m, 3H), 3.41–3.35 (m, 1H), 3.19–3.10 (m, 1H), 2.49–2.40 (m, 2H), 2.25–2.16 (m, 2H), 1.75–1.65 (m, 2H), 1.19 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). MALDI-MS: <i>m</i>/<i>z</i> 340.577 [M + H]<sup>+</sup>.</div><div class="NLM_p">(3<i>R</i>,5<i>R</i>)-4-(4-Chloro-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-3,5-dimethylmorpholine (<b>30</b>). Compound <b>30</b> was prepared according to general procedure 3 from (3<i>R</i>,5<i>R</i>)-3,5-dimethylmorpholine (193 mg, 1.27 mmol, 1.05 equiv) and compound <b>26</b> (300 mg, 1.20 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>30</b> as a colorless solid (267 mg, 0.81 mmol, 68%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.56–4.49 (m, 1H), 4.27–4.17 (m, 3H), 4.09 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.3 Hz, 2H), 3.88 (dd, <i>J</i><sub>H,H</sub> = 11.6, 3.6 Hz, 1H), 3.72–3.62 (m, 3H), 3.53 (d, <i>J</i><sub>H,H</sub> = 11.7 Hz, 1H), 3.38 (td, <i>J</i><sub>H,H</sub> = 12.0, 3.0 Hz, 1H), 3.17 (td, <i>J</i><sub>H,H</sub> = 13.0, 3.9 Hz, 1H), 1.33 (d, <i>J</i><sub>H,H</sub> = 6.7 Hz, 6H), 1.21 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). MALDI-MS: <i>m</i>/<i>z</i> 328.675 [M + H]<sup>+</sup>.</div><div class="NLM_p">(3<i>S</i>,5<i>S</i>)-4-(4-Chloro-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-3,5-dimethylmorpholine (<b>31</b>). Compound <b>31</b> was prepared according to general procedure 3 from (3<i>S</i>,5<i>S</i>)-3,5-dimethylmorpholine (193 mg, 1.27 mmol, 1.05 equiv) and compound <b>26</b> (300 mg, 1.20 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>31</b> as a colorless solid (244 mg, 0.74 mmol, 62%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.60–4.50 (m, 1H), 4.26–4.13 (m, 3H), 4.09 (dd, <i>J</i><sub>H,H</sub> = 11.4, 3.4 Hz, 2H), 3.89 (d, <i>J</i><sub>H,H</sub> = 11.2 Hz, 1H), 3.73–3.66 (m, 1H), 3.65 (dd, <i>J</i><sub>H,H</sub> = 11.4, 2.2 Hz, 2H), 3.53 (dd, <i>J</i><sub>H,H</sub> = 11.6, 3.3 Hz, 1H), 3.43–3.33 (m, 1H), 3.22–3.12 (m, 1H), 1.33 (d, <i>J</i><sub>H,H</sub> = 6.6 Hz, 6H), 1.21 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). MALDI-MS: <i>m</i>/<i>z</i> 328.692 [M + H]<sup>+</sup>.</div><div class="NLM_p">(3<i>R</i>,5<i>S</i>)-4-(4-Chloro-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-3,5-dimethylmorpholine (<b>32</b>). Compound <b>32</b> was prepared according to general procedure 2 from (<i>R</i>)-3-methylmorpholine (86 mg, 0.85 mmol, 1.05 equiv) and compound <b>47</b> (214 mg, 0.81 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>32</b> as a colorless solid (232 mg, 0.71 mmol, 87%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.57–4.50 (m, 1H), 4.44–4.35 (m, 2H), 4.27–4.12 (m, 1H), 3.88 (dd, <i>J</i><sub>H,H</sub> = 11.6, 3.6 Hz, 1H), 3.76–3.65 (m, 3H), 3.56–3.50 (m, 3H), 3.38 (td, <i>J</i><sub>H,H</sub> = 11.9, 3.0 Hz, 1H), 3.21–3.12 (m, 1H), 1.25 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 6H), 1.21 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). MALDI-MS: <i>m</i>/<i>z</i> 328.828 [M + H]<sup>+</sup>.</div><div class="NLM_p">(2<i>S</i>,6<i>R</i>)-4-(4-Chloro-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-2,6-dimethylmorpholine (<b>33</b>). Compound <b>33</b> was prepared according to general procedure 4 from (2<i>S</i>,6<i>R</i>)-2,6-dimethylmorpholine (145 mg, 1.27 mmol, 1.05 equiv) and compound <b>26</b> (300 mg, 1.20 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>33</b> as a colorless solid (220 mg, 0.67 mmol, 56%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.64–4.48 (m, 1H), 4.47–4.32 (m, 2H), 4.30–4.12 (m, 1H), 3.88 (dd, <i>J</i><sub>H,H</sub> = 11.6, 3.7 Hz, 1H), 3.68 (d, <i>J</i><sub>H,H</sub> = 11.5 Hz, 1H), 3.58–3.46 (m, 3H), 3.41–3.33 (m, 1H), 3.16 (td, <i>J</i><sub>H,H</sub> = 13.1, 3.8 Hz, 1H), 2.60–2.51 (m, 2H), 1.20 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H), 1.13 (d, <i>J</i><sub>H,H</sub> = 6.2 Hz, 6H). MALDI-MS: <i>m</i>/<i>z</i> 328.788 [M + H]<sup>+</sup>.</div><div class="NLM_p">(<i>R</i>)-4-(4-Chloro-6-((<i>R</i>)-3-ethylmorpholino)-1,3,5-triazin-2-yl)-3-methylmorpholine (<b>34</b>). Compound <b>34</b> was prepared according to general procedure 2 from (<i>R</i>)-3-ethylmorpholine hydrochloride (193 mg, 1.27 mmol, 1.05 equiv) and compound <b>26</b> (300 mg, 1.20 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>34</b> as a colorless solid (317 mg, 0.97 mmol, 81%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.60–4.47 (m, 1H), 4.46–4.10 (m, 3H), 3.92–3.80 (m, 2H), 3.77 (d, <i>J</i><sub>H,H</sub> = 11.7 Hz, 1H), 3.71–3.62 (m, 1H), 3.57–3.43 (m, 2H), 3.41–3.31 (m, 2H), 3.21–3.08 (m, 2H), 1.80–1.65 (m, 2H), 1.19 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H), 0.87–0.78 (m, 3H). MALDI-MS: <i>m</i>/<i>z</i> 328.709 [M + H]<sup>+</sup>.</div><div class="NLM_p">(<i>S</i>)-4-(4-Chloro-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-3-ethylmorpholine (<b>35</b>). Compound <b>35</b> was prepared according to general procedure 2 from (<i>S</i>)-3-ethylmorpholine hydrochloride (191 mg, 1.27 mmol, 1.05 equiv) and compound <b>26</b> (300 mg, 1.20 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>35</b> as a colorless solid (345 mg, 1.06 mmol, 88%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.59–4.47 (m, 1H), 4.46–4.10 (m, 3H), 3.91–3.80 (m, 2H), 3.77 (d, <i>J</i><sub>H,H</sub> = 11.7 Hz, 1H), 3.71–3.63 (m, 1H), 3.57–3.43 (m, 2H), 3.41–3.31 (m, 2H), 3.21–3.07 (m, 2H), 1.80–1.65 (m, 2H), 1.19 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H), 0.88–0.77 (m, 3H). MALDI-MS: <i>m</i>/<i>z</i> 328.635 [M + H]<sup>+</sup>.</div><div class="NLM_p">((<i>R</i>)-4-(4-Chloro-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)morpholin-3-yl)methanol (<b>36</b>). Compound <b>36</b> was prepared according to general procedure 2 from (<i>R</i>)-morpholin-3-ylmethanol hydrochloride (195 mg, 1.27 mmol, 1.05 equiv) and compound <b>26</b> (300 mg, 1.20 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>36</b> as a colorless solid (338 mg, 1.03 mmol, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.97–4.84 (m, 1H), 4.64–4.47 (m, 1H), 4.43–4.11 (m, 3H), 4.01–3.94 (m, 1H), 3.91–3.80 (m, 2H), 3.75–3.62 (m, 2H), 3.56–3.49 (m, 1H), 3.48–3.32 (m, 4H), 3.22–3.04 (m, 2H), 1.20 (d, <i>J</i><sub>H,H</sub> = 7.3 Hz, 3H). MALDI-MS: <i>m</i>/<i>z</i> 330.797 [M + H]<sup>+</sup>.</div><div class="NLM_p">((<i>S</i>)-4-(4-Chloro-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)morpholin-3-yl)methanol (<b>37</b>). Compound <b>37</b> was prepared according to general procedure 2 from (<i>S</i>)-morpholin-3-ylmethanol hydrochloride (124 mg, 1.05 mmol, 1.05 equiv) and compound <b>26</b> (250 mg, 1.00 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>37</b> as a colorless solid (253 mg, 0.77 mmol, 77%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.97–4.84 (m, 1H), 4.60–4.46 (m, 1H), 4.45–4.32 (m, 1H), 4.30–4.11 (m, 2H), 3.98 (d, <i>J</i><sub>H,H</sub> = 11.5 Hz, 1H), 3.93–3.81 (m, 2H), 3.73–3.63 (m, 2H), 3.57–3.49 (m, 1H), 3.48–3.35 (m, 4H), 3.21–3.04 (m, 2H), 1.20 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). MALDI-MS: <i>m</i>/<i>z</i> 330.661 [M + H]<sup>+</sup></div><div class="NLM_p">(<i>R</i>)-4-(4-Chloro-6-((<i>R</i>)-3-(methoxymethyl)morpholino)-1,3,5-triazin-2-yl)-3-methylmorpholine (<b>38</b>). Compound <b>38</b> was prepared according to general procedure 2 from (<i>R</i>)-3-(methoxymethyl)morpholine hydrochloride (224 mg, 1.27 mmol, 1.05 equiv) and compound <b>26</b> (300 mg, 1.20 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>38</b> as a colorless solid (309 mg, 0.90 mmol, 75%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.65–4.49 (m, 2H), 4.33–4.13 (m, 2H), 3.92–3.81 (m, 3H), 3.71–3.56 (m, 2H), 3.55–3.44 (m, 3H), 3.43–3.34 (m, 2H), 3.28 (s, 3H), 3.21–3.08 (m, 2H), 1.21 (d, <i>J</i><sub>H,H</sub> = 6.9 Hz, 3H). MALDI-MS: <i>m</i>/<i>z</i> 344.159 [M + H]<sup>+</sup>.</div><div class="NLM_p">6-(4-Chloro-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-3-oxa-6-azabicyclo[3.1.1]heptane (<b>39</b>). Compound <b>39</b> was prepared according to general procedure 2 from 3-oxa-6-azabicyclo[3.1.1]heptane (344 mg, 1.27 mmol, 1.05 equiv) and compound <b>26</b> (300 mg, 1.20 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>39</b> as a colorless solid (228 mg, 0.73 mmol, 61%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.57–4.49 (m, 1H), 4.41–4.34 (m, 2H), 4.24–4.11 (m, 2H), 4.04 (d, <i>J</i><sub>H,H</sub> = 10.1 Hz, 1H), 3.87 (dd, <i>J</i><sub>H,H</sub> = 11.6, 3.7 Hz, 1H), 3.79–3.72 (m, 2H), 3.67 (d, <i>J</i><sub>H,H</sub> = 11.5 Hz, 1H), 3.53 (dd, <i>J</i><sub>H,H</sub> = 11.3, 2.9 Hz, 1H), 3.42–3.33 (m, 1H), 3.21–3.12 (m, 1H), 2.67 (q, <i>J</i><sub>H,H</sub> = 6.9 Hz, 1H), 1.81 (d, <i>J</i><sub>H,H</sub> = 8.3 Hz, 1H), 1.20 (d, <i>J</i><sub>H,H</sub> = 6.9 Hz, 3H). MALDI-MS: <i>m</i>/<i>z</i> 312.708 [M + H]<sup>+</sup>.</div><div class="NLM_p">3-(4-Chloro-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-6-oxa-3-azabicyclo[3.1.1]heptane (<b>40</b>). Compound <b>40</b> was prepared according to general procedure 2 from 6-oxa-3-azabicyclo[3.1.1]heptane (344 mg, 1.27 mmol, 1.05 equiv) and compound <b>26</b> (300 mg, 1.20 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>40</b> as a colorless solid (230 mg, 0.74 mmol, 62%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.69–4.52 (m, 3H), 4.34–4.15 (m, 1H), 3.93–3.79 (m, 3H), 3.73–3.50 (m, 4H), 3.43–3.34 (m, 1H), 3.24–3.14 (m, 1H), 3.14–3.07 (m, 1H), 1.81 (d, <i>J</i><sub>H,H</sub> = 9.0 Hz, 1H), 1.22 (d, <i>J</i><sub>H,H</sub> = 6.9 Hz, 3H). MALDI-MS: <i>m</i>/<i>z</i> 312.749 [M + H]<sup>+</sup>.</div><div class="NLM_p">(1<i>R</i>,4<i>R</i>)-5-(4-Chloro-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-2-oxa-5-azabicyclo[2.2.1]heptane (<b>41</b>). Compound <b>41</b> was prepared according to general procedure 2 from (1<i>R</i>,4<i>R</i>)-2-oxa-5-azabicyclo[2.2.1]heptane (171 mg, 1.27 mmol, 1.05 equiv) and compound <b>26</b> (300 mg, 1.20 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>41</b> as a colorless solid (268 mg, 0.87 mmol, 72%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.95–4.87 (m, 1H), 4.69–4.63 (m, 1H), 4.63–4.49 (m, 1H), 4.29–4.13 (m, 1H), 3.88 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.6 Hz, 1H), 3.79–3.74 (m, 1H), 3.72–3.63 (m, 2H), 3.57–3.49 (m, 1H), 3.46–3.33 (m, 3H), 3.22–3.11 (m, 1H), 1.92–1.80 (m, 2H), 1.20 (d, <i>J</i><sub>H,H</sub> = 6.8 Hz, 3H). MALDI-MS: <i>m</i>/<i>z</i> 312.199 [M + H]<sup>+</sup>.</div><div class="NLM_p">(1<i>S</i>,4<i>S</i>)-5-(4-Chloro-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-2-oxa-5-azabicyclo[2.2.1]heptane (<b>42</b>). Compound <b>42</b> was prepared according to general procedure 2 from (1<i>S</i>,4<i>S</i>)-2-oxa-5-azabicyclo[2.2.1]heptane (171 mg, 1.27 mmol, 1.05 equiv) and compound <b>26</b> (300 mg, 1.20 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>42</b> as a colorless solid (271 mg, 0.87 mmol, 73%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.99–4.86 (m, 1H), 4.66–4.51 (m, 2H), 4.34–4.11 (m, 1H), 3.92–3.84 (dd, <i>J</i><sub>H,H</sub> = 11.3, 3.7 Hz, 1H), 3.76 (dd, <i>J</i><sub>H,H</sub> = 7.4, 1.6 Hz, 1H), 3.71–3.63 (m, 2H), 3.55–3.48 (m, 1H), 3.45–3.33 (m, 3H), 3.21–3.11 (m, 1H), 1.92–1.83 (m, 2H), 1.21 (d, <i>J</i><sub>H,H</sub> = 7.0 Hz, 3H). MALDI-MS: <i>m</i>/<i>z</i> 312.216 [M + H]<sup>+</sup>.</div><div class="NLM_p">8-(4-Chloro-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-3-oxa-8-azabicyclo[3.2.1]octane (<b>43</b>). Compound <b>43</b> was prepared according to general procedure 2 from 3-oxa-8-azabicyclo[3.2.1]octane hydrochloride (439 mg, 2.94 mmol, 1.05 equiv) and compound <b>26</b> (700 mg, 2.80 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>43</b> as a colorless solid (672 mg, 2.06 mmol, 74%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.71–4.57 (m, 3H), 4.36–4.28 (m, 1H), 3.93 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.8 Hz, 1H), 3.75–3.70 (m, 3H), 3.66–3.61 (m, 3H), 3.48 (td, <i>J</i><sub>H,H</sub> = 11.9, 3.0 Hz, 1H), 3.24 (td, <i>J</i><sub>H,H</sub> = 13.0, 3.8 Hz, 1H), 2.09–1.93 (m, 4H), 1.30 (d, <i>J</i><sub>H,H</sub> = 6.9 Hz, 3H). MALDI-MS: <i>m</i>/<i>z</i> 326.645 [M + H]<sup>+</sup>.</div><div class="NLM_p">3-(4-Chloro-6-((<i>R</i>)-3-methylmorpholino)-1,3,5-triazin-2-yl)-8-oxa-3-azabicyclo[3.2.1]octane (<b>44</b>). Compound <b>44</b> was prepared according to general procedure 2 from 8-oxa-3-azabicyclo[3.2.1]octane hydrochloride (253 mg, 2.23 mmol, 1.05 equiv) and compound <b>26</b> (500 mg, 2.03 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>44</b> as a colorless solid (504 mg, 1.55 mmol, 76%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.73–4.59 (m, 1H), 4.43–4.38 (m, 2H), 4.34–4.18 (m, 3H), 3.93 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.7 Hz, 1H), 3.73 (d, <i>J</i><sub>H,H</sub> = 11.5 Hz, 1H), 3.63 (dd, <i>J</i><sub>H,H</sub> = 11.5, 3.2 Hz, 1H), 3.48 (td, <i>J</i><sub>H,H</sub> = 11.9, 3.0 Hz, 1H), 3.26 (dd, <i>J</i><sub>H,H</sub> = 13.2, 3.8 Hz, 1H), 3.22–3.12 (m, 2H), 1.99–1.88 (m, 2H), 1.84–1.68 (m, 2H), 1.30 (d, <i>J</i><sub>H,H</sub> = 7.1 Hz, 3H). MALDI-MS: <i>m</i>/<i>z</i> 326.679 [M + H]<sup>+</sup>.</div><div class="NLM_p">(<i>R</i>)-6-(4-Chloro-6-(3-methylmorpholino)-1,3,5-triazin-2-yl)-2-oxa-6-azaspiro[3.3]heptane (<b>45</b>). Compound <b>45</b> was prepared according to general procedure 2 from 2-oxa-6-azaspiro[3.3]heptane oxalate (2:1, 183 mg, 1.27 mmol, 1.05 equiv) and compound <b>26</b> (300 mg, 1.21 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>45</b> as a colorless solid (212 mg, 0.68 mmol, 57%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.69 (br s, 4H), 4.57–4.49 (m, 1H), 4.24–4.11 (m, 5H), 3.88 (d, <i>J</i><sub>H,H</sub> = 9.8 Hz, 1H), 3.67 (d, <i>J</i><sub>H,H</sub> = 11.6 Hz, 1H), 3.50 (dd, <i>J</i><sub>H,H</sub> = 11.6, 3.2 Hz, 1H), 3.39–3.32 (m, 1H), 3.15 (ddd, <i>J</i><sub>H,H</sub> = 13.7, 12.3, 3.9 Hz, 1H), 1.19 (d, <i>J</i><sub>H,H</sub> = 6.9 Hz, 3H). MALDI-MS: <i>m</i>/<i>z</i> 312.598 [M + H]<sup>+</sup>.</div><div class="NLM_p">(<i>R</i>)-4-(4-Chloro-6-(3-methylmorpholino)-1,3,5-triazin-2-yl)-1,4-oxazepane (<b>46</b>). Compound <b>46</b> was prepared according to general procedure 2 from 1,4-oxazepane (128 mg, 1.27 mmol, 1.05 equiv) and compound <b>26</b> (300 mg, 1.21 mmol, 1.0 equiv). Purification by column chromatography on a silica gel (cyclohexane/ethyl acetate 1:0 → 0:1) gave compound <b>46</b> as a colorless solid (252 mg, 0.81 mmol, 67%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 4.59–4.50 (m, 1H), 4.30–4.11 (m, 1H), 3.92–3.85 (m, 1H), 3.86–3.59 (m, 8H), 3.56–3.49 (m, 1H), 3.42–3.35 (m, 1H), 3.21–3.11 (m, 2H), 1.88–1.76 (m, 2H), 1.23–1.18 (m, 3H). MALDI-MS: <i>m</i>/<i>z</i> 314.342 [M + H]<sup>+</sup>.</div><div class="NLM_p">(3<i>R</i>,5<i>S</i>)-4-(4,6-Dichloro-1,3,5-triazin-2-yl)-3,5-dimethylmorpholine (<b>47</b>). To a solution of cyanuric chloride (479 mg, 2.60 mmol, 1.0 equiv) in DCM (10 mL) at −50 °C, a solution of (3R,5S)-3,5-dimethylmorpholine (300 mg, 2.60 mmol, 1.0 equiv) and DIPEA (1 mL, 742 mg, 5.75 mmol, 2.1 equiv) in DCM (5 mL) was added dropwise over 20 min. The mixture was stirred at −50 °C for 2 h. After completion of the reaction monitored by TLC, the mixture was washed with NaHSO<sub>4</sub>, the organic layer was separated, dried over Na2<sub>S</sub>O<sub>4</sub>, filtered, and concentrated under reduced pressure. Recrystallization from dichloromethane/heptanes gave compound <b>47</b> as a colorless solid (423 mg, 1.60 mmol, 62%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 4.55 (qd, <i>J</i><sub>H,H</sub> = 7.0, 3.8 Hz, 2H), 3.84 (d, <i>J</i><sub>H,H</sub> = 11.8 Hz, 2H), 3.63 (dd, <i>J</i><sub>H,H</sub> = 11.7, 3.9 Hz, 2H), 1.41 (dd, <i>J</i><sub>H,H</sub> = 7.1, 0.7 Hz, 3H).</div><div class="NLM_p last"><i>N</i>′-[4-(Difluoromethyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]-<i>N</i>,<i>N</i>-dimethylmethanimidamide (<b>48</b>). Compound <b>48</b> was prepared according to the literature.<a onclick="showRef(event, 'ref35 ref54'); return false;" href="javascript:void(0);" class="ref ref35 ref54">(35,54)</a></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Structure Modeling of PI3K and mTOR Kinase Complexes</h3><div class="NLM_p last">The coordinates of mTOR kinase bound to PI103 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>; 3.6 Å) and PQR530 in PI3Kα complex (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OAC">6OAC</a>, resolution of 3.15 Å) were used as starting points for docking the molecules into the kinase ATP-binding site. Compounds were manually replaced/modified in crystal structures using Maestro 11.1, and energy minimization of the resulting protein-inhibitor complex was carried out. Measurements and figures were generated using Maestro Schrödinger 11.1 and Chimera UCSF.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Determination of Inhibitor Dissociation Constants</h3><div class="NLM_p last">The library’s dissociation constants (<i>K</i><sub>i</sub>) for p110α and mTOR were determined using a commercial LanthaScreen (Life Technologies) assay. The assays were performed as described in ref <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a>, and data analysis was carried out as previously reported in ref <a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a>. Briefly, AlexaFluor647-labeled Kinase Tracer314 (#PV6087) with a <i>K</i><sub>d</sub> of 2.2 nM was used at 20 nM for p110α and at a final concentration of 10 nM for mTOR (<i>K</i><sub>d</sub> of 19 nM; modifications see <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Table S1</a>). Recombinant N-terminally (His)<sub>6</sub>-tagged p110α was captured with biotinylated anti-(His)<sub>6</sub>-tag antibody (2 nM, #PV6089) and detected with LanthaScreen Eu-steptavidin (2 nM, #PV5899); N-terminal GST fused to truncated mTOR (amino acids 1360–2549; #PR8683B) was detected with a LanthaScreen Eu-labeled anti-GST antibody (2 nM, #PV5594). The p110α assay buffer was composed of 50 mM HEPES pH 7.5, 10 mM MgCl<sub>2</sub>, 1 mM EGTA, and 0.01% (v/v) Brij-35, and the mTOR assay buffer contained 50 mM HEPES; 5 mM MgCl<sub>2</sub>; 1 mM EGTA; 0.01% Pluronic F-127. IC<sub>50</sub>s were measured using a 10-point 1:4 serial dilution. Values at each concentration were determined in independent duplicate experiments.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Kinome Profiling</h3><div class="NLM_p">Compounds’ binding affinity and selectivity were determined using the ScanMax platform of DiscoverX.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Experiments were performed at DiscoverX, 11180 Roselle Street, Suite D, San Diego, using an automated and standardized <i>in vitro</i> assay. Inhibitor binding constants (<i>K</i><sub>d</sub> values) were calculated from duplicate 11-point dose–response curves. As described in the standard DiscoverX protocol, kinase-tagged T7 phage strains were grown in parallel in 24-well blocks in an <i>Escherichia coli</i> host derived from the BL21 strain. <i>E. coli</i> were grown to log-phase and infected with T7 phage from a frozen stock (multiplicity of infection = 0.4) and incubated with shaking at 32 °C until lysis (90–150 min). The lysates were centrifuged (6000<i>g</i>) and filtered (0.2 μm) to remove cell debris. The remaining kinases were produced in HEK-293 cells and subsequently tagged with DNA for qPCR detection. Streptavidin-coated magnetic beads were treated with biotinylated small-molecule ligands for 30 min at room temperature to generate affinity resins for kinase assays. The liganded beads were blocked with excess biotin and washed with a blocking buffer [SeaBlock (Pierce), 1% BSA, 0.05% Tween 20, 1 mM DTT] to remove unbound ligand and to reduce nonspecific phage binding. Binding reactions were assembled by combining kinases, liganded affinity beads, and test compounds in 1× binding buffer (20% SeaBlock, 0.17× PBS, 0.05% Tween 20, 6 mM DTT). Test compounds were prepared as 40× stocks in 100% DMSO and directly diluted into the assay. All reactions were performed in polypropylene 384-well plates in a final volume of 0.02 mL. The assay plates were incubated at room temperature with shaking for 1 h, and the affinity beads were washed with a wash buffer (1× PBS, 0.05% Tween 20). The beads were then resuspended in an elution buffer (1× PBS, 0.05% Tween 20, 0.5 μM non-biotinylated affinity ligand) and incubated at room temperature with shaking for 30 min. The kinase concentration in the eluates was measured by qPCR. Binding of the immobilized ligand to DNA-tagged kinases was competed with 10 μM compound. The amount of kinase bound to the immobilized ligand was measured by quantitative PCR of the respective DNA tags and was reported as % of control. The compounds’ binding constants for selected kinases were determined by competing the immobilized ligand kinase interactions with an 11-point threefold serial dilution of compound starting from 30 μM and subsequent quantitative PCR of DNA tags. Binding constants were calculated by a standard dose–response curve using the Hill equation (with Hill slope set to −1)<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_m001.gif" alt="" id="_i31" /></img></span></div><div class="NLM_p last">Selectivity scores<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> were calculated as reported below<span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_m002.gif" alt="" id="_i32" /></img></span>where <i>S</i>35, <i>S</i>10, and <i>S</i>1 were calculated using % Ctrl as a potency threshold (35, 10, 1%); for example, <i>S</i>(35) = (number of nonmutant kinases with % Ctrl < 35)/(number of nonmutant kinases tested).</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Cellular PI3K and mTOR Signaling</h3><div class="NLM_p last">In-cell western assays were used to measure phosphorylation of PKB/Akt at Ser473 and phosphorylation of ribosomal protein S6 at Ser235/236. ICW experiments and determination of IC<sub>50</sub> were performed as described in ref <a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a>. Briefly, A2058 cells were seeded at 2 × 10<sup>4</sup> cells/well in 96-well plates (Cell Carrier, Perkin Elmer) and grown for 24 h at 37 °C (at 5% CO<sub>2</sub>). Cells were then exposed to inhibitors or DMSO for 1 h. At this time, cells were fixed (4% PFA in PBS for 30 min at r.t.), blocked (1% BSA/0.1% Triton X-100/5% goat serum in PBS for 30 min, r.t.), and stained with CST primary anti-phosphoprotein antibodies [1:500; phosphorylation of Ser473 of PKB/Akt was detected with rabbit polyclonal antibody from Cell Signaling Technology (CST, #4058) and mTORC1 activity as phosphorylation of Ser235/236 on the ribosomal protein S6 with rabbit monoclonal antibody from CST, #4856]. Tubulin staining was assessed as the internal standard with mouse anti-α-tubulin, 1:2000, from Sigma (#T9026). Fluorescence outputs were detected on an Odyssey CLx infrared imaging scanner (LICOR) using secondary, species-specific antibodies, IR-dye-labeled antibodies (IRDye680-conjugated goat anti-mouse, and IRDye800-conjugated goat anti-rabbit antibodies [LICOR # 926-68070 and # 926-32211], both 1:500). Remaining phospho-protein signals were normalized to cellular tubulin and related to DMSO controls. IC<sub>50</sub>s were measured using a 7- or 11-point 1:2 serial dilution and each concentration was measured in independent triplicate (7-point dilution) or independent duplicate (11-point dilution).</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Hepatocyte Stability Assay</h3><div class="NLM_p">The hepatocyte stability was assessed using primary hepatocytes from mice (CD-1), rats (Sprague-Dawley, SD), dogs (Beagle), and humans. Assays were performed using cryopreserved hepatocytes in suspension, and each experiment was performed in duplicate. Stock solution of compound <b>8</b> was prepared with 10 mM in DMSO and diluted to the final concentration of 5 μM. 7-EC has been used as a positive control. Negative control incubations were run in line with all experiments using the incubation medium in the absence of hepatocytes to exclude nonmetabolic degradation processes. Further experimental details are reported in ref <a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>. As described in the standard Pharmacelsus protocol, 25 μL of a 10-fold stock of <b>8</b> or 7-EC (reference compound) was added to 225 μL of cell suspension, yielding a final concentration of 5 μM for <b>8</b> and 7-EC. The final solvent concentrations did not exceed 0.5% DMSO (for <b>8</b>) or 1% ACN (for 7-EC). Samples were collected after 0, 15, 60, 90, and 180 min of incubation for <b>8</b> and after 0, 60, and 180 min for 7-EC. Subsequently, proteins were precipitated using ACN (200 μL cell suspension plus 200 μL ACN/ISTD3). After centrifugation for 5 min at 4800<i>g</i>, particle-free supernatant was diluted with one volume of H<sub>2</sub>O and analyzed by LC–MS. To exclude nonmetabolic degradation processes, negative controls were performed. For example, the finding that the concentrations remained stable over the investigated time suggested that the decrease of the parent compound was mainly due to metabolism. Negative control incubations were performed in line with all experiments using the incubation medium in the absence of hepatocytes.</div><div class="NLM_p last">A HPLC system consisting of a LC pump Surveyor Plus and an auto sampler Surveyor Plus (Thermo Fisher, USA) was used to quantify compound <b>8</b> in samples from primary hepatocytes. Mass spectrometry was carried out on a TSQ Quantum Discovery Max triple quadrupole mass spectrometer equipped with an electro-spray ion source (ESI, Thermo Fisher Scientific, USA). Xcalibur 2.0.7. was used as software for data analysis.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> CYP Reactive Phenotyping with Human Recombinant CYP1A1 and CYP1A2 Isoenzymes</h3><div class="NLM_p">Human recombinant isoenzymes from insect cells infected by baculovirus and containing cDNA of a single human CYP isoenzyme (Supersomes, Corning) were employed. The compounds were tested in the CYP-reactive phenotyping at a concentration of 1 μM in the presence of 0.25% DMSO. The assays were performed in duplicate using human recombinant enzymes systems from Corning (BD Gentest P450 High Throughput Inhibitor Screening Kits). Further experimental details are reported in ref <a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>.</div><div class="NLM_p">As described in standard Pharmacelsus protocol, the cofactor-mix, containing the NADP<sup>+</sup>-regenerating system, was prepared according to the manufacturer’s instructions. For CYP1A1 and CYP1A2, 4 μL of the 50-fold concentrated working solution was added to 96 μL of the cofactor mix. The cofactor mix and test item were pipetted into the respective wells of a prewarmed 96-well plate and prewarmed for 10 min on a shaker with fitted heating block. The reactions were initiated by addition of 100 μL of prewarmed enzyme-mix. By default, the final protein concentration of all CYP isoenzymes was 25 pmol/mL. Incubations with a final volume of 200 μL were performed at 37 °C. After 0 and 60 min (30 min for positive control substrates), the reactions were stopped by the addition of 200 μL of stop solution, that is, ACN containing the internal standard. Two control groups were evaluated in parallel for each assay: specific substrates for each CYP isoform were used as positive controls (CYP1A1, melatonin and CYP1A2, phenacetin). Negative controls (<i>n</i> = 2) were performed without cofactors and glucose-6-phosphate-dehydrogenase to ensure that the potential loss of parent compound is due to the CYP-mediated metabolism.</div><div class="NLM_p last">For quantitative analysis of compounds <b>8</b> and <b>4</b>, the following equipment have been used: (1) LC–MS consisting of an Accela U-HPLC pump and an Accela auto sampler connected to an Exactive mass spectrometer (Orbitrap with accurate mass, Thermo Fisher Scientific, USA). Data analysis was performed with Xcalibur 2.1 software. (2) LC–HRMS consisting of an Accela U-HPLC pump and an Accela Open auto sampler (Thermo Fisher Scientific, USA) connected to a Q Exactive mass spectrometer (Orbitrap). Data analysis was performed with Xcalibur 2.2. (3) LC–MS consisting of a Surveyor MS Plus HPLC system connected to a TSQ Quantum Discovery Max (Thermo Electron) triple quadrupole mass spectrometer equipped with an electrospray (ESI) or APCI interface (Thermo Fisher Scientific, USA). Software used: Xcalibur 2.0.7.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> MDCK TransWell Assays</h3><div class="NLM_p">MDCK-hMDR1<sup>cMDR1-ko</sup> and MDCK<sup>cMDR1-ko</sup> cells were obtained from Karlgren <i>et al.</i>, Uppsala University,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> and cultured according to the provided protocol. Briefly, cells were cultured in DMEM with Glutamax (cat. no. 14190), 10% fetal bovine serum (cat. no. 10270), and 5% penicillin–streptomycin (cat. no. 10687). Hygromycin B (cat no 10687) was used as selection antibiotic for cells expressing hMDR1. Cells (100,000/well) were seeded into 12-well TransWell plates (cat. no. CLS3401) and grown for 5 days prior to experiments. Cell culture medium was exchanged every second day and the day before the experiment. For <i>P</i><sub>app</sub> experiments, the cell culture medium was replaced with prewarmed HBSS for 30 min at 37 °C under gentle stirring (300 rpm). The experiment was started by the addition of 0.4 mL of 1 μM drug solution in HBSS to the apical side (<i>P</i><sub>app</sub> A to B) or 1.2 mL of 1 μM drug solution to the basolateral side (<i>P</i><sub>app</sub> B to A). Samples of 100 μL were retrieved from the receiver chamber at time points 5, 10, and 20 min and replaced with fresh buffer. Samples (100 μL) were retrieved from the donor chamber at the end of the experiment for calculation of mass balance. Trans-epithelial electrical resistance (TEER) values were measured prior to addition of drug and 30 min after sampling of last time point [Epithelial Volt/Ohm Meter (EVOM), World Precision Instrument, equipped with Chopstick Electrode STX2].</div><div class="NLM_p">Immediately after the final sampling, the samples and calibration standards were diluted 1:1 with ACN containing the internal standard, vortexed, and centrifuged at 2000<i>g</i> for 15 min, and the supernatant was analyzed by UPLC–MS/MS. The UPLC-MS/MS system consisted of an Agilent 1290 Infinity Binary Pump coupled to an Agilent 6460 Triple Quad Mass Spectrometer with an AJS ESI interface. Mobile phases consisted of (A) water with 5% ACN, 0.05% formic acid, and 10 mM ammonium formate and (B) ACN with 0.05% formic acid. Separation was performed on an Acquity UPLC column (BEH C18 1.7 μm, 2.1 × 50 mm) with an integrated prefilter. Acquisition and quantification were performed with the Agilent MassHunter Workstation (Version 10.1).</div><div class="NLM_p">Finally, <i>P</i><sub>app</sub> was calculated according to the literature<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> using the equation<span class="NLM_disp-formula" id="ueq3"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_m003.gif" alt="" id="_i37" /></img></span>where d<i>Q</i>/d<i>t</i> is the steady-state flux (μmol/s), <i>A</i> is the surface area of the filter (cm<sup>2</sup>), and <i>C</i><sub>0</sub> is the initial concentration in the donor chamber (μM).</div><div class="NLM_p">The ER is the ratio between the secretory permeability and the absorptive permeability<span class="NLM_disp-formula" id="ueq4"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_m004.gif" alt="" id="_i38" /></img></span></div><div class="NLM_p last">Experiments were performed in triplicates on at least two independent occasions. <i>P</i><sub>app</sub> values were retained for experiments with a mass balance >75% and TEER in the range of 160–180 Ω·cm<sup>2</sup>. Citalopram has been used as control because it is a hMDR1 substrate for which literature data using these cell lines are available.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Pharmacokinetic Studies in Rats</h3><div class="NLM_p">Male Sprague Dawley rats purchased from Janvier Labs (France) were used for the study. The animals were 8 weeks old at delivery and were housed in a temperature-controlled room (20–24 °C) and kept in a 12 h light/12 h dark cycle. Food and water were available <i>ad libitum</i> throughout the duration of the study. Formulation of compound <b>8</b> was prepared by dissolving it in Captisol (40% w/w in water). Compound preparation and experiment setup were consistent with the previous literature reports.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Briefly, the compounds were administrated p.o. at 5 mg/kg (application volume: 5 mL/kg). At each time point (30 min, 2, 4, and 8 h), three rats were anesthetized with isoflurane and 1 mL of blood was collected, <i>via</i> heart puncture, in tubes containing lithium-heparin. After blood sampling, the rats were euthanized and brain, liver, and skin were collected.</div><div id="sec4_13_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Quantification of Plasma Insulin</h4><div class="NLM_p last">Plasma insulin was determined using an immunoassay kit (Rat/Mouse Insulin ELISA from Merck Millipore, cat. no. EZRMI-13K, lot 2688510, Germany), according to the manufacturer’s instructions<i>.</i> This Rat/Mouse Insulin ELISA kit was used for the nonradioactive quantification of insulin in rat sera. At each time point, three rats were anesthetized with isoflurane and 1 mL of blood was collected. Blood samples were stored on dry ice until centrifugation at 3000<i>g</i> (10 min, 4 °C). Plasma supernatants and tissue samples were stored at −80 °C until being assayed.</div></div><div id="sec4_13_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Quantification of Plasma Glucose</h4><div class="NLM_p last">Plasma glucose was determined using a glucose colorimetric assay (Cayman, cat. no. 10009582, lot 0478964, USA). The glucose assay uses the glucose oxidase–peroxide reaction for the determination of glucose concentrations. In this assay, glucose is oxidized to δ-gluconolactone with concomitant reduction of the flavin adenine dinucleotide-dependent enzyme glucose oxidase. The reduced form of glucose oxidase is regenerated to its oxidized form by molecular oxygen to produce hydrogen peroxide. Finally, hydrogen peroxide reacts with 3,5-dichloro-2-hydroxybenzenesulfonic acid and 4-aminoantipyrine to generate a pink dye with an optimal absorption at 514 nm. The plasma was collected and stored in ice or at −80 °C until being assayed.</div></div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Pharmacokinetic Studies in Mice</h3><div class="NLM_p">Female C57BL/6J mice purchased from Janvier Labs (France) were used for the study. The animals were 8 weeks old at delivery and were housed in a temperature-controlled room (20–24 °C) and maintained in a 12 h light/12 h dark cycle. Food and water were available <i>ad libitum</i> before and throughout the duration of the study. The animals were checked for clinical signs throughout the study. No adverse effects were observed. Dose formulations were prepared freshly on the day of the in-life phase.</div><div id="sec4_14_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Study PQR626 (<b>8</b>) versus Everolimus (<b>56</b>)</h4><div class="NLM_p last">The compounds were orally administered the following: compound <b>8</b> at 10 mg/kg, either as single or multiple (qd4) application in 20% Captisol and compound <b>56</b> at 10 mg/kg qd4 in 8% ethanol, 10% PEG 400, 10% Tween 80.</div></div><div id="sec4_14_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Study PQR626 (<b>8</b>) versus Everolimus (<b>56</b>) and AZD2014 (<b>51</b>)</h4><div class="NLM_p">The compounds were orally administered the following: compound <b>8</b> at 25 mg/kg in 20% Captisol; compound <b>56</b> at 10 mg/kg in 8% ethanol, 10% PEG 400, 10% Tween 80 and 72% water; and compound <b>51</b> at 25 mg/kg in 20% Captisol (SBECD).</div><div class="NLM_p">At each of the designated time points, three mice were subjected to isoflurane anesthesia to obtain about 0.5 mL of Li heparin blood by puncture of the retrobulbar venous plexus. Blood samples were stored on ice until centrifugation at 3000<i>g</i> (6000 rpm) for 10 min at 4 °C for the preparation of plasma samples. Subsequently, mice were sacrificed by inhalation of an overdose of isoflurane for the collection of the brain and muscles. All samples were frozen on dry ice and stored at −80 °C.</div><div class="NLM_p">The HPLC system consisted of a U-HPLC pump (Ultimate 3000 RS) and an Accela Open auto sampler (Thermo Fisher Scientific, USA). Mass spectrometry was performed on a Q Exactive (Orbitrap) accurate mass spectrometer equipped with a heated electrospray (H-ESI) interface (Thermo Fisher Scientific, USA). Xcalibur 4.0. software was used for data collection and analysis.</div><div class="NLM_p">For the quantification of plasma insulin and glucose, see the section above.</div><div class="NLM_p last">All experimental procedures in male Sprague Dawley rats and in female C57BL/6J mice were approved by and conducted in accordance with the regulations of the local Animal Welfare authorities (Landesamt für Gesundheit und Verbraucherschutz, Abteilung Lebensmittel und Veterinärwesen, Saarbrücken).</div></div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Determination of Phospho-Protein Levels in the Murine Cortex</h3><div id="sec4_15_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Tissue Lysis</h4><div class="NLM_p last">Snap-frozen murine cortical brain pieces of compound-treated animals were obtained from studies described in <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> in “Pharmacokinetic Studies in Mice” above and control animals were obtained from the same supplier and were stored at −80 °C. Cortical tissue was homogenized and lysed in 400 μL of ice-cold RIPA lysis buffer + protease/phosphatase inhibitor cocktail (Halt Protease Inhibitor Cocktail #87786; Halt Phosphatase Inhibitor Cocktail #78420, Thermo Fisher Scientific) in precooled 2 mL ScrewCup tubes by mechanical tissue disruption using a bead mill [MP Fast-Prep 24 with beads (#11079124zx, Biospec products), 1 cycle: 20s, speed 6 m/s]. The lysate was cleared in a cooled centrifuge (4 °C, 5 min, 16 000 g) and cleared lysate transferred and aliquoted in cooled Eppendorf tubes and snap frozen until further processing.</div></div><div id="sec4_15_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> SDS-PAGE</h4><div class="NLM_p last">The total protein content of cortex lysates was determined using a Bradford assay (Bio-Rad DC Protein Assay). Equal amounts of lysates were denatured in a SDS-PAGE sample buffer and heated to 97 °C for 5 min. Denatured protein samples were subjected to SDS-PAGE and transferred to Immobilon FL membranes (Millipore).</div></div><div id="sec4_15_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Immunodetection by Western Blotting</h4><div class="NLM_p last">Primary antibodies to pSer473-PKB/Akt (#4058L), PKB/AKT (#2929S), pS235/236 ribosomal protein S6 (#4856S), and ribosomal protein S6 (#2317S) were from Cell Signaling Technology; mouse monoclonal anti activated MAP Kinase (#M8159) and primary antibody to α-tubulin (#T9026) was from Sigma. HRP-conjugated secondary antibodies were visualized using enhanced chemiluminescence (Millipore) on a Fusion FX (Vilber Lourmat) imaging system. Levels of phosphorylated protein and total protein and α-tubulin signals were quantified using ImageJ. Phospho-protein levels in each sample were corrected for unequal loading using α-tubulin or total PKB signals. Resulting phospho-protein signals of compound-treated samples were subsequently normalized to control-treated samples and illustrated and analyzed using a GraphPad Prism. Statistical analysis was performed using unpaired <i>t</i>-test and the probability value (<i>p</i>-value) used to identify significance (<i>p</i> < 0.05).</div></div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Toxicokinetic Studies in Mice</h3><div class="NLM_p">Female Balb/c nude mice were purchased from Beijing Anikeeper Biological Technology Co. Ltd. (AK, Beijing, China). The animals were housed in a temperature-controlled room (20–26 °C) and maintained in a 12 h light/12 h dark cycle. Food and water were available <i>ad libitum</i> before and throughout the duration of the study. Treatment with compound <b>8</b> at 100, 150, and 200 mg/kg was carried out and compared to vehicle (20% Captisol). Ten mice, 6–8 weeks old at inoculation, were enrolled in the study. All animals were randomly allocated to the four different study groups. Randomization was performed based on body weight and randomized block design on day 1. The animals were checked daily for morbidity and mortality. At the time of routine monitoring, the animals were checked for treatments on normal behavior such as mobility, visual estimation of food and water consumption, body weight gain/loss, eye/hair matting, and any other abnormalities. The body weights were recorded daily. The entire procedure of dosing and body weight measurement was conducted in a laminar flow cabinet. Animals showing obvious signs of severe distress were euthanized. Gross necropsy was performed on euthanized animals, and observations on the major organs (heart, lung, liver, kidney, spleen, and intestine) were reported.</div><div class="NLM_p last">All studies were conducted following an approved Institutional Animal Care and Use Committee (IACUC) protocol of CrownBio. During the study, the care and use of animals were conducted in accordance with the regulations of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). All experimental data management and reporting procedures were in strict accordance with applicable Crown Bioscience, Inc. Guidelines and Standard Operating Procedures.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Efficacy on Survival in <i>Tsc1</i><sup>GFAP</sup> Knockout Mice</h3><div class="NLM_p">The study was performed at PsychoGenics, Inc., headquartered at 215 College Road, Paramus, NJ 07652, USA. Animals were used in accordance with humane laboratory animal care and used based on the Guide for the Care and Use of Laboratory Animals (NRC 2011) and PsychoGenics, Inc. internal IACUC program. PyschoGenics achieved AAALAC accreditation (Unit #001213) and holds PHS OLAW Assurance (#D16-00732 [A4471-0]).</div><div class="NLM_p"><i>Tsc1</i><sup>flox/flox</sup>-GFAP-Cre<sup>+</sup> (<i>Tsc1</i><sup>GFAP</sup> conditional knockout) male and female mice were bred at PsychoGenics using breeding pairs obtained from Prof. Michael Wong, MD, Ph.D. (Washington University, St. Louis, MO). Genotyping of mice was performed using PCR and primers for TSC1 and CRE according to the procedure provided by Dr. Wong. Kits were purchased from Lambda Biotech (catalog number D124R). All mice were acclimated to the environment, examined, handled, and weighed prior to the initiation of the study to assure adequate health and suitability and to minimize nonspecific stress associated with human handling. During the course of the study, 12 h/12 h light/dark cycles were maintained. The room temperature was maintained at 20–23 °C with a relative humidity maintained around 50%. Food and water were provided <i>ad libitum</i> for the duration of the study. Each mouse was randomly assigned to designated treatment groups. The dosing was performed during the animals’ light cycle phase. Body weights were determined twice per week from P21 to P90. Twice a week all mice were assessed for general health including biweekly body weights.</div><div class="NLM_p">Animals were checked at least once daily for survival. Survival curves were generated and represented as a percent of surviving animals for each treatment group over the course of the study. The first death was observed at P26, therefore data are plotted from P25 to P90 and recorded in intervals of 5 days. At end of study at P90, surviving mice were euthanized for plasma and brain collection 2 h after last dose.</div><div class="NLM_p">Blood was collected from submandibular vein in K2EDTA tubes and kept on ice for short-term storage. Within 15 min of blood collection, tubes were centrifuged for 10 min at 10 000 rpm in a refrigerated centrifuge. The plasma was extracted using a pipette and transferred into prelabeled tubes. Plasma were stored at −80 °C until shipment to Sponsor-designated laboratory.</div><div class="NLM_p">Whole brains were perfused by PBS first and then 4% PFA and collected into 4% PFA filled vials and stored at 4 °C overnight. Fixed brains were transferred to 30% sucrose and 0.05% sodium azide for storage and shipment. Brains were stored at −4 °C.</div><div class="NLM_p last">With the exception of compound <b>52</b> at 50 mg/kg, all compounds were dosed p.o. and daily from P21 to P90. A treatment group with <b>52</b> at 50 mg/kg was added at P27, and 6 days post-study comparing with compound <b>8</b> at 50 mg/kg was started. Four additional animals per group were dosed and sacrificed on day P45 for brain and plasma collection. See <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a> Table S33 for additional information (P21 and P23 were not measured for <b>52</b> at 50 mg/kg). Details on animals used in the study are reported in Table S35 of the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a>. Vehicle was 20% SBECD (sulfobutyl-ether-β-cyclodextrin, Captisol, Dexolve) pH 3.0. Compounds <b>52</b> and <b>8</b> were dissolved in vehicle. Compound <b>56</b> was dissolved in 10% PEG400/10% Tween-80/8% ethanol.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Statistical Reports for Survival Analysis</h3><div class="NLM_p last">Survival was determined from the start of the study (P21) to the day the animal was found dead or until P90 (<i>i.e.</i>, animals were censored at P90). A Chi-square survival analysis was performed in JMP Statistical Software (a division of SAS) with treatment as a factor. The log-rank test places more weight on larger survival times and is more useful when the ratio of hazard functions in the groups being compared is approximately constant where the hazard function is the instantaneous failure rate at a given time. Data are reported as percent of survival across days.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00620" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62206" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62206" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00620?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00620</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Comparison of PQR620 (<b>52</b>) PK profile in mice and cynomolgus monkeys; metabolites analysis of <b>52</b> in cynomolgus monkey; final compounds SAR studies: activity data and standard errors (SEM); TREEspot data visualization of KINOMEScan interactions of compounds PQR626 (<b>8</b>), PQR617 (<b>53</b>), PQR620 (<b>52</b>) and INK128 (<b>50</b>); selectivity profile calculated from KinomeScan data; kinase interactions (KINOMEscan data; <i>in vitro</i> pharmacology I—ligand binding asays with compound <b>8</b> at 10 μM; <i>in vitro</i> pharmacology II—enzyme assays with compound <b>8</b> at 10 μM; stability of compounds <b>8</b> and <b>52</b> in primary mouse, rat, dog, and human hepatocytes; plasma and brain concentration of compound <b>8</b> after a single p.o. dose of 5 mg/kg in rats; plasma insulin and glucose concentration after a single p.o. dose of 5 mg/kg of compound <b>8</b> and after vehicle administration in rats; plasma concentration of compound <b>8</b> after a p.o. single dosing and multiple dosing at 10 mg/kg and of everolimus (<b>56</b>) after a p.o. multiple dosing at 10 mg/kg in mice; brain concentration of compound <b>8</b> after a p.o. single dosing and multiple dosing at 10 mg/kg and of compound <b>56</b> after a p.o. multiple dosing at 10 mg/kg in mice; plasma and brain concentration after a p.o. single dosing of compound <b>8</b> at 25 mg/kg, of compound <b>56</b> at 10 mg/kg, and of AZD2014 (<b>51</b>) at 25 mg/kg in mice; plasma insulin and glucose concentration after a p.o. single dosing of compound <b>8</b> at 25 mg/kg, of compound <b>56</b> at 10 mg/kg, and of compound <b>51</b> at 25 mg/kg in mice; time-course of inhibition of mTOR signaling in murine brain cortex by compound <b>8</b>; body weight changes in nontumor bearing Balb/c mice; body weight of mice as a function of treatments in <i>Tsc1</i><sup>GFAP</sup> knockout mice; statistical reports for survival analysis in <i>Tsc1</i><sup>GFAP</sup> knockout mice; details on <i>Tsc1</i><sup>GFAP</sup> knockout mice used in the experiments; <sup>1</sup>H NMR spectra; <sup>13</sup>C{<sup>1</sup>H} NMR spectra; MALDI spectra; HRMS spectra; HPLC chromatograms; final compounds (chemical structures); intermediates (chemical structures); and reference compounds (chemical structures) (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of compounds <b>1</b>–<b>21</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">3D PDB Files for Figure 2 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_003.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Compound <b>8</b>_methyl up-mTOR (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound <b>8</b>_methyl down-mTOR (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound <b>8</b>_methyl up-PI3Kα (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_006.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound <b>8</b>_methyl down-PI3Kα (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_007.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound <b>4</b>_methyl right-mTOR (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_008.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound <b>4</b>_methyl left-mTOR (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_009.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound <b>4</b>_methyl right-PI3Kα (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_010.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound <b>4</b>_methyl left-PI3Kα (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_011.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf">jm0c00620_si_001.pdf (9.98 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_002.csv">jm0c00620_si_002.csv (2.93 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_003.pdf">jm0c00620_si_003.pdf (56.63 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_004.pdb">jm0c00620_si_004.pdb (997.48 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_005.pdb">jm0c00620_si_005.pdb (0.98 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_006.pdb">jm0c00620_si_006.pdb (1.7 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_007.pdb">jm0c00620_si_007.pdb (1.7 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_008.pdb">jm0c00620_si_008.pdb (0.98 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_009.pdb">jm0c00620_si_009.pdb (997.49 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_010.pdb">jm0c00620_si_010.pdb (1.7 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_011.pdb">jm0c00620_si_011.pdb (1.7 MB)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a> was used for docking of compounds PQR626 (<b>8</b>) and <b>4</b> into mTOR kinase. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OAC">6OAC</a> was used for docking of PQR626 (<b>8</b>) and <b>4</b> into PI3Kα.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c00620" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71055" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71055" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthias P. Wymann</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3349-4281" title="Orcid link">http://orcid.org/0000-0003-3349-4281</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#335e5247475b5a52401d444a5e525d5d73465d5a5152401d505b"><span class="__cf_email__" data-cfemail="d2bfb3a6a6babbb3a1fca5abbfb3bcbc92a7bcbbb0b3a1fcb1ba">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chiara Borsari</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4688-8362" title="Orcid link">http://orcid.org/0000-0002-4688-8362</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Erhan Keles</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Denise Rageot</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Treyer</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Biology, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4533-7761" title="Orcid link">http://orcid.org/0000-0002-4533-7761</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Thomas Bohnacker</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lukas Bissegger</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martina De Pascale</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Melone</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rohitha Sriramaratnam</span> - <span class="hlFld-Affiliation affiliation">Department
of Biomedicine, University of Basel, Mattenstrasse 28, 4058 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Florent Beaufils</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthias Hamburger</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
Biology, Pharmacenter, University of Basel, Klingelbergstrasse 50, 4056 Basel, Switzerland</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9331-273X" title="Orcid link">http://orcid.org/0000-0001-9331-273X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul Hebeisen</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wolfgang Löscher</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine, 30559 Hannover, Germany</span>; 
    <span class="hlFld-Affiliation affiliation">Center
for Systems Neuroscience, University of
Veterinary Medicine, 30559 Hannover, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Doriano Fabbro</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Petra Hillmann</span> - <span class="hlFld-Affiliation affiliation">PIQUR
Therapeutics AG, Hochbergerstrasse 60, 4057 Basel, Switzerland</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>This work was supported by the Innosuisse grant 37213.1 IP-LS, EU Horizon 2020, ITN 675392—Ph.D; the Novartis Foundation for medical-biological Research grant 14B095; the Swiss Commission for Technology and Innovation (CTI) by PFLS-LS grant 17241.1; the Stiftung für Krebsbekämpfung grant 341, the Swiss National Science Foundation grant 310030_189065 to MPW, the Peter and Traudl Engelhorn Foundation to RS, and a grant from the Epilepsy Foundation of America to WL.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): PHe, PHi, and DF are past employees of PIQUR Therapeutics AG, Basel; and PHe, DF, and MPW are shareholders of PIQUR Therapeutics AG.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_66082" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_66082" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank A. Pfaltz and A. M. Sele for advice and discussions; A. Dall’Asen and E. Teillet for contributions to synthetic efforts; and S. Bünger for technical assistance.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">mTOR</td><td class="NLM_def"><p class="first last">mechanistical (or mammalian) target of rapamycin</p></td></tr><tr><td class="NLM_term">TORC1</td><td class="NLM_def"><p class="first last">mTOR complex 1</p></td></tr><tr><td class="NLM_term">TORC2</td><td class="NLM_def"><p class="first last">mTOR complex 2</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">PKB</td><td class="NLM_def"><p class="first last">protein kinase B/Akt</p></td></tr><tr><td class="NLM_term">S6RP</td><td class="NLM_def"><p class="first last">ribosomal protein S6</p></td></tr><tr><td class="NLM_term">S6K</td><td class="NLM_def"><p class="first last">p70 S6 kinase</p></td></tr><tr><td class="NLM_term">VPS34</td><td class="NLM_def"><p class="first last">vacuolar protein sorting 34 (the class III PI3K)</p></td></tr><tr><td class="NLM_term">TORKi</td><td class="NLM_def"><p class="first last">mTOR kinase inhibitors</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">TR-FRET</td><td class="NLM_def"><p class="first last">time-resolved Förster resonance energy transfer</p></td></tr><tr><td class="NLM_term">TSC1</td><td class="NLM_def"><p class="first last">hamartin</p></td></tr><tr><td class="NLM_term">TSC2</td><td class="NLM_def"><p class="first last">tuberin</p></td></tr><tr><td class="NLM_term">TSC</td><td class="NLM_def"><p class="first last">tuberous sclerosis complex</p></td></tr><tr><td class="NLM_term">FKBP12</td><td class="NLM_def"><p class="first last">TORC1/rapalog/FK506 binding protein 12</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain barrier</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">EtOH</td><td class="NLM_def"><p class="first last">ethanol</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">CRISPR</td><td class="NLM_def"><p class="first last">clustered regularly interspaced short palindromic repeats</p></td></tr><tr><td class="NLM_term">Cas9</td><td class="NLM_def"><p class="first last">CRISPR-associated protein 9</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">efflux ratio</p></td></tr><tr><td class="NLM_term">MDCK</td><td class="NLM_def"><p class="first last">Madin–Darby canine kidney II cells</p></td></tr><tr><td class="NLM_term">MDR1</td><td class="NLM_def"><p class="first last">multidrug resistance protein 1, often referred to as P-glycoprotein</p></td></tr><tr><td class="NLM_term"><i>P</i><sub>app</sub></td><td class="NLM_def"><p class="first last">apparent permeability</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32423" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32423" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 56 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneiter, R.</span></span> <span> </span><span class="NLM_article-title">Lipid signalling in disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1038/nrm2335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fnrm2335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=18216772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=162-176&author=M.+P.+Wymannauthor=R.+Schneiter&title=Lipid+signalling+in+disease&doi=10.1038%2Fnrm2335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Lipid signalling in disease</span></div><div class="casAuthors">Wymann, Matthias P.; Schneiter, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-176</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Signaling lipids such as eicosanoids, phosphoinositides, sphingolipids and fatty acids control important cellular processes, including cell proliferation, apoptosis, metab. and migration.  Extracellular signals from cytokines, growth factors and nutrients control the activity of a key set of lipid-modifying enzymes: phospholipases, prostaglandin synthase, 5-lipoxygenase, phosphoinositide 3-kinase, sphingosine kinase and sphingomyelinase.  These enzymes and their downstream targets constitute a complex lipid signaling network with multiple nodes of interaction and cross-regulation.  Imbalances in this network contribute to the pathogenesis of human disease.  Although the function of a particular signaling lipid is traditionally studied in isolation, this review attempts a more integrated overview of the key role of these signaling lipids in inflammation, cancer and metabolic disease, and discusses emerging strategies for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZYZ1NX2T9QbVg90H21EOLACvtfcHk0lgw5s2eEefCSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D&md5=c96aabfdfa8e93c9e98386f1a407de85</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm2335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2335%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DSchneiter%26aufirst%3DR.%26atitle%3DLipid%2520signalling%2520in%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26spage%3D162%26epage%3D176%26doi%3D10.1038%2Fnrm2335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudge, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koos, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidialingam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">mTOR kinase structure, mechanism and regulation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>497</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/nature12122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fnature12122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=23636326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=497&publication_year=2013&pages=217-223&author=H.+Yangauthor=D.+G.+Rudgeauthor=J.+D.+Koosauthor=B.+Vaidialingamauthor=H.+J.+Yangauthor=N.+P.+Pavletich&title=mTOR+kinase+structure%2C+mechanism+and+regulation&doi=10.1038%2Fnature12122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR kinase structure, mechanism and regulation</span></div><div class="casAuthors">Yang, Haijuan; Rudge, Derek G.; Koos, Joseph D.; Vaidialingam, Bhamini; Yang, Hyo J.; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">497</span>
        (<span class="NLM_cas:issue">7448</span>),
    <span class="NLM_cas:pages">217-223</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase-related protein kinase, controls cell growth in response to nutrients and growth factors and is frequently deregulated in cancer.  Here we report co-crystal structures of a complex of truncated mTOR and mammalian lethal with SEC13 protein 8 (mLST8) with an ATP transition state mimic (MgF3-) and with ATP-site inhibitors (Torin2, PP242, and PI-103).  The structures reveal an intrinsically active kinase conformation, with catalytic residues and a catalytic mechanism remarkably similar to canonical protein kinases.  The active site is highly recessed owing to the FKBP12-rapamycin-binding (FRB) domain and an inhibitory helix protruding from the catalytic cleft.  MTOR-activating mutations map to the structural framework that holds these elements in place, indicating that the kinase is controlled by restricted access.  In vitro biochem. shows that the FRB domain acts as a gatekeeper, with its rapamycin-binding site interacting with substrates to grant them access to the restricted active site.  Rapamycin-FKBP12 inhibits the kinase by directly blocking substrate recruitment and by further restricting active-site access.  The structures also reveal active-site residues and conformational changes that underlie inhibitor potency and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjvPQtdm6yCbVg90H21EOLACvtfcHk0lgw5s2eEefCSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D&md5=07809555fbdf2004819a7f2da5727baf</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature12122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12122%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DRudge%26aufirst%3DD.%2BG.%26aulast%3DKoos%26aufirst%3DJ.%2BD.%26aulast%3DVaidialingam%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DH.%2BJ.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DmTOR%2520kinase%2520structure%252C%2520mechanism%2520and%2520regulation%26jtitle%3DNature%26date%3D2013%26volume%3D497%26spage%3D217%26epage%3D223%26doi%3D10.1038%2Fnature12122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarbassov, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1126/science.1106148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&author=D.+D.+Sarbassovauthor=D.+A.+Guertinauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Phosphorylation+and+regulation+of+Akt%2FPKB+by+the+rictor-mTOR+complex&doi=10.1126%2Fscience.1106148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0liPiT5pXICQKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DPhosphorylation%2520and%2520regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520rictor-mTOR%2520complex%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D1098%26epage%3D1101%26doi%3D10.1126%2Fscience.1106148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3-kinase in disease: timing, location, and scaffolding</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2005.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.ceb.2005.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=15780590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVCqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2005&pages=141-149&author=M.+P.+Wymannauthor=R.+Marone&title=Phosphoinositide+3-kinase+in+disease%3A+timing%2C+location%2C+and+scaffolding&doi=10.1016%2Fj.ceb.2005.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase in disease: timing, location, and scaffolding</span></div><div class="casAuthors">Wymann, Matthias P.; Marone, Romina</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-149</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  When PI3Ks are deregulated by aberrant surface receptors or modulators, accumulation of PtdIns(3,4,5)P3 leads to increased cell growth, proliferation and contact-independent survival.  The PI3K/PKB/TOR axis controls protein synthesis and growth, while PtdIns(3,4,5)P3-mediated activation of Rho GTPases directs cell motility.  PI3K activity has been linked to the formation of tumors, metastasis, chronic inflammation, allergy and cardiovascular disease.  Although increased PtdIns(3,4,5)P3 is a well-established cause of disease, it is seldom known which PI3K isoform is implied.  Recent work has demonstrated that PI3Kγ contributes to the control of cAMP levels in the cardiac system, where the protein acts as a scaffold, but not as a lipid kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhcm4IPHLzd7Vg90H21EOLACvtfcHk0liPiT5pXICQKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVCqtb4%253D&md5=d126dfae131b86e73e8842ec9149fd01</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2005.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2005.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DMarone%26aufirst%3DR.%26atitle%3DPhosphoinositide%25203-kinase%2520in%2520disease%253A%2520timing%252C%2520location%252C%2520and%2520scaffolding%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2005%26volume%3D17%26spage%3D141%26epage%3D149%26doi%3D10.1016%2Fj.ceb.2005.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fingar, D. C.</span></span> <span> </span><span class="NLM_article-title">Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>441</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1042/bj20110892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1042%2FBJ20110892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=22168436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgs7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=441&publication_year=2012&pages=1-21&author=B.+Magnusonauthor=B.+Ekimauthor=D.+C.+Fingar&title=Regulation+and+function+of+ribosomal+protein+S6+kinase+%28S6K%29+within+mTOR+signalling+networks&doi=10.1042%2Fbj20110892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks</span></div><div class="casAuthors">Magnuson, Brian; Ekim, Bilgen; Fingar, Diane C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">441</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The ribosomal protein S6K (S6 kinase) represents an extensively studied effector of the TORC1 [TOR (target of rapamycin) complex 1], which possesses important yet incompletely defined roles in cellular and organismal physiol.  TORC1 functions as an environmental sensor by integrating signals derived from diverse environmental cues to promote anabolic and inhibit catabolic cellular functions. mTORC1 (mammalian TORC1) phosphorylates and activates S6K1 and S6K2, whose first identified substrate was rpS6 (ribosomal protein S6), a component of the 40S ribosome.  Studies over the past decade have uncovered a no. of addnl. S6K1 substrates, revealing multiple levels at which the mTORC1-S6K1 axis regulates cell physiol.  The results thus far indicate that the mTORC1-S6K1 axis controls fundamental cellular processes, including transcription, translation, protein and lipid synthesis, cell growth/size and cell metab.  In the present review we summarize the regulation of S6Ks, their cellular substrates and functions, and their integration within rapidly expanding mTOR (mammalian TOR) signalling networks.  Although our understanding of the role of mTORC1-S6K1 signalling in physiol. remains in its infancy, evidence indicates that this signalling axis controls, at least in part, glucose homeostasis, insulin sensitivity, adipocyte metab., body mass and energy balance, tissue and organ size, learning, memory and aging.  As dysregulation of this signalling axis contributes to diverse disease states, improved understanding of S6K regulation and function within mTOR signalling networks may enable the development of novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAHhGhhxqDTbVg90H21EOLACvtfcHk0liPiT5pXICQKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgs7jK&md5=5d69e3be00deef02d3fce1ed2716873d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1042%2FBJ20110892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20110892%26sid%3Dliteratum%253Aachs%26aulast%3DMagnuson%26aufirst%3DB.%26aulast%3DEkim%26aufirst%3DB.%26aulast%3DFingar%26aufirst%3DD.%2BC.%26atitle%3DRegulation%2520and%2520function%2520of%2520ribosomal%2520protein%2520S6%2520kinase%2520%2528S6K%2529%2520within%2520mTOR%2520signalling%2520networks%26jtitle%3DBiochem.%2520J.%26date%3D2012%26volume%3D441%26spage%3D1%26epage%3D21%26doi%3D10.1042%2Fbj20110892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laplante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling in growth control and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.cell.2012.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=22500797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=274-293&author=M.+Laplanteauthor=D.+M.+Sabatini&title=mTOR+signaling+in+growth+control+and+disease&doi=10.1016%2Fj.cell.2012.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling in growth control and disease</span></div><div class="casAuthors">Laplante, Mathieu; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-293</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The mechanistic target of rapamycin (mTOR) signaling pathway senses and integrates a variety of environmental cues to regulate organismal growth and homeostasis.  The pathway regulates many major cellular processes and is implicated in an increasing no. of pathol. conditions, including cancer, obesity, type 2 diabetes, and neurodegeneration.  Here, we review recent advances in our understanding of the mTOR pathway and its role in health, disease, and aging.  We further discuss pharmacol. approaches to treat human pathologies linked to mTOR deregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjbKBX-sScfrVg90H21EOLACvtfcHk0lj0p0VHEOIO7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D&md5=d1adac8ec64da63358e0af26a17ceb4e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DLaplante%26aufirst%3DM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520in%2520growth%2520control%2520and%2520disease%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D274%26epage%3D293%26doi%3D10.1016%2Fj.cell.2012.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, B. D.</span></span> <span> </span><span class="NLM_article-title">The TSC1-TSC2 complex: a molecular switchboard controlling cell growth</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>412</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1042/bj20080281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1042%2FBJ20080281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=18466115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVWmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=412&publication_year=2008&pages=179-190&author=J.+Huangauthor=B.+D.+Manning&title=The+TSC1-TSC2+complex%3A+a+molecular+switchboard+controlling+cell+growth&doi=10.1042%2Fbj20080281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The TSC1-TSC2 complex: a molecular switchboard controlling cell growth</span></div><div class="casAuthors">Huang, Jingxiang; Manning, Brendan D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">412</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-190</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  TSC1 and TSC2 are the tumor-suppressor genes mutated in the tumor syndrome TSC (tuberous sclerosis complex).  Their gene products form a complex that has become the focus of many signal transduction researchers.  The TSC1-TSC2 (hamartin-tuberin) complex, through its GAP (GTPase-activating protein) activity towards the small G-protein Rheb (Ras homolog enriched in brain), is a crit. neg. regulator of mTORC1 (mammalian target of rapamycin complex 1).  As mTORC1 activity controls anabolic processes to promote cell growth, it is exquisitely sensitive to alterations in cell growth conditions.  Through numerous phosphorylation events, the TSC1-TSC2 complex has emerged as the sensor and integrator of these growth conditions, relaying signals from diverse cellular pathways to properly modulate mTORC1 activity.  In the present review we focus on the mol. details of TSC1-TSC2 complex regulation and function as it relates to the control of Rheb and mTORC1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp--nCqL_Pr2bVg90H21EOLACvtfcHk0lj0p0VHEOIO7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVWmsb8%253D&md5=6a9930e6edb37fdf9b1863fed58bf4a5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1042%2FBJ20080281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20080281%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DManning%26aufirst%3DB.%2BD.%26atitle%3DThe%2520TSC1-TSC2%2520complex%253A%2520a%2520molecular%2520switchboard%2520controlling%2520cell%2520growth%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D412%26spage%3D179%26epage%3D190%26doi%3D10.1042%2Fbj20080281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling in growth, metabolism, and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">960</span>– <span class="NLM_lpage">976</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.cell.2017.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=28283069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=960-976&author=R.+A.+Saxtonauthor=D.+M.+Sabatini&title=mTOR+signaling+in+growth%2C+metabolism%2C+and+disease&doi=10.1016%2Fj.cell.2017.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling in growth, metabolism, and disease</span></div><div class="casAuthors">Saxton, Robert A.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">960-976</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The mechanistic target of rapamycin (mTOR) coordinates eukaryotic cell growth and metab. with environmental inputs, including nutrients and growth factors.  Extensive research over the past two decades has established a central role for mTOR in regulating many fundamental cell processes, from protein synthesis to autophagy, and deregulated mTOR signaling is implicated in the progression of cancer and diabetes, as well as the aging process.  Here, we review recent advances in our understanding of mTOR function, regulation, and importance in mammalian physiol.  We also highlight how the mTOR signaling network contributes to human disease and discuss the current and future prospects for therapeutically targeting mTOR in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvvk5jg6e_MrVg90H21EOLACvtfcHk0lj0p0VHEOIO7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogtb4%253D&md5=3fdee3d04bf88d3aafc532d4e2f1e2dc</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DSaxton%26aufirst%3DR.%2BA.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520in%2520growth%252C%2520metabolism%252C%2520and%2520disease%26jtitle%3DCell%26date%3D2017%26volume%3D168%26spage%3D960%26epage%3D976%26doi%3D10.1016%2Fj.cell.2017.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiese, K.</span></span> <span> </span><span class="NLM_article-title">A critical kinase cascade in neurological disorders: PI 3-K, Akt, and mTOR</span>. <i>Future Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.2217/fnl.12.72</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.2217%2Ffnl.12.72" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=23144589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1arurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=733-748&author=Z.+Z.+Chongauthor=Y.+C.+Shangauthor=S.+Wangauthor=K.+Maiese&title=A+critical+kinase+cascade+in+neurological+disorders%3A+PI+3-K%2C+Akt%2C+and+mTOR&doi=10.2217%2Ffnl.12.72"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A critical kinase cascade in neurological disorders: PI3K, Akt and mTOR</span></div><div class="casAuthors">Chong, Zhao Zhong; Shang, Yan Chen; Wang, Shaohui; Maiese, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Future Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">733-748</span>CODEN:
                <span class="NLM_cas:coden">FNUEAM</span>;
        ISSN:<span class="NLM_cas:issn">1479-6708</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative disorders lead to disability and death in a significant proportion of the world's population.  However, many disorders of the nervous system remain with limited effective treatments.  Kinase pathways in the nervous system that involve PI3K, Akt and mTOR offer exciting prospects for the understanding of neurodegenerative pathways and the development of new avenues of treatment.  PI3K, Akt and mTOR pathways are vital cellular components that det. cell fate during acute and chronic disorders, such as Huntington's disease, Alzheimer's disease, Parkinson's disease, epilepsy, stroke and trauma.  However, the elaborate relationship among these kinases and the variable control of apoptosis and autophagy can lead to unanticipated biol. and clin. outcomes.  Crucial for the successful translation of PI3K, Akt and mTOR into robust and safe clin. strategies will be the further elucidation of the complex roles that these kinase pathways hold in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwPmFj7IKN_bVg90H21EOLACvtfcHk0ljfUc5kNCOcSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1arurzF&md5=c5cc5591ce4bff7df6fce079b5ad5147</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2217%2Ffnl.12.72&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffnl.12.72%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DZ.%2BZ.%26aulast%3DShang%26aufirst%3DY.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMaiese%26aufirst%3DK.%26atitle%3DA%2520critical%2520kinase%2520cascade%2520in%2520neurological%2520disorders%253A%2520PI%25203-K%252C%2520Akt%252C%2520and%2520mTOR%26jtitle%3DFuture%2520Neurol.%26date%3D2012%26volume%3D7%26spage%3D733%26epage%3D748%26doi%3D10.2217%2Ffnl.12.72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curatolo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moavero, R.</span></span> <span> </span><span class="NLM_article-title">mTOR inhibitors in tuberous sclerosis complex</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.2174/157015912804499537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.2174%2F157015912804499537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=23730262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1OltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=404-415&author=P.+Curatoloauthor=R.+Moavero&title=mTOR+inhibitors+in+tuberous+sclerosis+complex&doi=10.2174%2F157015912804499537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR inhibitors in tuberous sclerosis complex</span></div><div class="casAuthors">Curatolo, Paolo; Moavero, Romina</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">404-415</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tuberous sclerosis complex (TSC) is a genetic multiple organ system disorder that is characterized by the development of tumor-like lesions (hamartomas) and neurodevelopmental disorders.  Mutations in the TSC1 and TSC2 tumor suppressor genes occur in the majority of patients with TSC, resulting in hyperactivation of the mammalian target of rapamycin (mTOR) signaling pathway and subsequent abnormalities in numerous cell processes.  As a result, mTOR inhibitors such as sirolimus and everolimus have the potential to provide targeted therapy for patients with TSC.  Everolimus is the first mTOR inhibitor approved as a treatment option in the USA and in Europe for patients with subependymal giant-cell astrocytomas (SEGAs) assocd. with TSC.  The clin. evidence to date supports the use of mTOR inhibitors in a variety of TSC-assocd. disease manifestations, including SEGAs, renal angiomyolipoma, skin manifestations, and epilepsy.  Furthermore, ongoing clin. trials evaluating mTOR inhibitors in TSC are underway, and the results of these studies are expected to provide further evidence that will firmly establish their role in this setting.  This article will discuss the role of the mTOR pathway in TSC and review the pharmacokinetics, pharmacodynamics, clin. efficacy, and tolerability of mTOR inhibitors, along with their current place in clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3BCN87Zy1qbVg90H21EOLACvtfcHk0ljfUc5kNCOcSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1OltA%253D%253D&md5=553975de19df0a1cf004ff14459f5bf3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F157015912804499537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157015912804499537%26sid%3Dliteratum%253Aachs%26aulast%3DCuratolo%26aufirst%3DP.%26aulast%3DMoavero%26aufirst%3DR.%26atitle%3DmTOR%2520inhibitors%2520in%2520tuberous%2520sclerosis%2520complex%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2012%26volume%3D10%26spage%3D404%26epage%3D415%26doi%3D10.2174%2F157015912804499537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Structure of the FKBP1 2-rapamycin complex interacting with the binding domain of human FRAP</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1126/science.273.5272.239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1126%2Fscience.273.5272.239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=8662507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1996&pages=239-242&author=J.+Choiauthor=J.+Chenauthor=S.+L.+Schreiberauthor=J.+Clardy&title=Structure+of+the+FKBP1+2-rapamycin+complex+interacting+with+the+binding+domain+of+human+FRAP&doi=10.1126%2Fscience.273.5272.239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span></div><div class="casAuthors">Choi, Jungwon; Chen, Jie; Schreiber, Stuart L.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">5272</span>),
    <span class="NLM_cas:pages">239-242</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-assocd. protein (FRAP).  A crystal structure of the ternary complex of human FKBP12, rapamycin, and the FKBP12-rapamycin-binding (FRB) domain of human FRAP at a resoln. of 2.7 angstroms revealed the two proteins bound together as a result of the ability of rapamycin to occupy two different hydrophobic binding pockets simultaneously.  The structure shows extensive interactions between rapamycin and both proteins, but fewer interactions between the proteins.  The structure of the FRB domain of FRAP clarifies both rapamycin-independent and -dependent effects obsd. for mutants of FRAP and its homologs in the family of proteins related to the ataxia-telangiectasis mutant gene product, and it illustrates how a small cell-permeable mol. can mediate protein dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwBLM2PsItYLVg90H21EOLACvtfcHk0ljfUc5kNCOcSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D&md5=c72a82e14c09d9a705215b4ac0525336</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1126%2Fscience.273.5272.239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.273.5272.239%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520FKBP1%25202-rapamycin%2520complex%2520interacting%2520with%2520the%2520binding%2520domain%2520of%2520human%2520FRAP%26jtitle%3DScience%26date%3D1996%26volume%3D273%26spage%3D239%26epage%3D242%26doi%3D10.1126%2Fscience.273.5272.239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamming, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baur, J. A.</span></span> <span> </span><span class="NLM_article-title">Rapalogs and mTOR inhibitors as anti-aging therapeutics</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">980</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1172/jci64099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1172%2FJCI64099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=23454761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVyhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=980-989&author=D.+W.+Lammingauthor=L.+Yeauthor=D.+M.+Sabatiniauthor=J.+A.+Baur&title=Rapalogs+and+mTOR+inhibitors+as+anti-aging+therapeutics&doi=10.1172%2Fjci64099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Rapalogs and mTOR inhibitors as anti-aging therapeutics</span></div><div class="casAuthors">Lamming, Dudley W.; Ye, Lan; Sabatini, David M.; Baur, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">980-989</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest exptl. support to date as a potential anti-aging therapeutic in mammals.  Unlike many other compds. that have been claimed to influence longevity, rapamycin has been repeatedly tested in long-lived, genetically heterogeneous mice, in which it extends both mean and max. life spans.  However, the mechanism that accounts for these effects is far from clear, and a growing list of side effects make it doubtful that rapamycin would ultimately be beneficial in humans.  This Review discusses the prospects for developing newer, safer anti-aging therapies based on analogs of rapamycin (termed rapalogs) or other approaches targeting mTOR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEaK-wCiklj7Vg90H21EOLACvtfcHk0ljfUc5kNCOcSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVyhsLs%253D&md5=4e5478c2f66e1bb34368100a7d4c152a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1172%2FJCI64099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI64099%26sid%3Dliteratum%253Aachs%26aulast%3DLamming%26aufirst%3DD.%2BW.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26aulast%3DBaur%26aufirst%3DJ.%2BA.%26atitle%3DRapalogs%2520and%2520mTOR%2520inhibitors%2520as%2520anti-aging%2520therapeutics%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D980%26epage%3D989%26doi%3D10.1172%2Fjci64099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M.</span></span> <span> </span><span class="NLM_article-title">Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.1002/ana.21331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1002%2Fana.21331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=18389497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFGqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2008&pages=444-453&author=L.-H.+Zengauthor=L.+Xuauthor=D.+H.+Gutmannauthor=M.+Wong&title=Rapamycin+prevents+epilepsy+in+a+mouse+model+of+tuberous+sclerosis+complex&doi=10.1002%2Fana.21331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex</span></div><div class="casAuthors">Zeng, Ling-Hui; Xu, Lin; Gutmann, David H.; Wong, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">444-453</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: Tuberous sclerosis complex (TSC) represents one of the most common genetic causes of epilepsy.  TSC gene inactivation leads to hyperactivation of the mammalian target of rapamycin signaling pathway, raising the intriguing possibility that mammalian target of rapamycin inhibitors might be effective in preventing or treating epilepsy in patients with TSC.  Mice with conditional inactivation of the Tsc1 gene primarily in glia (Tsc1GFAPCKO mice) develop glial proliferation, progressive epilepsy, and premature death.  Here, we tested whether rapamycin could prevent or reverse epilepsy, as well as other cellular and mol. brain abnormalities in Tsc1GFAPCKO mice.  Methods: Tsc1GFAPCKO mice and littermate control animals were treated with rapamycin or vehicle starting at postnatal day 14 (early treatment) or 6 wk of age (late treatment), corresponding to times before and after onset of neurol. abnormalities in Tsc1GFAPCKO mice.  Mice were monitored for seizures by serial video-EEG and for long-term survival.  Brains were examd. histol. for astrogliosis and neuronal organization.  Expression of phospho-S6 and other mol. markers correlating with epileptogenesis was measured by Western blotting.  Results: Early treatment with rapamycin prevented the development of epilepsy and premature death obsd. in vehicle-treated Tsc1GFAPCKO mice.  Late treatment with rapamycin suppressed seizures and prolonged survival in Tsc1GFAPCKO mice that had already developed epilepsy.  Correspondingly, rapamycin inhibited the abnormal activation of the mammalian target of rapamycin pathway, astrogliosis, and neuronal disorganization, and increased brain size in Tsc1GFAPCKO mice.  Interpretation: Rapamycin has strong efficacy for preventing seizures and prolonging survival in Tsc1GFAPCKO mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDrvRnEyf-tLVg90H21EOLACvtfcHk0lgUa3yDn8zuDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFGqt7c%253D&md5=e4dbf8b71250ec0594029fed56c0d8c2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fana.21331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.21331%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DL.-H.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DGutmann%26aufirst%3DD.%2BH.%26aulast%3DWong%26aufirst%3DM.%26atitle%3DRapamycin%2520prevents%2520epilepsy%2520in%2520a%2520mouse%2520model%2520of%2520tuberous%2520sclerosis%2520complex%26jtitle%3DAnn.%2520Neurol.%26date%3D2008%26volume%3D63%26spage%3D444%26epage%3D453%26doi%3D10.1002%2Fana.21331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meikle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollizzi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egnor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramvis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. J.</span></span> <span> </span><span class="NLM_article-title">Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">5422</span>– <span class="NLM_lpage">5432</span>, <span class="refDoi"> DOI: 10.1523/jneurosci.0955-08.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1523%2FJNEUROSCI.0955-08.2008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=18495876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslWisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=5422-5432&author=L.+Meikleauthor=K.+Pollizziauthor=A.+Egnorauthor=I.+Kramvisauthor=H.+Laneauthor=M.+Sahinauthor=D.+J.+Kwiatkowski&title=Response+of+a+neuronal+model+of+tuberous+sclerosis+to+mammalian+target+of+rapamycin+%28mTOR%29+inhibitors%3A+effects+on+mTORC1+and+Akt+signaling+lead+to+improved+survival+and+function&doi=10.1523%2Fjneurosci.0955-08.2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function</span></div><div class="casAuthors">Meikle, Lynsey; Pollizzi, Kristen; Egnor, Anna; Kramvis, Ioannis; Lane, Heidi; Sahin, Mustafa; Kwiatkowski, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5422-5432</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Tuberous sclerosis (TSC) is a hamartoma syndrome attributable to mutations in either TSC1 or TSC2 in which brain involvement causes epilepsy, mental retardation, and autism.  We have reported recently a mouse neuronal model of TSC in which Tsc1 is ablated in most neurons during cortical development.  We have tested rapamycin and RAD001 [40-O-(2-hydroxyethyl)-rapamycin], both mammalian target of rapamycin mTORC1 inhibitors, as potential therapeutic agents in this model.  Median survival is improved from 33 d to more than 100 d; behavior, phenotype, and wt. gain are all also markedly improved.  There is brain penetration of both drugs, with accumulation over time with repetitive treatment, and effective redn. of levels of phospho-S6, a downstream target of mTORC1.  In addn., there is restoration of phospho-Akt and phospho-glycogen synthase kinase 3 levels in the treated mice, consistent with restoration of Akt function.  Neurofilament abnormalities, myelination, and cell enlargement are all improved by the treatment.  However, dysplastic neuronal features persist, and there are only modest changes in dendritic spine d. and length.  Strikingly, mice treated with rapamycin or RAD001 for 23 d only (postnatal days 7-30) displayed a persistent improvement in phenotype, with median survival of 78 d.  In summary, rapamycin/RAD001 are highly effective therapies for this neuronal model of TSC, with benefit apparently attributable to effects on mTORC1 and Akt signaling and, consequently, cell size and myelination.  Although caution is appropriate, the results suggest the possibility that rapamycin/RAD001 may have benefit in the treatment of TSC brain disease, including infantile spasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7NYIU5vQOo7Vg90H21EOLACvtfcHk0lgUa3yDn8zuDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslWisbY%253D&md5=213ca3d5a365d9fc0bddf139fd97a278</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0955-08.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0955-08.2008%26sid%3Dliteratum%253Aachs%26aulast%3DMeikle%26aufirst%3DL.%26aulast%3DPollizzi%26aufirst%3DK.%26aulast%3DEgnor%26aufirst%3DA.%26aulast%3DKramvis%26aufirst%3DI.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DSahin%26aufirst%3DM.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BJ.%26atitle%3DResponse%2520of%2520a%2520neuronal%2520model%2520of%2520tuberous%2520sclerosis%2520to%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitors%253A%2520effects%2520on%2520mTORC1%2520and%2520Akt%2520signaling%2520lead%2520to%2520improved%2520survival%2520and%2520function%26jtitle%3DJ.%2520Neurosci.%26date%3D2008%26volume%3D28%26spage%3D5422%26epage%3D5432%26doi%3D10.1523%2Fjneurosci.0955-08.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lechuga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz, D. N.</span></span> <span> </span><span class="NLM_article-title">Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">925</span>, <span class="refDoi"> DOI: 10.1080/14737175.2019.1635457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1080%2F14737175.2019.1635457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=31335226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVeru7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=913-925&author=L.+Lechugaauthor=D.+N.+Franz&title=Everolimus+as+adjunctive+therapy+for+tuberous+sclerosis+complex-associated+partial-onset+seizures&doi=10.1080%2F14737175.2019.1635457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures</span></div><div class="casAuthors">Lechuga, Lorena; Franz, David Neal</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">913-925</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Tuberous sclerosis complex (TSC) is a rare genetic disorder resulting in benign tumors in various organs.  It is caused by mutations in TSC1 or TSC2 genes causing hyperactivation of the mammalian target of rapamycin (mTOR) pathway.  The majority of patients with TSC develop epilepsy, and approx. two-thirds become refractory to antiepileptic drugs (AEDs).  Recently, the mTOR inhibitor everolimus was approved as adjunctive therapy for TSC-assocd. partial seizures.  This article covers different characteristics of everolimus, including major clin. trials leading to its approval in TSC-assocd.  Partial seizures, safety concerns, drug pharmacokinetics/pharmacodynamics, and an overview of potential competitors and other agents used to treat TSC-assocd. seizures.  Unlike many other therapies for treating TSC-assocd. seizures, everolimus addresses the underlying pathophysiol. of TSC, and since it has also been shown to improve other TSC manifestations such as subependymal giant cell astrocytomas and renal angiomyolipomas, everolimus provides a potential multisystemic therapy for TSC.  An important avenue for future research is exploring the possible use of everolimus as a preventative treatment for seizures as there is the potential to prevent neg. developmental outcomes assocd. with TSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnc7QK8A8_A7Vg90H21EOLACvtfcHk0lgUa3yDn8zuDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVeru7%252FJ&md5=f89e8a45cc0e69ecc0a5098f3240f36d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1080%2F14737175.2019.1635457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737175.2019.1635457%26sid%3Dliteratum%253Aachs%26aulast%3DLechuga%26aufirst%3DL.%26aulast%3DFranz%26aufirst%3DD.%2BN.%26atitle%3DEverolimus%2520as%2520adjunctive%2520therapy%2520for%2520tuberous%2520sclerosis%2520complex-associated%2520partial-onset%2520seizures%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2019%26volume%3D19%26spage%3D913%26epage%3D925%26doi%3D10.1080%2F14737175.2019.1635457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">French, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yapici, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polster, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabbout, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curatolo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dlugos, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz, D. N.</span></span> <span> </span><span class="NLM_article-title">Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>388</i></span>,  <span class="NLM_fpage">2153</span>– <span class="NLM_lpage">2163</span>, <span class="refDoi"> DOI: 10.1016/s0140-6736(16)31419-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2FS0140-6736%2816%2931419-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=27613521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2016&pages=2153-2163&author=J.+A.+Frenchauthor=J.+A.+Lawsonauthor=Z.+Yapiciauthor=H.+Ikedaauthor=T.+Polsterauthor=R.+Nabboutauthor=P.+Curatoloauthor=P.+J.+de+Vriesauthor=D.+J.+Dlugosauthor=N.+Berkowitzauthor=M.+Voiauthor=S.+Peyrardauthor=D.+Pelovauthor=D.+N.+Franz&title=Adjunctive+everolimus+therapy+for+treatment-resistant+focal-onset+seizures+associated+with+tuberous+sclerosis+%28EXIST-3%29%3A+a+phase+3%2C+randomised%2C+double-blind%2C+placebo-controlled+study&doi=10.1016%2Fs0140-6736%2816%2931419-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study</span></div><div class="casAuthors">French, Jacqueline A.; Lawson, John A.; Yapici, Zuhal; Ikeda, Hiroko; Polster, Tilman; Nabbout, Rima; Curatolo, Paolo; de Vries, Petrus J.; Dlugos, Dennis J.; Berkowitz, Noah; Voi, Maurizio; Peyrard, Severine; Pelov, Diana; Franz, David N.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">10056</span>),
    <span class="NLM_cas:pages">2153-2163</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used for various benign tumors assocd. with tuberous sclerosis complex.  We assessed the efficacy and safety of two trough exposure concns. of everolimus, 3-7 ng/mL (low exposure) and 9-15 ng/mL (high exposure), compared with placebo as adjunctive therapy for treatment-resistant focal-onset seizures in tuberous sclerosis complex.  In this phase 3, randomised, double-blind, placebo-controlled study, eligible patients aged 2-65 years with tuberous sclerosis complex and treatment-resistant seizures (≥16 in an 8-wk baseline phase) receiving one to three concomitant antiepileptic drugs were recruited from 99 centers across 25 countries.  Participants were randomly assigned (1:1:1), via permuted-block randomisation (block size of six) implemented by Interactive Response Technol. software, to receive placebo, low-exposure everolimus, or high-exposure everolimus.  Randomisation was stratified by age subgroup (<6 years, 6 to <12 years, 12 to <18 years, and ≥18 years).  Patients, investigators, site personnel, and the sponsor's study team were masked to treatment allocation.  The starting dose of everolimus depended on age, body-surface area, and concomitant use of cytochrome 3A4/P-glycoprotein inducers.  Dose adjustments were done to attain target trough ranges during a 6-wk titrn. period, and as needed during a 12-wk maintenance period of core phase.  Patients or their caregivers recorded events in a seizure diary throughout the study.  The primary endpoint was change from baseline in the frequency of seizures during the maintenance period, defined as response rate (the proportion of patients achieving ≥50% redn. in seizure frequency) and median percentage redn. in seizure frequency, in all randomised patients.  This study is registered with ClinicalTrials.gov, no. NCT01713946.  Between July 3, 2013, and May 29, 2015, 366 patients were enrolled and randomly assigned to placebo (n=119), low-exposure everolimus, (n=117), or high-exposure everolimus (n=130).  The response rate was 15·1% with placebo (95% CI 9·2-22·8; 18 patients) compared with 28·2% for low-exposure everolimus (95% CI 20·3-37·3; 33 patients; p=0·0077) and 40·0% for high-exposure everolimus (95% CI 31·5-49·0; 52 patients; p<0·0001).  The median percentage redn. in seizure frequency was 14·9% (95% CI 0·1-21·7) with placebo vs. 29·3% with low-exposure everolimus (95% CI 18·8-41·9; p=0·0028) and 39·6% with high-exposure everolimus (95% CI 35·0-48·7; p<0·0001).  Grade 3 or 4 adverse events occurred in 13 (11%) patients in the placebo group, 21 (18%) in the low-exposure group, and 31 (24%) in the high-exposure group.  Serious adverse events were reported in three (3%) patients who received placebo, 16 (14%) who received low-exposure everolimus, and 18 (14%) who received high-exposure everolimus.  Adverse events led to treatment discontinuation in two (2%) patients in the placebo group vs. six (5%) in the low-exposure group and four (3%) in the high-exposure group.  Adjunctive everolimus treatment significantly reduced seizure frequency with a tolerable safety profile compared with placebo in patients with tuberous sclerosis complex and treatment-resistant seizures.  Novartis Pharmaceuticals Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkOznXjnuKq7Vg90H21EOLACvtfcHk0ljSFyZYJpgxfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOmurnM&md5=2458350eed0afd4d990ff721ff01ab89</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2816%2931419-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252816%252931419-2%26sid%3Dliteratum%253Aachs%26aulast%3DFrench%26aufirst%3DJ.%2BA.%26aulast%3DLawson%26aufirst%3DJ.%2BA.%26aulast%3DYapici%26aufirst%3DZ.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DPolster%26aufirst%3DT.%26aulast%3DNabbout%26aufirst%3DR.%26aulast%3DCuratolo%26aufirst%3DP.%26aulast%3Dde%2BVries%26aufirst%3DP.%2BJ.%26aulast%3DDlugos%26aufirst%3DD.%2BJ.%26aulast%3DBerkowitz%26aufirst%3DN.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DPeyrard%26aufirst%3DS.%26aulast%3DPelov%26aufirst%3DD.%26aulast%3DFranz%26aufirst%3DD.%2BN.%26atitle%3DAdjunctive%2520everolimus%2520therapy%2520for%2520treatment-resistant%2520focal-onset%2520seizures%2520associated%2520with%2520tuberous%2520sclerosis%2520%2528EXIST-3%2529%253A%2520a%2520phase%25203%252C%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DLancet%26date%3D2016%26volume%3D388%26spage%3D2153%26epage%3D2163%26doi%3D10.1016%2Fs0140-6736%2816%2931419-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravikumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oroz, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaravilli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duden, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Kane, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinsztein, D. C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1038/ng1362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fng1362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=15146184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVajt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=585-595&author=B.+Ravikumarauthor=C.+Vacherauthor=Z.+Bergerauthor=J.+E.+Daviesauthor=S.+Luoauthor=L.+G.+Orozauthor=F.+Scaravilliauthor=D.+F.+Eastonauthor=R.+Dudenauthor=C.+J.+O%E2%80%99Kaneauthor=D.+C.+Rubinsztein&title=Inhibition+of+mTOR+induces+autophagy+and+reduces+toxicity+of+polyglutamine+expansions+in+fly+and+mouse+models+of+Huntington+disease&doi=10.1038%2Fng1362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease</span></div><div class="casAuthors">Ravikumar, Brinda; Vacher, Coralie; Berger, Zdenek; Davies, Janet E.; Luo, Shouqing; Oroz, Lourdes G.; Scaravilli, Francesco; Easton, Douglas F.; Duden, Rainer; O'Kane, Cahir J.; Rubinsztein, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">585-595</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Huntington disease is one of nine inherited neurodegenerative disorders caused by a polyglutamine tract expansion.  Expanded polyglutamine proteins accumulate abnormally in intracellular aggregates.  Here we show that mammalian target of rapamycin (mTOR) is sequestered in polyglutamine aggregates in cell models, transgenic mice and human brains.  Sequestration of mTOR impairs its kinase activity and induces autophagy, a key clearance pathway for mutant huntingtin fragments.  This protects against polyglutamine toxicity, as the specific mTOR inhibitor rapamycin attenuates huntingtin accumulation and cell death in cell models of Huntington disease, and inhibition of autophagy has the converse effects.  Furthermore, rapamycin protects against neurodegeneration in a fly model of Huntington disease, and the rapamycin analog CCI-779 improved performance on four different behavioral tasks and decreased aggregate formation in a mouse model of Huntington disease.  Our data provide proof-of-principle for the potential of inducing autophagy to treat Huntington disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe6pwZ9IPbhLVg90H21EOLACvtfcHk0ljSFyZYJpgxfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVajt7s%253D&md5=39f48bebe54daa65eb21715819b703c4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fng1362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1362%26sid%3Dliteratum%253Aachs%26aulast%3DRavikumar%26aufirst%3DB.%26aulast%3DVacher%26aufirst%3DC.%26aulast%3DBerger%26aufirst%3DZ.%26aulast%3DDavies%26aufirst%3DJ.%2BE.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DOroz%26aufirst%3DL.%2BG.%26aulast%3DScaravilli%26aufirst%3DF.%26aulast%3DEaston%26aufirst%3DD.%2BF.%26aulast%3DDuden%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DC.%2BJ.%26aulast%3DRubinsztein%26aufirst%3DD.%2BC.%26atitle%3DInhibition%2520of%2520mTOR%2520induces%2520autophagy%2520and%2520reduces%2520toxicity%2520of%2520polyglutamine%2520expansions%2520in%2520fly%2520and%2520mouse%2520models%2520of%2520Huntington%2520disease%26jtitle%3DNat.%2520Genet.%26date%3D2004%26volume%3D36%26spage%3D585%26epage%3D595%26doi%3D10.1038%2Fng1362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rischert, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riess, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. P.</span></span> <span> </span><span class="NLM_article-title">Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">107812</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2019.107812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.neuropharm.2019.107812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=31622602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrtrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2020&pages=107812&author=E.+Singerauthor=C.+Walterauthor=D.+Fabbroauthor=D.+Rageotauthor=F.+Beaufilsauthor=M.+P.+Wymannauthor=N.+Rischertauthor=O.+Riessauthor=P.+Hillmannauthor=H.+P.+Nguyen&title=Brain-penetrant+PQR620+mTOR+and+PQR530+PI3K%2FmTOR+inhibitor+reduce+huntingtin+levels+in+cell+models+of+HD&doi=10.1016%2Fj.neuropharm.2019.107812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD</span></div><div class="casAuthors">Singer, Elisabeth; Walter, Carolin; Fabbro, Doriano; Rageot, Denise; Beaufils, Florent; Wymann, Matthias P.; Rischert, Nadine; Riess, Olaf; Hillmann, Petra; Nguyen, Huu Phuc</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107812</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">One of the pathol. hallmarks of Huntington disease (HD) is accumulation of the disease-causing mutant huntingtin (mHTT), which leads to the disruption of a variety of cellular functions, ultimately resulting in cell death.  Induction of autophagy, for example by the inhibition of mechanistic target of rapamycin (mTOR) signaling, has been shown to reduce HTT levels and aggregates.  The ability to cross the blood-brain barrier of first generation catalytic mTOR inhibitors has so far been limited, and therefore sufficient target coverage in the brain could not be reached.  Two novel, brain penetrant compds. - the mTORC1/2 inhibitor PQR620, and the dual pan-phosphoinositide 3-kinase (PI3K) and mTORC1/2 kinase inhibitor PQR530 - were evaluated by assessing their potential to induce autophagy and reducing mHTT levels.  For this purpose, expression levels of autophagic markers and well-defined mTOR targets were analyzed in STHdh cells and HEK293T cells and in mouse brains.  Both compds. potently inhibited mTOR signaling in cell models as well as in mouse brain.  As proof of principle, redn. of aggregates and levels of sol. mHTT were demonstrated upon treatment with both compds.  Originally developed for cancer treatment, these second generation mTORC1/2 and PI3K/mTOR inhibitors show brain penetrance and efficacy in cell models of HD, making them candidate mols. for further investigations in HD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwQIRL7T6QKbVg90H21EOLACvtfcHk0ljSFyZYJpgxfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrtrzN&md5=d7c200ebfc6aa514973d8685d1e7e4ef</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2019.107812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2019.107812%26sid%3Dliteratum%253Aachs%26aulast%3DSinger%26aufirst%3DE.%26aulast%3DWalter%26aufirst%3DC.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DRischert%26aufirst%3DN.%26aulast%3DRiess%26aufirst%3DO.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DNguyen%26aufirst%3DH.%2BP.%26atitle%3DBrain-penetrant%2520PQR620%2520mTOR%2520and%2520PQR530%2520PI3K%252FmTOR%2520inhibitor%2520reduce%2520huntingtin%2520levels%2520in%2520cell%2520models%2520of%2520HD%26jtitle%3DNeuropharmacology%26date%3D2020%26volume%3D162%26spage%3D107812%26doi%3D10.1016%2Fj.neuropharm.2019.107812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talboom, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oddo, S.</span></span> <span> </span><span class="NLM_article-title">The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer’s disease</span>. <i>npj Aging Mech. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">15008</span>, <span class="refDoi"> DOI: 10.1038/npjamd.2015.8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fnpjamd.2015.8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=28721257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A280%3ADC%252BC1cjovFaisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=15008&author=J.+S.+Talboomauthor=R.+Velazquezauthor=S.+Oddo&title=The+mammalian+target+of+rapamycin+at+the+crossroad+between+cognitive+aging+and+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fnpjamd.2015.8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer's disease</span></div><div class="casAuthors">Talboom Joshua S; Velazquez Ramon; Oddo Salvatore; Oddo Salvatore</div><div class="citationInfo"><span class="NLM_cas:title">NPJ aging and mechanisms of disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15008</span>
        ISSN:<span class="NLM_cas:issn">2056-3973</span>.
    </div><div class="casAbstract">Age-dependent cognitive decline is a major debilitating event affecting even individuals who are otherwise healthy.  Understanding the molecular basis underlying these changes may increase the healthspan of the elderly population.  It may also reveal insights into the pathogenesis of numerous neurodegenerative disorders characterized by cognitive deficits, as aging is the major risk factor for most of these disorders.  Alzheimer's disease (AD), the most common neurodegenerative disorder, first manifests itself as deficits in encoding new memories.  As AD progresses, these deficits spread to other cognitive domains that further debilitate the person before contributing to their demise.  Suppression of the mammalian target of rapamycin (mTOR) increases healthspan and lifespan in several organisms.  Numerous reports have linked alterations in mTOR signaling to age-dependent cognitive decline and the pathogenesis of AD.  This review will discuss recent work highlighting the complex role of mTOR in cognitive aging and in the pathogenesis of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA0TQF8zU3rf69nzq6467DfW6udTcc2eYx58dYfi7Ltrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjovFaisg%253D%253D&md5=3a98d9e1b3facf63a929fa6d5d35667c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnpjamd.2015.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpjamd.2015.8%26sid%3Dliteratum%253Aachs%26aulast%3DTalboom%26aufirst%3DJ.%2BS.%26aulast%3DVelazquez%26aufirst%3DR.%26aulast%3DOddo%26aufirst%3DS.%26atitle%3DThe%2520mammalian%2520target%2520of%2520rapamycin%2520at%2520the%2520crossroad%2520between%2520cognitive%2520aging%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3Dnpj%2520Aging%2520Mech.%2520Dis.%26date%3D2015%26volume%3D1%26spage%3D15008%26doi%3D10.1038%2Fnpjamd.2015.8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyaswamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamoorthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreenivasmurthy, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, B. C.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span> <span> </span><span class="NLM_article-title">Balancing mTOR signaling and autophagy in the treatment of Parkinson’s disease</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">728</span>, <span class="refDoi"> DOI: 10.3390/ijms20030728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.3390%2Fijms20030728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlSiu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=728&author=Z.+Zhuauthor=C.+Yangauthor=A.+Iyaswamyauthor=S.+Krishnamoorthiauthor=S.+G.+Sreenivasmurthyauthor=J.+Liuauthor=Z.+Wangauthor=B.+C.-K.+Tongauthor=J.+Songauthor=J.+Luauthor=K.-H.+Cheungauthor=M.+Li&title=Balancing+mTOR+signaling+and+autophagy+in+the+treatment+of+Parkinson%E2%80%99s+disease&doi=10.3390%2Fijms20030728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Balancing mTOR signaling and autophagy in the treatment of Parkinson's disease</span></div><div class="casAuthors">Zhu, Zhou; Yang, Chuanbin; Iyaswamy, Ashok; Krishnamoorthi, Senthilkumar; Sreenivasmurthy, Sravan Gopalkrishnashetty; Liu, Jia; Wang, Ziying; Tong, Benjamin Chun-Kit; Song, Juxian; Lu, Jiahong; Cheung, King-Ho; Li, Min</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">728</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The mammalian target of rapamycin (mTOR) signaling pathway plays a crit. role in regulating cell growth, proliferation, and life span. mTOR signaling is a central regulator of autophagy by modulating multiple aspects of the autophagy process, such as initiation, process, and termination through controlling the activity of the unc51-like kinase 1 (ULK1) complex and vacuolar protein sorting 34 (VPS34) complex, and the intracellular distribution of TFEB/TFE3 and proto-lysosome tubule reformation.  Parkinson's disease (PD) is a serious, common neurodegenerative disease characterized by dopaminergic neuron loss in the substantia nigra pars compacta (SNpc) and the accumulation of Lewy bodies.  An increasing amt. of evidence indicates that mTOR and autophagy are crit. for the pathogenesis of PD.  In this review, we will summarize recent advances regarding the roles of mTOR and autophagy in PD pathogenesis and treatment.  Further characterizing the dysregulation of mTOR pathway and the clin. translation of mTOR modulators in PD may offer exciting new avenues for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHXDgDatWGKLVg90H21EOLACvtfcHk0ljgSV7Chw0tpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlSiu7%252FJ&md5=ab0cd13fd00eb28c9dbd2f4ac02110ff</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3390%2Fijms20030728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20030728%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DIyaswamy%26aufirst%3DA.%26aulast%3DKrishnamoorthi%26aufirst%3DS.%26aulast%3DSreenivasmurthy%26aufirst%3DS.%2BG.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTong%26aufirst%3DB.%2BC.-K.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DK.-H.%26aulast%3DLi%26aufirst%3DM.%26atitle%3DBalancing%2520mTOR%2520signaling%2520and%2520autophagy%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D728%26doi%3D10.3390%2Fijms20030728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilfong, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mays, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talley, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agricola, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tudor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland-Bouley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz, D. N.</span></span> <span> </span><span class="NLM_article-title">Long-term treatment of epilepsy with everolimus in tuberous sclerosis</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">2408</span>– <span class="NLM_lpage">2415</span>, <span class="refDoi"> DOI: 10.1212/wnl.0000000000003400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1212%2FWNL.0000000000003400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=27815402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGru7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2016&pages=2408-2415&author=D.+A.+Kruegerauthor=A.+A.+Wilfongauthor=M.+Maysauthor=C.+M.+Talleyauthor=K.+Agricolaauthor=C.+Tudorauthor=J.+Capalauthor=K.+Holland-Bouleyauthor=D.+N.+Franz&title=Long-term+treatment+of+epilepsy+with+everolimus+in+tuberous+sclerosis&doi=10.1212%2Fwnl.0000000000003400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term treatment of epilepsy with everolimus in tuberous sclerosis</span></div><div class="casAuthors">Krueger, Darcy A.; Wilfong, Angus A.; Mays, Maxwell; Talley, Christina M.; Agricola, Karen; Tudor, Cindy; Capal, Jamie; Holland-Bouley, Katherine; Franz, David Neal</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2408-2415</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To evaluate the long-term benefit and safety of everolimus for the treatment of medically refractory epilepsy in patients with tuberous sclerosis complex (TSC).  Methods: Everolimus was titrated over 4 wk and continued an addnl. 8 wk in a prospective, open-label, phase I/II clin. trial design.  Participants demonstrating initial benefit continued treatment until study completion (48 mo).  The primary endpoint was percentage of patients with a ≥50% redn. in seizure frequency compared to baseline.  Secondary endpoints assessed abs. seizure frequency, adverse events (AEs), behavior, and quality of life.  Results: Of the 20 participants who completed the initial study phase, 18 continued extended treatment.  Fourteen of 18 (78%) participants completed the study, all but 1 of whom reported ≥50% redn. in seizure frequency at 48 mo.  All participants reported at least 1 AE, the vast majority (94%) of which were graded mild or moderate severity.  Improvements in behavior and quality of life were also obsd., but failed to achieve statistical significance at 48 mo.  Conclusions: Improved seizure control was maintained for 4 years in the majority of patients with TSC with medically refractory epilepsy treated with everolimus.  Long-term treatment with everolimus is safe and well-tolerated in this population.  Everolimus may be a therapeutic option for refractory epilepsy in TSC.  Classification of evidence: This study provides Class IV evidence that for patients with TSC with medically refractory epilepsy everolimus improves seizure control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqH5vcit74VrVg90H21EOLACvtfcHk0ljgSV7Chw0tpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGru7bF&md5=ce3240ba5fd90b663de6706f511afdb8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1212%2FWNL.0000000000003400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.0000000000003400%26sid%3Dliteratum%253Aachs%26aulast%3DKrueger%26aufirst%3DD.%2BA.%26aulast%3DWilfong%26aufirst%3DA.%2BA.%26aulast%3DMays%26aufirst%3DM.%26aulast%3DTalley%26aufirst%3DC.%2BM.%26aulast%3DAgricola%26aufirst%3DK.%26aulast%3DTudor%26aufirst%3DC.%26aulast%3DCapal%26aufirst%3DJ.%26aulast%3DHolland-Bouley%26aufirst%3DK.%26aulast%3DFranz%26aufirst%3DD.%2BN.%26atitle%3DLong-term%2520treatment%2520of%2520epilepsy%2520with%2520everolimus%2520in%2520tuberous%2520sclerosis%26jtitle%3DNeurology%26date%3D2016%26volume%3D87%26spage%3D2408%26epage%3D2415%26doi%3D10.1212%2Fwnl.0000000000003400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noack, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Römermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öhler, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löscher, W.</span></span> <span> </span><span class="NLM_article-title">The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2018.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.neuropharm.2018.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=30081001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGhtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=107-120&author=C.+Brandtauthor=P.+Hillmannauthor=A.+Noackauthor=K.+R%C3%B6mermannauthor=L.+A.+%C3%96hlerauthor=D.+Rageotauthor=F.+Beaufilsauthor=A.+Meloneauthor=A.+M.+Seleauthor=M.+P.+Wymannauthor=D.+Fabbroauthor=W.+L%C3%B6scher&title=The+novel%2C+catalytic+mTORC1%2F2+inhibitor+PQR620+and+the+PI3K%2FmTORC1%2F2+inhibitor+PQR530+effectively+cross+the+blood-brain+barrier+and+increase+seizure+threshold+in+a+mouse+model+of+chronic+epilepsy&doi=10.1016%2Fj.neuropharm.2018.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy</span></div><div class="casAuthors">Brandt, Claudia; Hillmann, Petra; Noack, Andreas; Roemermann, Kerstin; Oehler, Leon A.; Rageot, Denise; Beaufils, Florent; Melone, Anna; Sele, Alexander M.; Wymann, Matthias P.; Fabbro, Doriano; Loescher, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107-120</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mTOR signaling pathway has emerged as a possible therapeutic target for epilepsy.  Clin. trials have shown that mTOR inhibitors such as everolimus reduce seizures in tuberous sclerosis complex patients with intractable epilepsy.  Furthermore, accumulating preclin. data suggest that mTOR inhibitors may have anti-seizure or anti-epileptogenic actions in other types of epilepsy.  However, the chronic use of rapalogs such as everolimus is limited by poor tolerability, particularly by immunosuppression, poor brain penetration and induction of feedback loops which might contribute to their limited therapeutic efficacy.  Here we describe two novel, brain-permeable and well tolerated small mol. 1,3,5-triazine derivs., the catalytic mTORC1/C2 inhibitor PQR620 and the dual pan-PI3K/mTOR inhibitor PQR530.  These derivs. were compared with the mTORC1 inhibitors rapamycin and everolimus as well as the anti-seizure drugs phenobarbital and levetiracetam.  The anti-seizure potential of these compds. was detd. by evaluating the electroconvulsive seizure threshold in normal and epileptic mice.  Rapamycin and everolimus only poorly penetrated into the brain (brain:plasma ratio 0.0057 for rapamycin and 0.016 for everolimus).  In contrast, the novel compds. rapidly entered the brain, reaching brain:plasma ratios of ∼1.6.  Furthermore, they significantly decreased phosphorylation of S6 ribosomal protein in the hippocampus of normal and epileptic mice, demonstrating effective mTOR inhibition.  PQR620 and PQR530 significantly increased seizure threshold at tolerable doses.  The effect of PQR620 was more marked in epileptic vs. nonepileptic mice, matching the efficacy of levetiracetam.  Overall, the novel compds. described here have the potential to overcome the disadvantages of rapalogs for treatment of epilepsy and mTORopathies directly connected to mutations in the mTOR signaling cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvQmF8jJglOLVg90H21EOLACvtfcHk0lgry2TtnNYogw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGhtbjJ&md5=38f76201f9fb8c4643e59979b2bb4121</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2018.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2018.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBrandt%26aufirst%3DC.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DNoack%26aufirst%3DA.%26aulast%3DR%25C3%25B6mermann%26aufirst%3DK.%26aulast%3D%25C3%2596hler%26aufirst%3DL.%2BA.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26atitle%3DThe%2520novel%252C%2520catalytic%2520mTORC1%252F2%2520inhibitor%2520PQR620%2520and%2520the%2520PI3K%252FmTORC1%252F2%2520inhibitor%2520PQR530%2520effectively%2520cross%2520the%2520blood-brain%2520barrier%2520and%2520increase%2520seizure%2520threshold%2520in%2520a%2520mouse%2520model%2520of%2520chronic%2520epilepsy%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D140%26spage%3D107%26epage%3D120%26doi%3D10.1016%2Fj.neuropharm.2018.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span> <span> </span><span class="NLM_article-title">Preclinical study of CC223 as a potential anti-ovarian cancer agent</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">58469</span>– <span class="NLM_lpage">58479</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.18632%2Foncotarget.17753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=28938571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FhtlOjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=58469-58479&author=Z.+Jinauthor=H.+Niuauthor=X.+Wangauthor=L.+Zhangauthor=Q.+Wangauthor=A.+Yang&title=Preclinical+study+of+CC223+as+a+potential+anti-ovarian+cancer+agent&doi=10.18632%2Foncotarget.17753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical study of CC223 as a potential anti-ovarian cancer agent</span></div><div class="casAuthors">Jin Zhenzhen; Niu Huanfu; Wang Xuenan; Wang Qin; Yang Aijun; Zhang Lei</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">58469-58479</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aberrant activation of mTOR contributes to ovarian cancer progression.  CC223 is a novel and potent mTOR kinase inhibitor.  The current study tested its activity against human ovarian cancer cells.  We showed that CC223, at nM concentrations, inhibited survival and proliferation of established/primary human ovarian cancer cells.  Further, significant apoptosis activation was observed in CC223-treated ovarian cancer cells.  CC223 disrupted assembly of mTOR complex 1 (mTORC1) and mTORC2 in SKOV3 cells.  Meanwhile, activation of mTORC1 and mTORC2 was almost completely blocked by CC223.  Intriguingly, restoring mTOR activation by introduction of a constitutively-active Akt1 only partially inhibited CC223-induced cytotoxicity in SKOV3 cells.  Further studies showed that CC223 inhibited sphingosine kinase 1 (SphK1) activity and induced reactive oxygen species (ROS) production in SKOV3 cells.  At last, oral administration of CC223 potently inhibited SKOV3 xenografted tumor growth in nude mice.  The results of this study imply that CC223 could be further studied as a potential anti-ovarian cancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcU4AE24nN2t1QT_1O5WBYfW6udTcc2eYDLIYcDL8JXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FhtlOjuw%253D%253D&md5=091fdb75cec2ddb9018ba74c124041e8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17753%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DNiu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DA.%26atitle%3DPreclinical%2520study%2520of%2520CC223%2520as%2520a%2520potential%2520anti-ovarian%2520cancer%2520agent%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D58469%26epage%3D58479%26doi%3D10.18632%2Foncotarget.17753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slotkin, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patwardhan, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudeva, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span> <span> </span><span class="NLM_article-title">MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-14-0711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1158%2F1535-7163.MCT-14-0711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=25519700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=395-406&author=E.+K.+Slotkinauthor=P.+P.+Patwardhanauthor=S.+D.+Vasudevaauthor=E.+de+Stanchinaauthor=W.+D.+Tapauthor=G.+K.+Schwartz&title=MLN0128%2C+an+ATP-competitive+mTOR+kinase+inhibitor+with+potent+in+vitro+and+in+vivo+antitumor+activity%2C+as+potential+therapy+for+bone+and+soft-tissue+sarcoma&doi=10.1158%2F1535-7163.mct-14-0711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma</span></div><div class="casAuthors">Slotkin, Emily K.; Patwardhan, Parag P.; Vasudeva, Shyamprasad D.; de Stanchina, Elisa; Tap, William D.; Schwartz, Gary K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">395-406</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that exists in two complexes (mTORC1 and mTORC2) and integrates extracellular and intracellular signals to act as a master regulator of cell growth, survival, and metab.  The PI3K/AKT/mTOR prosurvival pathway is often dysregulated in multiple sarcoma subtypes.  First-generation allosteric inhibitors of mTORC1 (rapalogues) have been extensively tested with great preclin. promise, but have had limited clin. utility.  Here, we report that MLN0128, a second-generation, ATP-competitive, pan-mTOR kinase inhibitor, acts on both mTORC1 and mTORC2 and has potent in vitro and in vivo antitumor activity in multiple sarcoma subtypes.  In vitro, MLN0128 inhibits mTORC1/2 targets in a concn.-dependent fashion and shows striking antiproliferative effect in rhabdomyosarcoma (RMS), Ewing sarcoma, malignant peripheral nerve sheath tumor, synovial sarcoma, osteosarcoma, and liposarcoma.  Unlike rapamycin, MLN0128 inhibits phosphorylation of 4EBP1 and NDRG1 as well as prevents the reactivation of pAKT that occurs via neg. feedback release with mTORC1 inhibition alone.  In xenograft models, MLN0128 treatment results in suppression of tumor growth with two dosing schedules (1 mg/kg daily and 3 mg/kg b.i.d. t.i.w.).  At the 3 mg/kg dosing schedule, MLN0128 treatment results in significantly better tumor growth suppression than rapamycin in RMS and Ewing sarcoma models.  In addn., MLN0128 induces apoptosis in models of RMS both in vitro and in vivo.  Results from our study strongly suggest that MLN0128 treatment should be explored further as potential therapy for sarcoma.  Mol Cancer Ther; 14(2); 395-406. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2RbwSW4yjmLVg90H21EOLACvtfcHk0lgry2TtnNYogw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbo%253D&md5=7c1d867aae6e5ca99c63b554295a539a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0711%26sid%3Dliteratum%253Aachs%26aulast%3DSlotkin%26aufirst%3DE.%2BK.%26aulast%3DPatwardhan%26aufirst%3DP.%2BP.%26aulast%3DVasudeva%26aufirst%3DS.%2BD.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DMLN0128%252C%2520an%2520ATP-competitive%2520mTOR%2520kinase%2520inhibitor%2520with%2520potent%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activity%252C%2520as%2520potential%2520therapy%2520for%2520bone%2520and%2520soft-tissue%2520sarcoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D395%26epage%3D406%26doi%3D10.1158%2F1535-7163.mct-14-0711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malagu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hummersone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menear, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, H. M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1212</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.01.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.bmcl.2013.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=23375793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFajs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1212-1216&author=K.+G.+Pikeauthor=K.+Malaguauthor=M.+G.+Hummersoneauthor=K.+A.+Menearauthor=H.+M.+E.+Dugganauthor=S.+Gomezauthor=N.+M.+B.+Martinauthor=L.+Rustonauthor=S.+L.+Passauthor=M.+Pass&title=Optimization+of+potent+and+selective+dual+mTORC1+and+mTORC2+inhibitors%3A+the+discovery+of+AZD8055+and+AZD2014&doi=10.1016%2Fj.bmcl.2013.01.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014</span></div><div class="casAuthors">Pike, Kurt G.; Malagu, Karine; Hummersone, Marc G.; Menear, Keith A.; Duggan, Heather M. E.; Gomez, Sylvie; Martin, Niall M. B.; Ruston, Linette; Pass, Sarah L.; Pass, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1212-1216</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described.  An initial focus on improving cellular potency while maintaining or improving other key parameters, such as aq. soly. and margins over hERG IC50, led to the discovery of the clin. candidate AZD8055.  Further optimization, particularly aimed at reducing the rate of metab. in human hepatocyte incubations, resulted in the discovery of the clin. candidate AZD2014.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo07emMEKp9mrVg90H21EOLACvtfcHk0li5fpD9lpZJEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFajs7c%253D&md5=325cb45f84bb4357005315ab3b27c0aa</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DMalagu%26aufirst%3DK.%26aulast%3DHummersone%26aufirst%3DM.%2BG.%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DDuggan%26aufirst%3DH.%2BM.%2BE.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DPass%26aufirst%3DS.%2BL.%26aulast%3DPass%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520potent%2520and%2520selective%2520dual%2520mTORC1%2520and%2520mTORC2%2520inhibitors%253A%2520the%2520discovery%2520of%2520AZD8055%2520and%2520AZD2014%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1212%26epage%3D1216%26doi%3D10.1016%2Fj.bmcl.2013.01.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löscher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoro methyl)pyridin-2-amine (PQR620), a highly potent and selective mTORC1/2 inhibitor for cancer and neurological disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">10084</span>– <span class="NLM_lpage">10105</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01262</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01262" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10084-10105&author=D.+Rageotauthor=T.+Bohnackerauthor=A.+Meloneauthor=J.-B.+Langloisauthor=C.+Borsariauthor=P.+Hillmannauthor=A.+M.+Seleauthor=F.+Beaufilsauthor=M.+Zvelebilauthor=P.+Hebeisenauthor=W.+L%C3%B6scherauthor=J.+Burkeauthor=D.+Fabbroauthor=M.+P.+Wymann&title=Discovery+and+preclinical+characterization+of+5-%5B4%2C6-Bis%28%7B3-oxa-8-azabicyclo%5B3.2.1%5Doctan-8-yl%7D%29-1%2C3%2C5-triazin-2-yl%5D-4-%28difluoro+methyl%29pyridin-2-amine+%28PQR620%29%2C+a+highly+potent+and+selective+mTORC1%2F2+inhibitor+for+cancer+and+neurological+disorders&doi=10.1021%2Facs.jmedchem.8b01262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders</span></div><div class="casAuthors">Rageot, Denise; Bohnacker, Thomas; Melone, Anna; Langlois, Jean-Baptiste; Borsari, Chiara; Hillmann, Petra; Sele, Alexander M.; Beaufils, Florent; Zvelebil, Marketa; Hebeisen, Paul; Loscher, Wolfgang; Burke, John; Fabbro, Doriano; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10084-10105</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mechanistic target of rapamycin (mTOR) promotes cell proliferation, growth, and survival and is overactivated in many tumors and central nervous system disorders.  I is a novel, potent, selective, and brain penetrable inhibitor of mTORC1/2 kinase.  I showed excellent selectivity for mTOR over PI3K and protein kinases and efficiently prevented cancer cell growth in a 66 cancer cell line panel.  In C57BL/6J and Sprague-Dawley mice, max. concn. (Cmax) in plasma and brain was reached after 30 min, with a half-life (t1/2) > 5 h.  In an ovarian carcinoma mouse xenograft model (OVCAR-3), daily dosing of I inhibited tumor growth significantly.  Moreover, I attenuated epileptic seizures in a tuberous sclerosis complex (TSC) mouse model.  In conclusion, I inhibits mTOR kinase potently and selectively, shows antitumor effects in vitro and in vivo, and promises advantages in CNS indications due to its brain/plasma distribution ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodTlRg0fJo97Vg90H21EOLACvtfcHk0li5fpD9lpZJEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtLjO&md5=e6ebf8147d6ba041285eb6538ade46ab</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01262%26sid%3Dliteratum%253Aachs%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DLanglois%26aufirst%3DJ.-B.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26aulast%3DBurke%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%25205-%255B4%252C6-Bis%2528%257B3-oxa-8-azabicyclo%255B3.2.1%255Doctan-8-yl%257D%2529-1%252C3%252C5-triazin-2-yl%255D-4-%2528difluoro%2520methyl%2529pyridin-2-amine%2520%2528PQR620%2529%252C%2520a%2520highly%2520potent%2520and%2520selective%2520mTORC1%252F2%2520inhibitor%2520for%2520cancer%2520and%2520neurological%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D10084%26epage%3D10105%26doi%3D10.1021%2Facs.jmedchem.8b01262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dall’Asen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">A conformational restriction strategy for the identification of a highly selective pyrimido-pyrrolo-oxazine mTOR inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8609</span>– <span class="NLM_lpage">8630</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00972</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00972" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1yhsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8609-8630&author=C.+Borsariauthor=D.+Rageotauthor=A.+Dall%E2%80%99Asenauthor=T.+Bohnackerauthor=A.+Meloneauthor=A.+M.+Seleauthor=E.+Jacksonauthor=J.-B.+Langloisauthor=F.+Beaufilsauthor=P.+Hebeisenauthor=D.+Fabbroauthor=P.+Hillmannauthor=M.+P.+Wymann&title=A+conformational+restriction+strategy+for+the+identification+of+a+highly+selective+pyrimido-pyrrolo-oxazine+mTOR+inhibitor&doi=10.1021%2Facs.jmedchem.9b00972"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor</span></div><div class="casAuthors">Borsari, Chiara; Rageot, Denise; Dall'Asen, Alix; Bohnacker, Thomas; Melone, Anna; Sele, Alexander M.; Jackson, Eileen; Langlois, Jean-Baptiste; Beaufils, Florent; Hebeisen, Paul; Fabbro, Doriano; Hillmann, Petra; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8609-8630</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment.  ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivs. in a wide range of malignancies.  Herein, we exploit a conformational restriction approach to explore a novel chem. space for the generation of TORKi.  Structure-activity relationship (SAR) studies led to the identification of compd. 12b with a ∼450-fold selectivity for mTOR over class I PI3K isoforms.  Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a min. brain penetration.  CYP450 reactive phenotyping pointed out the high metabolic stability of 12b.  These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkugVOj5N6vbVg90H21EOLACvtfcHk0lh_eV8OGXjzaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1yhsb3K&md5=5d2e9a5f28628f1a0a5ae43b10a3d680</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00972%26sid%3Dliteratum%253Aachs%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DDall%25E2%2580%2599Asen%26aufirst%3DA.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DJackson%26aufirst%3DE.%26aulast%3DLanglois%26aufirst%3DJ.-B.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DA%2520conformational%2520restriction%2520strategy%2520for%2520the%2520identification%2520of%2520a%2520highly%2520selective%2520pyrimido-pyrrolo-oxazine%2520mTOR%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8609%26epage%3D8630%26doi%3D10.1021%2Facs.jmedchem.9b00972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonazzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goold, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biag, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubicka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labbe-Giguere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keaney, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTighe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piizzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodart, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, L. O.</span></span> <span> </span><span class="NLM_article-title">Discovery of a brain-penetrant ATP-competitive inhibitor of the mechanistic target of rapamycin (mTOR) for CNS disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1068</span>– <span class="NLM_lpage">1083</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01398</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01398" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1CktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1068-1083&author=S.+Bonazziauthor=C.+P.+Gooldauthor=A.+Grayauthor=N.+M.+Thomsenauthor=J.+Nunezauthor=R.+G.+Karkiauthor=A.+Gordeauthor=J.+D.+Biagauthor=H.+A.+Malikauthor=Y.+Sunauthor=G.+Liangauthor=D.+Lubickaauthor=S.+Salasauthor=N.+Labbe-Giguereauthor=E.+P.+Keaneyauthor=S.+McTigheauthor=S.+Liuauthor=L.+Dengauthor=G.+Piizziauthor=F.+Lombardoauthor=D.+Burdetteauthor=J.-C.+Dodartauthor=C.+J.+Wilsonauthor=S.+Peukertauthor=D.+Curtisauthor=L.+G.+Hamannauthor=L.+O.+Murphy&title=Discovery+of+a+brain-penetrant+ATP-competitive+inhibitor+of+the+mechanistic+target+of+rapamycin+%28mTOR%29+for+CNS+disorders&doi=10.1021%2Facs.jmedchem.9b01398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS Disorders</span></div><div class="casAuthors">Bonazzi, Simone; Goold, Carleton P.; Gray, Audrey; Thomsen, Noel M.; Nunez, Jill; Karki, Rajeshri G.; Gorde, Aakruti; Biag, Jonathan D.; Malik, Hasnain A.; Sun, Yingchuan; Liang, Guiqing; Lubicka, Danuta; Salas, Sarah; Labbe-Giguere, Nancy; Keaney, Erin P.; McTighe, Stephanie; Liu, Shanming; Deng, Lin; Piizzi, Grazia; Lombardo, Franco; Burdette, Doug; Dodart, Jean-Cosme; Wilson, Christopher J.; Peukert, Stefan; Curtis, Daniel; Hamann, Lawrence G.; Murphy, Leon O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1068-1083</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent clin. evaluation of everolimus for seizure redn. in patients with tuberous sclerosis complex (TSC), a disease with overactivated mechanistic target of rapamycin (mTOR) signaling, has demonstrated the therapeutic value of mTOR inhibitors for central nervous system (CNS) indications.  Given that everolimus is an incomplete inhibitor of the mTOR function, we sought to develop a new mTOR inhibitor that has improved properties and is suitable for CNS disorders.  Starting from an inhouse purine-based compd., optimization of the physicochem. properties of a thiazolopyrimidine series led to the discovery of the small mol. 7, a potent and selective brain-penetrant ATP-competitive mTOR inhibitor.  In neuronal cell-based models of mTOR hyperactivity, 7 cor. the mTOR pathway activity and the resulting neuronal overgrowth phenotype.  The new mTOR inhibitor 7 showed good brain exposure and significantly improved the survival rate of mice with neuronal-specific ablation of the Tsc1 gene.  These results demonstrate the potential utility of this tool compd. to test therapeutic hypotheses that depend on mTOR hyperactivity in the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjXE6Yj_MC27Vg90H21EOLACvtfcHk0lh_eV8OGXjzaA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1CktLo%253D&md5=d52546d7050d5e45b4fd241506004ef1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01398%26sid%3Dliteratum%253Aachs%26aulast%3DBonazzi%26aufirst%3DS.%26aulast%3DGoold%26aufirst%3DC.%2BP.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DKarki%26aufirst%3DR.%2BG.%26aulast%3DGorde%26aufirst%3DA.%26aulast%3DBiag%26aufirst%3DJ.%2BD.%26aulast%3DMalik%26aufirst%3DH.%2BA.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DLubicka%26aufirst%3DD.%26aulast%3DSalas%26aufirst%3DS.%26aulast%3DLabbe-Giguere%26aufirst%3DN.%26aulast%3DKeaney%26aufirst%3DE.%2BP.%26aulast%3DMcTighe%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DPiizzi%26aufirst%3DG.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DBurdette%26aufirst%3DD.%26aulast%3DDodart%26aufirst%3DJ.-C.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DPeukert%26aufirst%3DS.%26aulast%3DCurtis%26aufirst%3DD.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DMurphy%26aufirst%3DL.%2BO.%26atitle%3DDiscovery%2520of%2520a%2520brain-penetrant%2520ATP-competitive%2520inhibitor%2520of%2520the%2520mechanistic%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520for%2520CNS%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1068%26epage%3D1083%26doi%3D10.1021%2Facs.jmedchem.9b01398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14683</span>, <span class="refDoi"> DOI: 10.1038/ncomms14683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fncomms14683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=28276440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14683&author=T.+Bohnackerauthor=A.+E.+Protaauthor=F.+Beaufilsauthor=J.+E.+Burkeauthor=A.+Meloneauthor=A.+J.+Inglisauthor=D.+Rageotauthor=A.+M.+Seleauthor=V.+Cmiljanovicauthor=N.+Cmiljanovicauthor=K.+Bargstenauthor=A.+Aherauthor=A.+Akhmanovaauthor=J.+F.+Diazauthor=D.+Fabbroauthor=M.+Zvelebilauthor=R.+L.+Williamsauthor=M.+O.+Steinmetzauthor=M.+P.+Wymann&title=Deconvolution+of+Buparlisib%E2%80%99s+mechanism+of+action+defines+specific+PI3K+and+tubulin+inhibitors+for+therapeutic+intervention&doi=10.1038%2Fncomms14683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span></div><div class="casAuthors">Bohnacker Thomas; Beaufils Florent; Melone Anna; Rageot Denise; Sele Alexander M; Cmiljanovic Vladimir; Cmiljanovic Natasa; Wymann Matthias P; Prota Andrea E; Bargsten Katja; Steinmetz Michel O; Burke John E; Inglis Alison J; Williams Roger L; Aher Amol; Akhmanova Anna; Diaz J Fernando; Fabbro Doriano; Zvelebil Marketa</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization.  Here, we developed two chemical derivatives that differ from BKM120 by only one atom.  We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors.  Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K.  Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs.  Our results raise concerns over BKM120's generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzPPj8gFbG6HWEEzDrymxmfW6udTcc2eZfgCJUQ374Ubntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D&md5=97d27a7d83bf6ab6094a587565f82bf6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fncomms14683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14683%26sid%3Dliteratum%253Aachs%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DInglis%26aufirst%3DA.%2BJ.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DAher%26aufirst%3DA.%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDeconvolution%2520of%2520Buparlisib%25E2%2580%2599s%2520mechanism%2520of%2520action%2520defines%2520specific%2520PI3K%2520and%2520tubulin%2520inhibitors%2520for%2520therapeutic%2520intervention%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14683%26doi%3D10.1038%2Fncomms14683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor as clinical candidate in oncology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7524</span>– <span class="NLM_lpage">7538</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00930</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00930" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7524-7538&author=F.+Beaufilsauthor=N.+Cmiljanovicauthor=V.+Cmiljanovicauthor=T.+Bohnackerauthor=A.+Meloneauthor=R.+Maroneauthor=E.+Jacksonauthor=X.+Zhangauthor=A.+Seleauthor=C.+Borsariauthor=J.+Mestanauthor=P.+Hebeisenauthor=P.+Hillmannauthor=B.+Gieseauthor=M.+Zvelebilauthor=D.+Fabbroauthor=R.+L.+Williamsauthor=D.+Rageotauthor=M.+P.+Wymann&title=5-%284%2C6-Dimorpholino-1%2C3%2C5-triazin-2-yl%29-4-%28trifluoromethyl%29pyridin-2-amine+%28PQR309%29%2C+a+potent%2C+brain-penetrant%2C+orally+bioavailable%2C+pan-class+I+PI3K%2FmTOR+inhibitor+as+clinical+candidate+in+oncology&doi=10.1021%2Facs.jmedchem.7b00930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology</span></div><div class="casAuthors">Beaufils, Florent; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Bohnacker, Thomas; Melone, Anna; Marone, Romina; Jackson, Eileen; Zhang, Xuxiao; Sele, Alexander; Borsari, Chiara; Mestan, Jurgen; Hebeisen, Paul; Hillmann, Petra; Giese, Bernd; Zvelebil, Marketa; Fabbro, Doriano; Williams, Roger L.; Rageot, Denise; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7524-7538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR).  Here we describe the preclin. characterization of compd. 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K inhibitor, which targets mTOR kinase in a balanced fashion at higher concns.  No off-target interactions were detected for 1 in a wide panel of protein kinase, enzyme, and receptor ligand assays.  Moreover, 1 did not bind tubulin, which was obsd. for the structurally related 4 (BKM120, buparlisib).  Compd. 1 is orally available, crosses the blood-brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs.  Compd. 1 demonstrated efficiency in inhibiting proliferation in tumor cell lines and a rat xenograft model.  This, together with the compd.'s safety profile, identifies 1 as a clin. candidate with a broad application range in oncol., including treatment of brain tumors or CNS metastasis.  Compd. 1 is currently in phase II clin. trials for advanced solid tumors and refractory lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtvYAarVqsarVg90H21EOLACvtfcHk0li5Hd6fa1c7Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP&md5=54d4db75f6a8bda3f12eaf1d196352fd</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00930%26sid%3Dliteratum%253Aachs%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSele%26aufirst%3DA.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3D5-%25284%252C6-Dimorpholino-1%252C3%252C5-triazin-2-yl%2529-4-%2528trifluoromethyl%2529pyridin-2-amine%2520%2528PQR309%2529%252C%2520a%2520potent%252C%2520brain-penetrant%252C%2520orally%2520bioavailable%252C%2520pan-class%2520I%2520PI3K%252FmTOR%2520inhibitor%2520as%2520clinical%2520candidate%2520in%2520oncology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7524%26epage%3D7538%26doi%3D10.1021%2Facs.jmedchem.7b00930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarantelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arribas, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrassa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittau, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritschard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dossena, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchetto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taborelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gattei, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stathis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stussi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, F.</span></span> <span> </span><span class="NLM_article-title">PQR309 is a novel dual PI3K/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-17-1041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1158%2F1078-0432.CCR-17-1041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=29066507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=120-129&author=C.+Tarantelliauthor=E.+Gaudioauthor=A.+J.+Arribasauthor=I.+Kweeauthor=P.+Hillmannauthor=A.+Rinaldiauthor=L.+Cascioneauthor=F.+Sprianoauthor=E.+Bernasconiauthor=F.+Guidettiauthor=L.+Carrassaauthor=R.+B.+Pittauauthor=F.+Beaufilsauthor=R.+Ritschardauthor=D.+Rageotauthor=A.+Seleauthor=B.+Dossenaauthor=F.+M.+Rossiauthor=A.+Zucchettoauthor=M.+Taborelliauthor=V.+Gatteiauthor=D.+Rossiauthor=A.+Stathisauthor=G.+Stussiauthor=M.+Brogginiauthor=M.+P.+Wymannauthor=A.+Wickiauthor=E.+Zuccaauthor=V.+Cmiljanovicauthor=D.+Fabbroauthor=F.+Bertoni&title=PQR309+is+a+novel+dual+PI3K%2FmTOR+inhibitor+with+preclinical+antitumor+activity+in+lymphomas+as+a+single+agent+and+in+combination+therapy&doi=10.1158%2F1078-0432.ccr-17-1041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy</span></div><div class="casAuthors">Tarantelli, Chiara; Gaudio, Eugenio; Arribas, Alberto J.; Kwee, Ivo; Hillmann, Petra; Rinaldi, Andrea; Cascione, Luciano; Spriano, Filippo; Bernasconi, Elena; Guidetti, Francesca; Carrassa, Laura; Pittau, Roberta Bordone; Beaufils, Florent; Ritschard, Reto; Rageot, Denise; Sele, Alexander; Dossena, Barbara; Rossi, Francesca Maria; Zucchetto, Antonella; Taborelli, Monica; Gattei, Valter; Rossi, Davide; Stathis, Anastasios; Stussi, Georg; Broggini, Massimo; Wymann, Matthias P.; Wicki, Andreas; Zucca, Emanuele; Cmiljanovic, Vladimir; Fabbro, Doriano; Bertoni, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-129</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Activation of the PI3K/mTOR signaling pathway is recurrent in different lymphoma types, and pharmacol. inhibition of the PI3K/mTOR pathway has shown activity in lymphoma patients.  Here, we extensively characterized the in vitro and in vivo activity and the mechanism of action of PQR309 (bimiralisib), a novel oral selective dual PI3K/mTOR inhibitor under clin. evaluation, in preclin. lymphoma models.  Exptl. Design: This study included preclin. in vitro activity screening on a large panel of cell lines, both as single agent and in combination, validation expts. on in vivo models and primary cells, proteomics and gene-expression profiling, and comparison with other signaling inhibitors.  Results: PQR309 had in vitro antilymphoma activity as single agent and in combination with venetoclax, panobinostat, ibrutinib, lenalidomide, ARV-825, marizomib, and rituximab.  Sensitivity to PQR309 was assocd. with specific baseline gene-expression features, such as high expression of transcripts coding for the BCR pathway.  Combining proteomics and RNA profiling, we identified the different contribution of PQR309-induced protein phosphorylation and gene expression changes to the drug mechanism of action.  Gene-expression signatures induced by PQR309 and by other signaling inhibitors largely overlapped.  PQR309 showed activity in cells with primary or secondary resistance to idelalisib.  Conclusions: On the basis of these results, PQR309 appeared as a novel and promising compd. that is worth developing in the lymphoma setting.  Clin Cancer Res; 24(1); 120-9. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEmEWXHaG3ObVg90H21EOLACvtfcHk0li5Hd6fa1c7Ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWktw%253D%253D&md5=730305c33b7f669b0eedd0614edd886c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1041%26sid%3Dliteratum%253Aachs%26aulast%3DTarantelli%26aufirst%3DC.%26aulast%3DGaudio%26aufirst%3DE.%26aulast%3DArribas%26aufirst%3DA.%2BJ.%26aulast%3DKwee%26aufirst%3DI.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DRinaldi%26aufirst%3DA.%26aulast%3DCascione%26aufirst%3DL.%26aulast%3DSpriano%26aufirst%3DF.%26aulast%3DBernasconi%26aufirst%3DE.%26aulast%3DGuidetti%26aufirst%3DF.%26aulast%3DCarrassa%26aufirst%3DL.%26aulast%3DPittau%26aufirst%3DR.%2BB.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DRitschard%26aufirst%3DR.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%26aulast%3DDossena%26aufirst%3DB.%26aulast%3DRossi%26aufirst%3DF.%2BM.%26aulast%3DZucchetto%26aufirst%3DA.%26aulast%3DTaborelli%26aufirst%3DM.%26aulast%3DGattei%26aufirst%3DV.%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DStathis%26aufirst%3DA.%26aulast%3DStussi%26aufirst%3DG.%26aulast%3DBroggini%26aufirst%3DM.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWicki%26aufirst%3DA.%26aulast%3DZucca%26aufirst%3DE.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DBertoni%26aufirst%3DF.%26atitle%3DPQR309%2520is%2520a%2520novel%2520dual%2520PI3K%252FmTOR%2520inhibitor%2520with%2520preclinical%2520antitumor%2520activity%2520in%2520lymphomas%2520as%2520a%2520single%2520agent%2520and%2520in%2520combination%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D120%26epage%3D129%26doi%3D10.1158%2F1078-0432.ccr-17-1041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keles, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buslov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Preclinical development of PQR514, a highly potent PI3K inhibitor bearing a difluoromethyl-pyrimidine moiety</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1473</span>– <span class="NLM_lpage">1479</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00333</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00333" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslSqtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1473-1479&author=C.+Borsariauthor=D.+Rageotauthor=F.+Beaufilsauthor=T.+Bohnackerauthor=E.+Kelesauthor=I.+Buslovauthor=A.+Meloneauthor=A.+M.+Seleauthor=P.+Hebeisenauthor=D.+Fabbroauthor=P.+Hillmannauthor=M.+P.+Wymann&title=Preclinical+development+of+PQR514%2C+a+highly+potent+PI3K+inhibitor+bearing+a+difluoromethyl-pyrimidine+moiety&doi=10.1021%2Facsmedchemlett.9b00333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety</span></div><div class="casAuthors">Borsari, Chiara; Rageot, Denise; Beaufils, Florent; Bohnacker, Thomas; Keles, Erhan; Buslov, Ivan; Melone, Anna; Sele, Alexander M.; Hebeisen, Paul; Fabbro, Doriano; Hillmann, Petra; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1473-1479</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is a crit. regulator of cell growth and is frequently hyperactivated in cancer.  Therefore, PI3K inhibitors represent a valuable asset in cancer therapy.  Herein we have developed a novel anticancer agent, the potent pan-PI3K inhibitor PQR514 (4), which is a follow-up compd. for the phase-II clin. compd. PQR309 (1).  Compd. 4 has an improved potency both in vitro and in cellular assays with respect to its predecessor compds.  It shows superiority in the suppression of cancer cell proliferation and demonstrates significant antitumor activity in an OVCAR-3 xenograft model at concns. approx. eight times lower than PQR309 (1).  The favorable pharmacokinetic profile and a minimal brain penetration promote PQR514 (4) as an optimized candidate for the treatment of systemic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ogn0EPMIeLVg90H21EOLACvtfcHk0lhF-Esp2AUKDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslSqtrzP&md5=3423dce039aa5b68a178ecea264e6f1f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00333%26sid%3Dliteratum%253Aachs%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DKeles%26aufirst%3DE.%26aulast%3DBuslov%26aufirst%3DI.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DPreclinical%2520development%2520of%2520PQR514%252C%2520a%2520highly%2520potent%2520PI3K%2520inhibitor%2520bearing%2520a%2520difluoromethyl-pyrimidine%2520moiety%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1473%26epage%3D1479%26doi%3D10.1021%2Facsmedchemlett.9b00333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarantelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartori, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aresu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stathis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, F.</span></span> <span> </span><span class="NLM_article-title">The novel TORC1/2 kinase inhibitor PQR620 has anti-tumor activity in lymphomas as a single agent and in combination with venetoclax</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">775</span>, <span class="refDoi"> DOI: 10.3390/cancers11060775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.3390%2Fcancers11060775" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=31167506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlGis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=775&author=C.+Tarantelliauthor=E.+Gaudioauthor=P.+Hillmannauthor=F.+Sprianoauthor=G.+Sartoriauthor=L.+Aresuauthor=L.+Cascioneauthor=D.+Rageotauthor=I.+Kweeauthor=F.+Beaufilsauthor=E.+Zuccaauthor=A.+Stathisauthor=M.+P.+Wymannauthor=V.+Cmiljanovicauthor=D.+Fabbroauthor=F.+Bertoni&title=The+novel+TORC1%2F2+kinase+inhibitor+PQR620+has+anti-tumor+activity+in+lymphomas+as+a+single+agent+and+in+combination+with+venetoclax&doi=10.3390%2Fcancers11060775"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The novel TORC1/2 kinase inhibitor PQR620 has anti-tumor activity in lymphomas as a single agent and in combination with venetoclax</span></div><div class="casAuthors">Tarantelli, Chiara; Gaudio, Eugenio; Hillmann, Petra; Spriano, Filippo; Sartori, Giulio; Aresu, Luca; Cascione, Luciano; Rageot, Denise; Kwee, Ivo; Beaufils, Florent; Zucca, Emanuele; Stathis, Anastasios; Wymann, Matthias P.; Cmiljanovic, Vladimir; Fabbro, Doriano; Bertoni, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">775</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling cascade is an important therapeutic target for lymphomas.  Rapamycin-derivates as allosteric mTOR complex 1 (TORC1) inhibitors have shown moderate preclin. and clin. anti-lymphoma activity.  Here, we assessed the anti-tumor activity of PQR620, a novel brain penetrant dual TORC1/2 inhibitor, in 56 lymphoma cell lines.  We obsd. anti-tumor activity across 56 lymphoma models with a median IC50 value of 250 nM after 72 h of exposure.  PQR620 was largely cytostatic, but the combination with the BCL2 inhibitor venetoclax led to cytotoxicity.  Both the single agent and the combination data were validated in xenograft models.  The data support further evaluation of PQR620 as a single agent or in combination with venetoclax.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4lC_3yR6dVLVg90H21EOLACvtfcHk0lhF-Esp2AUKDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlGis7w%253D&md5=3a21da65d4c9a2f8775f0e960aa4bbe5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3390%2Fcancers11060775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11060775%26sid%3Dliteratum%253Aachs%26aulast%3DTarantelli%26aufirst%3DC.%26aulast%3DGaudio%26aufirst%3DE.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DSpriano%26aufirst%3DF.%26aulast%3DSartori%26aufirst%3DG.%26aulast%3DAresu%26aufirst%3DL.%26aulast%3DCascione%26aufirst%3DL.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DKwee%26aufirst%3DI.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DZucca%26aufirst%3DE.%26aulast%3DStathis%26aufirst%3DA.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DBertoni%26aufirst%3DF.%26atitle%3DThe%2520novel%2520TORC1%252F2%2520kinase%2520inhibitor%2520PQR620%2520has%2520anti-tumor%2520activity%2520in%2520lymphomas%2520as%2520a%2520single%2520agent%2520and%2520in%2520combination%2520with%2520venetoclax%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26spage%3D775%26doi%3D10.3390%2Fcancers11060775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayral-Kaloustian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, T. S.</span></span> <span> </span><span class="NLM_article-title">PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5869</span>– <span class="NLM_lpage">5873</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.07.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.bmcl.2010.07.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=20797855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGnt7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5869-5873&author=A.+M.+Venkatesanauthor=Z.+Chenauthor=O.+D.+Santosauthor=C.+Dehnhardtauthor=E.+D.+Santosauthor=S.+Ayral-Kaloustianauthor=R.+Mallonauthor=I.+Hollanderauthor=L.+Feldbergauthor=J.+Lucasauthor=K.+Yuauthor=I.+Chaudharyauthor=T.+S.+Mansour&title=PKI-179%3A+An+orally+efficacious+dual+phosphatidylinositol-3-kinase+%28PI3K%29%2Fmammalian+target+of+rapamycin+%28mTOR%29+inhibitor&doi=10.1016%2Fj.bmcl.2010.07.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor</span></div><div class="casAuthors">Venkatesan, Aranapakam M.; Chen, Zecheng; Dos Santos, Osvaldo; Dehnhardt, Christoph; Santos, Efren Delos; Ayral-Kaloustian, Semiramis; Mallon, Robert; Hollander, Irwin; Feldberg, Larry; Lucas, Judy; Yu, Ker; Chaudhary, Inder; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5869-5873</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of mono-morpholino 1,3,5-triazine derivs. bearing a 3-oxa-8-azabicyclo[3.2.1]octane were prepd. and evaluated for PI3-kinase/mTOR activity.  Replacing one of the bis-morpholines in lead compd. I (PKI-587) with 3-oxa-8-azabicyclo[3.2.1]octane and reducing the mol. wt. led to compd. II (PKI-179), an orally efficacious dual PI3-kinase/mTOR inhibitor.  The in vitro activity, in vivo efficacy, and PK properties of II are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry2Q6kBXC_prVg90H21EOLACvtfcHk0ljHic0whqk0Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGnt7zK&md5=09729cdefa0fa05e890b02ce61607229</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.07.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.07.104%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatesan%26aufirst%3DA.%2BM.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSantos%26aufirst%3DO.%2BD.%26aulast%3DDehnhardt%26aufirst%3DC.%26aulast%3DSantos%26aufirst%3DE.%2BD.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DMallon%26aufirst%3DR.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DChaudhary%26aufirst%3DI.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DPKI-179%253A%2520An%2520orally%2520efficacious%2520dual%2520phosphatidylinositol-3-kinase%2520%2528PI3K%2529%252Fmammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5869%26epage%3D5873%26doi%3D10.1016%2Fj.bmcl.2010.07.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keles, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhail, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriramaratnam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">( S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)p yridin-2-amine (PQR530), a potent, orally bioavailable, and brain-penetrable dual inhibitor of class I PI3K and mTOR kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6241</span>– <span class="NLM_lpage">6261</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00525</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00525" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWgtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6241-6261&author=D.+Rageotauthor=T.+Bohnackerauthor=E.+Kelesauthor=J.+A.+McPhailauthor=R.+M.+Hoffmannauthor=A.+Meloneauthor=C.+Borsariauthor=R.+Sriramaratnamauthor=A.+M.+Seleauthor=F.+Beaufilsauthor=P.+Hebeisenauthor=D.+Fabbroauthor=P.+Hillmannauthor=J.+E.+Burkeauthor=M.+P.+Wymann&title=%28+S%29-4-%28Difluoromethyl%29-5-%284-%283-methylmorpholino%29-6-morpholino-1%2C3%2C5-triazin-2-yl%29p+yridin-2-amine+%28PQR530%29%2C+a+potent%2C+orally+bioavailable%2C+and+brain-penetrable+dual+inhibitor+of+class+I+PI3K+and+mTOR+kinase&doi=10.1021%2Facs.jmedchem.9b00525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase</span></div><div class="casAuthors">Rageot, Denise; Bohnacker, Thomas; Keles, Erhan; McPhail, Jacob A.; Hoffmann, Reece M.; Melone, Anna; Borsari, Chiara; Sriramaratnam, Rohitha; Sele, Alexander M.; Beaufils, Florent; Hebeisen, Paul; Fabbro, Doriano; Hillmann, Petra; Burke, John E.; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6241-6261</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is frequently overactivated in cancer, and drives cell growth, proliferation, survival, and metastasis.  Here, we report a structure-activity relationship study, which led to the discovery of a drug-like ATP-site PI3K/mTOR kinase inhibitor: (S)-4-(difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530, compd. 6), which qualifies as a clin. candidate due to its potency and specificity for PI3K and mTOR kinases, and its pharmacokinetic properties, including brain penetration.  Compd. 6 showed excellent selectivity over a wide panel of kinases and an excellent selectivity against unrelated receptor enzymes and ion channels.  Moreover, compd. 6 prevented cell growth in a cancer cell line panel.  The preclin. in vivo characterization of compd. 6 in an OVCAR-3 xenograft model demonstrated good oral bioavailability, excellent brain penetration, and efficacy.  Initial toxicity studies in rats and dogs qualify 6 for further development as a therapeutic agent in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8pi-7DrRAPLVg90H21EOLACvtfcHk0ljHic0whqk0Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWgtLrM&md5=48e0d98bf33ad5c98a1911b82bcccf03</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00525%26sid%3Dliteratum%253Aachs%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DKeles%26aufirst%3DE.%26aulast%3DMcPhail%26aufirst%3DJ.%2BA.%26aulast%3DHoffmann%26aufirst%3DR.%2BM.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DSriramaratnam%26aufirst%3DR.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3D%2528%2520S%2529-4-%2528Difluoromethyl%2529-5-%25284-%25283-methylmorpholino%2529-6-morpholino-1%252C3%252C5-triazin-2-yl%2529p%2520yridin-2-amine%2520%2528PQR530%2529%252C%2520a%2520potent%252C%2520orally%2520bioavailable%252C%2520and%2520brain-penetrable%2520dual%2520inhibitor%2520of%2520class%2520I%2520PI3K%2520and%2520mTOR%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6241%26epage%3D6261%26doi%3D10.1021%2Facs.jmedchem.9b00525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zask, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheijen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toral-Barza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayral-Kaloustian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span> <span> </span><span class="NLM_article-title">Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7942</span>– <span class="NLM_lpage">7945</span>, <span class="refDoi"> DOI: 10.1021/jm901415x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901415x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7942-7945&author=A.+Zaskauthor=J.+Kaplanauthor=J.+C.+Verheijenauthor=D.+J.+Richardauthor=K.+Curranauthor=N.+Brooijmansauthor=E.+M.+Bennettauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=S.+Ayral-Kaloustianauthor=K.+Yu&title=Morpholine+derivatives+greatly+enhance+the+selectivity+of+mammalian+target+of+rapamycin+%28mTOR%29+inhibitors&doi=10.1021%2Fjm901415x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR) Inhibitors</span></div><div class="casAuthors">Zask, Arie; Kaplan, Joshua; Verheijen, Jeroen C.; Richard, David J.; Curran, Kevin; Brooijmans, Natasja; Bennett, Eric M.; Toral-Barza, Lourdes; Hollander, Irwin; Ayral-Kaloustian, Semiramis; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7942-7945</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dramatic improvements in mTOR-targeting selectivity were achieved by replacing morpholine in pyrazolopyrimidine inhibitors with bridged morpholines.  Analogs I [R1 = (R)- or (S)-3-methyl-4-morpholinyl, 2-methyl-4-morpholinyl, 8-oxa-3-azabicyclo[3.2.1]octan-3-yl, etc.; R2 = Me, Et, cyclopropyl, FCH2CH2, 3-pyridyl, 4-pyridyl; R3 = F3CCH2, 1-methoxycarbonyl-4-piperidinyl, 1-ethoxycarbonyl-4-piperidinyl, 3-pyridylmethyl] with subnanomolar mTOR IC50 values and up to 26000-fold selectivity vs. PI3Kα were prepd.  Chiral morpholines gave inhibitors whose enantiomers had different selectivity and potency profiles.  Mol. modeling suggests that a single amino acid difference between PI3K and mTOR (Phe961Leu) accounts for the profound selectivity seen by creating a deeper pocket in mTOR that can accommodate bridged morpholines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK2HnMHqTHqbVg90H21EOLACvtfcHk0ljHic0whqk0Zw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J&md5=5ef1eee5aa79531970049d3d26b46eb2</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm901415x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901415x%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DMorpholine%2520derivatives%2520greatly%2520enhance%2520the%2520selectivity%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7942%26epage%3D7945%26doi%3D10.1021%2Fjm901415x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">PI3Kγ adaptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5)P<sub>3</sub> pools in mast cells</span>. <i>Sci. Signal.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">ra27</span>, <span class="refDoi"> DOI: 10.1126/scisignal.2000259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1126%2Fscisignal.2000259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=19509406" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=ra27&author=T.+Bohnackerauthor=R.+Maroneauthor=E.+Collmannauthor=R.+Calvezauthor=E.+Hirschauthor=M.+P.+Wymann&title=PI3K%CE%B3+adaptor+subunits+define+coupling+to+degranulation+and+cell+motility+by+distinct+PtdIns%283%2C4%2C5%29P3+pools+in+mast+cells&doi=10.1126%2Fscisignal.2000259"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2000259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2000259%26sid%3Dliteratum%253Aachs%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DCollmann%26aufirst%3DE.%26aulast%3DCalvez%26aufirst%3DR.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DPI3K%25CE%25B3%2520adaptor%2520subunits%2520define%2520coupling%2520to%2520degranulation%2520and%2520cell%2520motility%2520by%2520distinct%2520PtdIns%25283%252C4%252C5%2529P3%2520pools%2520in%2520mast%2520cells%26jtitle%3DSci.%2520Signal.%26date%3D2009%26volume%3D2%26spage%3Dra27%26doi%3D10.1126%2Fscisignal.2000259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haznedar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaror, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1021/ml200156t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200156t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=774-779&author=M.+T.+Burgerauthor=S.+Pecchiauthor=A.+Wagmanauthor=Z.-J.+Niauthor=M.+Knappauthor=T.+Hendricksonauthor=G.+Atallahauthor=K.+Pfisterauthor=Y.+Zhangauthor=S.+Bartulisauthor=K.+Frazierauthor=S.+Ngauthor=A.+Smithauthor=J.+Verhagenauthor=J.+Haznedarauthor=K.+Huhauthor=E.+Iwanowiczauthor=X.+Xinauthor=D.+Menezesauthor=H.+Merrittauthor=I.+Leeauthor=M.+Wiesmannauthor=S.+Kaufmanauthor=K.+Crawfordauthor=M.+Chinauthor=D.+Bussiereauthor=K.+Shoemakerauthor=I.+Zarorauthor=S.-M.+Mairaauthor=C.+F.+Voliva&title=Identification+of+NVP-BKM120+as+a+potent%2C+selective%2C+orally+bioavailable+class+I+PI3+kinase+inhibitor+for+treating+cancer&doi=10.1021%2Fml200156t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span></div><div class="casAuthors">Burger, Matthew T.; Pecchi, Sabina; Wagman, Allan; Ni, Zhi-Jie; Knapp, Mark; Hendrickson, Thomas; Atallah, Gordana; Pfister, Keith; Zhang, Yanchen; Bartulis, Sarah; Frazier, Kelly; Ng, Simon; Smith, Aaron; Verhagen, Joelle; Haznedar, Joshua; Huh, Kay; Iwanowicz, Ed; Xin, Xiaohua; Menezes, Daniel; Merritt, Hanne; Lee, Isabelle; Wiesmann, Marion; Kaufman, Susan; Crawford, Kenneth; Chin, Michael; Bussiere, Dirksen; Shoemaker, Kevin; Zaror, Isabel; Maira, Sauveur-Michel; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3Ks) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent.  The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma).  These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJ68B9pPbMbVg90H21EOLACvtfcHk0ljYsQUk-RFbew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI&md5=5d00d73dda1fc0d8f0f07d12900282ed</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fml200156t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200156t%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.-J.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DZaror%26aufirst%3DI.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520of%2520NVP-BKM120%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520class%2520I%2520PI3%2520kinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D774%26epage%3D779%26doi%3D10.1021%2Fml200156t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheijen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zask, A.</span></span> <span> </span><span class="NLM_article-title">Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kalpha</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2654</span>– <span class="NLM_lpage">2657</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.bmcl.2010.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=20223664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVGntrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2654-2657&author=D.+J.+Richardauthor=J.+C.+Verheijenauthor=K.+Yuauthor=A.+Zask&title=Triazines+incorporating+%28R%29-3-methylmorpholine+are+potent+inhibitors+of+the+mammalian+target+of+rapamycin+%28mTOR%29+with+selectivity+over+PI3Kalpha&doi=10.1016%2Fj.bmcl.2010.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kα</span></div><div class="casAuthors">Richard, David J.; Verheijen, Jeroen C.; Yu, Ker; Zask, Arie</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2654-2657</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Potent inhibitors of the mammalian target of rapamycin (mTOR) which contain the triazine scaffold and the (R)-3-Me morpholine moiety have been identified.  Such compds. also demonstrated good selectivity over the related lipid kinase PI3Kα.  Incorporation of addnl. functionality at the 4-position of the arylureidophenyl ring resulted in compds. with enhanced cellular activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfHbFQc9M8V7Vg90H21EOLACvtfcHk0ljYsQUk-RFbew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVGntrY%253D&md5=1091bba10aca6da4c6b5dd545b67e942</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DZask%26aufirst%3DA.%26atitle%3DTriazines%2520incorporating%2520%2528R%2529-3-methylmorpholine%2520are%2520potent%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520with%2520selectivity%2520over%2520PI3Kalpha%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2654%26epage%3D2657%26doi%3D10.1016%2Fj.bmcl.2010.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span> <span> </span><span class="NLM_article-title">Targeting PI3K in cancer: mechanisms and advances in clinical trials</span>. <i>Mol. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.1186/s12943-019-0954-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1186%2Fs12943-019-0954-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=30782187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A280%3ADC%252BB3cflt1Kluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=26&author=J.+Yangauthor=J.+Nieauthor=X.+Maauthor=Y.+Weiauthor=Y.+Pengauthor=X.+Wei&title=Targeting+PI3K+in+cancer%3A+mechanisms+and+advances+in+clinical+trials&doi=10.1186%2Fs12943-019-0954-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K in cancer: mechanisms and advances in clinical trials</span></div><div class="casAuthors">Yang Jing; Nie Ji; Ma Xuelei; Wei Yuquan; Peng Yong; Wei Xiawei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the most important intracellular pathways, which can be considered as a master regulator for cancer.  Enormous efforts have been dedicated to the development of drugs targeting PI3K signaling, many of which are currently employed in clinical trials evaluation, and it is becoming increasingly clear that PI3K inhibitors are effective in inhibiting tumor progression.  PI3K inhibitors are subdivided into dual PI3K/mTOR inhibitors, pan-PI3K inhibitors and isoform-specific inhibitors.  In this review, we performed a critical review to summarize the role of the PI3K pathway in tumor development, recent PI3K inhibitors development based on clinical trials, and the mechanisms of resistance to PI3K inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGm3fFMcHFSMScOqQTSkOffW6udTcc2eZ5luyBw3gs4rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cflt1Kluw%253D%253D&md5=4267e4df49544ebe11ab4255e69e5bbe</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-0954-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-0954-x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNie%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DX.%26atitle%3DTargeting%2520PI3K%2520in%2520cancer%253A%2520mechanisms%2520and%2520advances%2520in%2520clinical%2520trials%26jtitle%3DMol.%2520Canc.%26date%3D2019%26volume%3D18%26spage%3D26%26doi%3D10.1186%2Fs12943-019-0954-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fultz, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apuy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissonette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin-Ninkovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghaddam, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymon, H. K.</span></span> <span> </span><span class="NLM_article-title">CC-223, a potent and selective inhibitor of mTOR kinase: in vitro and in vivo characterization</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-14-1052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1158%2F1535-7163.MCT-14-1052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=25855786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFOgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1295-1305&author=D.+S.+Mortensenauthor=K.+E.+Fultzauthor=S.+Xuauthor=W.+Xuauthor=G.+Packardauthor=G.+Khambattaauthor=J.+C.+Gamezauthor=J.+Leistenauthor=J.+Zhaoauthor=J.+Apuyauthor=K.+Ghoreishiauthor=M.+Hickmanauthor=R.+K.+Narlaauthor=R.+Bissonetteauthor=S.+Richardsonauthor=S.+X.+Pengauthor=S.+Perrin-Ninkovicauthor=T.+Tranauthor=T.+Shiauthor=W.+Q.+Yangauthor=Z.+Tongauthor=B.+E.+Cathersauthor=M.+F.+Moghaddamauthor=S.+S.+Cananauthor=P.+Worlandauthor=S.+Sankarauthor=H.+K.+Raymon&title=CC-223%2C+a+potent+and+selective+inhibitor+of+mTOR+kinase%3A+in+vitro+and+in+vivo+characterization&doi=10.1158%2F1535-7163.mct-14-1052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization</span></div><div class="casAuthors">Mortensen, Deborah S.; Fultz, Kimberly E.; Xu, Shuichan; Xu, Weiming; Packard, Garrick; Khambatta, Godrej; Gamez, James C.; Leisten, Jim; Zhao, Jingjing; Apuy, Julius; Ghoreishi, Kamran; Hickman, Matt; Narla, Rama Krishna; Bissonette, Rene; Richardson, Samantha; Peng, Sophie X.; Perrin-Ninkovic, Sophie; Tran, Tam; Shi, Tao; Yang, Wen Qing; Tong, Zeen; Cathers, Brian E.; Moghaddam, Mehran F.; Canan, Stacie S.; Worland, Peter; Sankar, Sabita; Raymon, Heather K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1295-1305</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MTOR is a serine/threonine kinase that regulates cell growth, metab., proliferation, and survival. mTOR complex-1 (mTORC1) and mTOR complex-2 (mTORC2) are crit. mediators of the PI3K-AKT pathway, which is frequently mutated in many cancers, leading to hyperactivation of mTOR signaling.  Although rapamycin analogs, allosteric inhibitors that target only the mTORC1 complex, have shown some clin. activity, it is hypothesized that mTOR kinase inhibitors, blocking both mTORC1 and mTORC2 signaling, will have expanded therapeutic potential.  Here, we describe the preclin. characterization of CC-223.  CC-223 is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, demonstrating inhibition of mTORC1 (pS6RP and p4EBP1) and mTORC2 [pAKT(S473)] in cellular systems.  Growth inhibitory activity was demonstrated in hematol. and solid tumor cell lines. mTOR kinase inhibition in cells, by CC-223, resulted in more complete inhibition of the mTOR pathway biomarkers and improved antiproliferative activity as compared with rapamycin.  Growth inhibitory activity and apoptosis was demonstrated in a panel of hematol. cancer cell lines.  Correlative anal. revealed that IRF4 expression level assocs. with resistance, whereas mTOR pathway activation seems to assoc. with sensitivity.  Treatment with CC-223 afforded in vivo tumor biomarker inhibition in tumor-bearing mice, after a single oral dose.  CC-223 exhibited dose-dependent tumor growth inhibition in multiple solid tumor xenografts.  Significant inhibition of mTOR pathway markers pS6RP and pAKT in CC-223-treated tumors suggests that the obsd. antitumor activity of CC-223 was mediated through inhibition of both mTORC1 and mTORC2.  CC-223 is currently in phase I clin. trials.  Mol Cancer Ther; 14(6); 1295-305. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDt9130-L0z7Vg90H21EOLACvtfcHk0lgtPyLaMQeXpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFOgurk%253D&md5=f33b21dc89dedaf14fab54a819afb917</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-1052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-1052%26sid%3Dliteratum%253Aachs%26aulast%3DMortensen%26aufirst%3DD.%2BS.%26aulast%3DFultz%26aufirst%3DK.%2BE.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DPackard%26aufirst%3DG.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DGamez%26aufirst%3DJ.%2BC.%26aulast%3DLeisten%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DApuy%26aufirst%3DJ.%26aulast%3DGhoreishi%26aufirst%3DK.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DNarla%26aufirst%3DR.%2BK.%26aulast%3DBissonette%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DS.%2BX.%26aulast%3DPerrin-Ninkovic%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DW.%2BQ.%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DMoghaddam%26aufirst%3DM.%2BF.%26aulast%3DCanan%26aufirst%3DS.%2BS.%26aulast%3DWorland%26aufirst%3DP.%26aulast%3DSankar%26aufirst%3DS.%26aulast%3DRaymon%26aufirst%3DH.%2BK.%26atitle%3DCC-223%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520mTOR%2520kinase%253A%2520in%2520vitro%2520and%2520in%2520vivo%2520characterization%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D1295%26epage%3D1305%26doi%3D10.1158%2F1535-7163.mct-14-1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolgin, E.</span></span> <span> </span><span class="NLM_article-title">Anticancer autophagy inhibitors attract ’resurgent’ interest</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1038/d41573-019-00072-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fd41573-019-00072-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=31160763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2itbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=408-410&author=E.+Dolgin&title=Anticancer+autophagy+inhibitors+attract+%E2%80%99resurgent%E2%80%99+interest&doi=10.1038%2Fd41573-019-00072-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer autophagy inhibitors attract 'resurgent' interest</span></div><div class="casAuthors">Dolgin, Elie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">408-410</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Despite industry's past setbacks with autophagy inhibitors, preclin. and clin. findings are starting to revitalize a once written-off strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMOD6_MOuv9rVg90H21EOLACvtfcHk0lgtPyLaMQeXpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2itbvP&md5=25bbc81d3f1b2f37d7e0afd2bb02b6d8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fd41573-019-00072-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41573-019-00072-1%26sid%3Dliteratum%253Aachs%26aulast%3DDolgin%26aufirst%3DE.%26atitle%3DAnticancer%2520autophagy%2520inhibitors%2520attract%2520%25E2%2580%2599resurgent%25E2%2580%2599%2520interest%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2019%26volume%3D18%26spage%3D408%26epage%3D410%26doi%3D10.1038%2Fd41573-019-00072-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dyczynski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otrocka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parpal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zazzi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viklund, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandér, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Milito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokrovskaja Tamm, K.</span></span> <span> </span><span class="NLM_article-title">Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib</span>. <i>Canc. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>435</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2018.07.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.canlet.2018.07.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=30055290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVClsb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2018&pages=32-43&author=M.+Dyczynskiauthor=Y.+Yuauthor=M.+Otrockaauthor=S.+Parpalauthor=T.+Bragaauthor=A.+B.+Henleyauthor=H.+Zazziauthor=M.+Lernerauthor=K.+Wennerbergauthor=J.+Viklundauthor=J.+Martinssonauthor=D.+Grand%C3%A9rauthor=A.+De+Militoauthor=K.+Pokrovskaja+Tamm&title=Targeting+autophagy+by+small+molecule+inhibitors+of+vacuolar+protein+sorting+34+%28Vps34%29+improves+the+sensitivity+of+breast+cancer+cells+to+Sunitinib&doi=10.1016%2Fj.canlet.2018.07.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib</span></div><div class="casAuthors">Dyczynski, Matheus; Yu, Yasmin; Otrocka, Magdalena; Parpal, Santiago; Braga, Tiago; Henley, Aine Brigette; Zazzi, Henric; Lerner, Mikael; Wennerberg, Krister; Viklund, Jenny; Martinsson, Jessica; Grander, Dan; De Milito, Angelo; Pokrovskaja Tamm, Katja</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">435</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-43</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Resistance to chemotherapy is a challenging problem for treatment of cancer patients and autophagy has been shown to mediate development of resistance.  In this study we systematically screened a library of 306 known anti-cancer drugs for their ability to induce autophagy using a cell-based assay. 114 of the drugs were classified as autophagy inducers; for 16 drugs, the cytotoxicity was potentiated by siRNA-mediated knock-down of Atg7 and Vps34.  These drugs were further evaluated in breast cancer cell lines for autophagy induction, and two tyrosine kinase inhibitors, Sunitinib and Erlotinib, were selected for further studies.  For the pharmacol. inhibition of autophagy, we have characterized here a novel highly potent selective inhibitor of Vps34, SB02024.  SB02024 blocked autophagy in vitro and reduced xenograft growth of two breast cancer cell lines, MDA-MB-231 and MCF-7, in vivo.  Vps34 inhibitor significantly potentiated cytotoxicity of Sunitinib and Erlotinib in MCF-7 and MDA-MB-231 in vitro in monolayer cultures and when grown as multicellular spheroids.  Our data suggests that inhibition of autophagy significantly improves sensitivity to Sunitinib and Erlotinib and that Vps34 is a promising therapeutic target for combination strategies in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXkKf8QCte1LVg90H21EOLACvtfcHk0ljVA_a1PonNFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVClsb%252FI&md5=7d746f7e596ef83119e3a4b8575679d4</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2018.07.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2018.07.028%26sid%3Dliteratum%253Aachs%26aulast%3DDyczynski%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DOtrocka%26aufirst%3DM.%26aulast%3DParpal%26aufirst%3DS.%26aulast%3DBraga%26aufirst%3DT.%26aulast%3DHenley%26aufirst%3DA.%2BB.%26aulast%3DZazzi%26aufirst%3DH.%26aulast%3DLerner%26aufirst%3DM.%26aulast%3DWennerberg%26aufirst%3DK.%26aulast%3DViklund%26aufirst%3DJ.%26aulast%3DMartinsson%26aufirst%3DJ.%26aulast%3DGrand%25C3%25A9r%26aufirst%3DD.%26aulast%3DDe%2BMilito%26aufirst%3DA.%26aulast%3DPokrovskaja%2BTamm%26aufirst%3DK.%26atitle%3DTargeting%2520autophagy%2520by%2520small%2520molecule%2520inhibitors%2520of%2520vacuolar%2520protein%2520sorting%252034%2520%2528Vps34%2529%2520improves%2520the%2520sensitivity%2520of%2520breast%2520cancer%2520cells%2520to%2520Sunitinib%26jtitle%3DCanc.%2520Lett.%26date%3D2018%26volume%3D435%26spage%3D32%26epage%3D43%26doi%3D10.1016%2Fj.canlet.2018.07.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0ljVA_a1PonNFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karlgren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simoff, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backlund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundquist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jareborg, A.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oswald, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">A CRISPR-Cas9 generated MDCK cell line expressing human MDR1 without endogenous canine MDR1 (cABCB1): an improved tool for drug efflux studies</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">2909</span>– <span class="NLM_lpage">2913</span>, <span class="refDoi"> DOI: 10.1016/j.xphs.2017.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.xphs.2017.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=28450237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptFClsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2017&pages=2909-2913&author=M.+Karlgrenauthor=I.+Simoffauthor=M.+Backlundauthor=C.+Weglerauthor=M.+Keiserauthor=N.+Handinauthor=J.+M%C3%BCllerauthor=P.+Lundquistauthor=A.-C.+Jareborgauthor=S.+Oswaldauthor=P.+Artursson&title=A+CRISPR-Cas9+generated+MDCK+cell+line+expressing+human+MDR1+without+endogenous+canine+MDR1+%28cABCB1%29%3A+an+improved+tool+for+drug+efflux+studies&doi=10.1016%2Fj.xphs.2017.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A CRISPR-Cas9 Generated Madin-Darby Canine Kidney Expressing Human MDR1 Without Endogenous Canine MDR1 (cABCB1): An Improved Tool for Drug Efflux Studies</span></div><div class="casAuthors">Karlgren, Maria; Simoff, Ivailo; Backlund, Maria; Wegler, Christine; Keiser, Markus; Handin, Niklas; Muller, Janett; Lundquist, Patrik; Jareborg, Anne-Christine; Oswald, Stefan; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2909-2913</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Madin-Darby canine kidney (MDCK) II cells stably transfected with transport proteins are commonly used models for drug transport studies.  However, endogenous expression of esp. canine MDR1 (cMDR1) confounds the interpretation of such studies.  Here we have established an MDCK cell line stably overexpressing the human MDR1 transporter (hMDR1; P-glycoprotein), and used CRISPR-Cas9 gene editing to knockout the endogenous cMDR1.  Genomic screening revealed the generation of a clonal cell line homozygous for a 4-nucleotide deletion in the canine ABCB1 gene leading to a frameshift and a premature stop codon.  Knockout of cMDR1 expression was verified by quant. protein anal. and functional studies showing retained activity of the human MDR1 transporter.  Application of this cell line allowed unbiased reclassification of drugs previously defined as both substrates and non-substrates in different studies using commonly used MDCK-MDR1 clones.  Our new MDCK-hMDR1 cell line, together with a previously developed control cell line, both with identical deletions in the canine ABCB1 gene and lack of cMDR1 expression represent excellent in vitro tools for use in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowFgM8d_MR2LVg90H21EOLACvtfcHk0ljbyMQyKHEr9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptFClsL8%253D&md5=a6dad5423bbfe5395844667d938d8875</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.xphs.2017.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.xphs.2017.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DKarlgren%26aufirst%3DM.%26aulast%3DSimoff%26aufirst%3DI.%26aulast%3DBacklund%26aufirst%3DM.%26aulast%3DWegler%26aufirst%3DC.%26aulast%3DKeiser%26aufirst%3DM.%26aulast%3DHandin%26aufirst%3DN.%26aulast%3DM%25C3%25BCller%26aufirst%3DJ.%26aulast%3DLundquist%26aufirst%3DP.%26aulast%3DJareborg%26aufirst%3DA.-C.%26aulast%3DOswald%26aufirst%3DS.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DA%2520CRISPR-Cas9%2520generated%2520MDCK%2520cell%2520line%2520expressing%2520human%2520MDR1%2520without%2520endogenous%2520canine%2520MDR1%2520%2528cABCB1%2529%253A%2520an%2520improved%2520tool%2520for%2520drug%2520efflux%2520studies%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D106%26spage%3D2909%26epage%3D2913%26doi%3D10.1016%2Fj.xphs.2017.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadiume, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodakoski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundquist, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bareja, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sboner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Suppression of insulin feedback enhances the efficacy of PI3K inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>560</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0343-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fs41586-018-0343-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=30051890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVynsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=560&publication_year=2018&pages=499-503&author=B.+D.+Hopkinsauthor=C.+Pauliauthor=X.+Duauthor=D.+G.+Wangauthor=X.+Liauthor=D.+Wuauthor=S.+C.+Amadiumeauthor=M.+D.+Goncalvesauthor=C.+Hodakoskiauthor=M.+R.+Lundquistauthor=R.+Barejaauthor=Y.+Maauthor=E.+M.+Harrisauthor=A.+Sbonerauthor=H.+Beltranauthor=M.+A.+Rubinauthor=S.+Mukherjeeauthor=L.+C.+Cantley&title=Suppression+of+insulin+feedback+enhances+the+efficacy+of+PI3K+inhibitors&doi=10.1038%2Fs41586-018-0343-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of insulin feedback enhances the efficacy of PI3K inhibitors</span></div><div class="casAuthors">Hopkins, Benjamin D.; Pauli, Chantal; Xing, Du; Wang, Diana G.; Li, Xiang; Wu, David; Amadiume, Solomon C.; Goncalves, Marcus D.; Hodakoski, Cindy; Lundquist, Mark R.; Bareja, Rohan; Ma, Yan; Harris, Emily M.; Sboner, Andrea; Beltran, Himisha; Rubin, Mark A.; Mukherjee, Siddhartha; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">560</span>
        (<span class="NLM_cas:issue">7719</span>),
    <span class="NLM_cas:pages">499-503</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Mutations in PIK3CA, which encodes the p110α subunit of the insulin-activated phosphatidylinositol-3 kinase (PI3K), and loss of function mutations in PTEN, which encodes a phosphatase that degrades the phosphoinositide lipids generated by PI3K, are among the most frequent events in human cancers1,2.  However, pharmacol. inhibition of PI3K has resulted in variable clin. responses, raising the possibility of an inherent mechanism of resistance to treatment.  As p110α mediates virtually all cellular responses to insulin, targeted inhibition of this enzyme disrupts glucose metab. in multiple tissues.  For example, blocking insulin signalling promotes glycogen breakdown in the liver and prevents glucose uptake in the skeletal muscle and adipose tissue, resulting in transient hyperglycemia within a few hours of PI3K inhibition.  The effect is usually transient because compensatory insulin release from the pancreas (insulin feedback) restores normal glucose homeostasis3.  However, the hyperglycemia may be exacerbated or prolonged in patients with any degree of insulin resistance and, in these cases, necessitates discontinuation of therapy3-6.  We hypothesized that insulin feedback induced by PI3K inhibitors may reactivate the PI3K-mTOR signalling axis in tumors, thereby compromising treatment effectiveness7,8.  Here we show, in several model tumors in mice, that systemic glucose-insulin feedback caused by targeted inhibition of this pathway is sufficient to activate PI3K signalling, even in the presence of PI3K inhibitors.  This insulin feedback can be prevented using dietary or pharmaceutical approaches, which greatly enhance the efficacy/toxicity ratios of PI3K inhibitors.  These findings have direct clin. implications for the multiple p110α inhibitors that are in clin. trials and provide a way to increase treatment efficacy for patients with many types of tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTJSeU1MUvt7Vg90H21EOLACvtfcHk0ljbyMQyKHEr9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVynsrjJ&md5=e673e3a3956e4b4039d99646695adde9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0343-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0343-4%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DB.%2BD.%26aulast%3DPauli%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DAmadiume%26aufirst%3DS.%2BC.%26aulast%3DGoncalves%26aufirst%3DM.%2BD.%26aulast%3DHodakoski%26aufirst%3DC.%26aulast%3DLundquist%26aufirst%3DM.%2BR.%26aulast%3DBareja%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DHarris%26aufirst%3DE.%2BM.%26aulast%3DSboner%26aufirst%3DA.%26aulast%3DBeltran%26aufirst%3DH.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DSuppression%2520of%2520insulin%2520feedback%2520enhances%2520the%2520efficacy%2520of%2520PI3K%2520inhibitors%26jtitle%3DNature%26date%3D2018%26volume%3D560%26spage%3D499%26epage%3D503%26doi%3D10.1038%2Fs41586-018-0343-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xyrafas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bize, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanović, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanović, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrijević, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prêtre, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritschard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzankov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hierro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joerger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Moos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R.</span></span> <span> </span><span class="NLM_article-title">First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)</span>. <i>Eur. J. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2018.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.ejca.2018.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=29660598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1Snu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2018&pages=6-16&author=A.+Wickiauthor=N.+Brownauthor=A.+Xyrafasauthor=V.+Bizeauthor=H.+Hawleauthor=S.+Berardiauthor=N.+Cmiljanovi%C4%87author=V.+Cmiljanovi%C4%87author=M.+Stummauthor=S.+Dimitrijevi%C4%87author=R.+Herrmannauthor=V.+Pr%C3%AAtreauthor=R.+Ritschardauthor=A.+Tzankovauthor=V.+Hessauthor=A.+Childsauthor=C.+Hierroauthor=J.+Rodonauthor=D.+Hessauthor=M.+Joergerauthor=R.+von+Moosauthor=C.+Sessaauthor=R.+Kristeleit&title=First-in+human%2C+phase+1%2C+dose-escalation+pharmacokinetic+and+pharmacodynamic+study+of+the+oral+dual+PI3K+and+mTORC1%2F2+inhibitor+PQR309+in+patients+with+advanced+solid+tumors+%28SAKK+67%2F13%29&doi=10.1016%2Fj.ejca.2018.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)</span></div><div class="casAuthors">Wicki, Andreas; Brown, Nicholas; Xyrafas, Alexandros; Bize, Vincent; Hawle, Hanne; Berardi, Simona; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Stumm, Michael; Dimitrijevic, Sasa; Herrmann, Richard; Pretre, Vincent; Ritschard, Reto; Tzankov, Alexandar; Hess, Viviane; Childs, Alexa; Hierro, Cinta; Rodon, Jordi; Hess, Dagmar; Joerger, Markus; von Moos, Roger; Sessa, Cristiana; Kristeleit, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6-16</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">PQR309 is an orally bioavailable, balanced pan-phosphatidylinositol-3-kinase (PI3K), mammalian target of rapamycin (mTOR) C1 and mTORC2 inhibitor.  This is an accelerated titrn., 3 D 3 dose-escalation, open-label phase Itrial of continuous once-daily (OD) PQR309 administration to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics in patients with advanced solid tumors.  Primary objectives were to det. the max. tolerated dose (MTD) and recommended phase 2 dose (RP2D).Twenty-eight patients were included in six dosing cohorts and treated at a daily PQR309 dose ranging from 10 to 150 mg.  Common adverse events (AEs; ≥30% patients) included fatigue, hyperglycemia, nausea, diarrhea, constipation, rash, anorexia and vomiting.  Grade (G) 3 or 4 drug-related AEs were seen in 13 (46%) and three (11%) patients, resp.  Dose-limiting toxicity (DLT) was obsd. in two patients at 100 mg OD (>14-d interruption in PQR309 due to G3 rash, G2 hyperbilirubinemia, G4 suicide attempt; dose redn. due to G3 fatigue, G2 diarrhoea, G4 transaminitis) and one patient at 80 mg (G3 hyperglycemia >7 d).  PK shows fast absorption (Tmax 1-2 h) and dose proportionality for Cmax and area under the curve.  A partial response in a patient with metastatic thymus cancer, 24% disease vol. redn. in a patient with sinonasal cancer and stable disease for more than 16 wk in a patient with clear cell Bartholin's gland cancer were obsd.The MTD and RP2D of PQR309 is 80 mg of orally OD.  PK is dose-proportional.  PD shows PI3K pathway phosphoprotein downregulation in paired tumor biopsies.  Clin. activity was obsd. in patients with and without PI3K pathway dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdVIhZzSTJb7Vg90H21EOLACvtfcHk0ljbyMQyKHEr9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1Snu70%253D&md5=acbdfdb59498f5543ba7f02ed9709d0e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2018.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2018.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DWicki%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DXyrafas%26aufirst%3DA.%26aulast%3DBize%26aufirst%3DV.%26aulast%3DHawle%26aufirst%3DH.%26aulast%3DBerardi%26aufirst%3DS.%26aulast%3DCmiljanovi%25C4%2587%26aufirst%3DN.%26aulast%3DCmiljanovi%25C4%2587%26aufirst%3DV.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DDimitrijevi%25C4%2587%26aufirst%3DS.%26aulast%3DHerrmann%26aufirst%3DR.%26aulast%3DPr%25C3%25AAtre%26aufirst%3DV.%26aulast%3DRitschard%26aufirst%3DR.%26aulast%3DTzankov%26aufirst%3DA.%26aulast%3DHess%26aufirst%3DV.%26aulast%3DChilds%26aufirst%3DA.%26aulast%3DHierro%26aufirst%3DC.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DJoerger%26aufirst%3DM.%26aulast%3Dvon%2BMoos%26aufirst%3DR.%26aulast%3DSessa%26aufirst%3DC.%26aulast%3DKristeleit%26aufirst%3DR.%26atitle%3DFirst-in%2520human%252C%2520phase%25201%252C%2520dose-escalation%2520pharmacokinetic%2520and%2520pharmacodynamic%2520study%2520of%2520the%2520oral%2520dual%2520PI3K%2520and%2520mTORC1%252F2%2520inhibitor%2520PQR309%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%2520%2528SAKK%252067%252F13%2529%26jtitle%3DEur.%2520J.%2520Canc.%26date%3D2018%26volume%3D96%26spage%3D6%26epage%3D16%26doi%3D10.1016%2Fj.ejca.2018.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronica, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Vliet, E. A.</span></span> <span> </span><span class="NLM_article-title">The roof is leaking and a storm is raging: repairing the blood-brain barrier in the fight against epilepsy</span>. <i>Epilepsy Current</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1177/1535759719844750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1177%2F1535759719844750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=31037960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A280%3ADC%252BB3M7gslWjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=177-181&author=J.+A.+Gorterauthor=E.+Aronicaauthor=E.+A.+van+Vliet&title=The+roof+is+leaking+and+a+storm+is+raging%3A+repairing+the+blood-brain+barrier+in+the+fight+against+epilepsy&doi=10.1177%2F1535759719844750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The Roof is Leaking and a Storm is Raging: Repairing the Blood-Brain Barrier in the Fight Against Epilepsy</span></div><div class="casAuthors">Gorter J A; van Vliet E A; Aronica E; van Vliet E A; Aronica E</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsy currents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">177-181</span>
        ISSN:<span class="NLM_cas:issn">1535-7597</span>.
    </div><div class="casAbstract">A large body of evidence that has accumulated over the past decade strongly supports the role of both blood-brain barrier (BBB) dysfunction and perivascular inflammation in the pathophysiology of epilepsy.  Recent preclinical studies indicate that prolonged seizure- or brain injury-induced BBB dysfunction and subsequent perivascular inflammation may play an important role in post-traumatic epileptogenesis.  In turn, perivascular inflammation can further sustain BBB dysfunction.  In genetic epilepsies, such as tuberous sclerosis complex and other related epileptogenic developmental pathologies, there is an association between the underlying gene mutation, BBB dysfunction, and perivascular inflammation, but evidence for a causal link to epilepsy is lacking.  Future neuroimaging studies might shed light on the role of BBB function in different epilepsies and address the potential for disease modification by targeting both the BBB and perivascular inflammation in acquired and genetic epilepsies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLEiap4sK8sYNpW7w2tapOfW6udTcc2eYkcLqfGqT_87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7gslWjtg%253D%253D&md5=f2e286f9d69fd2e92737449ce1ffb78b</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1177%2F1535759719844750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1535759719844750%26sid%3Dliteratum%253Aachs%26aulast%3DGorter%26aufirst%3DJ.%2BA.%26aulast%3DAronica%26aufirst%3DE.%26aulast%3Dvan%2BVliet%26aufirst%3DE.%2BA.%26atitle%3DThe%2520roof%2520is%2520leaking%2520and%2520a%2520storm%2520is%2520raging%253A%2520repairing%2520the%2520blood-brain%2520barrier%2520in%2520the%2520fight%2520against%2520epilepsy%26jtitle%3DEpilepsy%2520Current%26date%3D2019%26volume%3D19%26spage%3D177%26epage%3D181%26doi%3D10.1177%2F1535759719844750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Löscher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potschka, H.</span></span> <span> </span><span class="NLM_article-title">Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2005.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.pneurobio.2005.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=16011870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A280%3ADC%252BD2MzpvFSgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2005&pages=22-76&author=W.+L%C3%B6scherauthor=H.+Potschka&title=Role+of+drug+efflux+transporters+in+the+brain+for+drug+disposition+and+treatment+of+brain+diseases&doi=10.1016%2Fj.pneurobio.2005.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases</span></div><div class="casAuthors">Loscher Wolfgang; Potschka Heidrun</div><div class="citationInfo"><span class="NLM_cas:title">Progress in neurobiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-76</span>
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    </div><div class="casAbstract">The blood-brain barrier (BBB) serves as a protective mechanism for the brain by preventing entry of potentially harmful substances from free access to the central nervous system (CNS).  Tight junctions present between the brain microvessel endothelial cells form a diffusion barrier, which selectively excludes most blood-borne substances from entering the brain.  Astrocytic end-feet tightly ensheath the vessel wall and appear to be critical for the induction and maintenance of the barrier properties of the brain capillary endothelial cells.  Because of these properties, the BBB only allows entry of lipophilic compounds with low molecular weights by passive diffusion.  However, many lipophilic drugs show negligible brain uptake.  They are substrates for drug efflux transporters such as P-glycoprotein (Pgp), multidrug resistance proteins (MRPs) or organic anion transporting polypeptides (OATPs) that are expressed at brain capillary endothelial cells and/or astrocytic end-feet and are key elements of the molecular machinery that confers the special permeability properties to the BBB.  The combined action of these carrier systems results in rapid efflux of xenobiotics from the CNS.  The objective of this review is to summarize transporter characteristics (cellular localization, specificity, regulation, and potential inhibition) for drug efflux transport systems identified in the BBB and blood-cerebrospinal fluid (CSF) barrier.  A variety of experimental approaches available to ascertain or predict the impact of efflux transport on brain access of therapeutic drugs also are described and critically discussed.  The potential impact of efflux transport on the pharmacodynamics of agents acting in the CNS is illustrated.  Furthermore, the current knowledge about drug efflux transporters as a major determinant of multidrug resistance of brain diseases such as epilepsy is reviewed.  Finally, we summarize strategies for modulating or by-passing drug efflux transporters at the BBB as novel therapeutic approaches to drug-resistant brain diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRe07yo5jk4UPSAs_PE1QvifW6udTcc2eYkcLqfGqT_87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzpvFSgtw%253D%253D&md5=146aa11977c71b08a1182aba1354db84</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2005.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2005.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26aulast%3DPotschka%26aufirst%3DH.%26atitle%3DRole%2520of%2520drug%2520efflux%2520transporters%2520in%2520the%2520brain%2520for%2520drug%2520disposition%2520and%2520treatment%2520of%2520brain%2520diseases%26jtitle%3DProg.%2520Neurobiol.%26date%3D2005%26volume%3D76%26spage%3D22%26epage%3D76%26doi%3D10.1016%2Fj.pneurobio.2005.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Löscher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potschka, H.</span></span> <span> </span><span class="NLM_article-title">Drug resistance in brain diseases and the role of drug efflux transporters</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1038/nrn1728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fnrn1728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=16025095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A280%3ADC%252BD2MvgtFKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=591-602&author=W.+L%C3%B6scherauthor=H.+Potschka&title=Drug+resistance+in+brain+diseases+and+the+role+of+drug+efflux+transporters&doi=10.1038%2Fnrn1728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Drug resistance in brain diseases and the role of drug efflux transporters</span></div><div class="casAuthors">Loscher Wolfgang; Potschka Heidrun</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">591-602</span>
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    </div><div class="casAbstract">Resistance to drug treatment is an important hurdle in the therapy of many brain disorders, including brain cancer, epilepsy, schizophrenia, depression and infection of the brain with HIV.  Consequently, there is a pressing need to develop new and more effective treatment strategies.  Mechanisms of resistance that operate in cancer and infectious diseases might also be relevant in drug-resistant brain disorders.  In particular, drug efflux transporters that are expressed at the blood-brain barrier limit the ability of many drugs to access the brain.  There is increasing evidence that drug efflux transporters have an important role in drug-resistant brain disorders, and this information should allow more efficacious treatment strategies to be developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBI4VWCsjP46-9TkgmBqTqfW6udTcc2eZZ4gjnXKVX67ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MvgtFKisg%253D%253D&md5=26af8b7a7f5b210decf788b837e52b3e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnrn1728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn1728%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26aulast%3DPotschka%26aufirst%3DH.%26atitle%3DDrug%2520resistance%2520in%2520brain%2520diseases%2520and%2520the%2520role%2520of%2520drug%2520efflux%2520transporters%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2005%26volume%3D6%26spage%3D591%26epage%3D602%26doi%3D10.1038%2Fnrn1728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anglicheau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassinat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Méria, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaune, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legendre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thervet, E.</span></span> <span> </span><span class="NLM_article-title">Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine–sirolimus interaction</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1019</span>– <span class="NLM_lpage">1025</span>, <span class="refDoi"> DOI: 10.1038/sj.ki.5001649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fsj.ki.5001649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=16837925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD28XptFCmu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=1019-1025&author=D.+Anglicheauauthor=N.+Palletauthor=M.+Rabantauthor=P.+Marquetauthor=B.+Cassinatauthor=P.+M%C3%A9riaauthor=P.+Beauneauthor=C.+Legendreauthor=E.+Thervet&title=Role+of+P-glycoprotein+in+cyclosporine+cytotoxicity+in+the+cyclosporine%E2%80%93sirolimus+interaction&doi=10.1038%2Fsj.ki.5001649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction</span></div><div class="casAuthors">Anglicheau, D.; Pallet, N.; Rabant, M.; Marquet, P.; Cassinat, B.; Meria, P.; Beaune, P.; Legendre, C.; Thervet, E.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1019-1025</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cyclosporine nephrotoxicity remains a major side effect in solid organ transplantation, and can be exacerbated by concomitant administration of sirolimus.  Cyclosporine and sirolimus are P-glycoprotein (Pgp) substrates.  We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.  Cyclosporine cytotoxicity was evaluated in primary cultures of normal human renal epithelial cells (HRECs) by cell viability and cytotoxicity assays.  Verapamil, quinine, PSC833, and PGP-4008 were used as Pgp inhibitors.  Rhodamine-123 (R-123), a fluorescent substrate of Pgp, was used to assess Pgp-mediated transport.  Cellular cyclosporine concn. was measured by high-performance liq. chromatog. coupled to tandem mass spectrometry.  Pgp expression and function were confirmed in HRECs and cyclosporine and sirolimus were shown to be Pgp inhibitors in this model.  Verapamil-induced inhibition of Pgp led to a significant increase in cellular concn. of cyclosporine (P<0.05).  Cyclosporine exerted a concn.-dependent cytotoxic effect on HRECs that was significantly increased by inhibition of Pgp activity.  Sirolimus exerted an inhibitory effect on R-123 efflux in HRECs and increased cellular cyclosporine concns. in a dose-dependent manner.  These data demonstrate that Pgp plays a crit. role in protecting renal epithelial cells from cyclosporine toxicity.  The inhibitory effect of sirolimus on Pgp-mediated efflux and the cellular concn. of cyclosporine could explain the exacerbation of cyclosporine nephrotoxicity obsd. clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrclBi-hm7QPbVg90H21EOLACvtfcHk0liRElFhQvqleQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptFCmu7c%253D&md5=f591bec42e4d8daf19e4cc776c604b24</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fsj.ki.5001649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ki.5001649%26sid%3Dliteratum%253Aachs%26aulast%3DAnglicheau%26aufirst%3DD.%26aulast%3DPallet%26aufirst%3DN.%26aulast%3DRabant%26aufirst%3DM.%26aulast%3DMarquet%26aufirst%3DP.%26aulast%3DCassinat%26aufirst%3DB.%26aulast%3DM%25C3%25A9ria%26aufirst%3DP.%26aulast%3DBeaune%26aufirst%3DP.%26aulast%3DLegendre%26aufirst%3DC.%26aulast%3DThervet%26aufirst%3DE.%26atitle%3DRole%2520of%2520P-glycoprotein%2520in%2520cyclosporine%2520cytotoxicity%2520in%2520the%2520cyclosporine%25E2%2580%2593sirolimus%2520interaction%26jtitle%3DKidney%2520Int.%26date%3D2006%26volume%3D70%26spage%3D1019%26epage%3D1025%26doi%3D10.1038%2Fsj.ki.5001649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franz, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yapici, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohrman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemer-Kruel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coello, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, J. A.</span></span> <span> </span><span class="NLM_article-title">Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1188</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1111/epi.14085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1111%2Fepi.14085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=29727013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFSrsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=1188-1197&author=D.+N.+Franzauthor=J.+A.+Lawsonauthor=Z.+Yapiciauthor=C.+Brandtauthor=M.+H.+Kohrmanauthor=M.+Wongauthor=M.+Milhauthor=A.+Wiemer-Kruelauthor=M.+Voiauthor=N.+Coelloauthor=W.+Cheungauthor=K.+Groschauthor=J.+A.+French&title=Everolimus+dosing+recommendations+for+tuberous+sclerosis+complex%E2%80%93associated+refractory+seizures&doi=10.1111%2Fepi.14085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures</span></div><div class="casAuthors">Franz, David N.; Lawson, John A.; Yapici, Zuhal; Brandt, Christian; Kohrman, Michael H.; Wong, Michael; Milh, Mathieu; Wiemer-Kruel, Adelheid; Voi, Maurizio; Coello, Neva; Cheung, Wing; Grosch, Kai; French, Jacqueline A.</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1188-1197</span>CODEN:
                <span class="NLM_cas:coden">EPILAK</span>;
        ISSN:<span class="NLM_cas:issn">0013-9580</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The present anal. examd. the exposure-response relationship by means of the predose everolimus concn. (Cmin) and the seizure response in patients with tuberous sclerosis complex-assocd. seizures in the EXIST-3 study.  TN-Cmin was used to link exposure to efficacy and safety end points via model-based approaches.  A conditional logistic regression stratified by age subgroup was used to est. the probability of response in relation to exposure.  A multiplicative linear regression model was used to est. the exposure-response relationship for seizure frequency (SF).  An extended Cox regression model was used to link exposure to the time to first adverse event.  There was a strong, consistent, and highly significant relationship between everolimus exposure and efficacy, measured by TN-Cmin and SF, regardless of patient's age and concomitant use of cytochrome P 450 3A4 (CYP3A4) inhibitors/inducers.  Results of an extended Cox regression analyses indicated that twofold increases in TN-Cmin were not assocd. with statistically significant increases in the risk of stomatitis or infections.  The recommended TDM is to target everolimus Cmin within a range of 5-7 ng/mL initially and 5-15 ng/mL in the event of an inadequate clin. response, and safety is consistent with previous reports.  Starting doses depend on age and the concomitant use of CYP3A4/P-glycoprotein inducers/inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr073QVPfzprVg90H21EOLACvtfcHk0liRElFhQvqleQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFSrsbzE&md5=65f6d261ba702aa94a7827a4fa4b9f86</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1111%2Fepi.14085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fepi.14085%26sid%3Dliteratum%253Aachs%26aulast%3DFranz%26aufirst%3DD.%2BN.%26aulast%3DLawson%26aufirst%3DJ.%2BA.%26aulast%3DYapici%26aufirst%3DZ.%26aulast%3DBrandt%26aufirst%3DC.%26aulast%3DKohrman%26aufirst%3DM.%2BH.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DMilh%26aufirst%3DM.%26aulast%3DWiemer-Kruel%26aufirst%3DA.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DCoello%26aufirst%3DN.%26aulast%3DCheung%26aufirst%3DW.%26aulast%3DGrosch%26aufirst%3DK.%26aulast%3DFrench%26aufirst%3DJ.%2BA.%26atitle%3DEverolimus%2520dosing%2520recommendations%2520for%2520tuberous%2520sclerosis%2520complex%25E2%2580%2593associated%2520refractory%2520seizures%26jtitle%3DEpilepsia%26date%3D2018%26volume%3D59%26spage%3D1188%26epage%3D1197%26doi%3D10.1111%2Fepi.14085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theilmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gericke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schidlitzki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muneeb Anjum, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsdorf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harries, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberds, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguiar, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiser, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löscher, W.</span></span> <span> </span><span class="NLM_article-title">Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">108297</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2020.108297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.neuropharm.2020.108297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=32890589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVymsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2020&pages=108297&author=W.+Theilmannauthor=B.+Gerickeauthor=A.+Schidlitzkiauthor=S.+M.+Muneeb+Anjumauthor=S.+Borsdorfauthor=T.+Harriesauthor=S.+L.+Roberdsauthor=D.+J.+Aguiarauthor=D.+Brunnerauthor=S.+C.+Leiserauthor=D.+Songauthor=D.+Fabbroauthor=P.+Hillmannauthor=M.+P.+Wymannauthor=W.+L%C3%B6scher&title=Novel+brain+permeant+mTORC1%2F2+inhibitors+are+as+efficacious+as+rapamycin+or+everolimus+in+mouse+models+of+acquired+partial+epilepsy+and+tuberous+sclerosis+complex&doi=10.1016%2Fj.neuropharm.2020.108297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex</span></div><div class="casAuthors">Theilmann, Wiebke; Gericke, Birthe; Schidlitzki, Alina; Muneeb Anjum, Syed Muhammad; Borsdorf, Saskia; Harries, Timon; Roberds, Steven L.; Aguiar, Dean J.; Brunner, Daniela; Leiser, Steven C.; Song, Dekun; Fabbro, Doriano; Hillmann, Petra; Wymann, Matthias P.; Loescher, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">108297</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mechanistic target of rapamycin (mTOR) regulates cell proliferation, growth and survival, and is activated in cancer and neurol. disorders, including epilepsy.  The rapamycin deriv. ("rapalog") everolimus, which allosterically inhibits the mTOR pathway, is approved for the treatment of partial epilepsy with spontaneous recurrent seizures (SRS) in individuals with tuberous sclerosis complex (TSC).  In contrast to the efficacy in TSC, the efficacy of rapalogs on SRS in other types of epilepsy is equivocal.  Furthermore, rapalogs only poorly penetrate into the brain and are assocd. with peripheral adverse effects, which may compromise their therapeutic efficacy.  Here we compare the antiseizure efficacy of two novel, brain-permeable ATP-competitive and selective mTORC1/2 inhibitors, PQR620 and PQR626, and the selective dual pan-PI3K/mTORC1/2 inhibitor PQR530 in two mouse models of chronic epilepsy with SRS, the intrahippocampal kainate (IHK) mouse model of acquired temporal lobe epilepsy and Tsc1GFAP CKO mice, a well-characterized mouse model of epilepsy in TSC.  During prolonged treatment of IHK mice with rapamycin, everolimus, PQR620, PQR626, or PQR530; only PQR620 exerted a transient antiseizure effect on SRS, at well tolerated doses whereas the other compds. were ineffective.  In contrast, all of the examd. compds. markedly suppressed SRS in Tsc1GFAP CKO mice during chronic treatment at well tolerated doses.  Thus, against our expectation, no clear differences in antiseizure efficacy were found across the three classes of mTOR inhibitors examd. in mouse models of genetic and acquired epilepsies.  The main advantage of the novel 1,3,5-triazine derivs. is their excellent tolerability compared to rapalogs, which would favor their development as new therapies for TORopathies such as TSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprLM7kWwUgnLVg90H21EOLACvtfcHk0li35x3lf2vwpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVymsL7M&md5=1edbe813fdd4424a0fef421283e6f1b9</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2020.108297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2020.108297%26sid%3Dliteratum%253Aachs%26aulast%3DTheilmann%26aufirst%3DW.%26aulast%3DGericke%26aufirst%3DB.%26aulast%3DSchidlitzki%26aufirst%3DA.%26aulast%3DMuneeb%2BAnjum%26aufirst%3DS.%2BM.%26aulast%3DBorsdorf%26aufirst%3DS.%26aulast%3DHarries%26aufirst%3DT.%26aulast%3DRoberds%26aufirst%3DS.%2BL.%26aulast%3DAguiar%26aufirst%3DD.%2BJ.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DLeiser%26aufirst%3DS.%2BC.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26atitle%3DNovel%2520brain%2520permeant%2520mTORC1%252F2%2520inhibitors%2520are%2520as%2520efficacious%2520as%2520rapamycin%2520or%2520everolimus%2520in%2520mouse%2520models%2520of%2520acquired%2520partial%2520epilepsy%2520and%2520tuberous%2520sclerosis%2520complex%26jtitle%3DNeuropharmacology%26date%3D2020%26volume%3D180%26spage%3D108297%26doi%3D10.1016%2Fj.neuropharm.2020.108297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dall’Asen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuburger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Scalable, economical, and practical synthesis of 4-(difluoromethyl)pyridin-2-amine, a key intermediate for lipid kinase inhibitors</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2416</span>– <span class="NLM_lpage">2424</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.9b00312</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.9b00312" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVCnt77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=2416-2424&author=D.+Rageotauthor=F.+Beaufilsauthor=C.+Borsariauthor=A.+Dall%E2%80%99Asenauthor=M.+Neuburgerauthor=P.+Hebeisenauthor=M.+P.+Wymann&title=Scalable%2C+economical%2C+and+practical+synthesis+of+4-%28difluoromethyl%29pyridin-2-amine%2C+a+key+intermediate+for+lipid+kinase+inhibitors&doi=10.1021%2Facs.oprd.9b00312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Scalable, Economical, and Practical Synthesis of 4-(Difluoromethyl)pyridin-2-amine, a Key Intermediate for Lipid Kinase Inhibitors</span></div><div class="casAuthors">Rageot, Denise; Beaufils, Florent; Borsari, Chiara; Dall'Asen, Alix; Neuburger, Markus; Hebeisen, Paul; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2416-2424</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new, scalable, rapid, high yielding, and practical synthesis of 4-(difluoromethyl)pyridin-2-amine provides a key intermediate for the prepn. of numerous protein kinase inhibitors and clin. candidates targeting phosphoinositide 3-kinase (PI3K) and the mechanistic target of rapamycin (mTOR) kinase.  Starting from 2,2-difluoroacetic anhydride, an efficient five-step and two-pot procedure to prep. 4-(difluoromethyl)pyridin-2-amine (I) has been developed.  Noteworthy aspects of this strategy include the avoidance of an amination process using a sealed vessel.  Each step of the synthetic route has been optimized, and key intermediates have been isolated and characterized prior to the final two-pot procedure, which has been successfully applied for large-scale prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq73k6UZX7MsrVg90H21EOLACvtfcHk0li35x3lf2vwpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVCnt77O&md5=a2e2a7228585935793d88d56751e6fb2</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.9b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.9b00312%26sid%3Dliteratum%253Aachs%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DDall%25E2%2580%2599Asen%26aufirst%3DA.%26aulast%3DNeuburger%26aufirst%3DM.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DScalable%252C%2520economical%252C%2520and%2520practical%2520synthesis%2520of%25204-%2528difluoromethyl%2529pyridin-2-amine%252C%2520a%2520key%2520intermediate%2520for%2520lipid%2520kinase%2520inhibitors%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2019%26volume%3D23%26spage%3D2416%26epage%3D2424%26doi%3D10.1021%2Facs.oprd.9b00312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lirtnX9RiUgtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubatsch, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragnarsson, E. G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2111</span>– <span class="NLM_lpage">2119</span>, <span class="refDoi"> DOI: 10.1038/nprot.2007.303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fnprot.2007.303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=17853866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFagsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=2111-2119&author=I.+Hubatschauthor=E.+G.+E.+Ragnarssonauthor=P.+Artursson&title=Determination+of+drug+permeability+and+prediction+of+drug+absorption+in+Caco-2+monolayers&doi=10.1038%2Fnprot.2007.303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers</span></div><div class="casAuthors">Hubatsch, Ina; Ragnarsson, Eva G. E.; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2111-2119</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Permeability coeffs. across monolayers of the human colon carcinoma cell line Caco-2, cultured on permeable supports, are commonly used to predict the absorption of orally administered drugs and other xenobiotics.  This protocol describes our method for the cultivation, characterization and detn. of permeability coeffs. of xenobiotics (which are, typically, drug-like compds.) in the Caco-2 model.  A few modifications that have been introduced over the years are incorporated in the protocol.  The method can be used to trace the permeability of a test compd. in two directions, from the apical to the basolateral side or vice versa, and both passive and active transport processes can be studied.  The permeability assay can be completed within one working day, provided that the Caco-2 monolayers have been cultured and differentiated on the permeable supports 3 wk in advance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX7zGXziU_VLVg90H21EOLACvtfcHk0lirtnX9RiUgtw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFagsb%252FN&md5=85e2f95420919ee61c2d691c305bc1ef</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2007.303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2007.303%26sid%3Dliteratum%253Aachs%26aulast%3DHubatsch%26aufirst%3DI.%26aulast%3DRagnarsson%26aufirst%3DE.%2BG.%2BE.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DDetermination%2520of%2520drug%2520permeability%2520and%2520prediction%2520of%2520drug%2520absorption%2520in%2520Caco-2%2520monolayers%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26spage%3D2111%26epage%3D2119%26doi%3D10.1038%2Fnprot.2007.303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 8 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Borsari</span>, <span class="hlFld-ContribAuthor ">Martina  De Pascale</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Chemical and Structural Strategies to Selectively Target mTOR Kinase. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.1002/cmdc.202100332" title="DOI URL">https://doi.org/10.1002/cmdc.202100332</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202100332&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202100332%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DChemical%252Band%252BStructural%252BStrategies%252Bto%252BSelectively%252BTarget%252BmTOR%252BKinase%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2021%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Han-Yue  Qiu</span>, <span class="hlFld-ContribAuthor ">Peng-Fei  Wang</span>, <span class="hlFld-ContribAuthor ">Min  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">A patent review of mTOR inhibitors for cancer therapy (2011–2020). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2021,</strong> <em> </em>, 1-11. <a href="https://doi.org/10.1080/13543776.2021.1940137" title="DOI URL">https://doi.org/10.1080/13543776.2021.1940137</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2021.1940137&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2021.1940137%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DA%252Bpatent%252Breview%252Bof%252BmTOR%252Binhibitors%252Bfor%252Bcancer%252Btherapy%252B%2525282011%2525E2%252580%2525932020%252529%26aulast%3DQiu%26aufirst%3DHan-Yue%26date%3D2021%26date%3D2021%26spage%3D1%26epage%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Borsari</span>, <span class="hlFld-ContribAuthor ">Erhan  Keles</span>, <span class="hlFld-ContribAuthor ">Andrea  Treyer</span>, <span class="hlFld-ContribAuthor ">Martina  De Pascale</span>, <span class="hlFld-ContribAuthor ">Paul  Hebeisen</span>, <span class="hlFld-ContribAuthor ">Matthias  Hamburger</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>. </span><span class="cited-content_cbyCitation_article-title">Second-generation tricyclic pyrimido-pyrrolo-oxazine mTOR inhibitor with predicted blood–brain barrier permeability. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 579-583. <a href="https://doi.org/10.1039/D0MD00408A" title="DOI URL">https://doi.org/10.1039/D0MD00408A</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00408A&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00408A%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DSecond-generation%252Btricyclic%252Bpyrimido-pyrrolo-oxazine%252BmTOR%252Binhibitor%252Bwith%252Bpredicted%252Bblood%2525E2%252580%252593brain%252Bbarrier%252Bpermeability%26aulast%3DBorsari%26aufirst%3DChiara%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D579%26epage%3D583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">A Brain-Penetrant mTOR Kinase Inhibitor for the Treatment of Neurological Disorders. </span><span class="cited-content_cbyCitation_journal-name">Synfacts</span><span> <strong>2021,</strong>,, 0334. <a href="https://doi.org/10.1055/s-0040-1719413" title="DOI URL">https://doi.org/10.1055/s-0040-1719413</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0040-1719413&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0040-1719413%26sid%3Dliteratum%253Aachs%26jtitle%3DSynfacts%26atitle%3DA%252BBrain-Penetrant%252BmTOR%252BKinase%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BNeurological%252BDisorders%26date%3D2021%26date%3D2021%26volume%3D17%26issue%3D03%26spage%3D0334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">S. V.  Fedoseev</span>, <span class="hlFld-ContribAuthor ">O. E.  Ershov</span>. </span><span class="cited-content_cbyCitation_article-title">Reaction of 4-Halo-3-hydroxyfuro[3,4-c]pyridin-1(3H)-ones with Morpholine and Thiomorpholine. </span><span class="cited-content_cbyCitation_journal-name">Russian Journal of Organic Chemistry</span><span> <strong>2021,</strong> <em>57 </em>
                                    (3)
                                     , 483-485. <a href="https://doi.org/10.1134/S1070428021030234" title="DOI URL">https://doi.org/10.1134/S1070428021030234</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1134/S1070428021030234&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1134%2FS1070428021030234%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DReaction%252Bof%252B4-Halo-3-hydroxyfuro%25255B3%25252C4-c%25255Dpyridin-1%2525283H%252529-ones%252Bwith%252BMorpholine%252Band%252BThiomorpholine%26aulast%3DFedoseev%26aufirst%3DS.%2BV.%26date%3D2021%26date%3D2021%26volume%3D57%26issue%3D3%26spage%3D483%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruoyu  He</span>, <span class="hlFld-ContribAuthor ">Bingyong  Xu</span>, <span class="hlFld-ContribAuthor ">Li  Ping</span>, <span class="hlFld-ContribAuthor ">Xiaoqing  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>214 </em>, 113249. <a href="https://doi.org/10.1016/j.ejmech.2021.113249" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113249</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113249&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113249%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructural%252Boptimization%252Btowards%252Bpromising%252B%2525CE%2525B2-methyl-4-acrylamido%252Bquinoline%252Bderivatives%252Bas%252BPI3K%25252FmTOR%252Bdual%252Binhibitors%252Bfor%252Banti-cancer%252Btherapy%25253A%252BThe%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Bbiological%252Bevaluation%26aulast%3DHe%26aufirst%3DRuoyu%26date%3D2021%26volume%3D214%26spage%3D113249" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maximillian Taro William  Lee</span>, <span class="hlFld-ContribAuthor ">William  Mahy</span>, <span class="hlFld-ContribAuthor ">Mark David  Rackham</span>. </span><span class="cited-content_cbyCitation_article-title">The medicinal chemistry of mitochondrial dysfunction: a critical overview of efforts to modulate mitochondrial health. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>7 </em><a href="https://doi.org/10.1039/D1MD00113B" title="DOI URL">https://doi.org/10.1039/D1MD00113B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1MD00113B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1MD00113B%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bmedicinal%252Bchemistry%252Bof%252Bmitochondrial%252Bdysfunction%25253A%252Ba%252Bcritical%252Boverview%252Bof%252Befforts%252Bto%252Bmodulate%252Bmitochondrial%252Bhealth%26aulast%3DLee%26aufirst%3DMaximillian%2BTaro%2BWilliam%26date%3D2021%26date%3D2021%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wiebke  Theilmann</span>, <span class="hlFld-ContribAuthor ">Birthe  Gericke</span>, <span class="hlFld-ContribAuthor ">Alina  Schidlitzki</span>, <span class="hlFld-ContribAuthor ">Syed Muhammad  Muneeb Anjum</span>, <span class="hlFld-ContribAuthor ">Saskia  Borsdorf</span>, <span class="hlFld-ContribAuthor ">Timon  Harries</span>, <span class="hlFld-ContribAuthor ">Steven L.  Roberds</span>, <span class="hlFld-ContribAuthor ">Dean J.  Aguiar</span>, <span class="hlFld-ContribAuthor ">Daniela  Brunner</span>, <span class="hlFld-ContribAuthor ">Steven C.  Leiser</span>, <span class="hlFld-ContribAuthor ">Dekun  Song</span>, <span class="hlFld-ContribAuthor ">Doriano  Fabbro</span>, <span class="hlFld-ContribAuthor ">Petra  Hillmann</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Wymann</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Löscher</span>. </span><span class="cited-content_cbyCitation_article-title">Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. </span><span class="cited-content_cbyCitation_journal-name">Neuropharmacology</span><span> <strong>2020,</strong> <em>180 </em>, 108297. <a href="https://doi.org/10.1016/j.neuropharm.2020.108297" title="DOI URL">https://doi.org/10.1016/j.neuropharm.2020.108297</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.neuropharm.2020.108297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.neuropharm.2020.108297%26sid%3Dliteratum%253Aachs%26jtitle%3DNeuropharmacology%26atitle%3DNovel%252Bbrain%252Bpermeant%252BmTORC1%25252F2%252Binhibitors%252Bare%252Bas%252Befficacious%252Bas%252Brapamycin%252Bor%252Beverolimus%252Bin%252Bmouse%252Bmodels%252Bof%252Bacquired%252Bpartial%252Bepilepsy%252Band%252Btuberous%252Bsclerosis%252Bcomplex%26aulast%3DTheilmann%26aufirst%3DWiebke%26date%3D2020%26volume%3D180%26spage%3D108297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0014.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Chemical structures of selected TORKi, including <b>49</b>,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a><b>50</b>,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a><b>51</b>,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a><b>52</b>,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a><b>53</b>,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> and a thiazolopyrimidine derivative (<b>54</b>).<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> (B) Chemical structures of <b>55</b> and rapalogs (<i>e.g.</i>, <b>56</b>), which function as allosteric inhibitors of TORC1, forming a TORC1-rapalog-FKBP12 complex.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. (A–C) Synthesis of the Compound Library (<b>1–22</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (i) morpholine, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), EtOH, 0 °C → rt, o/n as reported in the literature;<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (ii) (1) boronate <b>48</b>, XPhosPdG2 (cat.), K<sub>3</sub>PO<sub>4</sub>, dioxane/H<sub>2</sub>O, 95 °C, 2–16 h; (2) HCl, H<sub>2</sub>O, 60 °C, 3–16 h; (iii) morpholine derivative (M<sub>n</sub>–H), DIPEA, DCM, 0 °C → rt, o/n as reported in the literature;<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (iv) morpholine derivative (M<sub>n</sub>–H), DCM, −50 °C, 2 h; (v) M<sub>n</sub>–H, DIPEA, DCM, 0 °C → rt, o/n (for <b>27–29</b>, <b>32</b>, <b>34–46</b>); (vi) M<sub>n</sub>–H, DIPEA, THF, 0 °C → rt → 70 °C, o/n (for <b>30</b> and <b>31</b>); (vii) see (i) for intermediate <b>33</b>. *Compound <b>3</b> is reported in ref <a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a>.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Docking of <b>8</b> (light blue) to mTOR (gray) starting from PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a>. H-bonds are represented as dashed black lines. The backbone amide (Val2240) essential for binding is shown in a ball-and-stick representation. (B) Sphere representation of mTOR-<b>8</b> complex and (C) of PI3Kα-<b>8</b> complex. Ile2163 (mTOR) is depicted as dark gray while Met772 (PI3Kα) in magenta. Both conformations (“methyl-up” in light blue and “methyl-down” in orange) are displayed. Docking of <b>8</b> (light blue) to PI3Kα (pink) was performed starting from PDB: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OAC">6OAC</a>. (D) Superimposition of mTOR-<b>8</b> and PI3Kα-<b>8</b> complex; mTOR (gray) and PI3Kα (pink). (E) Superimposition of mTOR-<b>4</b> and PI3Kα-<b>4</b> complexes; mTOR (gray) and PI3Kα (pink). Both conformations (“methyl-right” in green and “methyl-left” in yellow) are displayed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Stability of <b>8</b> at 5 μM in primary hepatocyte cultures from mice, rats, dogs, and humans (<i>n</i> = 2; mean ± SEM; error bars are not shown when smaller than symbols). Values are tabulated in Table S6 of the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a>. (B,C) Pie chart displaying the % of remaining (B) compound <b>8</b> (blue) and (C) compound <b>4</b> (blue) after 60 min of incubation with the indicated human recombinant CYP isoenzymes.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. (A) ER in MDCK-hMDR1<sup>cMDR1-ko</sup> and MDCK<sup>cMDR1-ko</sup> cells. The dotted line shows ER = 1, indicative of equal apparent permeability across the cell monolayer in both directions. High ER in MDCK-hMDR1<sup>cMDR1-ko</sup> cells indicates hMDR1 affinity of the compound. Citalopram, a hMDR1 substrate,<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> has been used as positive control. <b>57</b> and <b>52</b> are known to have a good BBB penetration <i>in vivo</i>, while <b>53</b> has a limited BBB penetration <i>in vivo</i>. (B) Apparent permeability (<i>P</i><sub>app</sub>) in direction from apical to basolateral compartment across MDCK-hMDR1<sup>cMDR1-ko</sup> monolayers seeded on TransWell plates. Results are shown as mean ± SD (<i>n</i> > 3), *<i>p</i>-value < 0.05 (unpaired <i>t</i>-test, GraphPad Prism 8.0.2).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Pharmacokinetics and pharmacodynamics in male Sprague Dawley rats. (A) Plasma (square) and brain (circle) levels of <b>8</b> and <b>53</b> after p.o. dosing at 5 mg/kg. (B) Calculation of brain/plasma ratio over time using the values reported in (A). (C) Insulin and (D) glucose plasma levels after oral administration of <b>8</b> in male Sprague Dawley rats (<i>n</i> = 3; mean ± SEM; error bars not shown when < symbols). Exact values can be found in Tables S8–S13 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Pharmacokinetic study in female C57BL/6J mice. (A–C) <b>8</b> was administered at 10 mg/kg in 20% Captisol p.o. either as single dose or administered once a day for 4 consecutive days and the blood sampling performed after the last treatment on day 4 (qd4). <b>56</b> was administered at 10 mg/kg in 8% ethanol, 10% PEG 400, and 10% Tween 80 p.o. qd4. (A) Plasma and (B) brain levels of compounds <b>8</b> and <b>56</b>. (C) Calculation of brain/plasma ratio over time using the values reported in (A,B). Values are reported in Tables S14–S19 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a>. (D–F) <b>8</b> and <b>51</b> were administered p.o. as a single dose of 25 mg/kg. <b>56</b> was administered at 10 mg/kg p.o. single dose. (D) Plasma and (E) brain levels of compounds <b>8</b>, <b>51</b>, and <b>56</b>. (C) Brain/plasma ratio over time calculated from the values reported in (D,E). Values are depicted in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Tables S20–S25</a>. All values: mean ± SEM. Error bars not shown are smaller than the symbols.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (A) Insulin and (B) glucose plasma levels after oral administration of <b>8</b> (25 mg/kg), <b>56</b> (10 mg/kg), and <b>51</b> (25 mg/kg) in female C57BL/6J mice and of PQR514 (10 mg/kg)<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> in male C57BL/6J mice. All values: mean ± SEM. Error bars are not shown when smaller than the symbols. Values are reported in Tables S26–S31 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Inhibition of mTOR signaling in murine brain cortex by PQR626 (<b>8</b>) and everolimus (<b>56</b>). (A–C) Brain cortex was collected from female C57BL/6J mice or from mice treated with <b>8</b> (25 mg/kg, p.o.) or <b>56</b> (10 mg/kg, p.o.) for 30 min. Cortex was lysed and equal amount proteins subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and western blotting, followed by the detection of pPKB, pS6, phosphorylated MAP kinases, total PKB, or α-tubulin using specific primary antibodies and respective HRP-coupled secondary antibodies and enhanced chemiluminescence. (A,B) Quantification of (A) pS6 and (B) pPKB levels in compound-treated murine cortex given as % of control cortex. For details, see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> [<i>n</i> = 3, mean ± SEM, *<i>p</i>-value < 0.05. <i>p</i>-value using an unpaired <i>t</i>-test <i>vs</i> control: compound <b>8</b>: 0.0125 (pS6); 0.0044 (pPKB)]. (C) Western blot images used for quantification of (A,B). (D) Time-course of inhibition of mTOR signaling in murine brain cortex by <b>8</b>. Brain cortex was collected from <b>8</b> (25 mg/kg, p.o.) treated female C57BL/6J mice at indicated time-points in [h] and from control mice. Western blot images are reported in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Figure S4</a>. Phosphorylated proteins and α-tubulin levels were quantified using ImageJ, and phospho-protein/tubulin levels are presented as % of control cortex (left <i>y</i>-axis) as a function of time [<i>n</i> = 9 for control animals, <i>n</i> = 3 for each timepoint of <b>8</b> treatment, mean ± SEM]. Right <i>y</i>-axis: brain concentration of <b>8</b> in ng/mL from the same mice (<i>n</i> = 3, mean ± SEM for each time point).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/medium/jm0c00620_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Body weight changes in BALB/c nude female mice to assess MTD. Group 1: vehicle (20% Captisol in water) once a day (qd) × 14 from day 1 p.o. (<i>n</i> = 1). Group 2: compound <b>8</b> at 100 mg/kg qd × 14 from day 1 p.o. (<i>n</i> = 3). Group 3: compound <b>8</b> at 150 mg/kg qd × 14 from day 8 p.o. (<i>n</i> = 3). Group 4: compound <b>8</b> at 200 mg/kg qd × 14 from day 15 p.o. (<i>n</i> = 3). Raw data are depicted in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Table S32</a>. (B). Body weight of <i>Tsc1</i><sup>GFAP</sup>CKO mice as a function of treatments. Data are shown as mean ± SEM. Raw data are depicted in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Table S33</a>. (C) Effects of treatments on the survival rate of <i>Tsc1</i><sup>GFAP</sup>CKO mice. All treatments started at P21, with the exception of <b>52</b> (50 mg/kg p.o. qd) which started on P27. Compound <b>56</b> at 10 mg/kg, <i>n</i> = 12; compound <b>52</b> at 100 and 50 mg/kg, <i>n</i> = 12 and 8, respectively; compound <b>8</b> at 50 bid, 50, 25, and 10 mg/kg, <i>n</i> = 7, 10, 10, and 10, respectively. Mid-study (day P45) brain and plasma collection: four additional animals per group were dosed and sacrificed on day P45. Data are presented as percent surviving at each time point. Survival was determined from the start of the study (P21) to the day the animal was found dead or until P90 (<i>i.e.</i>, animals were censored at P90). A χ<sup>2</sup> survival analysis was performed in JMP Statistical Software (a division of SAS) with treatment as a factor. The statistical report for survival analysis: Table S34 in the <a href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf" class="ext-link">Supporting Information</a>. *<i>p</i>-value < 0.05. <i>p</i>-values using the log-rank test <i>vs</i> vehicle—compound <b>52</b> at 50 and 100 mg/kg: <i>p</i>-value 0.1336 and 0.0093, respectively; compound <b>8</b> at 10, 25, 50, and 50 bid mg/kg: <i>p</i>-value 0.6530, 0.4502, 0.4489, and 0.0469, respectively. <sup>$</sup><i>p</i>-value < 0.05. <i>p</i>-values using the log–rank test <i>vs</i> everolimus (<b>56</b>)—compound <b>52</b> at 50 and 100 mg/kg: <i>p</i>-value 0.0228 and 0.1483, respectively; compound <b>8</b> at 10, 25, 50, and 50 bid mg/kg: 0.0002, 0.0016, 0.0016, and 0.0542, respectively.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-22/acs.jmedchem.0c00620/20210105/images/large/jm0c00620_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00620&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i57">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47142" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47142" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 56 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneiter, R.</span></span> <span> </span><span class="NLM_article-title">Lipid signalling in disease</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">176</span>, <span class="refDoi"> DOI: 10.1038/nrm2335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fnrm2335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=18216772" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2008&pages=162-176&author=M.+P.+Wymannauthor=R.+Schneiter&title=Lipid+signalling+in+disease&doi=10.1038%2Fnrm2335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Lipid signalling in disease</span></div><div class="casAuthors">Wymann, Matthias P.; Schneiter, Roger</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-176</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Signaling lipids such as eicosanoids, phosphoinositides, sphingolipids and fatty acids control important cellular processes, including cell proliferation, apoptosis, metab. and migration.  Extracellular signals from cytokines, growth factors and nutrients control the activity of a key set of lipid-modifying enzymes: phospholipases, prostaglandin synthase, 5-lipoxygenase, phosphoinositide 3-kinase, sphingosine kinase and sphingomyelinase.  These enzymes and their downstream targets constitute a complex lipid signaling network with multiple nodes of interaction and cross-regulation.  Imbalances in this network contribute to the pathogenesis of human disease.  Although the function of a particular signaling lipid is traditionally studied in isolation, this review attempts a more integrated overview of the key role of these signaling lipids in inflammation, cancer and metabolic disease, and discusses emerging strategies for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZYZ1NX2T9QbVg90H21EOLACvtfcHk0liXOAzvsPLjKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXovFOgug%253D%253D&md5=c96aabfdfa8e93c9e98386f1a407de85</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrm2335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm2335%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DSchneiter%26aufirst%3DR.%26atitle%3DLipid%2520signalling%2520in%2520disease%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2008%26volume%3D9%26spage%3D162%26epage%3D176%26doi%3D10.1038%2Fnrm2335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rudge, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koos, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaidialingam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pavletich, N. P.</span></span> <span> </span><span class="NLM_article-title">mTOR kinase structure, mechanism and regulation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>497</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">223</span>, <span class="refDoi"> DOI: 10.1038/nature12122</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fnature12122" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=23636326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=497&publication_year=2013&pages=217-223&author=H.+Yangauthor=D.+G.+Rudgeauthor=J.+D.+Koosauthor=B.+Vaidialingamauthor=H.+J.+Yangauthor=N.+P.+Pavletich&title=mTOR+kinase+structure%2C+mechanism+and+regulation&doi=10.1038%2Fnature12122"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR kinase structure, mechanism and regulation</span></div><div class="casAuthors">Yang, Haijuan; Rudge, Derek G.; Koos, Joseph D.; Vaidialingam, Bhamini; Yang, Hyo J.; Pavletich, Nikola P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">497</span>
        (<span class="NLM_cas:issue">7448</span>),
    <span class="NLM_cas:pages">217-223</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR), a phosphoinositide 3-kinase-related protein kinase, controls cell growth in response to nutrients and growth factors and is frequently deregulated in cancer.  Here we report co-crystal structures of a complex of truncated mTOR and mammalian lethal with SEC13 protein 8 (mLST8) with an ATP transition state mimic (MgF3-) and with ATP-site inhibitors (Torin2, PP242, and PI-103).  The structures reveal an intrinsically active kinase conformation, with catalytic residues and a catalytic mechanism remarkably similar to canonical protein kinases.  The active site is highly recessed owing to the FKBP12-rapamycin-binding (FRB) domain and an inhibitory helix protruding from the catalytic cleft.  MTOR-activating mutations map to the structural framework that holds these elements in place, indicating that the kinase is controlled by restricted access.  In vitro biochem. shows that the FRB domain acts as a gatekeeper, with its rapamycin-binding site interacting with substrates to grant them access to the restricted active site.  Rapamycin-FKBP12 inhibits the kinase by directly blocking substrate recruitment and by further restricting active-site access.  The structures also reveal active-site residues and conformational changes that underlie inhibitor potency and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrjvPQtdm6yCbVg90H21EOLACvtfcHk0lj1yFIIEli4Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvFyns7k%253D&md5=07809555fbdf2004819a7f2da5727baf</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnature12122&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12122%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DH.%26aulast%3DRudge%26aufirst%3DD.%2BG.%26aulast%3DKoos%26aufirst%3DJ.%2BD.%26aulast%3DVaidialingam%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DH.%2BJ.%26aulast%3DPavletich%26aufirst%3DN.%2BP.%26atitle%3DmTOR%2520kinase%2520structure%252C%2520mechanism%2520and%2520regulation%26jtitle%3DNature%26date%3D2013%26volume%3D497%26spage%3D217%26epage%3D223%26doi%3D10.1038%2Fnature12122" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sarbassov, D. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guertin, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>307</i></span>,  <span class="NLM_fpage">1098</span>– <span class="NLM_lpage">1101</span>, <span class="refDoi"> DOI: 10.1126/science.1106148</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1126%2Fscience.1106148" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=15718470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=307&publication_year=2005&pages=1098-1101&author=D.+D.+Sarbassovauthor=D.+A.+Guertinauthor=S.+M.+Aliauthor=D.+M.+Sabatini&title=Phosphorylation+and+regulation+of+Akt%2FPKB+by+the+rictor-mTOR+complex&doi=10.1126%2Fscience.1106148"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex</span></div><div class="casAuthors">Sarbassov, Dos D.; Guertin, David A.; Ali, Siraj M.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">307</span>
        (<span class="NLM_cas:issue">5712</span>),
    <span class="NLM_cas:pages">1098-1101</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Deregulation of Akt/protein kinase B (PKB) is implicated in the pathogenesis of cancer and diabetes.  Akt/PKB activation requires the phosphorylation of Thr308 in the activation loop by the phosphoinositide-dependent kinase 1 (PDK1) and Ser473 within the carboxyl-terminal hydrophobic motif by an unknown kinase.  We show that in Drosophila and human cells the target of rapamycin (TOR) kinase and its assocd. protein rictor are necessary for Ser473 phosphorylation and that a redn. in rictor or mammalian TOR (mTOR) expression inhibited an Akt/PKB effector.  The rictor-mTOR complex directly phosphorylated Akt/PKB on Ser473 in vitro and facilitated Thr308 phosphorylation by PDK1.  Rictor-mTOR may serve as a drug target in tumors that have lost the expression of PTEN, a tumor suppressor that opposes Akt/PKB activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfO1KyVE3glrVg90H21EOLACvtfcHk0lj1yFIIEli4Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlSrtbY%253D&md5=de758fd8128561e34301e67a42ae13a6</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1126%2Fscience.1106148&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1106148%26sid%3Dliteratum%253Aachs%26aulast%3DSarbassov%26aufirst%3DD.%2BD.%26aulast%3DGuertin%26aufirst%3DD.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DPhosphorylation%2520and%2520regulation%2520of%2520Akt%252FPKB%2520by%2520the%2520rictor-mTOR%2520complex%26jtitle%3DScience%26date%3D2005%26volume%3D307%26spage%3D1098%26epage%3D1101%26doi%3D10.1126%2Fscience.1106148" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span> <span> </span><span class="NLM_article-title">Phosphoinositide 3-kinase in disease: timing, location, and scaffolding</span>. <i>Curr. Opin. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">149</span>, <span class="refDoi"> DOI: 10.1016/j.ceb.2005.02.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.ceb.2005.02.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=15780590" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD2MXisVCqtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2005&pages=141-149&author=M.+P.+Wymannauthor=R.+Marone&title=Phosphoinositide+3-kinase+in+disease%3A+timing%2C+location%2C+and+scaffolding&doi=10.1016%2Fj.ceb.2005.02.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoinositide 3-kinase in disease: timing, location, and scaffolding</span></div><div class="casAuthors">Wymann, Matthias P.; Marone, Romina</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Cell Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-149</span>CODEN:
                <span class="NLM_cas:coden">COCBE3</span>;
        ISSN:<span class="NLM_cas:issn">0955-0674</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  When PI3Ks are deregulated by aberrant surface receptors or modulators, accumulation of PtdIns(3,4,5)P3 leads to increased cell growth, proliferation and contact-independent survival.  The PI3K/PKB/TOR axis controls protein synthesis and growth, while PtdIns(3,4,5)P3-mediated activation of Rho GTPases directs cell motility.  PI3K activity has been linked to the formation of tumors, metastasis, chronic inflammation, allergy and cardiovascular disease.  Although increased PtdIns(3,4,5)P3 is a well-established cause of disease, it is seldom known which PI3K isoform is implied.  Recent work has demonstrated that PI3Kγ contributes to the control of cAMP levels in the cardiac system, where the protein acts as a scaffold, but not as a lipid kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhcm4IPHLzd7Vg90H21EOLACvtfcHk0lj1yFIIEli4Bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXisVCqtb4%253D&md5=d126dfae131b86e73e8842ec9149fd01</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ceb.2005.02.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ceb.2005.02.011%26sid%3Dliteratum%253Aachs%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DMarone%26aufirst%3DR.%26atitle%3DPhosphoinositide%25203-kinase%2520in%2520disease%253A%2520timing%252C%2520location%252C%2520and%2520scaffolding%26jtitle%3DCurr.%2520Opin.%2520Cell%2520Biol.%26date%3D2005%26volume%3D17%26spage%3D141%26epage%3D149%26doi%3D10.1016%2Fj.ceb.2005.02.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Magnuson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ekim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fingar, D. C.</span></span> <span> </span><span class="NLM_article-title">Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>441</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">21</span>, <span class="refDoi"> DOI: 10.1042/bj20110892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1042%2FBJ20110892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=22168436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgs7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=441&publication_year=2012&pages=1-21&author=B.+Magnusonauthor=B.+Ekimauthor=D.+C.+Fingar&title=Regulation+and+function+of+ribosomal+protein+S6+kinase+%28S6K%29+within+mTOR+signalling+networks&doi=10.1042%2Fbj20110892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks</span></div><div class="casAuthors">Magnuson, Brian; Ekim, Bilgen; Fingar, Diane C.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">441</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-21</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  The ribosomal protein S6K (S6 kinase) represents an extensively studied effector of the TORC1 [TOR (target of rapamycin) complex 1], which possesses important yet incompletely defined roles in cellular and organismal physiol.  TORC1 functions as an environmental sensor by integrating signals derived from diverse environmental cues to promote anabolic and inhibit catabolic cellular functions. mTORC1 (mammalian TORC1) phosphorylates and activates S6K1 and S6K2, whose first identified substrate was rpS6 (ribosomal protein S6), a component of the 40S ribosome.  Studies over the past decade have uncovered a no. of addnl. S6K1 substrates, revealing multiple levels at which the mTORC1-S6K1 axis regulates cell physiol.  The results thus far indicate that the mTORC1-S6K1 axis controls fundamental cellular processes, including transcription, translation, protein and lipid synthesis, cell growth/size and cell metab.  In the present review we summarize the regulation of S6Ks, their cellular substrates and functions, and their integration within rapidly expanding mTOR (mammalian TOR) signalling networks.  Although our understanding of the role of mTORC1-S6K1 signalling in physiol. remains in its infancy, evidence indicates that this signalling axis controls, at least in part, glucose homeostasis, insulin sensitivity, adipocyte metab., body mass and energy balance, tissue and organ size, learning, memory and aging.  As dysregulation of this signalling axis contributes to diverse disease states, improved understanding of S6K regulation and function within mTOR signalling networks may enable the development of novel therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrAHhGhhxqDTbVg90H21EOLACvtfcHk0liWP_IO0wvecA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Cgs7jK&md5=5d69e3be00deef02d3fce1ed2716873d</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1042%2FBJ20110892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20110892%26sid%3Dliteratum%253Aachs%26aulast%3DMagnuson%26aufirst%3DB.%26aulast%3DEkim%26aufirst%3DB.%26aulast%3DFingar%26aufirst%3DD.%2BC.%26atitle%3DRegulation%2520and%2520function%2520of%2520ribosomal%2520protein%2520S6%2520kinase%2520%2528S6K%2529%2520within%2520mTOR%2520signalling%2520networks%26jtitle%3DBiochem.%2520J.%26date%3D2012%26volume%3D441%26spage%3D1%26epage%3D21%26doi%3D10.1042%2Fbj20110892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Laplante, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling in growth control and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">274</span>– <span class="NLM_lpage">293</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.03.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.cell.2012.03.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=22500797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=274-293&author=M.+Laplanteauthor=D.+M.+Sabatini&title=mTOR+signaling+in+growth+control+and+disease&doi=10.1016%2Fj.cell.2012.03.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling in growth control and disease</span></div><div class="casAuthors">Laplante, Mathieu; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">274-293</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The mechanistic target of rapamycin (mTOR) signaling pathway senses and integrates a variety of environmental cues to regulate organismal growth and homeostasis.  The pathway regulates many major cellular processes and is implicated in an increasing no. of pathol. conditions, including cancer, obesity, type 2 diabetes, and neurodegeneration.  Here, we review recent advances in our understanding of the mTOR pathway and its role in health, disease, and aging.  We further discuss pharmacol. approaches to treat human pathologies linked to mTOR deregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjbKBX-sScfrVg90H21EOLACvtfcHk0liWP_IO0wvecA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xls1eguro%253D&md5=d1adac8ec64da63358e0af26a17ceb4e</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.03.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.03.017%26sid%3Dliteratum%253Aachs%26aulast%3DLaplante%26aufirst%3DM.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520in%2520growth%2520control%2520and%2520disease%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D274%26epage%3D293%26doi%3D10.1016%2Fj.cell.2012.03.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, B. D.</span></span> <span> </span><span class="NLM_article-title">The TSC1-TSC2 complex: a molecular switchboard controlling cell growth</span>. <i>Biochem. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>412</i></span>,  <span class="NLM_fpage">179</span>– <span class="NLM_lpage">190</span>, <span class="refDoi"> DOI: 10.1042/bj20080281</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1042%2FBJ20080281" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=18466115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD1cXlvVWmsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=412&publication_year=2008&pages=179-190&author=J.+Huangauthor=B.+D.+Manning&title=The+TSC1-TSC2+complex%3A+a+molecular+switchboard+controlling+cell+growth&doi=10.1042%2Fbj20080281"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The TSC1-TSC2 complex: a molecular switchboard controlling cell growth</span></div><div class="casAuthors">Huang, Jingxiang; Manning, Brendan D.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">412</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">179-190</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">A review.  TSC1 and TSC2 are the tumor-suppressor genes mutated in the tumor syndrome TSC (tuberous sclerosis complex).  Their gene products form a complex that has become the focus of many signal transduction researchers.  The TSC1-TSC2 (hamartin-tuberin) complex, through its GAP (GTPase-activating protein) activity towards the small G-protein Rheb (Ras homolog enriched in brain), is a crit. neg. regulator of mTORC1 (mammalian target of rapamycin complex 1).  As mTORC1 activity controls anabolic processes to promote cell growth, it is exquisitely sensitive to alterations in cell growth conditions.  Through numerous phosphorylation events, the TSC1-TSC2 complex has emerged as the sensor and integrator of these growth conditions, relaying signals from diverse cellular pathways to properly modulate mTORC1 activity.  In the present review we focus on the mol. details of TSC1-TSC2 complex regulation and function as it relates to the control of Rheb and mTORC1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp--nCqL_Pr2bVg90H21EOLACvtfcHk0liWP_IO0wvecA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXlvVWmsb8%253D&md5=6a9930e6edb37fdf9b1863fed58bf4a5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1042%2FBJ20080281&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20080281%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DManning%26aufirst%3DB.%2BD.%26atitle%3DThe%2520TSC1-TSC2%2520complex%253A%2520a%2520molecular%2520switchboard%2520controlling%2520cell%2520growth%26jtitle%3DBiochem.%2520J.%26date%3D2008%26volume%3D412%26spage%3D179%26epage%3D190%26doi%3D10.1042%2Fbj20080281" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Saxton, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span> <span> </span><span class="NLM_article-title">mTOR signaling in growth, metabolism, and disease</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>168</i></span>,  <span class="NLM_fpage">960</span>– <span class="NLM_lpage">976</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2017.02.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.cell.2017.02.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=28283069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=168&publication_year=2017&pages=960-976&author=R.+A.+Saxtonauthor=D.+M.+Sabatini&title=mTOR+signaling+in+growth%2C+metabolism%2C+and+disease&doi=10.1016%2Fj.cell.2017.02.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR signaling in growth, metabolism, and disease</span></div><div class="casAuthors">Saxton, Robert A.; Sabatini, David M.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">168</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">960-976</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  The mechanistic target of rapamycin (mTOR) coordinates eukaryotic cell growth and metab. with environmental inputs, including nutrients and growth factors.  Extensive research over the past two decades has established a central role for mTOR in regulating many fundamental cell processes, from protein synthesis to autophagy, and deregulated mTOR signaling is implicated in the progression of cancer and diabetes, as well as the aging process.  Here, we review recent advances in our understanding of mTOR function, regulation, and importance in mammalian physiol.  We also highlight how the mTOR signaling network contributes to human disease and discuss the current and future prospects for therapeutically targeting mTOR in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvvk5jg6e_MrVg90H21EOLACvtfcHk0lg6DDkIa83zDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXkt1Ogtb4%253D&md5=3fdee3d04bf88d3aafc532d4e2f1e2dc</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2017.02.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2017.02.004%26sid%3Dliteratum%253Aachs%26aulast%3DSaxton%26aufirst%3DR.%2BA.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26atitle%3DmTOR%2520signaling%2520in%2520growth%252C%2520metabolism%252C%2520and%2520disease%26jtitle%3DCell%26date%3D2017%26volume%3D168%26spage%3D960%26epage%3D976%26doi%3D10.1016%2Fj.cell.2017.02.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, Z. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shang, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maiese, K.</span></span> <span> </span><span class="NLM_article-title">A critical kinase cascade in neurological disorders: PI 3-K, Akt, and mTOR</span>. <i>Future Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">733</span>– <span class="NLM_lpage">748</span>, <span class="refDoi"> DOI: 10.2217/fnl.12.72</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.2217%2Ffnl.12.72" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=23144589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1arurzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=733-748&author=Z.+Z.+Chongauthor=Y.+C.+Shangauthor=S.+Wangauthor=K.+Maiese&title=A+critical+kinase+cascade+in+neurological+disorders%3A+PI+3-K%2C+Akt%2C+and+mTOR&doi=10.2217%2Ffnl.12.72"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A critical kinase cascade in neurological disorders: PI3K, Akt and mTOR</span></div><div class="casAuthors">Chong, Zhao Zhong; Shang, Yan Chen; Wang, Shaohui; Maiese, Kenneth</div><div class="citationInfo"><span class="NLM_cas:title">Future Neurology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">733-748</span>CODEN:
                <span class="NLM_cas:coden">FNUEAM</span>;
        ISSN:<span class="NLM_cas:issn">1479-6708</span>.
    
            (<span class="NLM_cas:orgname">Future Medicine Ltd.</span>)
        </div><div class="casAbstract">A review.  Neurodegenerative disorders lead to disability and death in a significant proportion of the world's population.  However, many disorders of the nervous system remain with limited effective treatments.  Kinase pathways in the nervous system that involve PI3K, Akt and mTOR offer exciting prospects for the understanding of neurodegenerative pathways and the development of new avenues of treatment.  PI3K, Akt and mTOR pathways are vital cellular components that det. cell fate during acute and chronic disorders, such as Huntington's disease, Alzheimer's disease, Parkinson's disease, epilepsy, stroke and trauma.  However, the elaborate relationship among these kinases and the variable control of apoptosis and autophagy can lead to unanticipated biol. and clin. outcomes.  Crucial for the successful translation of PI3K, Akt and mTOR into robust and safe clin. strategies will be the further elucidation of the complex roles that these kinase pathways hold in the nervous system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwPmFj7IKN_bVg90H21EOLACvtfcHk0lg6DDkIa83zDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1arurzF&md5=c5cc5591ce4bff7df6fce079b5ad5147</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2217%2Ffnl.12.72&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2217%252Ffnl.12.72%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DZ.%2BZ.%26aulast%3DShang%26aufirst%3DY.%2BC.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DMaiese%26aufirst%3DK.%26atitle%3DA%2520critical%2520kinase%2520cascade%2520in%2520neurological%2520disorders%253A%2520PI%25203-K%252C%2520Akt%252C%2520and%2520mTOR%26jtitle%3DFuture%2520Neurol.%26date%3D2012%26volume%3D7%26spage%3D733%26epage%3D748%26doi%3D10.2217%2Ffnl.12.72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Curatolo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moavero, R.</span></span> <span> </span><span class="NLM_article-title">mTOR inhibitors in tuberous sclerosis complex</span>. <i>Curr. Neuropharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">404</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.2174/157015912804499537</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.2174%2F157015912804499537" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=23730262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlt1OltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=404-415&author=P.+Curatoloauthor=R.+Moavero&title=mTOR+inhibitors+in+tuberous+sclerosis+complex&doi=10.2174%2F157015912804499537"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">mTOR inhibitors in tuberous sclerosis complex</span></div><div class="casAuthors">Curatolo, Paolo; Moavero, Romina</div><div class="citationInfo"><span class="NLM_cas:title">Current Neuropharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">404-415</span>CODEN:
                <span class="NLM_cas:coden">CNUEAN</span>;
        ISSN:<span class="NLM_cas:issn">1875-6190</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Tuberous sclerosis complex (TSC) is a genetic multiple organ system disorder that is characterized by the development of tumor-like lesions (hamartomas) and neurodevelopmental disorders.  Mutations in the TSC1 and TSC2 tumor suppressor genes occur in the majority of patients with TSC, resulting in hyperactivation of the mammalian target of rapamycin (mTOR) signaling pathway and subsequent abnormalities in numerous cell processes.  As a result, mTOR inhibitors such as sirolimus and everolimus have the potential to provide targeted therapy for patients with TSC.  Everolimus is the first mTOR inhibitor approved as a treatment option in the USA and in Europe for patients with subependymal giant-cell astrocytomas (SEGAs) assocd. with TSC.  The clin. evidence to date supports the use of mTOR inhibitors in a variety of TSC-assocd. disease manifestations, including SEGAs, renal angiomyolipoma, skin manifestations, and epilepsy.  Furthermore, ongoing clin. trials evaluating mTOR inhibitors in TSC are underway, and the results of these studies are expected to provide further evidence that will firmly establish their role in this setting.  This article will discuss the role of the mTOR pathway in TSC and review the pharmacokinetics, pharmacodynamics, clin. efficacy, and tolerability of mTOR inhibitors, along with their current place in clin. practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3BCN87Zy1qbVg90H21EOLACvtfcHk0lg6DDkIa83zDA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlt1OltA%253D%253D&md5=553975de19df0a1cf004ff14459f5bf3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.2174%2F157015912804499537&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F157015912804499537%26sid%3Dliteratum%253Aachs%26aulast%3DCuratolo%26aufirst%3DP.%26aulast%3DMoavero%26aufirst%3DR.%26atitle%3DmTOR%2520inhibitors%2520in%2520tuberous%2520sclerosis%2520complex%26jtitle%3DCurr.%2520Neuropharmacol.%26date%3D2012%26volume%3D10%26spage%3D404%26epage%3D415%26doi%3D10.2174%2F157015912804499537" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schreiber, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clardy, J.</span></span> <span> </span><span class="NLM_article-title">Structure of the FKBP1 2-rapamycin complex interacting with the binding domain of human FRAP</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>273</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1126/science.273.5272.239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1126%2Fscience.273.5272.239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=8662507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=273&publication_year=1996&pages=239-242&author=J.+Choiauthor=J.+Chenauthor=S.+L.+Schreiberauthor=J.+Clardy&title=Structure+of+the+FKBP1+2-rapamycin+complex+interacting+with+the+binding+domain+of+human+FRAP&doi=10.1126%2Fscience.273.5272.239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP</span></div><div class="casAuthors">Choi, Jungwon; Chen, Jie; Schreiber, Stuart L.; Clardy, Jon</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">273</span>
        (<span class="NLM_cas:issue">5272</span>),
    <span class="NLM_cas:pages">239-242</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Rapamycin, a potent immunosuppressive agent, binds two proteins: the FK506-binding protein (FKBP12) and the FKBP-rapamycin-assocd. protein (FRAP).  A crystal structure of the ternary complex of human FKBP12, rapamycin, and the FKBP12-rapamycin-binding (FRB) domain of human FRAP at a resoln. of 2.7 angstroms revealed the two proteins bound together as a result of the ability of rapamycin to occupy two different hydrophobic binding pockets simultaneously.  The structure shows extensive interactions between rapamycin and both proteins, but fewer interactions between the proteins.  The structure of the FRB domain of FRAP clarifies both rapamycin-independent and -dependent effects obsd. for mutants of FRAP and its homologs in the family of proteins related to the ataxia-telangiectasis mutant gene product, and it illustrates how a small cell-permeable mol. can mediate protein dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwBLM2PsItYLVg90H21EOLACvtfcHk0lgMhLF1kTw8oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xkt1Crs7k%253D&md5=c72a82e14c09d9a705215b4ac0525336</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1126%2Fscience.273.5272.239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.273.5272.239%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DSchreiber%26aufirst%3DS.%2BL.%26aulast%3DClardy%26aufirst%3DJ.%26atitle%3DStructure%2520of%2520the%2520FKBP1%25202-rapamycin%2520complex%2520interacting%2520with%2520the%2520binding%2520domain%2520of%2520human%2520FRAP%26jtitle%3DScience%26date%3D1996%26volume%3D273%26spage%3D239%26epage%3D242%26doi%3D10.1126%2Fscience.273.5272.239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lamming, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabatini, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baur, J. A.</span></span> <span> </span><span class="NLM_article-title">Rapalogs and mTOR inhibitors as anti-aging therapeutics</span>. <i>J. Clin. Invest.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">980</span>– <span class="NLM_lpage">989</span>, <span class="refDoi"> DOI: 10.1172/jci64099</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1172%2FJCI64099" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=23454761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVyhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=980-989&author=D.+W.+Lammingauthor=L.+Yeauthor=D.+M.+Sabatiniauthor=J.+A.+Baur&title=Rapalogs+and+mTOR+inhibitors+as+anti-aging+therapeutics&doi=10.1172%2Fjci64099"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Rapalogs and mTOR inhibitors as anti-aging therapeutics</span></div><div class="casAuthors">Lamming, Dudley W.; Ye, Lan; Sabatini, David M.; Baur, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Investigation</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">980-989</span>CODEN:
                <span class="NLM_cas:coden">JCINAO</span>;
        ISSN:<span class="NLM_cas:issn">0021-9738</span>.
    
            (<span class="NLM_cas:orgname">American Society for Clinical Investigation</span>)
        </div><div class="casAbstract">A review.  Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest exptl. support to date as a potential anti-aging therapeutic in mammals.  Unlike many other compds. that have been claimed to influence longevity, rapamycin has been repeatedly tested in long-lived, genetically heterogeneous mice, in which it extends both mean and max. life spans.  However, the mechanism that accounts for these effects is far from clear, and a growing list of side effects make it doubtful that rapamycin would ultimately be beneficial in humans.  This Review discusses the prospects for developing newer, safer anti-aging therapies based on analogs of rapamycin (termed rapalogs) or other approaches targeting mTOR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEaK-wCiklj7Vg90H21EOLACvtfcHk0lgMhLF1kTw8oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVyhsLs%253D&md5=4e5478c2f66e1bb34368100a7d4c152a</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1172%2FJCI64099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI64099%26sid%3Dliteratum%253Aachs%26aulast%3DLamming%26aufirst%3DD.%2BW.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DSabatini%26aufirst%3DD.%2BM.%26aulast%3DBaur%26aufirst%3DJ.%2BA.%26atitle%3DRapalogs%2520and%2520mTOR%2520inhibitors%2520as%2520anti-aging%2520therapeutics%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D980%26epage%3D989%26doi%3D10.1172%2Fjci64099" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, L.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M.</span></span> <span> </span><span class="NLM_article-title">Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">444</span>– <span class="NLM_lpage">453</span>, <span class="refDoi"> DOI: 10.1002/ana.21331</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1002%2Fana.21331" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=18389497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmsFGqt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2008&pages=444-453&author=L.-H.+Zengauthor=L.+Xuauthor=D.+H.+Gutmannauthor=M.+Wong&title=Rapamycin+prevents+epilepsy+in+a+mouse+model+of+tuberous+sclerosis+complex&doi=10.1002%2Fana.21331"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex</span></div><div class="casAuthors">Zeng, Ling-Hui; Xu, Lin; Gutmann, David H.; Wong, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Neurology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">444-453</span>CODEN:
                <span class="NLM_cas:coden">ANNED3</span>;
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Objective: Tuberous sclerosis complex (TSC) represents one of the most common genetic causes of epilepsy.  TSC gene inactivation leads to hyperactivation of the mammalian target of rapamycin signaling pathway, raising the intriguing possibility that mammalian target of rapamycin inhibitors might be effective in preventing or treating epilepsy in patients with TSC.  Mice with conditional inactivation of the Tsc1 gene primarily in glia (Tsc1GFAPCKO mice) develop glial proliferation, progressive epilepsy, and premature death.  Here, we tested whether rapamycin could prevent or reverse epilepsy, as well as other cellular and mol. brain abnormalities in Tsc1GFAPCKO mice.  Methods: Tsc1GFAPCKO mice and littermate control animals were treated with rapamycin or vehicle starting at postnatal day 14 (early treatment) or 6 wk of age (late treatment), corresponding to times before and after onset of neurol. abnormalities in Tsc1GFAPCKO mice.  Mice were monitored for seizures by serial video-EEG and for long-term survival.  Brains were examd. histol. for astrogliosis and neuronal organization.  Expression of phospho-S6 and other mol. markers correlating with epileptogenesis was measured by Western blotting.  Results: Early treatment with rapamycin prevented the development of epilepsy and premature death obsd. in vehicle-treated Tsc1GFAPCKO mice.  Late treatment with rapamycin suppressed seizures and prolonged survival in Tsc1GFAPCKO mice that had already developed epilepsy.  Correspondingly, rapamycin inhibited the abnormal activation of the mammalian target of rapamycin pathway, astrogliosis, and neuronal disorganization, and increased brain size in Tsc1GFAPCKO mice.  Interpretation: Rapamycin has strong efficacy for preventing seizures and prolonging survival in Tsc1GFAPCKO mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDrvRnEyf-tLVg90H21EOLACvtfcHk0lgMhLF1kTw8oQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmsFGqt7c%253D&md5=e4dbf8b71250ec0594029fed56c0d8c2</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1002%2Fana.21331&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.21331%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DL.-H.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DGutmann%26aufirst%3DD.%2BH.%26aulast%3DWong%26aufirst%3DM.%26atitle%3DRapamycin%2520prevents%2520epilepsy%2520in%2520a%2520mouse%2520model%2520of%2520tuberous%2520sclerosis%2520complex%26jtitle%3DAnn.%2520Neurol.%26date%3D2008%26volume%3D63%26spage%3D444%26epage%3D453%26doi%3D10.1002%2Fana.21331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meikle, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollizzi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egnor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kramvis, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, D. J.</span></span> <span> </span><span class="NLM_article-title">Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">5422</span>– <span class="NLM_lpage">5432</span>, <span class="refDoi"> DOI: 10.1523/jneurosci.0955-08.2008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1523%2FJNEUROSCI.0955-08.2008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=18495876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD1cXmslWisbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=5422-5432&author=L.+Meikleauthor=K.+Pollizziauthor=A.+Egnorauthor=I.+Kramvisauthor=H.+Laneauthor=M.+Sahinauthor=D.+J.+Kwiatkowski&title=Response+of+a+neuronal+model+of+tuberous+sclerosis+to+mammalian+target+of+rapamycin+%28mTOR%29+inhibitors%3A+effects+on+mTORC1+and+Akt+signaling+lead+to+improved+survival+and+function&doi=10.1523%2Fjneurosci.0955-08.2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function</span></div><div class="casAuthors">Meikle, Lynsey; Pollizzi, Kristen; Egnor, Anna; Kramvis, Ioannis; Lane, Heidi; Sahin, Mustafa; Kwiatkowski, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">5422-5432</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Tuberous sclerosis (TSC) is a hamartoma syndrome attributable to mutations in either TSC1 or TSC2 in which brain involvement causes epilepsy, mental retardation, and autism.  We have reported recently a mouse neuronal model of TSC in which Tsc1 is ablated in most neurons during cortical development.  We have tested rapamycin and RAD001 [40-O-(2-hydroxyethyl)-rapamycin], both mammalian target of rapamycin mTORC1 inhibitors, as potential therapeutic agents in this model.  Median survival is improved from 33 d to more than 100 d; behavior, phenotype, and wt. gain are all also markedly improved.  There is brain penetration of both drugs, with accumulation over time with repetitive treatment, and effective redn. of levels of phospho-S6, a downstream target of mTORC1.  In addn., there is restoration of phospho-Akt and phospho-glycogen synthase kinase 3 levels in the treated mice, consistent with restoration of Akt function.  Neurofilament abnormalities, myelination, and cell enlargement are all improved by the treatment.  However, dysplastic neuronal features persist, and there are only modest changes in dendritic spine d. and length.  Strikingly, mice treated with rapamycin or RAD001 for 23 d only (postnatal days 7-30) displayed a persistent improvement in phenotype, with median survival of 78 d.  In summary, rapamycin/RAD001 are highly effective therapies for this neuronal model of TSC, with benefit apparently attributable to effects on mTORC1 and Akt signaling and, consequently, cell size and myelination.  Although caution is appropriate, the results suggest the possibility that rapamycin/RAD001 may have benefit in the treatment of TSC brain disease, including infantile spasms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp7NYIU5vQOo7Vg90H21EOLACvtfcHk0lgcpYwWFvrwkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXmslWisbY%253D&md5=213ca3d5a365d9fc0bddf139fd97a278</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.0955-08.2008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.0955-08.2008%26sid%3Dliteratum%253Aachs%26aulast%3DMeikle%26aufirst%3DL.%26aulast%3DPollizzi%26aufirst%3DK.%26aulast%3DEgnor%26aufirst%3DA.%26aulast%3DKramvis%26aufirst%3DI.%26aulast%3DLane%26aufirst%3DH.%26aulast%3DSahin%26aufirst%3DM.%26aulast%3DKwiatkowski%26aufirst%3DD.%2BJ.%26atitle%3DResponse%2520of%2520a%2520neuronal%2520model%2520of%2520tuberous%2520sclerosis%2520to%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitors%253A%2520effects%2520on%2520mTORC1%2520and%2520Akt%2520signaling%2520lead%2520to%2520improved%2520survival%2520and%2520function%26jtitle%3DJ.%2520Neurosci.%26date%3D2008%26volume%3D28%26spage%3D5422%26epage%3D5432%26doi%3D10.1523%2Fjneurosci.0955-08.2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lechuga, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz, D. N.</span></span> <span> </span><span class="NLM_article-title">Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures</span>. <i>Expert Rev. Neurother.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">913</span>– <span class="NLM_lpage">925</span>, <span class="refDoi"> DOI: 10.1080/14737175.2019.1635457</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1080%2F14737175.2019.1635457" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=31335226" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsVeru7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=913-925&author=L.+Lechugaauthor=D.+N.+Franz&title=Everolimus+as+adjunctive+therapy+for+tuberous+sclerosis+complex-associated+partial-onset+seizures&doi=10.1080%2F14737175.2019.1635457"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures</span></div><div class="casAuthors">Lechuga, Lorena; Franz, David Neal</div><div class="citationInfo"><span class="NLM_cas:title">Expert Review of Neurotherapeutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">913-925</span>CODEN:
                <span class="NLM_cas:coden">ERNXAR</span>;
        ISSN:<span class="NLM_cas:issn">1473-7175</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  : Tuberous sclerosis complex (TSC) is a rare genetic disorder resulting in benign tumors in various organs.  It is caused by mutations in TSC1 or TSC2 genes causing hyperactivation of the mammalian target of rapamycin (mTOR) pathway.  The majority of patients with TSC develop epilepsy, and approx. two-thirds become refractory to antiepileptic drugs (AEDs).  Recently, the mTOR inhibitor everolimus was approved as adjunctive therapy for TSC-assocd. partial seizures.  This article covers different characteristics of everolimus, including major clin. trials leading to its approval in TSC-assocd.  Partial seizures, safety concerns, drug pharmacokinetics/pharmacodynamics, and an overview of potential competitors and other agents used to treat TSC-assocd. seizures.  Unlike many other therapies for treating TSC-assocd. seizures, everolimus addresses the underlying pathophysiol. of TSC, and since it has also been shown to improve other TSC manifestations such as subependymal giant cell astrocytomas and renal angiomyolipomas, everolimus provides a potential multisystemic therapy for TSC.  An important avenue for future research is exploring the possible use of everolimus as a preventative treatment for seizures as there is the potential to prevent neg. developmental outcomes assocd. with TSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnc7QK8A8_A7Vg90H21EOLACvtfcHk0lgcpYwWFvrwkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsVeru7%252FJ&md5=f89e8a45cc0e69ecc0a5098f3240f36d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1080%2F14737175.2019.1635457&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14737175.2019.1635457%26sid%3Dliteratum%253Aachs%26aulast%3DLechuga%26aufirst%3DL.%26aulast%3DFranz%26aufirst%3DD.%2BN.%26atitle%3DEverolimus%2520as%2520adjunctive%2520therapy%2520for%2520tuberous%2520sclerosis%2520complex-associated%2520partial-onset%2520seizures%26jtitle%3DExpert%2520Rev.%2520Neurother.%26date%3D2019%26volume%3D19%26spage%3D913%26epage%3D925%26doi%3D10.1080%2F14737175.2019.1635457" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">French, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yapici, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikeda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polster, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabbout, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curatolo, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Vries, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dlugos, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berkowitz, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peyrard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz, D. N.</span></span> <span> </span><span class="NLM_article-title">Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>388</i></span>,  <span class="NLM_fpage">2153</span>– <span class="NLM_lpage">2163</span>, <span class="refDoi"> DOI: 10.1016/s0140-6736(16)31419-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2FS0140-6736%2816%2931419-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=27613521" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslOmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=2016&pages=2153-2163&author=J.+A.+Frenchauthor=J.+A.+Lawsonauthor=Z.+Yapiciauthor=H.+Ikedaauthor=T.+Polsterauthor=R.+Nabboutauthor=P.+Curatoloauthor=P.+J.+de+Vriesauthor=D.+J.+Dlugosauthor=N.+Berkowitzauthor=M.+Voiauthor=S.+Peyrardauthor=D.+Pelovauthor=D.+N.+Franz&title=Adjunctive+everolimus+therapy+for+treatment-resistant+focal-onset+seizures+associated+with+tuberous+sclerosis+%28EXIST-3%29%3A+a+phase+3%2C+randomised%2C+double-blind%2C+placebo-controlled+study&doi=10.1016%2Fs0140-6736%2816%2931419-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study</span></div><div class="casAuthors">French, Jacqueline A.; Lawson, John A.; Yapici, Zuhal; Ikeda, Hiroko; Polster, Tilman; Nabbout, Rima; Curatolo, Paolo; de Vries, Petrus J.; Dlugos, Dennis J.; Berkowitz, Noah; Voi, Maurizio; Peyrard, Severine; Pelov, Diana; Franz, David N.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">10056</span>),
    <span class="NLM_cas:pages">2153-2163</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Everolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been used for various benign tumors assocd. with tuberous sclerosis complex.  We assessed the efficacy and safety of two trough exposure concns. of everolimus, 3-7 ng/mL (low exposure) and 9-15 ng/mL (high exposure), compared with placebo as adjunctive therapy for treatment-resistant focal-onset seizures in tuberous sclerosis complex.  In this phase 3, randomised, double-blind, placebo-controlled study, eligible patients aged 2-65 years with tuberous sclerosis complex and treatment-resistant seizures (≥16 in an 8-wk baseline phase) receiving one to three concomitant antiepileptic drugs were recruited from 99 centers across 25 countries.  Participants were randomly assigned (1:1:1), via permuted-block randomisation (block size of six) implemented by Interactive Response Technol. software, to receive placebo, low-exposure everolimus, or high-exposure everolimus.  Randomisation was stratified by age subgroup (<6 years, 6 to <12 years, 12 to <18 years, and ≥18 years).  Patients, investigators, site personnel, and the sponsor's study team were masked to treatment allocation.  The starting dose of everolimus depended on age, body-surface area, and concomitant use of cytochrome 3A4/P-glycoprotein inducers.  Dose adjustments were done to attain target trough ranges during a 6-wk titrn. period, and as needed during a 12-wk maintenance period of core phase.  Patients or their caregivers recorded events in a seizure diary throughout the study.  The primary endpoint was change from baseline in the frequency of seizures during the maintenance period, defined as response rate (the proportion of patients achieving ≥50% redn. in seizure frequency) and median percentage redn. in seizure frequency, in all randomised patients.  This study is registered with ClinicalTrials.gov, no. NCT01713946.  Between July 3, 2013, and May 29, 2015, 366 patients were enrolled and randomly assigned to placebo (n=119), low-exposure everolimus, (n=117), or high-exposure everolimus (n=130).  The response rate was 15·1% with placebo (95% CI 9·2-22·8; 18 patients) compared with 28·2% for low-exposure everolimus (95% CI 20·3-37·3; 33 patients; p=0·0077) and 40·0% for high-exposure everolimus (95% CI 31·5-49·0; 52 patients; p<0·0001).  The median percentage redn. in seizure frequency was 14·9% (95% CI 0·1-21·7) with placebo vs. 29·3% with low-exposure everolimus (95% CI 18·8-41·9; p=0·0028) and 39·6% with high-exposure everolimus (95% CI 35·0-48·7; p<0·0001).  Grade 3 or 4 adverse events occurred in 13 (11%) patients in the placebo group, 21 (18%) in the low-exposure group, and 31 (24%) in the high-exposure group.  Serious adverse events were reported in three (3%) patients who received placebo, 16 (14%) who received low-exposure everolimus, and 18 (14%) who received high-exposure everolimus.  Adverse events led to treatment discontinuation in two (2%) patients in the placebo group vs. six (5%) in the low-exposure group and four (3%) in the high-exposure group.  Adjunctive everolimus treatment significantly reduced seizure frequency with a tolerable safety profile compared with placebo in patients with tuberous sclerosis complex and treatment-resistant seizures.  Novartis Pharmaceuticals Corporation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkOznXjnuKq7Vg90H21EOLACvtfcHk0ljxKjfJ5p3qyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslOmurnM&md5=2458350eed0afd4d990ff721ff01ab89</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2816%2931419-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252816%252931419-2%26sid%3Dliteratum%253Aachs%26aulast%3DFrench%26aufirst%3DJ.%2BA.%26aulast%3DLawson%26aufirst%3DJ.%2BA.%26aulast%3DYapici%26aufirst%3DZ.%26aulast%3DIkeda%26aufirst%3DH.%26aulast%3DPolster%26aufirst%3DT.%26aulast%3DNabbout%26aufirst%3DR.%26aulast%3DCuratolo%26aufirst%3DP.%26aulast%3Dde%2BVries%26aufirst%3DP.%2BJ.%26aulast%3DDlugos%26aufirst%3DD.%2BJ.%26aulast%3DBerkowitz%26aufirst%3DN.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DPeyrard%26aufirst%3DS.%26aulast%3DPelov%26aufirst%3DD.%26aulast%3DFranz%26aufirst%3DD.%2BN.%26atitle%3DAdjunctive%2520everolimus%2520therapy%2520for%2520treatment-resistant%2520focal-onset%2520seizures%2520associated%2520with%2520tuberous%2520sclerosis%2520%2528EXIST-3%2529%253A%2520a%2520phase%25203%252C%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%2520study%26jtitle%3DLancet%26date%3D2016%26volume%3D388%26spage%3D2153%26epage%3D2163%26doi%3D10.1016%2Fs0140-6736%2816%2931419-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ravikumar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vacher, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oroz, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scaravilli, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duden, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Kane, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubinsztein, D. C.</span></span> <span> </span><span class="NLM_article-title">Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease</span>. <i>Nat. Genet.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">585</span>– <span class="NLM_lpage">595</span>, <span class="refDoi"> DOI: 10.1038/ng1362</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fng1362" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=15146184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVajt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2004&pages=585-595&author=B.+Ravikumarauthor=C.+Vacherauthor=Z.+Bergerauthor=J.+E.+Daviesauthor=S.+Luoauthor=L.+G.+Orozauthor=F.+Scaravilliauthor=D.+F.+Eastonauthor=R.+Dudenauthor=C.+J.+O%E2%80%99Kaneauthor=D.+C.+Rubinsztein&title=Inhibition+of+mTOR+induces+autophagy+and+reduces+toxicity+of+polyglutamine+expansions+in+fly+and+mouse+models+of+Huntington+disease&doi=10.1038%2Fng1362"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease</span></div><div class="casAuthors">Ravikumar, Brinda; Vacher, Coralie; Berger, Zdenek; Davies, Janet E.; Luo, Shouqing; Oroz, Lourdes G.; Scaravilli, Francesco; Easton, Douglas F.; Duden, Rainer; O'Kane, Cahir J.; Rubinsztein, David C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">585-595</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Huntington disease is one of nine inherited neurodegenerative disorders caused by a polyglutamine tract expansion.  Expanded polyglutamine proteins accumulate abnormally in intracellular aggregates.  Here we show that mammalian target of rapamycin (mTOR) is sequestered in polyglutamine aggregates in cell models, transgenic mice and human brains.  Sequestration of mTOR impairs its kinase activity and induces autophagy, a key clearance pathway for mutant huntingtin fragments.  This protects against polyglutamine toxicity, as the specific mTOR inhibitor rapamycin attenuates huntingtin accumulation and cell death in cell models of Huntington disease, and inhibition of autophagy has the converse effects.  Furthermore, rapamycin protects against neurodegeneration in a fly model of Huntington disease, and the rapamycin analog CCI-779 improved performance on four different behavioral tasks and decreased aggregate formation in a mouse model of Huntington disease.  Our data provide proof-of-principle for the potential of inducing autophagy to treat Huntington disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpe6pwZ9IPbhLVg90H21EOLACvtfcHk0ljxKjfJ5p3qyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVajt7s%253D&md5=39f48bebe54daa65eb21715819b703c4</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fng1362&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng1362%26sid%3Dliteratum%253Aachs%26aulast%3DRavikumar%26aufirst%3DB.%26aulast%3DVacher%26aufirst%3DC.%26aulast%3DBerger%26aufirst%3DZ.%26aulast%3DDavies%26aufirst%3DJ.%2BE.%26aulast%3DLuo%26aufirst%3DS.%26aulast%3DOroz%26aufirst%3DL.%2BG.%26aulast%3DScaravilli%26aufirst%3DF.%26aulast%3DEaston%26aufirst%3DD.%2BF.%26aulast%3DDuden%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Kane%26aufirst%3DC.%2BJ.%26aulast%3DRubinsztein%26aufirst%3DD.%2BC.%26atitle%3DInhibition%2520of%2520mTOR%2520induces%2520autophagy%2520and%2520reduces%2520toxicity%2520of%2520polyglutamine%2520expansions%2520in%2520fly%2520and%2520mouse%2520models%2520of%2520Huntington%2520disease%26jtitle%3DNat.%2520Genet.%26date%3D2004%26volume%3D36%26spage%3D585%26epage%3D595%26doi%3D10.1038%2Fng1362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Singer, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rischert, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riess, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. P.</span></span> <span> </span><span class="NLM_article-title">Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>162</i></span>,  <span class="NLM_fpage">107812</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2019.107812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.neuropharm.2019.107812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=31622602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitVKrtrzN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=162&publication_year=2020&pages=107812&author=E.+Singerauthor=C.+Walterauthor=D.+Fabbroauthor=D.+Rageotauthor=F.+Beaufilsauthor=M.+P.+Wymannauthor=N.+Rischertauthor=O.+Riessauthor=P.+Hillmannauthor=H.+P.+Nguyen&title=Brain-penetrant+PQR620+mTOR+and+PQR530+PI3K%2FmTOR+inhibitor+reduce+huntingtin+levels+in+cell+models+of+HD&doi=10.1016%2Fj.neuropharm.2019.107812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Brain-penetrant PQR620 mTOR and PQR530 PI3K/mTOR inhibitor reduce huntingtin levels in cell models of HD</span></div><div class="casAuthors">Singer, Elisabeth; Walter, Carolin; Fabbro, Doriano; Rageot, Denise; Beaufils, Florent; Wymann, Matthias P.; Rischert, Nadine; Riess, Olaf; Hillmann, Petra; Nguyen, Huu Phuc</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">162</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107812</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">One of the pathol. hallmarks of Huntington disease (HD) is accumulation of the disease-causing mutant huntingtin (mHTT), which leads to the disruption of a variety of cellular functions, ultimately resulting in cell death.  Induction of autophagy, for example by the inhibition of mechanistic target of rapamycin (mTOR) signaling, has been shown to reduce HTT levels and aggregates.  The ability to cross the blood-brain barrier of first generation catalytic mTOR inhibitors has so far been limited, and therefore sufficient target coverage in the brain could not be reached.  Two novel, brain penetrant compds. - the mTORC1/2 inhibitor PQR620, and the dual pan-phosphoinositide 3-kinase (PI3K) and mTORC1/2 kinase inhibitor PQR530 - were evaluated by assessing their potential to induce autophagy and reducing mHTT levels.  For this purpose, expression levels of autophagic markers and well-defined mTOR targets were analyzed in STHdh cells and HEK293T cells and in mouse brains.  Both compds. potently inhibited mTOR signaling in cell models as well as in mouse brain.  As proof of principle, redn. of aggregates and levels of sol. mHTT were demonstrated upon treatment with both compds.  Originally developed for cancer treatment, these second generation mTORC1/2 and PI3K/mTOR inhibitors show brain penetrance and efficacy in cell models of HD, making them candidate mols. for further investigations in HD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrwQIRL7T6QKbVg90H21EOLACvtfcHk0ljxKjfJ5p3qyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitVKrtrzN&md5=d7c200ebfc6aa514973d8685d1e7e4ef</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2019.107812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2019.107812%26sid%3Dliteratum%253Aachs%26aulast%3DSinger%26aufirst%3DE.%26aulast%3DWalter%26aufirst%3DC.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DRischert%26aufirst%3DN.%26aulast%3DRiess%26aufirst%3DO.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DNguyen%26aufirst%3DH.%2BP.%26atitle%3DBrain-penetrant%2520PQR620%2520mTOR%2520and%2520PQR530%2520PI3K%252FmTOR%2520inhibitor%2520reduce%2520huntingtin%2520levels%2520in%2520cell%2520models%2520of%2520HD%26jtitle%3DNeuropharmacology%26date%3D2020%26volume%3D162%26spage%3D107812%26doi%3D10.1016%2Fj.neuropharm.2019.107812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Talboom, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velazquez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oddo, S.</span></span> <span> </span><span class="NLM_article-title">The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer’s disease</span>. <i>npj Aging Mech. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">15008</span>, <span class="refDoi"> DOI: 10.1038/npjamd.2015.8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fnpjamd.2015.8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=28721257" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A280%3ADC%252BC1cjovFaisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2015&pages=15008&author=J.+S.+Talboomauthor=R.+Velazquezauthor=S.+Oddo&title=The+mammalian+target+of+rapamycin+at+the+crossroad+between+cognitive+aging+and+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fnpjamd.2015.8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The mammalian target of rapamycin at the crossroad between cognitive aging and Alzheimer's disease</span></div><div class="casAuthors">Talboom Joshua S; Velazquez Ramon; Oddo Salvatore; Oddo Salvatore</div><div class="citationInfo"><span class="NLM_cas:title">NPJ aging and mechanisms of disease</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">15008</span>
        ISSN:<span class="NLM_cas:issn">2056-3973</span>.
    </div><div class="casAbstract">Age-dependent cognitive decline is a major debilitating event affecting even individuals who are otherwise healthy.  Understanding the molecular basis underlying these changes may increase the healthspan of the elderly population.  It may also reveal insights into the pathogenesis of numerous neurodegenerative disorders characterized by cognitive deficits, as aging is the major risk factor for most of these disorders.  Alzheimer's disease (AD), the most common neurodegenerative disorder, first manifests itself as deficits in encoding new memories.  As AD progresses, these deficits spread to other cognitive domains that further debilitate the person before contributing to their demise.  Suppression of the mammalian target of rapamycin (mTOR) increases healthspan and lifespan in several organisms.  Numerous reports have linked alterations in mTOR signaling to age-dependent cognitive decline and the pathogenesis of AD.  This review will discuss recent work highlighting the complex role of mTOR in cognitive aging and in the pathogenesis of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSA0TQF8zU3rf69nzq6467DfW6udTcc2eZc4znnw62xOLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cjovFaisg%253D%253D&md5=3a98d9e1b3facf63a929fa6d5d35667c</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnpjamd.2015.8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpjamd.2015.8%26sid%3Dliteratum%253Aachs%26aulast%3DTalboom%26aufirst%3DJ.%2BS.%26aulast%3DVelazquez%26aufirst%3DR.%26aulast%3DOddo%26aufirst%3DS.%26atitle%3DThe%2520mammalian%2520target%2520of%2520rapamycin%2520at%2520the%2520crossroad%2520between%2520cognitive%2520aging%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3Dnpj%2520Aging%2520Mech.%2520Dis.%26date%3D2015%26volume%3D1%26spage%3D15008%26doi%3D10.1038%2Fnpjamd.2015.8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iyaswamy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnamoorthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sreenivasmurthy, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, B. C.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, K.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span> <span> </span><span class="NLM_article-title">Balancing mTOR signaling and autophagy in the treatment of Parkinson’s disease</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">728</span>, <span class="refDoi"> DOI: 10.3390/ijms20030728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.3390%2Fijms20030728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtlSiu7%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2019&pages=728&author=Z.+Zhuauthor=C.+Yangauthor=A.+Iyaswamyauthor=S.+Krishnamoorthiauthor=S.+G.+Sreenivasmurthyauthor=J.+Liuauthor=Z.+Wangauthor=B.+C.-K.+Tongauthor=J.+Songauthor=J.+Luauthor=K.-H.+Cheungauthor=M.+Li&title=Balancing+mTOR+signaling+and+autophagy+in+the+treatment+of+Parkinson%E2%80%99s+disease&doi=10.3390%2Fijms20030728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Balancing mTOR signaling and autophagy in the treatment of Parkinson's disease</span></div><div class="casAuthors">Zhu, Zhou; Yang, Chuanbin; Iyaswamy, Ashok; Krishnamoorthi, Senthilkumar; Sreenivasmurthy, Sravan Gopalkrishnashetty; Liu, Jia; Wang, Ziying; Tong, Benjamin Chun-Kit; Song, Juxian; Lu, Jiahong; Cheung, King-Ho; Li, Min</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">728</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">A review.  The mammalian target of rapamycin (mTOR) signaling pathway plays a crit. role in regulating cell growth, proliferation, and life span. mTOR signaling is a central regulator of autophagy by modulating multiple aspects of the autophagy process, such as initiation, process, and termination through controlling the activity of the unc51-like kinase 1 (ULK1) complex and vacuolar protein sorting 34 (VPS34) complex, and the intracellular distribution of TFEB/TFE3 and proto-lysosome tubule reformation.  Parkinson's disease (PD) is a serious, common neurodegenerative disease characterized by dopaminergic neuron loss in the substantia nigra pars compacta (SNpc) and the accumulation of Lewy bodies.  An increasing amt. of evidence indicates that mTOR and autophagy are crit. for the pathogenesis of PD.  In this review, we will summarize recent advances regarding the roles of mTOR and autophagy in PD pathogenesis and treatment.  Further characterizing the dysregulation of mTOR pathway and the clin. translation of mTOR modulators in PD may offer exciting new avenues for future drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHXDgDatWGKLVg90H21EOLACvtfcHk0lgOtTfNkH_wUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtlSiu7%252FJ&md5=ab0cd13fd00eb28c9dbd2f4ac02110ff</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.3390%2Fijms20030728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms20030728%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DIyaswamy%26aufirst%3DA.%26aulast%3DKrishnamoorthi%26aufirst%3DS.%26aulast%3DSreenivasmurthy%26aufirst%3DS.%2BG.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DTong%26aufirst%3DB.%2BC.-K.%26aulast%3DSong%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DJ.%26aulast%3DCheung%26aufirst%3DK.-H.%26aulast%3DLi%26aufirst%3DM.%26atitle%3DBalancing%2520mTOR%2520signaling%2520and%2520autophagy%2520in%2520the%2520treatment%2520of%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2019%26volume%3D20%26spage%3D728%26doi%3D10.3390%2Fijms20030728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Krueger, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilfong, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mays, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Talley, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Agricola, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tudor, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland-Bouley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Franz, D. N.</span></span> <span> </span><span class="NLM_article-title">Long-term treatment of epilepsy with everolimus in tuberous sclerosis</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>87</i></span>,  <span class="NLM_fpage">2408</span>– <span class="NLM_lpage">2415</span>, <span class="refDoi"> DOI: 10.1212/wnl.0000000000003400</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1212%2FWNL.0000000000003400" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=27815402" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVGru7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2016&pages=2408-2415&author=D.+A.+Kruegerauthor=A.+A.+Wilfongauthor=M.+Maysauthor=C.+M.+Talleyauthor=K.+Agricolaauthor=C.+Tudorauthor=J.+Capalauthor=K.+Holland-Bouleyauthor=D.+N.+Franz&title=Long-term+treatment+of+epilepsy+with+everolimus+in+tuberous+sclerosis&doi=10.1212%2Fwnl.0000000000003400"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term treatment of epilepsy with everolimus in tuberous sclerosis</span></div><div class="casAuthors">Krueger, Darcy A.; Wilfong, Angus A.; Mays, Maxwell; Talley, Christina M.; Agricola, Karen; Tudor, Cindy; Capal, Jamie; Holland-Bouley, Katherine; Franz, David Neal</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">2408-2415</span>CODEN:
                <span class="NLM_cas:coden">NEURAI</span>;
        ISSN:<span class="NLM_cas:issn">0028-3878</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Objective: To evaluate the long-term benefit and safety of everolimus for the treatment of medically refractory epilepsy in patients with tuberous sclerosis complex (TSC).  Methods: Everolimus was titrated over 4 wk and continued an addnl. 8 wk in a prospective, open-label, phase I/II clin. trial design.  Participants demonstrating initial benefit continued treatment until study completion (48 mo).  The primary endpoint was percentage of patients with a ≥50% redn. in seizure frequency compared to baseline.  Secondary endpoints assessed abs. seizure frequency, adverse events (AEs), behavior, and quality of life.  Results: Of the 20 participants who completed the initial study phase, 18 continued extended treatment.  Fourteen of 18 (78%) participants completed the study, all but 1 of whom reported ≥50% redn. in seizure frequency at 48 mo.  All participants reported at least 1 AE, the vast majority (94%) of which were graded mild or moderate severity.  Improvements in behavior and quality of life were also obsd., but failed to achieve statistical significance at 48 mo.  Conclusions: Improved seizure control was maintained for 4 years in the majority of patients with TSC with medically refractory epilepsy treated with everolimus.  Long-term treatment with everolimus is safe and well-tolerated in this population.  Everolimus may be a therapeutic option for refractory epilepsy in TSC.  Classification of evidence: This study provides Class IV evidence that for patients with TSC with medically refractory epilepsy everolimus improves seizure control.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqH5vcit74VrVg90H21EOLACvtfcHk0lgOtTfNkH_wUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVGru7bF&md5=ce3240ba5fd90b663de6706f511afdb8</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1212%2FWNL.0000000000003400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252FWNL.0000000000003400%26sid%3Dliteratum%253Aachs%26aulast%3DKrueger%26aufirst%3DD.%2BA.%26aulast%3DWilfong%26aufirst%3DA.%2BA.%26aulast%3DMays%26aufirst%3DM.%26aulast%3DTalley%26aufirst%3DC.%2BM.%26aulast%3DAgricola%26aufirst%3DK.%26aulast%3DTudor%26aufirst%3DC.%26aulast%3DCapal%26aufirst%3DJ.%26aulast%3DHolland-Bouley%26aufirst%3DK.%26aulast%3DFranz%26aufirst%3DD.%2BN.%26atitle%3DLong-term%2520treatment%2520of%2520epilepsy%2520with%2520everolimus%2520in%2520tuberous%2520sclerosis%26jtitle%3DNeurology%26date%3D2016%26volume%3D87%26spage%3D2408%26epage%3D2415%26doi%3D10.1212%2Fwnl.0000000000003400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noack, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Römermann, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Öhler, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löscher, W.</span></span> <span> </span><span class="NLM_article-title">The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>140</i></span>,  <span class="NLM_fpage">107</span>– <span class="NLM_lpage">120</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2018.08.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.neuropharm.2018.08.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=30081001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVGhtbjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=140&publication_year=2018&pages=107-120&author=C.+Brandtauthor=P.+Hillmannauthor=A.+Noackauthor=K.+R%C3%B6mermannauthor=L.+A.+%C3%96hlerauthor=D.+Rageotauthor=F.+Beaufilsauthor=A.+Meloneauthor=A.+M.+Seleauthor=M.+P.+Wymannauthor=D.+Fabbroauthor=W.+L%C3%B6scher&title=The+novel%2C+catalytic+mTORC1%2F2+inhibitor+PQR620+and+the+PI3K%2FmTORC1%2F2+inhibitor+PQR530+effectively+cross+the+blood-brain+barrier+and+increase+seizure+threshold+in+a+mouse+model+of+chronic+epilepsy&doi=10.1016%2Fj.neuropharm.2018.08.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy</span></div><div class="casAuthors">Brandt, Claudia; Hillmann, Petra; Noack, Andreas; Roemermann, Kerstin; Oehler, Leon A.; Rageot, Denise; Beaufils, Florent; Melone, Anna; Sele, Alexander M.; Wymann, Matthias P.; Fabbro, Doriano; Loescher, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">140</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">107-120</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The mTOR signaling pathway has emerged as a possible therapeutic target for epilepsy.  Clin. trials have shown that mTOR inhibitors such as everolimus reduce seizures in tuberous sclerosis complex patients with intractable epilepsy.  Furthermore, accumulating preclin. data suggest that mTOR inhibitors may have anti-seizure or anti-epileptogenic actions in other types of epilepsy.  However, the chronic use of rapalogs such as everolimus is limited by poor tolerability, particularly by immunosuppression, poor brain penetration and induction of feedback loops which might contribute to their limited therapeutic efficacy.  Here we describe two novel, brain-permeable and well tolerated small mol. 1,3,5-triazine derivs., the catalytic mTORC1/C2 inhibitor PQR620 and the dual pan-PI3K/mTOR inhibitor PQR530.  These derivs. were compared with the mTORC1 inhibitors rapamycin and everolimus as well as the anti-seizure drugs phenobarbital and levetiracetam.  The anti-seizure potential of these compds. was detd. by evaluating the electroconvulsive seizure threshold in normal and epileptic mice.  Rapamycin and everolimus only poorly penetrated into the brain (brain:plasma ratio 0.0057 for rapamycin and 0.016 for everolimus).  In contrast, the novel compds. rapidly entered the brain, reaching brain:plasma ratios of ∼1.6.  Furthermore, they significantly decreased phosphorylation of S6 ribosomal protein in the hippocampus of normal and epileptic mice, demonstrating effective mTOR inhibition.  PQR620 and PQR530 significantly increased seizure threshold at tolerable doses.  The effect of PQR620 was more marked in epileptic vs. nonepileptic mice, matching the efficacy of levetiracetam.  Overall, the novel compds. described here have the potential to overcome the disadvantages of rapalogs for treatment of epilepsy and mTORopathies directly connected to mutations in the mTOR signaling cascade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvQmF8jJglOLVg90H21EOLACvtfcHk0li577_phRoqAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVGhtbjJ&md5=38f76201f9fb8c4643e59979b2bb4121</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2018.08.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2018.08.002%26sid%3Dliteratum%253Aachs%26aulast%3DBrandt%26aufirst%3DC.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DNoack%26aufirst%3DA.%26aulast%3DR%25C3%25B6mermann%26aufirst%3DK.%26aulast%3D%25C3%2596hler%26aufirst%3DL.%2BA.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26atitle%3DThe%2520novel%252C%2520catalytic%2520mTORC1%252F2%2520inhibitor%2520PQR620%2520and%2520the%2520PI3K%252FmTORC1%252F2%2520inhibitor%2520PQR530%2520effectively%2520cross%2520the%2520blood-brain%2520barrier%2520and%2520increase%2520seizure%2520threshold%2520in%2520a%2520mouse%2520model%2520of%2520chronic%2520epilepsy%26jtitle%3DNeuropharmacology%26date%3D2018%26volume%3D140%26spage%3D107%26epage%3D120%26doi%3D10.1016%2Fj.neuropharm.2018.08.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, A.</span></span> <span> </span><span class="NLM_article-title">Preclinical study of CC223 as a potential anti-ovarian cancer agent</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">58469</span>– <span class="NLM_lpage">58479</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.18632%2Foncotarget.17753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=28938571" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FhtlOjuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=58469-58479&author=Z.+Jinauthor=H.+Niuauthor=X.+Wangauthor=L.+Zhangauthor=Q.+Wangauthor=A.+Yang&title=Preclinical+study+of+CC223+as+a+potential+anti-ovarian+cancer+agent&doi=10.18632%2Foncotarget.17753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical study of CC223 as a potential anti-ovarian cancer agent</span></div><div class="casAuthors">Jin Zhenzhen; Niu Huanfu; Wang Xuenan; Wang Qin; Yang Aijun; Zhang Lei</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">58469-58479</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Aberrant activation of mTOR contributes to ovarian cancer progression.  CC223 is a novel and potent mTOR kinase inhibitor.  The current study tested its activity against human ovarian cancer cells.  We showed that CC223, at nM concentrations, inhibited survival and proliferation of established/primary human ovarian cancer cells.  Further, significant apoptosis activation was observed in CC223-treated ovarian cancer cells.  CC223 disrupted assembly of mTOR complex 1 (mTORC1) and mTORC2 in SKOV3 cells.  Meanwhile, activation of mTORC1 and mTORC2 was almost completely blocked by CC223.  Intriguingly, restoring mTOR activation by introduction of a constitutively-active Akt1 only partially inhibited CC223-induced cytotoxicity in SKOV3 cells.  Further studies showed that CC223 inhibited sphingosine kinase 1 (SphK1) activity and induced reactive oxygen species (ROS) production in SKOV3 cells.  At last, oral administration of CC223 potently inhibited SKOV3 xenografted tumor growth in nude mice.  The results of this study imply that CC223 could be further studied as a potential anti-ovarian cancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRcU4AE24nN2t1QT_1O5WBYfW6udTcc2eYzeT7Jvr_eabntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FhtlOjuw%253D%253D&md5=091fdb75cec2ddb9018ba74c124041e8</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17753%26sid%3Dliteratum%253Aachs%26aulast%3DJin%26aufirst%3DZ.%26aulast%3DNiu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYang%26aufirst%3DA.%26atitle%3DPreclinical%2520study%2520of%2520CC223%2520as%2520a%2520potential%2520anti-ovarian%2520cancer%2520agent%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D58469%26epage%3D58479%26doi%3D10.18632%2Foncotarget.17753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Slotkin, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patwardhan, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasudeva, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, G. K.</span></span> <span> </span><span class="NLM_article-title">MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">395</span>– <span class="NLM_lpage">406</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-14-0711</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1158%2F1535-7163.MCT-14-0711" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=25519700" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=395-406&author=E.+K.+Slotkinauthor=P.+P.+Patwardhanauthor=S.+D.+Vasudevaauthor=E.+de+Stanchinaauthor=W.+D.+Tapauthor=G.+K.+Schwartz&title=MLN0128%2C+an+ATP-competitive+mTOR+kinase+inhibitor+with+potent+in+vitro+and+in+vivo+antitumor+activity%2C+as+potential+therapy+for+bone+and+soft-tissue+sarcoma&doi=10.1158%2F1535-7163.mct-14-0711"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">MLN0128, an ATP-Competitive mTOR Kinase Inhibitor with Potent In Vitro and In Vivo Antitumor Activity, as Potential Therapy for Bone and Soft-Tissue Sarcoma</span></div><div class="casAuthors">Slotkin, Emily K.; Patwardhan, Parag P.; Vasudeva, Shyamprasad D.; de Stanchina, Elisa; Tap, William D.; Schwartz, Gary K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">395-406</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that exists in two complexes (mTORC1 and mTORC2) and integrates extracellular and intracellular signals to act as a master regulator of cell growth, survival, and metab.  The PI3K/AKT/mTOR prosurvival pathway is often dysregulated in multiple sarcoma subtypes.  First-generation allosteric inhibitors of mTORC1 (rapalogues) have been extensively tested with great preclin. promise, but have had limited clin. utility.  Here, we report that MLN0128, a second-generation, ATP-competitive, pan-mTOR kinase inhibitor, acts on both mTORC1 and mTORC2 and has potent in vitro and in vivo antitumor activity in multiple sarcoma subtypes.  In vitro, MLN0128 inhibits mTORC1/2 targets in a concn.-dependent fashion and shows striking antiproliferative effect in rhabdomyosarcoma (RMS), Ewing sarcoma, malignant peripheral nerve sheath tumor, synovial sarcoma, osteosarcoma, and liposarcoma.  Unlike rapamycin, MLN0128 inhibits phosphorylation of 4EBP1 and NDRG1 as well as prevents the reactivation of pAKT that occurs via neg. feedback release with mTORC1 inhibition alone.  In xenograft models, MLN0128 treatment results in suppression of tumor growth with two dosing schedules (1 mg/kg daily and 3 mg/kg b.i.d. t.i.w.).  At the 3 mg/kg dosing schedule, MLN0128 treatment results in significantly better tumor growth suppression than rapamycin in RMS and Ewing sarcoma models.  In addn., MLN0128 induces apoptosis in models of RMS both in vitro and in vivo.  Results from our study strongly suggest that MLN0128 treatment should be explored further as potential therapy for sarcoma.  Mol Cancer Ther; 14(2); 395-406. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2RbwSW4yjmLVg90H21EOLACvtfcHk0li577_phRoqAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitlOjsbo%253D&md5=7c1d867aae6e5ca99c63b554295a539a</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-0711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-0711%26sid%3Dliteratum%253Aachs%26aulast%3DSlotkin%26aufirst%3DE.%2BK.%26aulast%3DPatwardhan%26aufirst%3DP.%2BP.%26aulast%3DVasudeva%26aufirst%3DS.%2BD.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DSchwartz%26aufirst%3DG.%2BK.%26atitle%3DMLN0128%252C%2520an%2520ATP-competitive%2520mTOR%2520kinase%2520inhibitor%2520with%2520potent%2520in%2520vitro%2520and%2520in%2520vivo%2520antitumor%2520activity%252C%2520as%2520potential%2520therapy%2520for%2520bone%2520and%2520soft-tissue%2520sarcoma%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D395%26epage%3D406%26doi%3D10.1158%2F1535-7163.mct-14-0711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pike, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malagu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hummersone, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menear, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duggan, H. M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N. M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruston, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pass, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1212</span>– <span class="NLM_lpage">1216</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2013.01.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.bmcl.2013.01.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=23375793" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFajs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=1212-1216&author=K.+G.+Pikeauthor=K.+Malaguauthor=M.+G.+Hummersoneauthor=K.+A.+Menearauthor=H.+M.+E.+Dugganauthor=S.+Gomezauthor=N.+M.+B.+Martinauthor=L.+Rustonauthor=S.+L.+Passauthor=M.+Pass&title=Optimization+of+potent+and+selective+dual+mTORC1+and+mTORC2+inhibitors%3A+the+discovery+of+AZD8055+and+AZD2014&doi=10.1016%2Fj.bmcl.2013.01.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014</span></div><div class="casAuthors">Pike, Kurt G.; Malagu, Karine; Hummersone, Marc G.; Menear, Keith A.; Duggan, Heather M. E.; Gomez, Sylvie; Martin, Niall M. B.; Ruston, Linette; Pass, Sarah L.; Pass, Martin</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1212-1216</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The optimization of a potent and highly selective series of dual mTORC1 and mTORC2 inhibitors is described.  An initial focus on improving cellular potency while maintaining or improving other key parameters, such as aq. soly. and margins over hERG IC50, led to the discovery of the clin. candidate AZD8055.  Further optimization, particularly aimed at reducing the rate of metab. in human hepatocyte incubations, resulted in the discovery of the clin. candidate AZD2014.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo07emMEKp9mrVg90H21EOLACvtfcHk0lgvAvCnRuPl6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFajs7c%253D&md5=325cb45f84bb4357005315ab3b27c0aa</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.01.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.01.019%26sid%3Dliteratum%253Aachs%26aulast%3DPike%26aufirst%3DK.%2BG.%26aulast%3DMalagu%26aufirst%3DK.%26aulast%3DHummersone%26aufirst%3DM.%2BG.%26aulast%3DMenear%26aufirst%3DK.%2BA.%26aulast%3DDuggan%26aufirst%3DH.%2BM.%2BE.%26aulast%3DGomez%26aufirst%3DS.%26aulast%3DMartin%26aufirst%3DN.%2BM.%2BB.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DPass%26aufirst%3DS.%2BL.%26aulast%3DPass%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520potent%2520and%2520selective%2520dual%2520mTORC1%2520and%2520mTORC2%2520inhibitors%253A%2520the%2520discovery%2520of%2520AZD8055%2520and%2520AZD2014%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D1212%26epage%3D1216%26doi%3D10.1016%2Fj.bmcl.2013.01.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löscher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Discovery and preclinical characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoro methyl)pyridin-2-amine (PQR620), a highly potent and selective mTORC1/2 inhibitor for cancer and neurological disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">10084</span>– <span class="NLM_lpage">10105</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01262</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01262" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=10084-10105&author=D.+Rageotauthor=T.+Bohnackerauthor=A.+Meloneauthor=J.-B.+Langloisauthor=C.+Borsariauthor=P.+Hillmannauthor=A.+M.+Seleauthor=F.+Beaufilsauthor=M.+Zvelebilauthor=P.+Hebeisenauthor=W.+L%C3%B6scherauthor=J.+Burkeauthor=D.+Fabbroauthor=M.+P.+Wymann&title=Discovery+and+preclinical+characterization+of+5-%5B4%2C6-Bis%28%7B3-oxa-8-azabicyclo%5B3.2.1%5Doctan-8-yl%7D%29-1%2C3%2C5-triazin-2-yl%5D-4-%28difluoro+methyl%29pyridin-2-amine+%28PQR620%29%2C+a+highly+potent+and+selective+mTORC1%2F2+inhibitor+for+cancer+and+neurological+disorders&doi=10.1021%2Facs.jmedchem.8b01262"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders</span></div><div class="casAuthors">Rageot, Denise; Bohnacker, Thomas; Melone, Anna; Langlois, Jean-Baptiste; Borsari, Chiara; Hillmann, Petra; Sele, Alexander M.; Beaufils, Florent; Zvelebil, Marketa; Hebeisen, Paul; Loscher, Wolfgang; Burke, John; Fabbro, Doriano; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10084-10105</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Mechanistic target of rapamycin (mTOR) promotes cell proliferation, growth, and survival and is overactivated in many tumors and central nervous system disorders.  I is a novel, potent, selective, and brain penetrable inhibitor of mTORC1/2 kinase.  I showed excellent selectivity for mTOR over PI3K and protein kinases and efficiently prevented cancer cell growth in a 66 cancer cell line panel.  In C57BL/6J and Sprague-Dawley mice, max. concn. (Cmax) in plasma and brain was reached after 30 min, with a half-life (t1/2) > 5 h.  In an ovarian carcinoma mouse xenograft model (OVCAR-3), daily dosing of I inhibited tumor growth significantly.  Moreover, I attenuated epileptic seizures in a tuberous sclerosis complex (TSC) mouse model.  In conclusion, I inhibits mTOR kinase potently and selectively, shows antitumor effects in vitro and in vivo, and promises advantages in CNS indications due to its brain/plasma distribution ratio.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodTlRg0fJo97Vg90H21EOLACvtfcHk0lgvAvCnRuPl6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvF2mtLjO&md5=e6ebf8147d6ba041285eb6538ade46ab</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01262&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01262%26sid%3Dliteratum%253Aachs%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DLanglois%26aufirst%3DJ.-B.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26aulast%3DBurke%26aufirst%3DJ.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDiscovery%2520and%2520preclinical%2520characterization%2520of%25205-%255B4%252C6-Bis%2528%257B3-oxa-8-azabicyclo%255B3.2.1%255Doctan-8-yl%257D%2529-1%252C3%252C5-triazin-2-yl%255D-4-%2528difluoro%2520methyl%2529pyridin-2-amine%2520%2528PQR620%2529%252C%2520a%2520highly%2520potent%2520and%2520selective%2520mTORC1%252F2%2520inhibitor%2520for%2520cancer%2520and%2520neurological%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D10084%26epage%3D10105%26doi%3D10.1021%2Facs.jmedchem.8b01262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dall’Asen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlois, J.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">A conformational restriction strategy for the identification of a highly selective pyrimido-pyrrolo-oxazine mTOR inhibitor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">8609</span>– <span class="NLM_lpage">8630</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00972</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00972" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1yhsb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=8609-8630&author=C.+Borsariauthor=D.+Rageotauthor=A.+Dall%E2%80%99Asenauthor=T.+Bohnackerauthor=A.+Meloneauthor=A.+M.+Seleauthor=E.+Jacksonauthor=J.-B.+Langloisauthor=F.+Beaufilsauthor=P.+Hebeisenauthor=D.+Fabbroauthor=P.+Hillmannauthor=M.+P.+Wymann&title=A+conformational+restriction+strategy+for+the+identification+of+a+highly+selective+pyrimido-pyrrolo-oxazine+mTOR+inhibitor&doi=10.1021%2Facs.jmedchem.9b00972"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor</span></div><div class="casAuthors">Borsari, Chiara; Rageot, Denise; Dall'Asen, Alix; Bohnacker, Thomas; Melone, Anna; Sele, Alexander M.; Jackson, Eileen; Langlois, Jean-Baptiste; Beaufils, Florent; Hebeisen, Paul; Fabbro, Doriano; Hillmann, Petra; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8609-8630</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment.  ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivs. in a wide range of malignancies.  Herein, we exploit a conformational restriction approach to explore a novel chem. space for the generation of TORKi.  Structure-activity relationship (SAR) studies led to the identification of compd. 12b with a ∼450-fold selectivity for mTOR over class I PI3K isoforms.  Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a min. brain penetration.  CYP450 reactive phenotyping pointed out the high metabolic stability of 12b.  These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpkugVOj5N6vbVg90H21EOLACvtfcHk0lgFwAIPBcYPHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1yhsb3K&md5=5d2e9a5f28628f1a0a5ae43b10a3d680</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00972&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00972%26sid%3Dliteratum%253Aachs%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DDall%25E2%2580%2599Asen%26aufirst%3DA.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DJackson%26aufirst%3DE.%26aulast%3DLanglois%26aufirst%3DJ.-B.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DA%2520conformational%2520restriction%2520strategy%2520for%2520the%2520identification%2520of%2520a%2520highly%2520selective%2520pyrimido-pyrrolo-oxazine%2520mTOR%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D8609%26epage%3D8630%26doi%3D10.1021%2Facs.jmedchem.9b00972" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bonazzi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goold, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomsen, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biag, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubicka, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labbe-Giguere, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keaney, E. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTighe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piizzi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lombardo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burdette, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodart, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peukert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curtis, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamann, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, L. O.</span></span> <span> </span><span class="NLM_article-title">Discovery of a brain-penetrant ATP-competitive inhibitor of the mechanistic target of rapamycin (mTOR) for CNS disorders</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">1068</span>– <span class="NLM_lpage">1083</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01398</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01398" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1CktLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=1068-1083&author=S.+Bonazziauthor=C.+P.+Gooldauthor=A.+Grayauthor=N.+M.+Thomsenauthor=J.+Nunezauthor=R.+G.+Karkiauthor=A.+Gordeauthor=J.+D.+Biagauthor=H.+A.+Malikauthor=Y.+Sunauthor=G.+Liangauthor=D.+Lubickaauthor=S.+Salasauthor=N.+Labbe-Giguereauthor=E.+P.+Keaneyauthor=S.+McTigheauthor=S.+Liuauthor=L.+Dengauthor=G.+Piizziauthor=F.+Lombardoauthor=D.+Burdetteauthor=J.-C.+Dodartauthor=C.+J.+Wilsonauthor=S.+Peukertauthor=D.+Curtisauthor=L.+G.+Hamannauthor=L.+O.+Murphy&title=Discovery+of+a+brain-penetrant+ATP-competitive+inhibitor+of+the+mechanistic+target+of+rapamycin+%28mTOR%29+for+CNS+disorders&doi=10.1021%2Facs.jmedchem.9b01398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Brain-Penetrant ATP-Competitive Inhibitor of the Mechanistic Target of Rapamycin (mTOR) for CNS Disorders</span></div><div class="casAuthors">Bonazzi, Simone; Goold, Carleton P.; Gray, Audrey; Thomsen, Noel M.; Nunez, Jill; Karki, Rajeshri G.; Gorde, Aakruti; Biag, Jonathan D.; Malik, Hasnain A.; Sun, Yingchuan; Liang, Guiqing; Lubicka, Danuta; Salas, Sarah; Labbe-Giguere, Nancy; Keaney, Erin P.; McTighe, Stephanie; Liu, Shanming; Deng, Lin; Piizzi, Grazia; Lombardo, Franco; Burdette, Doug; Dodart, Jean-Cosme; Wilson, Christopher J.; Peukert, Stefan; Curtis, Daniel; Hamann, Lawrence G.; Murphy, Leon O.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1068-1083</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Recent clin. evaluation of everolimus for seizure redn. in patients with tuberous sclerosis complex (TSC), a disease with overactivated mechanistic target of rapamycin (mTOR) signaling, has demonstrated the therapeutic value of mTOR inhibitors for central nervous system (CNS) indications.  Given that everolimus is an incomplete inhibitor of the mTOR function, we sought to develop a new mTOR inhibitor that has improved properties and is suitable for CNS disorders.  Starting from an inhouse purine-based compd., optimization of the physicochem. properties of a thiazolopyrimidine series led to the discovery of the small mol. 7, a potent and selective brain-penetrant ATP-competitive mTOR inhibitor.  In neuronal cell-based models of mTOR hyperactivity, 7 cor. the mTOR pathway activity and the resulting neuronal overgrowth phenotype.  The new mTOR inhibitor 7 showed good brain exposure and significantly improved the survival rate of mice with neuronal-specific ablation of the Tsc1 gene.  These results demonstrate the potential utility of this tool compd. to test therapeutic hypotheses that depend on mTOR hyperactivity in the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjXE6Yj_MC27Vg90H21EOLACvtfcHk0lgFwAIPBcYPHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1CktLo%253D&md5=d52546d7050d5e45b4fd241506004ef1</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01398%26sid%3Dliteratum%253Aachs%26aulast%3DBonazzi%26aufirst%3DS.%26aulast%3DGoold%26aufirst%3DC.%2BP.%26aulast%3DGray%26aufirst%3DA.%26aulast%3DThomsen%26aufirst%3DN.%2BM.%26aulast%3DNunez%26aufirst%3DJ.%26aulast%3DKarki%26aufirst%3DR.%2BG.%26aulast%3DGorde%26aufirst%3DA.%26aulast%3DBiag%26aufirst%3DJ.%2BD.%26aulast%3DMalik%26aufirst%3DH.%2BA.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DLiang%26aufirst%3DG.%26aulast%3DLubicka%26aufirst%3DD.%26aulast%3DSalas%26aufirst%3DS.%26aulast%3DLabbe-Giguere%26aufirst%3DN.%26aulast%3DKeaney%26aufirst%3DE.%2BP.%26aulast%3DMcTighe%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DDeng%26aufirst%3DL.%26aulast%3DPiizzi%26aufirst%3DG.%26aulast%3DLombardo%26aufirst%3DF.%26aulast%3DBurdette%26aufirst%3DD.%26aulast%3DDodart%26aufirst%3DJ.-C.%26aulast%3DWilson%26aufirst%3DC.%2BJ.%26aulast%3DPeukert%26aufirst%3DS.%26aulast%3DCurtis%26aufirst%3DD.%26aulast%3DHamann%26aufirst%3DL.%2BG.%26aulast%3DMurphy%26aufirst%3DL.%2BO.%26atitle%3DDiscovery%2520of%2520a%2520brain-penetrant%2520ATP-competitive%2520inhibitor%2520of%2520the%2520mechanistic%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520for%2520CNS%2520disorders%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D1068%26epage%3D1083%26doi%3D10.1021%2Facs.jmedchem.9b01398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prota, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inglis, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bargsten, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aher, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akhmanova, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diaz, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmetz, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Deconvolution of Buparlisib’s mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14683</span>, <span class="refDoi"> DOI: 10.1038/ncomms14683</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fncomms14683" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=28276440" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14683&author=T.+Bohnackerauthor=A.+E.+Protaauthor=F.+Beaufilsauthor=J.+E.+Burkeauthor=A.+Meloneauthor=A.+J.+Inglisauthor=D.+Rageotauthor=A.+M.+Seleauthor=V.+Cmiljanovicauthor=N.+Cmiljanovicauthor=K.+Bargstenauthor=A.+Aherauthor=A.+Akhmanovaauthor=J.+F.+Diazauthor=D.+Fabbroauthor=M.+Zvelebilauthor=R.+L.+Williamsauthor=M.+O.+Steinmetzauthor=M.+P.+Wymann&title=Deconvolution+of+Buparlisib%E2%80%99s+mechanism+of+action+defines+specific+PI3K+and+tubulin+inhibitors+for+therapeutic+intervention&doi=10.1038%2Fncomms14683"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Deconvolution of Buparlisib's mechanism of action defines specific PI3K and tubulin inhibitors for therapeutic intervention</span></div><div class="casAuthors">Bohnacker Thomas; Beaufils Florent; Melone Anna; Rageot Denise; Sele Alexander M; Cmiljanovic Vladimir; Cmiljanovic Natasa; Wymann Matthias P; Prota Andrea E; Bargsten Katja; Steinmetz Michel O; Burke John E; Inglis Alison J; Williams Roger L; Aher Amol; Akhmanova Anna; Diaz J Fernando; Fabbro Doriano; Zvelebil Marketa</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14683</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BKM120 (Buparlisib) is one of the most advanced phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer, but it interferes as an off-target effect with microtubule polymerization.  Here, we developed two chemical derivatives that differ from BKM120 by only one atom.  We show that these minute changes separate the dual activity of BKM120 into discrete PI3K and tubulin inhibitors.  Analysis of the compounds cellular growth arrest phenotypes and microtubule dynamics suggest that the antiproliferative activity of BKM120 is mainly due to microtubule-dependent cytotoxicity rather than through inhibition of PI3K.  Crystal structures of BKM120 and derivatives in complex with tubulin and PI3K provide insights into the selective mode of action of this class of drugs.  Our results raise concerns over BKM120's generally accepted mode of action, and provide a unique mechanistic basis for next-generation PI3K inhibitors with improved safety profiles and flexibility for use in combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRzPPj8gFbG6HWEEzDrymxmfW6udTcc2eaRKOZpwKR1S7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1czksV2ruw%253D%253D&md5=97d27a7d83bf6ab6094a587565f82bf6</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fncomms14683&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14683%26sid%3Dliteratum%253Aachs%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DProta%26aufirst%3DA.%2BE.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DInglis%26aufirst%3DA.%2BJ.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DBargsten%26aufirst%3DK.%26aulast%3DAher%26aufirst%3DA.%26aulast%3DAkhmanova%26aufirst%3DA.%26aulast%3DDiaz%26aufirst%3DJ.%2BF.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DSteinmetz%26aufirst%3DM.%2BO.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DDeconvolution%2520of%2520Buparlisib%25E2%2580%2599s%2520mechanism%2520of%2520action%2520defines%2520specific%2520PI3K%2520and%2520tubulin%2520inhibitors%2520for%2520therapeutic%2520intervention%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14683%26doi%3D10.1038%2Fncomms14683" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jackson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mestan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvelebil, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K/mTOR inhibitor as clinical candidate in oncology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>60</i></span>,  <span class="NLM_fpage">7524</span>– <span class="NLM_lpage">7538</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b00930</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b00930" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2017&pages=7524-7538&author=F.+Beaufilsauthor=N.+Cmiljanovicauthor=V.+Cmiljanovicauthor=T.+Bohnackerauthor=A.+Meloneauthor=R.+Maroneauthor=E.+Jacksonauthor=X.+Zhangauthor=A.+Seleauthor=C.+Borsariauthor=J.+Mestanauthor=P.+Hebeisenauthor=P.+Hillmannauthor=B.+Gieseauthor=M.+Zvelebilauthor=D.+Fabbroauthor=R.+L.+Williamsauthor=D.+Rageotauthor=M.+P.+Wymann&title=5-%284%2C6-Dimorpholino-1%2C3%2C5-triazin-2-yl%29-4-%28trifluoromethyl%29pyridin-2-amine+%28PQR309%29%2C+a+potent%2C+brain-penetrant%2C+orally+bioavailable%2C+pan-class+I+PI3K%2FmTOR+inhibitor+as+clinical+candidate+in+oncology&doi=10.1021%2Facs.jmedchem.7b00930"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology</span></div><div class="casAuthors">Beaufils, Florent; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Bohnacker, Thomas; Melone, Anna; Marone, Romina; Jackson, Eileen; Zhang, Xuxiao; Sele, Alexander; Borsari, Chiara; Mestan, Jurgen; Hebeisen, Paul; Hillmann, Petra; Giese, Bernd; Zvelebil, Marketa; Fabbro, Doriano; Williams, Roger L.; Rageot, Denise; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7524-7538</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide 3-kinase (PI3K) is deregulated in a wide variety of human tumors and triggers activation of protein kinase B (PKB/Akt) and mammalian target of rapamycin (mTOR).  Here we describe the preclin. characterization of compd. 1 (PQR309, bimiralisib), a potent 4,6-dimorpholino-1,3,5-triazine-based pan-class I PI3K inhibitor, which targets mTOR kinase in a balanced fashion at higher concns.  No off-target interactions were detected for 1 in a wide panel of protein kinase, enzyme, and receptor ligand assays.  Moreover, 1 did not bind tubulin, which was obsd. for the structurally related 4 (BKM120, buparlisib).  Compd. 1 is orally available, crosses the blood-brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs.  Compd. 1 demonstrated efficiency in inhibiting proliferation in tumor cell lines and a rat xenograft model.  This, together with the compd.'s safety profile, identifies 1 as a clin. candidate with a broad application range in oncol., including treatment of brain tumors or CNS metastasis.  Compd. 1 is currently in phase II clin. trials for advanced solid tumors and refractory lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtvYAarVqsarVg90H21EOLACvtfcHk0ligptmhmsIYnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtlKhurrP&md5=54d4db75f6a8bda3f12eaf1d196352fd</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b00930&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b00930%26sid%3Dliteratum%253Aachs%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DCmiljanovic%26aufirst%3DN.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DJackson%26aufirst%3DE.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DSele%26aufirst%3DA.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DMestan%26aufirst%3DJ.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DGiese%26aufirst%3DB.%26aulast%3DZvelebil%26aufirst%3DM.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DR.%2BL.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3D5-%25284%252C6-Dimorpholino-1%252C3%252C5-triazin-2-yl%2529-4-%2528trifluoromethyl%2529pyridin-2-amine%2520%2528PQR309%2529%252C%2520a%2520potent%252C%2520brain-penetrant%252C%2520orally%2520bioavailable%252C%2520pan-class%2520I%2520PI3K%252FmTOR%2520inhibitor%2520as%2520clinical%2520candidate%2520in%2520oncology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2017%26volume%3D60%26spage%3D7524%26epage%3D7538%26doi%3D10.1021%2Facs.jmedchem.7b00930" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarantelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arribas, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinaldi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernasconi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidetti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrassa, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittau, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritschard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dossena, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, F. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucchetto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taborelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gattei, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stathis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stussi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Broggini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, F.</span></span> <span> </span><span class="NLM_article-title">PQR309 is a novel dual PI3K/mTOR inhibitor with preclinical antitumor activity in lymphomas as a single agent and in combination therapy</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">120</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.ccr-17-1041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1158%2F1078-0432.CCR-17-1041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=29066507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVWktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=120-129&author=C.+Tarantelliauthor=E.+Gaudioauthor=A.+J.+Arribasauthor=I.+Kweeauthor=P.+Hillmannauthor=A.+Rinaldiauthor=L.+Cascioneauthor=F.+Sprianoauthor=E.+Bernasconiauthor=F.+Guidettiauthor=L.+Carrassaauthor=R.+B.+Pittauauthor=F.+Beaufilsauthor=R.+Ritschardauthor=D.+Rageotauthor=A.+Seleauthor=B.+Dossenaauthor=F.+M.+Rossiauthor=A.+Zucchettoauthor=M.+Taborelliauthor=V.+Gatteiauthor=D.+Rossiauthor=A.+Stathisauthor=G.+Stussiauthor=M.+Brogginiauthor=M.+P.+Wymannauthor=A.+Wickiauthor=E.+Zuccaauthor=V.+Cmiljanovicauthor=D.+Fabbroauthor=F.+Bertoni&title=PQR309+is+a+novel+dual+PI3K%2FmTOR+inhibitor+with+preclinical+antitumor+activity+in+lymphomas+as+a+single+agent+and+in+combination+therapy&doi=10.1158%2F1078-0432.ccr-17-1041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy</span></div><div class="casAuthors">Tarantelli, Chiara; Gaudio, Eugenio; Arribas, Alberto J.; Kwee, Ivo; Hillmann, Petra; Rinaldi, Andrea; Cascione, Luciano; Spriano, Filippo; Bernasconi, Elena; Guidetti, Francesca; Carrassa, Laura; Pittau, Roberta Bordone; Beaufils, Florent; Ritschard, Reto; Rageot, Denise; Sele, Alexander; Dossena, Barbara; Rossi, Francesca Maria; Zucchetto, Antonella; Taborelli, Monica; Gattei, Valter; Rossi, Davide; Stathis, Anastasios; Stussi, Georg; Broggini, Massimo; Wymann, Matthias P.; Wicki, Andreas; Zucca, Emanuele; Cmiljanovic, Vladimir; Fabbro, Doriano; Bertoni, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">120-129</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Activation of the PI3K/mTOR signaling pathway is recurrent in different lymphoma types, and pharmacol. inhibition of the PI3K/mTOR pathway has shown activity in lymphoma patients.  Here, we extensively characterized the in vitro and in vivo activity and the mechanism of action of PQR309 (bimiralisib), a novel oral selective dual PI3K/mTOR inhibitor under clin. evaluation, in preclin. lymphoma models.  Exptl. Design: This study included preclin. in vitro activity screening on a large panel of cell lines, both as single agent and in combination, validation expts. on in vivo models and primary cells, proteomics and gene-expression profiling, and comparison with other signaling inhibitors.  Results: PQR309 had in vitro antilymphoma activity as single agent and in combination with venetoclax, panobinostat, ibrutinib, lenalidomide, ARV-825, marizomib, and rituximab.  Sensitivity to PQR309 was assocd. with specific baseline gene-expression features, such as high expression of transcripts coding for the BCR pathway.  Combining proteomics and RNA profiling, we identified the different contribution of PQR309-induced protein phosphorylation and gene expression changes to the drug mechanism of action.  Gene-expression signatures induced by PQR309 and by other signaling inhibitors largely overlapped.  PQR309 showed activity in cells with primary or secondary resistance to idelalisib.  Conclusions: On the basis of these results, PQR309 appeared as a novel and promising compd. that is worth developing in the lymphoma setting.  Clin Cancer Res; 24(1); 120-9. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEmEWXHaG3ObVg90H21EOLACvtfcHk0ligptmhmsIYnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVWktw%253D%253D&md5=730305c33b7f669b0eedd0614edd886c</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-1041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-1041%26sid%3Dliteratum%253Aachs%26aulast%3DTarantelli%26aufirst%3DC.%26aulast%3DGaudio%26aufirst%3DE.%26aulast%3DArribas%26aufirst%3DA.%2BJ.%26aulast%3DKwee%26aufirst%3DI.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DRinaldi%26aufirst%3DA.%26aulast%3DCascione%26aufirst%3DL.%26aulast%3DSpriano%26aufirst%3DF.%26aulast%3DBernasconi%26aufirst%3DE.%26aulast%3DGuidetti%26aufirst%3DF.%26aulast%3DCarrassa%26aufirst%3DL.%26aulast%3DPittau%26aufirst%3DR.%2BB.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DRitschard%26aufirst%3DR.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DSele%26aufirst%3DA.%26aulast%3DDossena%26aufirst%3DB.%26aulast%3DRossi%26aufirst%3DF.%2BM.%26aulast%3DZucchetto%26aufirst%3DA.%26aulast%3DTaborelli%26aufirst%3DM.%26aulast%3DGattei%26aufirst%3DV.%26aulast%3DRossi%26aufirst%3DD.%26aulast%3DStathis%26aufirst%3DA.%26aulast%3DStussi%26aufirst%3DG.%26aulast%3DBroggini%26aufirst%3DM.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DWicki%26aufirst%3DA.%26aulast%3DZucca%26aufirst%3DE.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DBertoni%26aufirst%3DF.%26atitle%3DPQR309%2520is%2520a%2520novel%2520dual%2520PI3K%252FmTOR%2520inhibitor%2520with%2520preclinical%2520antitumor%2520activity%2520in%2520lymphomas%2520as%2520a%2520single%2520agent%2520and%2520in%2520combination%2520therapy%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D120%26epage%3D129%26doi%3D10.1158%2F1078-0432.ccr-17-1041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keles, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buslov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Preclinical development of PQR514, a highly potent PI3K inhibitor bearing a difluoromethyl-pyrimidine moiety</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1473</span>– <span class="NLM_lpage">1479</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00333</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00333" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslSqtrzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1473-1479&author=C.+Borsariauthor=D.+Rageotauthor=F.+Beaufilsauthor=T.+Bohnackerauthor=E.+Kelesauthor=I.+Buslovauthor=A.+Meloneauthor=A.+M.+Seleauthor=P.+Hebeisenauthor=D.+Fabbroauthor=P.+Hillmannauthor=M.+P.+Wymann&title=Preclinical+development+of+PQR514%2C+a+highly+potent+PI3K+inhibitor+bearing+a+difluoromethyl-pyrimidine+moiety&doi=10.1021%2Facsmedchemlett.9b00333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical Development of PQR514, a Highly Potent PI3K Inhibitor Bearing a Difluoromethyl-Pyrimidine Moiety</span></div><div class="casAuthors">Borsari, Chiara; Rageot, Denise; Beaufils, Florent; Bohnacker, Thomas; Keles, Erhan; Buslov, Ivan; Melone, Anna; Sele, Alexander M.; Hebeisen, Paul; Fabbro, Doriano; Hillmann, Petra; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1473-1479</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is a crit. regulator of cell growth and is frequently hyperactivated in cancer.  Therefore, PI3K inhibitors represent a valuable asset in cancer therapy.  Herein we have developed a novel anticancer agent, the potent pan-PI3K inhibitor PQR514 (4), which is a follow-up compd. for the phase-II clin. compd. PQR309 (1).  Compd. 4 has an improved potency both in vitro and in cellular assays with respect to its predecessor compds.  It shows superiority in the suppression of cancer cell proliferation and demonstrates significant antitumor activity in an OVCAR-3 xenograft model at concns. approx. eight times lower than PQR309 (1).  The favorable pharmacokinetic profile and a minimal brain penetration promote PQR514 (4) as an optimized candidate for the treatment of systemic tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2ogn0EPMIeLVg90H21EOLACvtfcHk0lhDs8xp_oJOQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslSqtrzP&md5=3423dce039aa5b68a178ecea264e6f1f</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00333%26sid%3Dliteratum%253Aachs%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DKeles%26aufirst%3DE.%26aulast%3DBuslov%26aufirst%3DI.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DPreclinical%2520development%2520of%2520PQR514%252C%2520a%2520highly%2520potent%2520PI3K%2520inhibitor%2520bearing%2520a%2520difluoromethyl-pyrimidine%2520moiety%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D10%26spage%3D1473%26epage%3D1479%26doi%3D10.1021%2Facsmedchemlett.9b00333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tarantelli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudio, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spriano, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sartori, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aresu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cascione, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zucca, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stathis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanovic, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertoni, F.</span></span> <span> </span><span class="NLM_article-title">The novel TORC1/2 kinase inhibitor PQR620 has anti-tumor activity in lymphomas as a single agent and in combination with venetoclax</span>. <i>Cancers</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">775</span>, <span class="refDoi"> DOI: 10.3390/cancers11060775</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.3390%2Fcancers11060775" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=31167506" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjtlGis7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=775&author=C.+Tarantelliauthor=E.+Gaudioauthor=P.+Hillmannauthor=F.+Sprianoauthor=G.+Sartoriauthor=L.+Aresuauthor=L.+Cascioneauthor=D.+Rageotauthor=I.+Kweeauthor=F.+Beaufilsauthor=E.+Zuccaauthor=A.+Stathisauthor=M.+P.+Wymannauthor=V.+Cmiljanovicauthor=D.+Fabbroauthor=F.+Bertoni&title=The+novel+TORC1%2F2+kinase+inhibitor+PQR620+has+anti-tumor+activity+in+lymphomas+as+a+single+agent+and+in+combination+with+venetoclax&doi=10.3390%2Fcancers11060775"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The novel TORC1/2 kinase inhibitor PQR620 has anti-tumor activity in lymphomas as a single agent and in combination with venetoclax</span></div><div class="casAuthors">Tarantelli, Chiara; Gaudio, Eugenio; Hillmann, Petra; Spriano, Filippo; Sartori, Giulio; Aresu, Luca; Cascione, Luciano; Rageot, Denise; Kwee, Ivo; Beaufils, Florent; Zucca, Emanuele; Stathis, Anastasios; Wymann, Matthias P.; Cmiljanovic, Vladimir; Fabbro, Doriano; Bertoni, Francesco</div><div class="citationInfo"><span class="NLM_cas:title">Cancers</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">775</span>CODEN:
                <span class="NLM_cas:coden">CANCCT</span>;
        ISSN:<span class="NLM_cas:issn">2072-6694</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling cascade is an important therapeutic target for lymphomas.  Rapamycin-derivates as allosteric mTOR complex 1 (TORC1) inhibitors have shown moderate preclin. and clin. anti-lymphoma activity.  Here, we assessed the anti-tumor activity of PQR620, a novel brain penetrant dual TORC1/2 inhibitor, in 56 lymphoma cell lines.  We obsd. anti-tumor activity across 56 lymphoma models with a median IC50 value of 250 nM after 72 h of exposure.  PQR620 was largely cytostatic, but the combination with the BCL2 inhibitor venetoclax led to cytotoxicity.  Both the single agent and the combination data were validated in xenograft models.  The data support further evaluation of PQR620 as a single agent or in combination with venetoclax.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4lC_3yR6dVLVg90H21EOLACvtfcHk0lhDs8xp_oJOQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjtlGis7w%253D&md5=3a21da65d4c9a2f8775f0e960aa4bbe5</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.3390%2Fcancers11060775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fcancers11060775%26sid%3Dliteratum%253Aachs%26aulast%3DTarantelli%26aufirst%3DC.%26aulast%3DGaudio%26aufirst%3DE.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DSpriano%26aufirst%3DF.%26aulast%3DSartori%26aufirst%3DG.%26aulast%3DAresu%26aufirst%3DL.%26aulast%3DCascione%26aufirst%3DL.%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DKwee%26aufirst%3DI.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DZucca%26aufirst%3DE.%26aulast%3DStathis%26aufirst%3DA.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DCmiljanovic%26aufirst%3DV.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DBertoni%26aufirst%3DF.%26atitle%3DThe%2520novel%2520TORC1%252F2%2520kinase%2520inhibitor%2520PQR620%2520has%2520anti-tumor%2520activity%2520in%2520lymphomas%2520as%2520a%2520single%2520agent%2520and%2520in%2520combination%2520with%2520venetoclax%26jtitle%3DCancers%26date%3D2019%26volume%3D11%26spage%3D775%26doi%3D10.3390%2Fcancers11060775" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venkatesan, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, O. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dehnhardt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayral-Kaloustian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallon, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feldberg, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhary, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansour, T. S.</span></span> <span> </span><span class="NLM_article-title">PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5869</span>– <span class="NLM_lpage">5873</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.07.104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.bmcl.2010.07.104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=20797855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFGnt7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5869-5873&author=A.+M.+Venkatesanauthor=Z.+Chenauthor=O.+D.+Santosauthor=C.+Dehnhardtauthor=E.+D.+Santosauthor=S.+Ayral-Kaloustianauthor=R.+Mallonauthor=I.+Hollanderauthor=L.+Feldbergauthor=J.+Lucasauthor=K.+Yuauthor=I.+Chaudharyauthor=T.+S.+Mansour&title=PKI-179%3A+An+orally+efficacious+dual+phosphatidylinositol-3-kinase+%28PI3K%29%2Fmammalian+target+of+rapamycin+%28mTOR%29+inhibitor&doi=10.1016%2Fj.bmcl.2010.07.104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor</span></div><div class="casAuthors">Venkatesan, Aranapakam M.; Chen, Zecheng; Dos Santos, Osvaldo; Dehnhardt, Christoph; Santos, Efren Delos; Ayral-Kaloustian, Semiramis; Mallon, Robert; Hollander, Irwin; Feldberg, Larry; Lucas, Judy; Yu, Ker; Chaudhary, Inder; Mansour, Tarek S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5869-5873</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of mono-morpholino 1,3,5-triazine derivs. bearing a 3-oxa-8-azabicyclo[3.2.1]octane were prepd. and evaluated for PI3-kinase/mTOR activity.  Replacing one of the bis-morpholines in lead compd. I (PKI-587) with 3-oxa-8-azabicyclo[3.2.1]octane and reducing the mol. wt. led to compd. II (PKI-179), an orally efficacious dual PI3-kinase/mTOR inhibitor.  The in vitro activity, in vivo efficacy, and PK properties of II are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry2Q6kBXC_prVg90H21EOLACvtfcHk0lhDs8xp_oJOQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFGnt7zK&md5=09729cdefa0fa05e890b02ce61607229</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.07.104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.07.104%26sid%3Dliteratum%253Aachs%26aulast%3DVenkatesan%26aufirst%3DA.%2BM.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSantos%26aufirst%3DO.%2BD.%26aulast%3DDehnhardt%26aufirst%3DC.%26aulast%3DSantos%26aufirst%3DE.%2BD.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DMallon%26aufirst%3DR.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DFeldberg%26aufirst%3DL.%26aulast%3DLucas%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DChaudhary%26aufirst%3DI.%26aulast%3DMansour%26aufirst%3DT.%2BS.%26atitle%3DPKI-179%253A%2520An%2520orally%2520efficacious%2520dual%2520phosphatidylinositol-3-kinase%2520%2528PI3K%2529%252Fmammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitor%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5869%26epage%3D5873%26doi%3D10.1016%2Fj.bmcl.2010.07.104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keles, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McPhail, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sriramaratnam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sele, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">( S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)p yridin-2-amine (PQR530), a potent, orally bioavailable, and brain-penetrable dual inhibitor of class I PI3K and mTOR kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">6241</span>– <span class="NLM_lpage">6261</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00525</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00525" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtFWgtLrM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=6241-6261&author=D.+Rageotauthor=T.+Bohnackerauthor=E.+Kelesauthor=J.+A.+McPhailauthor=R.+M.+Hoffmannauthor=A.+Meloneauthor=C.+Borsariauthor=R.+Sriramaratnamauthor=A.+M.+Seleauthor=F.+Beaufilsauthor=P.+Hebeisenauthor=D.+Fabbroauthor=P.+Hillmannauthor=J.+E.+Burkeauthor=M.+P.+Wymann&title=%28+S%29-4-%28Difluoromethyl%29-5-%284-%283-methylmorpholino%29-6-morpholino-1%2C3%2C5-triazin-2-yl%29p+yridin-2-amine+%28PQR530%29%2C+a+potent%2C+orally+bioavailable%2C+and+brain-penetrable+dual+inhibitor+of+class+I+PI3K+and+mTOR+kinase&doi=10.1021%2Facs.jmedchem.9b00525"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase</span></div><div class="casAuthors">Rageot, Denise; Bohnacker, Thomas; Keles, Erhan; McPhail, Jacob A.; Hoffmann, Reece M.; Melone, Anna; Borsari, Chiara; Sriramaratnam, Rohitha; Sele, Alexander M.; Beaufils, Florent; Hebeisen, Paul; Fabbro, Doriano; Hillmann, Petra; Burke, John E.; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6241-6261</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is frequently overactivated in cancer, and drives cell growth, proliferation, survival, and metastasis.  Here, we report a structure-activity relationship study, which led to the discovery of a drug-like ATP-site PI3K/mTOR kinase inhibitor: (S)-4-(difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530, compd. 6), which qualifies as a clin. candidate due to its potency and specificity for PI3K and mTOR kinases, and its pharmacokinetic properties, including brain penetration.  Compd. 6 showed excellent selectivity over a wide panel of kinases and an excellent selectivity against unrelated receptor enzymes and ion channels.  Moreover, compd. 6 prevented cell growth in a cancer cell line panel.  The preclin. in vivo characterization of compd. 6 in an OVCAR-3 xenograft model demonstrated good oral bioavailability, excellent brain penetration, and efficacy.  Initial toxicity studies in rats and dogs qualify 6 for further development as a therapeutic agent in oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8pi-7DrRAPLVg90H21EOLACvtfcHk0ljECj9sxOxtHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtFWgtLrM&md5=48e0d98bf33ad5c98a1911b82bcccf03</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00525%26sid%3Dliteratum%253Aachs%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DKeles%26aufirst%3DE.%26aulast%3DMcPhail%26aufirst%3DJ.%2BA.%26aulast%3DHoffmann%26aufirst%3DR.%2BM.%26aulast%3DMelone%26aufirst%3DA.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DSriramaratnam%26aufirst%3DR.%26aulast%3DSele%26aufirst%3DA.%2BM.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DBurke%26aufirst%3DJ.%2BE.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3D%2528%2520S%2529-4-%2528Difluoromethyl%2529-5-%25284-%25283-methylmorpholino%2529-6-morpholino-1%252C3%252C5-triazin-2-yl%2529p%2520yridin-2-amine%2520%2528PQR530%2529%252C%2520a%2520potent%252C%2520orally%2520bioavailable%252C%2520and%2520brain-penetrable%2520dual%2520inhibitor%2520of%2520class%2520I%2520PI3K%2520and%2520mTOR%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D6241%26epage%3D6261%26doi%3D10.1021%2Facs.jmedchem.9b00525" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zask, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaplan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheijen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curran, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brooijmans, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toral-Barza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollander, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ayral-Kaloustian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span> <span> </span><span class="NLM_article-title">Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">7942</span>– <span class="NLM_lpage">7945</span>, <span class="refDoi"> DOI: 10.1021/jm901415x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901415x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=7942-7945&author=A.+Zaskauthor=J.+Kaplanauthor=J.+C.+Verheijenauthor=D.+J.+Richardauthor=K.+Curranauthor=N.+Brooijmansauthor=E.+M.+Bennettauthor=L.+Toral-Barzaauthor=I.+Hollanderauthor=S.+Ayral-Kaloustianauthor=K.+Yu&title=Morpholine+derivatives+greatly+enhance+the+selectivity+of+mammalian+target+of+rapamycin+%28mTOR%29+inhibitors&doi=10.1021%2Fjm901415x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Morpholine Derivatives Greatly Enhance the Selectivity of Mammalian Target of Rapamycin (mTOR) Inhibitors</span></div><div class="casAuthors">Zask, Arie; Kaplan, Joshua; Verheijen, Jeroen C.; Richard, David J.; Curran, Kevin; Brooijmans, Natasja; Bennett, Eric M.; Toral-Barza, Lourdes; Hollander, Irwin; Ayral-Kaloustian, Semiramis; Yu, Ker</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7942-7945</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dramatic improvements in mTOR-targeting selectivity were achieved by replacing morpholine in pyrazolopyrimidine inhibitors with bridged morpholines.  Analogs I [R1 = (R)- or (S)-3-methyl-4-morpholinyl, 2-methyl-4-morpholinyl, 8-oxa-3-azabicyclo[3.2.1]octan-3-yl, etc.; R2 = Me, Et, cyclopropyl, FCH2CH2, 3-pyridyl, 4-pyridyl; R3 = F3CCH2, 1-methoxycarbonyl-4-piperidinyl, 1-ethoxycarbonyl-4-piperidinyl, 3-pyridylmethyl] with subnanomolar mTOR IC50 values and up to 26000-fold selectivity vs. PI3Kα were prepd.  Chiral morpholines gave inhibitors whose enantiomers had different selectivity and potency profiles.  Mol. modeling suggests that a single amino acid difference between PI3K and mTOR (Phe961Leu) accounts for the profound selectivity seen by creating a deeper pocket in mTOR that can accommodate bridged morpholines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK2HnMHqTHqbVg90H21EOLACvtfcHk0ljECj9sxOxtHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVWrtb3J&md5=5ef1eee5aa79531970049d3d26b46eb2</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fjm901415x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901415x%26sid%3Dliteratum%253Aachs%26aulast%3DZask%26aufirst%3DA.%26aulast%3DKaplan%26aufirst%3DJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DCurran%26aufirst%3DK.%26aulast%3DBrooijmans%26aufirst%3DN.%26aulast%3DBennett%26aufirst%3DE.%2BM.%26aulast%3DToral-Barza%26aufirst%3DL.%26aulast%3DHollander%26aufirst%3DI.%26aulast%3DAyral-Kaloustian%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DK.%26atitle%3DMorpholine%2520derivatives%2520greatly%2520enhance%2520the%2520selectivity%2520of%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D7942%26epage%3D7945%26doi%3D10.1021%2Fjm901415x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bohnacker, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marone, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collmann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">PI3Kγ adaptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5)P<sub>3</sub> pools in mast cells</span>. <i>Sci. Signal.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">ra27</span>, <span class="refDoi"> DOI: 10.1126/scisignal.2000259</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1126%2Fscisignal.2000259" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=19509406" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2009&pages=ra27&author=T.+Bohnackerauthor=R.+Maroneauthor=E.+Collmannauthor=R.+Calvezauthor=E.+Hirschauthor=M.+P.+Wymann&title=PI3K%CE%B3+adaptor+subunits+define+coupling+to+degranulation+and+cell+motility+by+distinct+PtdIns%283%2C4%2C5%29P3+pools+in+mast+cells&doi=10.1126%2Fscisignal.2000259"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2000259&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2000259%26sid%3Dliteratum%253Aachs%26aulast%3DBohnacker%26aufirst%3DT.%26aulast%3DMarone%26aufirst%3DR.%26aulast%3DCollmann%26aufirst%3DE.%26aulast%3DCalvez%26aufirst%3DR.%26aulast%3DHirsch%26aufirst%3DE.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DPI3K%25CE%25B3%2520adaptor%2520subunits%2520define%2520coupling%2520to%2520degranulation%2520and%2520cell%2520motility%2520by%2520distinct%2520PtdIns%25283%252C4%252C5%2529P3%2520pools%2520in%2520mast%2520cells%26jtitle%3DSci.%2520Signal.%26date%3D2009%26volume%3D2%26spage%3Dra27%26doi%3D10.1126%2Fscisignal.2000259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Burger, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pecchi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendrickson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atallah, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pfister, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartulis, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frazier, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verhagen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haznedar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Menezes, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merritt, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiesmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaufman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bussiere, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shoemaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaror, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maira, S.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voliva, C. F.</span></span> <span> </span><span class="NLM_article-title">Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">774</span>– <span class="NLM_lpage">779</span>, <span class="refDoi"> DOI: 10.1021/ml200156t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200156t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=774-779&author=M.+T.+Burgerauthor=S.+Pecchiauthor=A.+Wagmanauthor=Z.-J.+Niauthor=M.+Knappauthor=T.+Hendricksonauthor=G.+Atallahauthor=K.+Pfisterauthor=Y.+Zhangauthor=S.+Bartulisauthor=K.+Frazierauthor=S.+Ngauthor=A.+Smithauthor=J.+Verhagenauthor=J.+Haznedarauthor=K.+Huhauthor=E.+Iwanowiczauthor=X.+Xinauthor=D.+Menezesauthor=H.+Merrittauthor=I.+Leeauthor=M.+Wiesmannauthor=S.+Kaufmanauthor=K.+Crawfordauthor=M.+Chinauthor=D.+Bussiereauthor=K.+Shoemakerauthor=I.+Zarorauthor=S.-M.+Mairaauthor=C.+F.+Voliva&title=Identification+of+NVP-BKM120+as+a+potent%2C+selective%2C+orally+bioavailable+class+I+PI3+kinase+inhibitor+for+treating+cancer&doi=10.1021%2Fml200156t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer</span></div><div class="casAuthors">Burger, Matthew T.; Pecchi, Sabina; Wagman, Allan; Ni, Zhi-Jie; Knapp, Mark; Hendrickson, Thomas; Atallah, Gordana; Pfister, Keith; Zhang, Yanchen; Bartulis, Sarah; Frazier, Kelly; Ng, Simon; Smith, Aaron; Verhagen, Joelle; Haznedar, Joshua; Huh, Kay; Iwanowicz, Ed; Xin, Xiaohua; Menezes, Daniel; Merritt, Hanne; Lee, Isabelle; Wiesmann, Marion; Kaufman, Susan; Crawford, Kenneth; Chin, Michael; Bussiere, Dirksen; Shoemaker, Kevin; Zaror, Isabel; Maira, Sauveur-Michel; Voliva, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">774-779</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinases (PI3Ks) are important oncol. targets due to the deregulation of this signaling pathway in a wide variety of human cancers.  Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-position heterocycle, and the overall druglike properties were fine-tuned further by modification of the 4-position substituent.  The resulting 2,4-bismorpholino 6-heterocyclic pyrimidines are potent class I PI3K inhibitors showing mechanism modulation in PI3K dependent cell lines and in vivo efficacy in tumor xenograft models with PI3K pathway deregulation (A2780 ovarian and U87MG glioma).  These efforts culminated in the discovery of 15 (NVP-BKM120), currently in Phase II clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzJ68B9pPbMbVg90H21EOLACvtfcHk0lgYBdRBQIkrPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVOktrrI&md5=5d00d73dda1fc0d8f0f07d12900282ed</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fml200156t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200156t%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DM.%2BT.%26aulast%3DPecchi%26aufirst%3DS.%26aulast%3DWagman%26aufirst%3DA.%26aulast%3DNi%26aufirst%3DZ.-J.%26aulast%3DKnapp%26aufirst%3DM.%26aulast%3DHendrickson%26aufirst%3DT.%26aulast%3DAtallah%26aufirst%3DG.%26aulast%3DPfister%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBartulis%26aufirst%3DS.%26aulast%3DFrazier%26aufirst%3DK.%26aulast%3DNg%26aufirst%3DS.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DVerhagen%26aufirst%3DJ.%26aulast%3DHaznedar%26aufirst%3DJ.%26aulast%3DHuh%26aufirst%3DK.%26aulast%3DIwanowicz%26aufirst%3DE.%26aulast%3DXin%26aufirst%3DX.%26aulast%3DMenezes%26aufirst%3DD.%26aulast%3DMerritt%26aufirst%3DH.%26aulast%3DLee%26aufirst%3DI.%26aulast%3DWiesmann%26aufirst%3DM.%26aulast%3DKaufman%26aufirst%3DS.%26aulast%3DCrawford%26aufirst%3DK.%26aulast%3DChin%26aufirst%3DM.%26aulast%3DBussiere%26aufirst%3DD.%26aulast%3DShoemaker%26aufirst%3DK.%26aulast%3DZaror%26aufirst%3DI.%26aulast%3DMaira%26aufirst%3DS.-M.%26aulast%3DVoliva%26aufirst%3DC.%2BF.%26atitle%3DIdentification%2520of%2520NVP-BKM120%2520as%2520a%2520potent%252C%2520selective%252C%2520orally%2520bioavailable%2520class%2520I%2520PI3%2520kinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D774%26epage%3D779%26doi%3D10.1021%2Fml200156t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Richard, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verheijen, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zask, A.</span></span> <span> </span><span class="NLM_article-title">Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kalpha</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">2654</span>– <span class="NLM_lpage">2657</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.02.029</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.bmcl.2010.02.029" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=20223664" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC3cXksVGntrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=2654-2657&author=D.+J.+Richardauthor=J.+C.+Verheijenauthor=K.+Yuauthor=A.+Zask&title=Triazines+incorporating+%28R%29-3-methylmorpholine+are+potent+inhibitors+of+the+mammalian+target+of+rapamycin+%28mTOR%29+with+selectivity+over+PI3Kalpha&doi=10.1016%2Fj.bmcl.2010.02.029"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Triazines incorporating (R)-3-methylmorpholine are potent inhibitors of the mammalian target of rapamycin (mTOR) with selectivity over PI3Kα</span></div><div class="casAuthors">Richard, David J.; Verheijen, Jeroen C.; Yu, Ker; Zask, Arie</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2654-2657</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Potent inhibitors of the mammalian target of rapamycin (mTOR) which contain the triazine scaffold and the (R)-3-Me morpholine moiety have been identified.  Such compds. also demonstrated good selectivity over the related lipid kinase PI3Kα.  Incorporation of addnl. functionality at the 4-position of the arylureidophenyl ring resulted in compds. with enhanced cellular activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfHbFQc9M8V7Vg90H21EOLACvtfcHk0lgYBdRBQIkrPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXksVGntrY%253D&md5=1091bba10aca6da4c6b5dd545b67e942</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.02.029%26sid%3Dliteratum%253Aachs%26aulast%3DRichard%26aufirst%3DD.%2BJ.%26aulast%3DVerheijen%26aufirst%3DJ.%2BC.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DZask%26aufirst%3DA.%26atitle%3DTriazines%2520incorporating%2520%2528R%2529-3-methylmorpholine%2520are%2520potent%2520inhibitors%2520of%2520the%2520mammalian%2520target%2520of%2520rapamycin%2520%2528mTOR%2529%2520with%2520selectivity%2520over%2520PI3Kalpha%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D2654%26epage%3D2657%26doi%3D10.1016%2Fj.bmcl.2010.02.029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, X.</span></span> <span> </span><span class="NLM_article-title">Targeting PI3K in cancer: mechanisms and advances in clinical trials</span>. <i>Mol. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">26</span>, <span class="refDoi"> DOI: 10.1186/s12943-019-0954-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1186%2Fs12943-019-0954-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=30782187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A280%3ADC%252BB3cflt1Kluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=26&author=J.+Yangauthor=J.+Nieauthor=X.+Maauthor=Y.+Weiauthor=Y.+Pengauthor=X.+Wei&title=Targeting+PI3K+in+cancer%3A+mechanisms+and+advances+in+clinical+trials&doi=10.1186%2Fs12943-019-0954-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting PI3K in cancer: mechanisms and advances in clinical trials</span></div><div class="casAuthors">Yang Jing; Nie Ji; Ma Xuelei; Wei Yuquan; Peng Yong; Wei Xiawei</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the most important intracellular pathways, which can be considered as a master regulator for cancer.  Enormous efforts have been dedicated to the development of drugs targeting PI3K signaling, many of which are currently employed in clinical trials evaluation, and it is becoming increasingly clear that PI3K inhibitors are effective in inhibiting tumor progression.  PI3K inhibitors are subdivided into dual PI3K/mTOR inhibitors, pan-PI3K inhibitors and isoform-specific inhibitors.  In this review, we performed a critical review to summarize the role of the PI3K pathway in tumor development, recent PI3K inhibitors development based on clinical trials, and the mechanisms of resistance to PI3K inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQGm3fFMcHFSMScOqQTSkOffW6udTcc2eYl9KvPraU96bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cflt1Kluw%253D%253D&md5=4267e4df49544ebe11ab4255e69e5bbe</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1186%2Fs12943-019-0954-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-019-0954-x%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DNie%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DWei%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DY.%26aulast%3DWei%26aufirst%3DX.%26atitle%3DTargeting%2520PI3K%2520in%2520cancer%253A%2520mechanisms%2520and%2520advances%2520in%2520clinical%2520trials%26jtitle%3DMol.%2520Canc.%26date%3D2019%26volume%3D18%26spage%3D26%26doi%3D10.1186%2Fs12943-019-0954-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mortensen, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fultz, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packard, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khambatta, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamez, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leisten, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Apuy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoreishi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hickman, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bissonette, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, S. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perrin-Ninkovic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W. Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cathers, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moghaddam, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Canan, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Worland, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sankar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raymon, H. K.</span></span> <span> </span><span class="NLM_article-title">CC-223, a potent and selective inhibitor of mTOR kinase: in vitro and in vivo characterization</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">1295</span>– <span class="NLM_lpage">1305</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.mct-14-1052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1158%2F1535-7163.MCT-14-1052" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=25855786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC2MXpsFOgurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=1295-1305&author=D.+S.+Mortensenauthor=K.+E.+Fultzauthor=S.+Xuauthor=W.+Xuauthor=G.+Packardauthor=G.+Khambattaauthor=J.+C.+Gamezauthor=J.+Leistenauthor=J.+Zhaoauthor=J.+Apuyauthor=K.+Ghoreishiauthor=M.+Hickmanauthor=R.+K.+Narlaauthor=R.+Bissonetteauthor=S.+Richardsonauthor=S.+X.+Pengauthor=S.+Perrin-Ninkovicauthor=T.+Tranauthor=T.+Shiauthor=W.+Q.+Yangauthor=Z.+Tongauthor=B.+E.+Cathersauthor=M.+F.+Moghaddamauthor=S.+S.+Cananauthor=P.+Worlandauthor=S.+Sankarauthor=H.+K.+Raymon&title=CC-223%2C+a+potent+and+selective+inhibitor+of+mTOR+kinase%3A+in+vitro+and+in+vivo+characterization&doi=10.1158%2F1535-7163.mct-14-1052"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization</span></div><div class="casAuthors">Mortensen, Deborah S.; Fultz, Kimberly E.; Xu, Shuichan; Xu, Weiming; Packard, Garrick; Khambatta, Godrej; Gamez, James C.; Leisten, Jim; Zhao, Jingjing; Apuy, Julius; Ghoreishi, Kamran; Hickman, Matt; Narla, Rama Krishna; Bissonette, Rene; Richardson, Samantha; Peng, Sophie X.; Perrin-Ninkovic, Sophie; Tran, Tam; Shi, Tao; Yang, Wen Qing; Tong, Zeen; Cathers, Brian E.; Moghaddam, Mehran F.; Canan, Stacie S.; Worland, Peter; Sankar, Sabita; Raymon, Heather K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1295-1305</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">MTOR is a serine/threonine kinase that regulates cell growth, metab., proliferation, and survival. mTOR complex-1 (mTORC1) and mTOR complex-2 (mTORC2) are crit. mediators of the PI3K-AKT pathway, which is frequently mutated in many cancers, leading to hyperactivation of mTOR signaling.  Although rapamycin analogs, allosteric inhibitors that target only the mTORC1 complex, have shown some clin. activity, it is hypothesized that mTOR kinase inhibitors, blocking both mTORC1 and mTORC2 signaling, will have expanded therapeutic potential.  Here, we describe the preclin. characterization of CC-223.  CC-223 is a potent, selective, and orally bioavailable inhibitor of mTOR kinase, demonstrating inhibition of mTORC1 (pS6RP and p4EBP1) and mTORC2 [pAKT(S473)] in cellular systems.  Growth inhibitory activity was demonstrated in hematol. and solid tumor cell lines. mTOR kinase inhibition in cells, by CC-223, resulted in more complete inhibition of the mTOR pathway biomarkers and improved antiproliferative activity as compared with rapamycin.  Growth inhibitory activity and apoptosis was demonstrated in a panel of hematol. cancer cell lines.  Correlative anal. revealed that IRF4 expression level assocs. with resistance, whereas mTOR pathway activation seems to assoc. with sensitivity.  Treatment with CC-223 afforded in vivo tumor biomarker inhibition in tumor-bearing mice, after a single oral dose.  CC-223 exhibited dose-dependent tumor growth inhibition in multiple solid tumor xenografts.  Significant inhibition of mTOR pathway markers pS6RP and pAKT in CC-223-treated tumors suggests that the obsd. antitumor activity of CC-223 was mediated through inhibition of both mTORC1 and mTORC2.  CC-223 is currently in phase I clin. trials.  Mol Cancer Ther; 14(6); 1295-305. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDt9130-L0z7Vg90H21EOLACvtfcHk0lgb-YUMSaHyAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXpsFOgurk%253D&md5=f33b21dc89dedaf14fab54a819afb917</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-14-1052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-14-1052%26sid%3Dliteratum%253Aachs%26aulast%3DMortensen%26aufirst%3DD.%2BS.%26aulast%3DFultz%26aufirst%3DK.%2BE.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DPackard%26aufirst%3DG.%26aulast%3DKhambatta%26aufirst%3DG.%26aulast%3DGamez%26aufirst%3DJ.%2BC.%26aulast%3DLeisten%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DApuy%26aufirst%3DJ.%26aulast%3DGhoreishi%26aufirst%3DK.%26aulast%3DHickman%26aufirst%3DM.%26aulast%3DNarla%26aufirst%3DR.%2BK.%26aulast%3DBissonette%26aufirst%3DR.%26aulast%3DRichardson%26aufirst%3DS.%26aulast%3DPeng%26aufirst%3DS.%2BX.%26aulast%3DPerrin-Ninkovic%26aufirst%3DS.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DShi%26aufirst%3DT.%26aulast%3DYang%26aufirst%3DW.%2BQ.%26aulast%3DTong%26aufirst%3DZ.%26aulast%3DCathers%26aufirst%3DB.%2BE.%26aulast%3DMoghaddam%26aufirst%3DM.%2BF.%26aulast%3DCanan%26aufirst%3DS.%2BS.%26aulast%3DWorland%26aufirst%3DP.%26aulast%3DSankar%26aufirst%3DS.%26aulast%3DRaymon%26aufirst%3DH.%2BK.%26atitle%3DCC-223%252C%2520a%2520potent%2520and%2520selective%2520inhibitor%2520of%2520mTOR%2520kinase%253A%2520in%2520vitro%2520and%2520in%2520vivo%2520characterization%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2015%26volume%3D14%26spage%3D1295%26epage%3D1305%26doi%3D10.1158%2F1535-7163.mct-14-1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolgin, E.</span></span> <span> </span><span class="NLM_article-title">Anticancer autophagy inhibitors attract ’resurgent’ interest</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">410</span>, <span class="refDoi"> DOI: 10.1038/d41573-019-00072-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fd41573-019-00072-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=31160763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtV2itbvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2019&pages=408-410&author=E.+Dolgin&title=Anticancer+autophagy+inhibitors+attract+%E2%80%99resurgent%E2%80%99+interest&doi=10.1038%2Fd41573-019-00072-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Anticancer autophagy inhibitors attract 'resurgent' interest</span></div><div class="casAuthors">Dolgin, Elie</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">408-410</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Despite industry's past setbacks with autophagy inhibitors, preclin. and clin. findings are starting to revitalize a once written-off strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMOD6_MOuv9rVg90H21EOLACvtfcHk0lgb-YUMSaHyAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtV2itbvP&md5=25bbc81d3f1b2f37d7e0afd2bb02b6d8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1038%2Fd41573-019-00072-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fd41573-019-00072-1%26sid%3Dliteratum%253Aachs%26aulast%3DDolgin%26aufirst%3DE.%26atitle%3DAnticancer%2520autophagy%2520inhibitors%2520attract%2520%25E2%2580%2599resurgent%25E2%2580%2599%2520interest%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2019%26volume%3D18%26spage%3D408%26epage%3D410%26doi%3D10.1038%2Fd41573-019-00072-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dyczynski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otrocka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parpal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Braga, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henley, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zazzi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lerner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wennerberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viklund, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grandér, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Milito, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokrovskaja Tamm, K.</span></span> <span> </span><span class="NLM_article-title">Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib</span>. <i>Canc. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>435</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">43</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2018.07.028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.canlet.2018.07.028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=30055290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVClsb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2018&pages=32-43&author=M.+Dyczynskiauthor=Y.+Yuauthor=M.+Otrockaauthor=S.+Parpalauthor=T.+Bragaauthor=A.+B.+Henleyauthor=H.+Zazziauthor=M.+Lernerauthor=K.+Wennerbergauthor=J.+Viklundauthor=J.+Martinssonauthor=D.+Grand%C3%A9rauthor=A.+De+Militoauthor=K.+Pokrovskaja+Tamm&title=Targeting+autophagy+by+small+molecule+inhibitors+of+vacuolar+protein+sorting+34+%28Vps34%29+improves+the+sensitivity+of+breast+cancer+cells+to+Sunitinib&doi=10.1016%2Fj.canlet.2018.07.028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib</span></div><div class="casAuthors">Dyczynski, Matheus; Yu, Yasmin; Otrocka, Magdalena; Parpal, Santiago; Braga, Tiago; Henley, Aine Brigette; Zazzi, Henric; Lerner, Mikael; Wennerberg, Krister; Viklund, Jenny; Martinsson, Jessica; Grander, Dan; De Milito, Angelo; Pokrovskaja Tamm, Katja</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">435</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">32-43</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Resistance to chemotherapy is a challenging problem for treatment of cancer patients and autophagy has been shown to mediate development of resistance.  In this study we systematically screened a library of 306 known anti-cancer drugs for their ability to induce autophagy using a cell-based assay. 114 of the drugs were classified as autophagy inducers; for 16 drugs, the cytotoxicity was potentiated by siRNA-mediated knock-down of Atg7 and Vps34.  These drugs were further evaluated in breast cancer cell lines for autophagy induction, and two tyrosine kinase inhibitors, Sunitinib and Erlotinib, were selected for further studies.  For the pharmacol. inhibition of autophagy, we have characterized here a novel highly potent selective inhibitor of Vps34, SB02024.  SB02024 blocked autophagy in vitro and reduced xenograft growth of two breast cancer cell lines, MDA-MB-231 and MCF-7, in vivo.  Vps34 inhibitor significantly potentiated cytotoxicity of Sunitinib and Erlotinib in MCF-7 and MDA-MB-231 in vitro in monolayer cultures and when grown as multicellular spheroids.  Our data suggests that inhibition of autophagy significantly improves sensitivity to Sunitinib and Erlotinib and that Vps34 is a promising therapeutic target for combination strategies in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXkKf8QCte1LVg90H21EOLACvtfcHk0lgb-YUMSaHyAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVClsb%252FI&md5=7d746f7e596ef83119e3a4b8575679d4</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2018.07.028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2018.07.028%26sid%3Dliteratum%253Aachs%26aulast%3DDyczynski%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DOtrocka%26aufirst%3DM.%26aulast%3DParpal%26aufirst%3DS.%26aulast%3DBraga%26aufirst%3DT.%26aulast%3DHenley%26aufirst%3DA.%2BB.%26aulast%3DZazzi%26aufirst%3DH.%26aulast%3DLerner%26aufirst%3DM.%26aulast%3DWennerberg%26aufirst%3DK.%26aulast%3DViklund%26aufirst%3DJ.%26aulast%3DMartinsson%26aufirst%3DJ.%26aulast%3DGrand%25C3%25A9r%26aufirst%3DD.%26aulast%3DDe%2BMilito%26aufirst%3DA.%26aulast%3DPokrovskaja%2BTamm%26aufirst%3DK.%26atitle%3DTargeting%2520autophagy%2520by%2520small%2520molecule%2520inhibitors%2520of%2520vacuolar%2520protein%2520sorting%252034%2520%2528Vps34%2529%2520improves%2520the%2520sensitivity%2520of%2520breast%2520cancer%2520cells%2520to%2520Sunitinib%26jtitle%3DCanc.%2520Lett.%26date%3D2018%26volume%3D435%26spage%3D32%26epage%3D43%26doi%3D10.1016%2Fj.canlet.2018.07.028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0ljBckUa_P6lNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karlgren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simoff, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Backlund, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keiser, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundquist, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jareborg, A.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oswald, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">A CRISPR-Cas9 generated MDCK cell line expressing human MDR1 without endogenous canine MDR1 (cABCB1): an improved tool for drug efflux studies</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">2909</span>– <span class="NLM_lpage">2913</span>, <span class="refDoi"> DOI: 10.1016/j.xphs.2017.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.xphs.2017.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=28450237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptFClsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2017&pages=2909-2913&author=M.+Karlgrenauthor=I.+Simoffauthor=M.+Backlundauthor=C.+Weglerauthor=M.+Keiserauthor=N.+Handinauthor=J.+M%C3%BCllerauthor=P.+Lundquistauthor=A.-C.+Jareborgauthor=S.+Oswaldauthor=P.+Artursson&title=A+CRISPR-Cas9+generated+MDCK+cell+line+expressing+human+MDR1+without+endogenous+canine+MDR1+%28cABCB1%29%3A+an+improved+tool+for+drug+efflux+studies&doi=10.1016%2Fj.xphs.2017.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">A CRISPR-Cas9 Generated Madin-Darby Canine Kidney Expressing Human MDR1 Without Endogenous Canine MDR1 (cABCB1): An Improved Tool for Drug Efflux Studies</span></div><div class="casAuthors">Karlgren, Maria; Simoff, Ivailo; Backlund, Maria; Wegler, Christine; Keiser, Markus; Handin, Niklas; Muller, Janett; Lundquist, Patrik; Jareborg, Anne-Christine; Oswald, Stefan; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2909-2913</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Madin-Darby canine kidney (MDCK) II cells stably transfected with transport proteins are commonly used models for drug transport studies.  However, endogenous expression of esp. canine MDR1 (cMDR1) confounds the interpretation of such studies.  Here we have established an MDCK cell line stably overexpressing the human MDR1 transporter (hMDR1; P-glycoprotein), and used CRISPR-Cas9 gene editing to knockout the endogenous cMDR1.  Genomic screening revealed the generation of a clonal cell line homozygous for a 4-nucleotide deletion in the canine ABCB1 gene leading to a frameshift and a premature stop codon.  Knockout of cMDR1 expression was verified by quant. protein anal. and functional studies showing retained activity of the human MDR1 transporter.  Application of this cell line allowed unbiased reclassification of drugs previously defined as both substrates and non-substrates in different studies using commonly used MDCK-MDR1 clones.  Our new MDCK-hMDR1 cell line, together with a previously developed control cell line, both with identical deletions in the canine ABCB1 gene and lack of cMDR1 expression represent excellent in vitro tools for use in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowFgM8d_MR2LVg90H21EOLACvtfcHk0ljBckUa_P6lNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptFClsL8%253D&md5=a6dad5423bbfe5395844667d938d8875</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1016%2Fj.xphs.2017.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.xphs.2017.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DKarlgren%26aufirst%3DM.%26aulast%3DSimoff%26aufirst%3DI.%26aulast%3DBacklund%26aufirst%3DM.%26aulast%3DWegler%26aufirst%3DC.%26aulast%3DKeiser%26aufirst%3DM.%26aulast%3DHandin%26aufirst%3DN.%26aulast%3DM%25C3%25BCller%26aufirst%3DJ.%26aulast%3DLundquist%26aufirst%3DP.%26aulast%3DJareborg%26aufirst%3DA.-C.%26aulast%3DOswald%26aufirst%3DS.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DA%2520CRISPR-Cas9%2520generated%2520MDCK%2520cell%2520line%2520expressing%2520human%2520MDR1%2520without%2520endogenous%2520canine%2520MDR1%2520%2528cABCB1%2529%253A%2520an%2520improved%2520tool%2520for%2520drug%2520efflux%2520studies%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2017%26volume%3D106%26spage%3D2909%26epage%3D2913%26doi%3D10.1016%2Fj.xphs.2017.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pauli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amadiume, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goncalves, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodakoski, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lundquist, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bareja, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sboner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beltran, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantley, L. C.</span></span> <span> </span><span class="NLM_article-title">Suppression of insulin feedback enhances the efficacy of PI3K inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>560</i></span>,  <span class="NLM_fpage">499</span>– <span class="NLM_lpage">503</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0343-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fs41586-018-0343-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=30051890" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVynsrjJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=560&publication_year=2018&pages=499-503&author=B.+D.+Hopkinsauthor=C.+Pauliauthor=X.+Duauthor=D.+G.+Wangauthor=X.+Liauthor=D.+Wuauthor=S.+C.+Amadiumeauthor=M.+D.+Goncalvesauthor=C.+Hodakoskiauthor=M.+R.+Lundquistauthor=R.+Barejaauthor=Y.+Maauthor=E.+M.+Harrisauthor=A.+Sbonerauthor=H.+Beltranauthor=M.+A.+Rubinauthor=S.+Mukherjeeauthor=L.+C.+Cantley&title=Suppression+of+insulin+feedback+enhances+the+efficacy+of+PI3K+inhibitors&doi=10.1038%2Fs41586-018-0343-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of insulin feedback enhances the efficacy of PI3K inhibitors</span></div><div class="casAuthors">Hopkins, Benjamin D.; Pauli, Chantal; Xing, Du; Wang, Diana G.; Li, Xiang; Wu, David; Amadiume, Solomon C.; Goncalves, Marcus D.; Hodakoski, Cindy; Lundquist, Mark R.; Bareja, Rohan; Ma, Yan; Harris, Emily M.; Sboner, Andrea; Beltran, Himisha; Rubin, Mark A.; Mukherjee, Siddhartha; Cantley, Lewis C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">560</span>
        (<span class="NLM_cas:issue">7719</span>),
    <span class="NLM_cas:pages">499-503</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Mutations in PIK3CA, which encodes the p110α subunit of the insulin-activated phosphatidylinositol-3 kinase (PI3K), and loss of function mutations in PTEN, which encodes a phosphatase that degrades the phosphoinositide lipids generated by PI3K, are among the most frequent events in human cancers1,2.  However, pharmacol. inhibition of PI3K has resulted in variable clin. responses, raising the possibility of an inherent mechanism of resistance to treatment.  As p110α mediates virtually all cellular responses to insulin, targeted inhibition of this enzyme disrupts glucose metab. in multiple tissues.  For example, blocking insulin signalling promotes glycogen breakdown in the liver and prevents glucose uptake in the skeletal muscle and adipose tissue, resulting in transient hyperglycemia within a few hours of PI3K inhibition.  The effect is usually transient because compensatory insulin release from the pancreas (insulin feedback) restores normal glucose homeostasis3.  However, the hyperglycemia may be exacerbated or prolonged in patients with any degree of insulin resistance and, in these cases, necessitates discontinuation of therapy3-6.  We hypothesized that insulin feedback induced by PI3K inhibitors may reactivate the PI3K-mTOR signalling axis in tumors, thereby compromising treatment effectiveness7,8.  Here we show, in several model tumors in mice, that systemic glucose-insulin feedback caused by targeted inhibition of this pathway is sufficient to activate PI3K signalling, even in the presence of PI3K inhibitors.  This insulin feedback can be prevented using dietary or pharmaceutical approaches, which greatly enhance the efficacy/toxicity ratios of PI3K inhibitors.  These findings have direct clin. implications for the multiple p110α inhibitors that are in clin. trials and provide a way to increase treatment efficacy for patients with many types of tumor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTJSeU1MUvt7Vg90H21EOLACvtfcHk0ljq-Jw__WvkdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVynsrjJ&md5=e673e3a3956e4b4039d99646695adde9</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0343-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0343-4%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DB.%2BD.%26aulast%3DPauli%26aufirst%3DC.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DD.%2BG.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DD.%26aulast%3DAmadiume%26aufirst%3DS.%2BC.%26aulast%3DGoncalves%26aufirst%3DM.%2BD.%26aulast%3DHodakoski%26aufirst%3DC.%26aulast%3DLundquist%26aufirst%3DM.%2BR.%26aulast%3DBareja%26aufirst%3DR.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DHarris%26aufirst%3DE.%2BM.%26aulast%3DSboner%26aufirst%3DA.%26aulast%3DBeltran%26aufirst%3DH.%26aulast%3DRubin%26aufirst%3DM.%2BA.%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DCantley%26aufirst%3DL.%2BC.%26atitle%3DSuppression%2520of%2520insulin%2520feedback%2520enhances%2520the%2520efficacy%2520of%2520PI3K%2520inhibitors%26jtitle%3DNature%26date%3D2018%26volume%3D560%26spage%3D499%26epage%3D503%26doi%3D10.1038%2Fs41586-018-0343-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wicki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xyrafas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bize, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hawle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berardi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanović, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cmiljanović, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumm, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrijević, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrmann, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prêtre, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ritschard, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tzankov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Childs, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hierro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodon, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hess, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joerger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Moos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sessa, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kristeleit, R.</span></span> <span> </span><span class="NLM_article-title">First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)</span>. <i>Eur. J. Canc.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>96</i></span>,  <span class="NLM_fpage">6</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2018.03.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.ejca.2018.03.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=29660598" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1Snu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2018&pages=6-16&author=A.+Wickiauthor=N.+Brownauthor=A.+Xyrafasauthor=V.+Bizeauthor=H.+Hawleauthor=S.+Berardiauthor=N.+Cmiljanovi%C4%87author=V.+Cmiljanovi%C4%87author=M.+Stummauthor=S.+Dimitrijevi%C4%87author=R.+Herrmannauthor=V.+Pr%C3%AAtreauthor=R.+Ritschardauthor=A.+Tzankovauthor=V.+Hessauthor=A.+Childsauthor=C.+Hierroauthor=J.+Rodonauthor=D.+Hessauthor=M.+Joergerauthor=R.+von+Moosauthor=C.+Sessaauthor=R.+Kristeleit&title=First-in+human%2C+phase+1%2C+dose-escalation+pharmacokinetic+and+pharmacodynamic+study+of+the+oral+dual+PI3K+and+mTORC1%2F2+inhibitor+PQR309+in+patients+with+advanced+solid+tumors+%28SAKK+67%2F13%29&doi=10.1016%2Fj.ejca.2018.03.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)</span></div><div class="casAuthors">Wicki, Andreas; Brown, Nicholas; Xyrafas, Alexandros; Bize, Vincent; Hawle, Hanne; Berardi, Simona; Cmiljanovic, Natasa; Cmiljanovic, Vladimir; Stumm, Michael; Dimitrijevic, Sasa; Herrmann, Richard; Pretre, Vincent; Ritschard, Reto; Tzankov, Alexandar; Hess, Viviane; Childs, Alexa; Hierro, Cinta; Rodon, Jordi; Hess, Dagmar; Joerger, Markus; von Moos, Roger; Sessa, Cristiana; Kristeleit, Rebecca</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">6-16</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">PQR309 is an orally bioavailable, balanced pan-phosphatidylinositol-3-kinase (PI3K), mammalian target of rapamycin (mTOR) C1 and mTORC2 inhibitor.  This is an accelerated titrn., 3 D 3 dose-escalation, open-label phase Itrial of continuous once-daily (OD) PQR309 administration to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics in patients with advanced solid tumors.  Primary objectives were to det. the max. tolerated dose (MTD) and recommended phase 2 dose (RP2D).Twenty-eight patients were included in six dosing cohorts and treated at a daily PQR309 dose ranging from 10 to 150 mg.  Common adverse events (AEs; ≥30% patients) included fatigue, hyperglycemia, nausea, diarrhea, constipation, rash, anorexia and vomiting.  Grade (G) 3 or 4 drug-related AEs were seen in 13 (46%) and three (11%) patients, resp.  Dose-limiting toxicity (DLT) was obsd. in two patients at 100 mg OD (>14-d interruption in PQR309 due to G3 rash, G2 hyperbilirubinemia, G4 suicide attempt; dose redn. due to G3 fatigue, G2 diarrhoea, G4 transaminitis) and one patient at 80 mg (G3 hyperglycemia >7 d).  PK shows fast absorption (Tmax 1-2 h) and dose proportionality for Cmax and area under the curve.  A partial response in a patient with metastatic thymus cancer, 24% disease vol. redn. in a patient with sinonasal cancer and stable disease for more than 16 wk in a patient with clear cell Bartholin's gland cancer were obsd.The MTD and RP2D of PQR309 is 80 mg of orally OD.  PK is dose-proportional.  PD shows PI3K pathway phosphoprotein downregulation in paired tumor biopsies.  Clin. activity was obsd. in patients with and without PI3K pathway dysregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdVIhZzSTJb7Vg90H21EOLACvtfcHk0lhkJYXRJvnHug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1Snu70%253D&md5=acbdfdb59498f5543ba7f02ed9709d0e</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2018.03.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2018.03.012%26sid%3Dliteratum%253Aachs%26aulast%3DWicki%26aufirst%3DA.%26aulast%3DBrown%26aufirst%3DN.%26aulast%3DXyrafas%26aufirst%3DA.%26aulast%3DBize%26aufirst%3DV.%26aulast%3DHawle%26aufirst%3DH.%26aulast%3DBerardi%26aufirst%3DS.%26aulast%3DCmiljanovi%25C4%2587%26aufirst%3DN.%26aulast%3DCmiljanovi%25C4%2587%26aufirst%3DV.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DDimitrijevi%25C4%2587%26aufirst%3DS.%26aulast%3DHerrmann%26aufirst%3DR.%26aulast%3DPr%25C3%25AAtre%26aufirst%3DV.%26aulast%3DRitschard%26aufirst%3DR.%26aulast%3DTzankov%26aufirst%3DA.%26aulast%3DHess%26aufirst%3DV.%26aulast%3DChilds%26aufirst%3DA.%26aulast%3DHierro%26aufirst%3DC.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DHess%26aufirst%3DD.%26aulast%3DJoerger%26aufirst%3DM.%26aulast%3Dvon%2BMoos%26aufirst%3DR.%26aulast%3DSessa%26aufirst%3DC.%26aulast%3DKristeleit%26aufirst%3DR.%26atitle%3DFirst-in%2520human%252C%2520phase%25201%252C%2520dose-escalation%2520pharmacokinetic%2520and%2520pharmacodynamic%2520study%2520of%2520the%2520oral%2520dual%2520PI3K%2520and%2520mTORC1%252F2%2520inhibitor%2520PQR309%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%2520%2528SAKK%252067%252F13%2529%26jtitle%3DEur.%2520J.%2520Canc.%26date%3D2018%26volume%3D96%26spage%3D6%26epage%3D16%26doi%3D10.1016%2Fj.ejca.2018.03.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gorter, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronica, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Vliet, E. A.</span></span> <span> </span><span class="NLM_article-title">The roof is leaking and a storm is raging: repairing the blood-brain barrier in the fight against epilepsy</span>. <i>Epilepsy Current</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">177</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1177/1535759719844750</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1177%2F1535759719844750" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=31037960" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A280%3ADC%252BB3M7gslWjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2019&pages=177-181&author=J.+A.+Gorterauthor=E.+Aronicaauthor=E.+A.+van+Vliet&title=The+roof+is+leaking+and+a+storm+is+raging%3A+repairing+the+blood-brain+barrier+in+the+fight+against+epilepsy&doi=10.1177%2F1535759719844750"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">The Roof is Leaking and a Storm is Raging: Repairing the Blood-Brain Barrier in the Fight Against Epilepsy</span></div><div class="casAuthors">Gorter J A; van Vliet E A; Aronica E; van Vliet E A; Aronica E</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsy currents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">177-181</span>
        ISSN:<span class="NLM_cas:issn">1535-7597</span>.
    </div><div class="casAbstract">A large body of evidence that has accumulated over the past decade strongly supports the role of both blood-brain barrier (BBB) dysfunction and perivascular inflammation in the pathophysiology of epilepsy.  Recent preclinical studies indicate that prolonged seizure- or brain injury-induced BBB dysfunction and subsequent perivascular inflammation may play an important role in post-traumatic epileptogenesis.  In turn, perivascular inflammation can further sustain BBB dysfunction.  In genetic epilepsies, such as tuberous sclerosis complex and other related epileptogenic developmental pathologies, there is an association between the underlying gene mutation, BBB dysfunction, and perivascular inflammation, but evidence for a causal link to epilepsy is lacking.  Future neuroimaging studies might shed light on the role of BBB function in different epilepsies and address the potential for disease modification by targeting both the BBB and perivascular inflammation in acquired and genetic epilepsies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTLEiap4sK8sYNpW7w2tapOfW6udTcc2eb3DLgcnEdLerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7gslWjtg%253D%253D&md5=f2e286f9d69fd2e92737449ce1ffb78b</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1177%2F1535759719844750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1535759719844750%26sid%3Dliteratum%253Aachs%26aulast%3DGorter%26aufirst%3DJ.%2BA.%26aulast%3DAronica%26aufirst%3DE.%26aulast%3Dvan%2BVliet%26aufirst%3DE.%2BA.%26atitle%3DThe%2520roof%2520is%2520leaking%2520and%2520a%2520storm%2520is%2520raging%253A%2520repairing%2520the%2520blood-brain%2520barrier%2520in%2520the%2520fight%2520against%2520epilepsy%26jtitle%3DEpilepsy%2520Current%26date%3D2019%26volume%3D19%26spage%3D177%26epage%3D181%26doi%3D10.1177%2F1535759719844750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Löscher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potschka, H.</span></span> <span> </span><span class="NLM_article-title">Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">22</span>– <span class="NLM_lpage">76</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2005.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.pneurobio.2005.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=16011870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A280%3ADC%252BD2MzpvFSgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2005&pages=22-76&author=W.+L%C3%B6scherauthor=H.+Potschka&title=Role+of+drug+efflux+transporters+in+the+brain+for+drug+disposition+and+treatment+of+brain+diseases&doi=10.1016%2Fj.pneurobio.2005.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases</span></div><div class="casAuthors">Loscher Wolfgang; Potschka Heidrun</div><div class="citationInfo"><span class="NLM_cas:title">Progress in neurobiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">22-76</span>
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    </div><div class="casAbstract">The blood-brain barrier (BBB) serves as a protective mechanism for the brain by preventing entry of potentially harmful substances from free access to the central nervous system (CNS).  Tight junctions present between the brain microvessel endothelial cells form a diffusion barrier, which selectively excludes most blood-borne substances from entering the brain.  Astrocytic end-feet tightly ensheath the vessel wall and appear to be critical for the induction and maintenance of the barrier properties of the brain capillary endothelial cells.  Because of these properties, the BBB only allows entry of lipophilic compounds with low molecular weights by passive diffusion.  However, many lipophilic drugs show negligible brain uptake.  They are substrates for drug efflux transporters such as P-glycoprotein (Pgp), multidrug resistance proteins (MRPs) or organic anion transporting polypeptides (OATPs) that are expressed at brain capillary endothelial cells and/or astrocytic end-feet and are key elements of the molecular machinery that confers the special permeability properties to the BBB.  The combined action of these carrier systems results in rapid efflux of xenobiotics from the CNS.  The objective of this review is to summarize transporter characteristics (cellular localization, specificity, regulation, and potential inhibition) for drug efflux transport systems identified in the BBB and blood-cerebrospinal fluid (CSF) barrier.  A variety of experimental approaches available to ascertain or predict the impact of efflux transport on brain access of therapeutic drugs also are described and critically discussed.  The potential impact of efflux transport on the pharmacodynamics of agents acting in the CNS is illustrated.  Furthermore, the current knowledge about drug efflux transporters as a major determinant of multidrug resistance of brain diseases such as epilepsy is reviewed.  Finally, we summarize strategies for modulating or by-passing drug efflux transporters at the BBB as novel therapeutic approaches to drug-resistant brain diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRe07yo5jk4UPSAs_PE1QvifW6udTcc2eb3DLgcnEdLerntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzpvFSgtw%253D%253D&md5=146aa11977c71b08a1182aba1354db84</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2005.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2005.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26aulast%3DPotschka%26aufirst%3DH.%26atitle%3DRole%2520of%2520drug%2520efflux%2520transporters%2520in%2520the%2520brain%2520for%2520drug%2520disposition%2520and%2520treatment%2520of%2520brain%2520diseases%26jtitle%3DProg.%2520Neurobiol.%26date%3D2005%26volume%3D76%26spage%3D22%26epage%3D76%26doi%3D10.1016%2Fj.pneurobio.2005.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Löscher, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potschka, H.</span></span> <span> </span><span class="NLM_article-title">Drug resistance in brain diseases and the role of drug efflux transporters</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">591</span>– <span class="NLM_lpage">602</span>, <span class="refDoi"> DOI: 10.1038/nrn1728</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fnrn1728" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=16025095" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A280%3ADC%252BD2MvgtFKisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=591-602&author=W.+L%C3%B6scherauthor=H.+Potschka&title=Drug+resistance+in+brain+diseases+and+the+role+of+drug+efflux+transporters&doi=10.1038%2Fnrn1728"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Drug resistance in brain diseases and the role of drug efflux transporters</span></div><div class="casAuthors">Loscher Wolfgang; Potschka Heidrun</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">591-602</span>
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    </div><div class="casAbstract">Resistance to drug treatment is an important hurdle in the therapy of many brain disorders, including brain cancer, epilepsy, schizophrenia, depression and infection of the brain with HIV.  Consequently, there is a pressing need to develop new and more effective treatment strategies.  Mechanisms of resistance that operate in cancer and infectious diseases might also be relevant in drug-resistant brain disorders.  In particular, drug efflux transporters that are expressed at the blood-brain barrier limit the ability of many drugs to access the brain.  There is increasing evidence that drug efflux transporters have an important role in drug-resistant brain disorders, and this information should allow more efficacious treatment strategies to be developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBI4VWCsjP46-9TkgmBqTqfW6udTcc2eaVn6l6k6UnXrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MvgtFKisg%253D%253D&md5=26af8b7a7f5b210decf788b837e52b3e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1038%2Fnrn1728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn1728%26sid%3Dliteratum%253Aachs%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26aulast%3DPotschka%26aufirst%3DH.%26atitle%3DDrug%2520resistance%2520in%2520brain%2520diseases%2520and%2520the%2520role%2520of%2520drug%2520efflux%2520transporters%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2005%26volume%3D6%26spage%3D591%26epage%3D602%26doi%3D10.1038%2Fnrn1728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anglicheau, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallet, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marquet, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassinat, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Méria, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaune, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Legendre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thervet, E.</span></span> <span> </span><span class="NLM_article-title">Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine–sirolimus interaction</span>. <i>Kidney Int.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">1019</span>– <span class="NLM_lpage">1025</span>, <span class="refDoi"> DOI: 10.1038/sj.ki.5001649</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fsj.ki.5001649" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=16837925" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD28XptFCmu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2006&pages=1019-1025&author=D.+Anglicheauauthor=N.+Palletauthor=M.+Rabantauthor=P.+Marquetauthor=B.+Cassinatauthor=P.+M%C3%A9riaauthor=P.+Beauneauthor=C.+Legendreauthor=E.+Thervet&title=Role+of+P-glycoprotein+in+cyclosporine+cytotoxicity+in+the+cyclosporine%E2%80%93sirolimus+interaction&doi=10.1038%2Fsj.ki.5001649"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction</span></div><div class="casAuthors">Anglicheau, D.; Pallet, N.; Rabant, M.; Marquet, P.; Cassinat, B.; Meria, P.; Beaune, P.; Legendre, C.; Thervet, E.</div><div class="citationInfo"><span class="NLM_cas:title">Kidney International</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1019-1025</span>CODEN:
                <span class="NLM_cas:coden">KDYIA5</span>;
        ISSN:<span class="NLM_cas:issn">0085-2538</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cyclosporine nephrotoxicity remains a major side effect in solid organ transplantation, and can be exacerbated by concomitant administration of sirolimus.  Cyclosporine and sirolimus are P-glycoprotein (Pgp) substrates.  We hypothesized that the Pgp activity level may affect cyclosporine cytotoxicity by interfering with the ability of Pgp to remove cyclosporine from within tubular cells, and that an interaction between cyclosporine and sirolimus on Pgp function may explain the enhancement of cyclosporine nephrotoxicity by sirolimus.  Cyclosporine cytotoxicity was evaluated in primary cultures of normal human renal epithelial cells (HRECs) by cell viability and cytotoxicity assays.  Verapamil, quinine, PSC833, and PGP-4008 were used as Pgp inhibitors.  Rhodamine-123 (R-123), a fluorescent substrate of Pgp, was used to assess Pgp-mediated transport.  Cellular cyclosporine concn. was measured by high-performance liq. chromatog. coupled to tandem mass spectrometry.  Pgp expression and function were confirmed in HRECs and cyclosporine and sirolimus were shown to be Pgp inhibitors in this model.  Verapamil-induced inhibition of Pgp led to a significant increase in cellular concn. of cyclosporine (P<0.05).  Cyclosporine exerted a concn.-dependent cytotoxic effect on HRECs that was significantly increased by inhibition of Pgp activity.  Sirolimus exerted an inhibitory effect on R-123 efflux in HRECs and increased cellular cyclosporine concns. in a dose-dependent manner.  These data demonstrate that Pgp plays a crit. role in protecting renal epithelial cells from cyclosporine toxicity.  The inhibitory effect of sirolimus on Pgp-mediated efflux and the cellular concn. of cyclosporine could explain the exacerbation of cyclosporine nephrotoxicity obsd. clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrclBi-hm7QPbVg90H21EOLACvtfcHk0li7EjUhsB-2ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptFCmu7c%253D&md5=f591bec42e4d8daf19e4cc776c604b24</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fsj.ki.5001649&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.ki.5001649%26sid%3Dliteratum%253Aachs%26aulast%3DAnglicheau%26aufirst%3DD.%26aulast%3DPallet%26aufirst%3DN.%26aulast%3DRabant%26aufirst%3DM.%26aulast%3DMarquet%26aufirst%3DP.%26aulast%3DCassinat%26aufirst%3DB.%26aulast%3DM%25C3%25A9ria%26aufirst%3DP.%26aulast%3DBeaune%26aufirst%3DP.%26aulast%3DLegendre%26aufirst%3DC.%26aulast%3DThervet%26aufirst%3DE.%26atitle%3DRole%2520of%2520P-glycoprotein%2520in%2520cyclosporine%2520cytotoxicity%2520in%2520the%2520cyclosporine%25E2%2580%2593sirolimus%2520interaction%26jtitle%3DKidney%2520Int.%26date%3D2006%26volume%3D70%26spage%3D1019%26epage%3D1025%26doi%3D10.1038%2Fsj.ki.5001649" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Franz, D. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawson, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yapici, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brandt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohrman, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiemer-Kruel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Voi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coello, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheung, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">French, J. A.</span></span> <span> </span><span class="NLM_article-title">Everolimus dosing recommendations for tuberous sclerosis complex–associated refractory seizures</span>. <i>Epilepsia</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1188</span>– <span class="NLM_lpage">1197</span>, <span class="refDoi"> DOI: 10.1111/epi.14085</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1111%2Fepi.14085" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=29727013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtFSrsbzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2018&pages=1188-1197&author=D.+N.+Franzauthor=J.+A.+Lawsonauthor=Z.+Yapiciauthor=C.+Brandtauthor=M.+H.+Kohrmanauthor=M.+Wongauthor=M.+Milhauthor=A.+Wiemer-Kruelauthor=M.+Voiauthor=N.+Coelloauthor=W.+Cheungauthor=K.+Groschauthor=J.+A.+French&title=Everolimus+dosing+recommendations+for+tuberous+sclerosis+complex%E2%80%93associated+refractory+seizures&doi=10.1111%2Fepi.14085"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures</span></div><div class="casAuthors">Franz, David N.; Lawson, John A.; Yapici, Zuhal; Brandt, Christian; Kohrman, Michael H.; Wong, Michael; Milh, Mathieu; Wiemer-Kruel, Adelheid; Voi, Maurizio; Coello, Neva; Cheung, Wing; Grosch, Kai; French, Jacqueline A.</div><div class="citationInfo"><span class="NLM_cas:title">Epilepsia</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1188-1197</span>CODEN:
                <span class="NLM_cas:coden">EPILAK</span>;
        ISSN:<span class="NLM_cas:issn">0013-9580</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The present anal. examd. the exposure-response relationship by means of the predose everolimus concn. (Cmin) and the seizure response in patients with tuberous sclerosis complex-assocd. seizures in the EXIST-3 study.  TN-Cmin was used to link exposure to efficacy and safety end points via model-based approaches.  A conditional logistic regression stratified by age subgroup was used to est. the probability of response in relation to exposure.  A multiplicative linear regression model was used to est. the exposure-response relationship for seizure frequency (SF).  An extended Cox regression model was used to link exposure to the time to first adverse event.  There was a strong, consistent, and highly significant relationship between everolimus exposure and efficacy, measured by TN-Cmin and SF, regardless of patient's age and concomitant use of cytochrome P 450 3A4 (CYP3A4) inhibitors/inducers.  Results of an extended Cox regression analyses indicated that twofold increases in TN-Cmin were not assocd. with statistically significant increases in the risk of stomatitis or infections.  The recommended TDM is to target everolimus Cmin within a range of 5-7 ng/mL initially and 5-15 ng/mL in the event of an inadequate clin. response, and safety is consistent with previous reports.  Starting doses depend on age and the concomitant use of CYP3A4/P-glycoprotein inducers/inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr073QVPfzprVg90H21EOLACvtfcHk0li7EjUhsB-2ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtFSrsbzE&md5=65f6d261ba702aa94a7827a4fa4b9f86</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1111%2Fepi.14085&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fepi.14085%26sid%3Dliteratum%253Aachs%26aulast%3DFranz%26aufirst%3DD.%2BN.%26aulast%3DLawson%26aufirst%3DJ.%2BA.%26aulast%3DYapici%26aufirst%3DZ.%26aulast%3DBrandt%26aufirst%3DC.%26aulast%3DKohrman%26aufirst%3DM.%2BH.%26aulast%3DWong%26aufirst%3DM.%26aulast%3DMilh%26aufirst%3DM.%26aulast%3DWiemer-Kruel%26aufirst%3DA.%26aulast%3DVoi%26aufirst%3DM.%26aulast%3DCoello%26aufirst%3DN.%26aulast%3DCheung%26aufirst%3DW.%26aulast%3DGrosch%26aufirst%3DK.%26aulast%3DFrench%26aufirst%3DJ.%2BA.%26atitle%3DEverolimus%2520dosing%2520recommendations%2520for%2520tuberous%2520sclerosis%2520complex%25E2%2580%2593associated%2520refractory%2520seizures%26jtitle%3DEpilepsia%26date%3D2018%26volume%3D59%26spage%3D1188%26epage%3D1197%26doi%3D10.1111%2Fepi.14085" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Theilmann, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gericke, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schidlitzki, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muneeb Anjum, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsdorf, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harries, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberds, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aguiar, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leiser, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabbro, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillmann, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Löscher, W.</span></span> <span> </span><span class="NLM_article-title">Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>180</i></span>,  <span class="NLM_fpage">108297</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2020.108297</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1016%2Fj.neuropharm.2020.108297" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=32890589" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvVymsL7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=180&publication_year=2020&pages=108297&author=W.+Theilmannauthor=B.+Gerickeauthor=A.+Schidlitzkiauthor=S.+M.+Muneeb+Anjumauthor=S.+Borsdorfauthor=T.+Harriesauthor=S.+L.+Roberdsauthor=D.+J.+Aguiarauthor=D.+Brunnerauthor=S.+C.+Leiserauthor=D.+Songauthor=D.+Fabbroauthor=P.+Hillmannauthor=M.+P.+Wymannauthor=W.+L%C3%B6scher&title=Novel+brain+permeant+mTORC1%2F2+inhibitors+are+as+efficacious+as+rapamycin+or+everolimus+in+mouse+models+of+acquired+partial+epilepsy+and+tuberous+sclerosis+complex&doi=10.1016%2Fj.neuropharm.2020.108297"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex</span></div><div class="casAuthors">Theilmann, Wiebke; Gericke, Birthe; Schidlitzki, Alina; Muneeb Anjum, Syed Muhammad; Borsdorf, Saskia; Harries, Timon; Roberds, Steven L.; Aguiar, Dean J.; Brunner, Daniela; Leiser, Steven C.; Song, Dekun; Fabbro, Doriano; Hillmann, Petra; Wymann, Matthias P.; Loescher, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">180</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">108297</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Mechanistic target of rapamycin (mTOR) regulates cell proliferation, growth and survival, and is activated in cancer and neurol. disorders, including epilepsy.  The rapamycin deriv. ("rapalog") everolimus, which allosterically inhibits the mTOR pathway, is approved for the treatment of partial epilepsy with spontaneous recurrent seizures (SRS) in individuals with tuberous sclerosis complex (TSC).  In contrast to the efficacy in TSC, the efficacy of rapalogs on SRS in other types of epilepsy is equivocal.  Furthermore, rapalogs only poorly penetrate into the brain and are assocd. with peripheral adverse effects, which may compromise their therapeutic efficacy.  Here we compare the antiseizure efficacy of two novel, brain-permeable ATP-competitive and selective mTORC1/2 inhibitors, PQR620 and PQR626, and the selective dual pan-PI3K/mTORC1/2 inhibitor PQR530 in two mouse models of chronic epilepsy with SRS, the intrahippocampal kainate (IHK) mouse model of acquired temporal lobe epilepsy and Tsc1GFAP CKO mice, a well-characterized mouse model of epilepsy in TSC.  During prolonged treatment of IHK mice with rapamycin, everolimus, PQR620, PQR626, or PQR530; only PQR620 exerted a transient antiseizure effect on SRS, at well tolerated doses whereas the other compds. were ineffective.  In contrast, all of the examd. compds. markedly suppressed SRS in Tsc1GFAP CKO mice during chronic treatment at well tolerated doses.  Thus, against our expectation, no clear differences in antiseizure efficacy were found across the three classes of mTOR inhibitors examd. in mouse models of genetic and acquired epilepsies.  The main advantage of the novel 1,3,5-triazine derivs. is their excellent tolerability compared to rapalogs, which would favor their development as new therapies for TORopathies such as TSC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprLM7kWwUgnLVg90H21EOLACvtfcHk0liot89tAGV6nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvVymsL7M&md5=1edbe813fdd4424a0fef421283e6f1b9</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2020.108297&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2020.108297%26sid%3Dliteratum%253Aachs%26aulast%3DTheilmann%26aufirst%3DW.%26aulast%3DGericke%26aufirst%3DB.%26aulast%3DSchidlitzki%26aufirst%3DA.%26aulast%3DMuneeb%2BAnjum%26aufirst%3DS.%2BM.%26aulast%3DBorsdorf%26aufirst%3DS.%26aulast%3DHarries%26aufirst%3DT.%26aulast%3DRoberds%26aufirst%3DS.%2BL.%26aulast%3DAguiar%26aufirst%3DD.%2BJ.%26aulast%3DBrunner%26aufirst%3DD.%26aulast%3DLeiser%26aufirst%3DS.%2BC.%26aulast%3DSong%26aufirst%3DD.%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DHillmann%26aufirst%3DP.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26aulast%3DL%25C3%25B6scher%26aufirst%3DW.%26atitle%3DNovel%2520brain%2520permeant%2520mTORC1%252F2%2520inhibitors%2520are%2520as%2520efficacious%2520as%2520rapamycin%2520or%2520everolimus%2520in%2520mouse%2520models%2520of%2520acquired%2520partial%2520epilepsy%2520and%2520tuberous%2520sclerosis%2520complex%26jtitle%3DNeuropharmacology%26date%3D2020%26volume%3D180%26spage%3D108297%26doi%3D10.1016%2Fj.neuropharm.2020.108297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rageot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaufils, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borsari, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dall’Asen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neuburger, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hebeisen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wymann, M. P.</span></span> <span> </span><span class="NLM_article-title">Scalable, economical, and practical synthesis of 4-(difluoromethyl)pyridin-2-amine, a key intermediate for lipid kinase inhibitors</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">2416</span>– <span class="NLM_lpage">2424</span>, <span class="refDoi"> DOI: 10.1021/acs.oprd.9b00312</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.oprd.9b00312" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhvVCnt77O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2019&pages=2416-2424&author=D.+Rageotauthor=F.+Beaufilsauthor=C.+Borsariauthor=A.+Dall%E2%80%99Asenauthor=M.+Neuburgerauthor=P.+Hebeisenauthor=M.+P.+Wymann&title=Scalable%2C+economical%2C+and+practical+synthesis+of+4-%28difluoromethyl%29pyridin-2-amine%2C+a+key+intermediate+for+lipid+kinase+inhibitors&doi=10.1021%2Facs.oprd.9b00312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Scalable, Economical, and Practical Synthesis of 4-(Difluoromethyl)pyridin-2-amine, a Key Intermediate for Lipid Kinase Inhibitors</span></div><div class="casAuthors">Rageot, Denise; Beaufils, Florent; Borsari, Chiara; Dall'Asen, Alix; Neuburger, Markus; Hebeisen, Paul; Wymann, Matthias P.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2416-2424</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A new, scalable, rapid, high yielding, and practical synthesis of 4-(difluoromethyl)pyridin-2-amine provides a key intermediate for the prepn. of numerous protein kinase inhibitors and clin. candidates targeting phosphoinositide 3-kinase (PI3K) and the mechanistic target of rapamycin (mTOR) kinase.  Starting from 2,2-difluoroacetic anhydride, an efficient five-step and two-pot procedure to prep. 4-(difluoromethyl)pyridin-2-amine (I) has been developed.  Noteworthy aspects of this strategy include the avoidance of an amination process using a sealed vessel.  Each step of the synthetic route has been optimized, and key intermediates have been isolated and characterized prior to the final two-pot procedure, which has been successfully applied for large-scale prodn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq73k6UZX7MsrVg90H21EOLACvtfcHk0liot89tAGV6nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhvVCnt77O&md5=a2e2a7228585935793d88d56751e6fb2</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Facs.oprd.9b00312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.oprd.9b00312%26sid%3Dliteratum%253Aachs%26aulast%3DRageot%26aufirst%3DD.%26aulast%3DBeaufils%26aufirst%3DF.%26aulast%3DBorsari%26aufirst%3DC.%26aulast%3DDall%25E2%2580%2599Asen%26aufirst%3DA.%26aulast%3DNeuburger%26aufirst%3DM.%26aulast%3DHebeisen%26aufirst%3DP.%26aulast%3DWymann%26aufirst%3DM.%2BP.%26atitle%3DScalable%252C%2520economical%252C%2520and%2520practical%2520synthesis%2520of%25204-%2528difluoromethyl%2529pyridin-2-amine%252C%2520a%2520key%2520intermediate%2520for%2520lipid%2520kinase%2520inhibitors%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2019%26volume%3D23%26spage%3D2416%26epage%3D2424%26doi%3D10.1021%2Facs.oprd.9b00312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.,  3rd</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lélias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">336</span>, <span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0liot89tAGV6nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hubatsch, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ragnarsson, E. G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artursson, P.</span></span> <span> </span><span class="NLM_article-title">Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers</span>. <i>Nat. Protoc.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">2111</span>– <span class="NLM_lpage">2119</span>, <span class="refDoi"> DOI: 10.1038/nprot.2007.303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=10.1038%2Fnprot.2007.303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=17853866" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFagsb%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2007&pages=2111-2119&author=I.+Hubatschauthor=E.+G.+E.+Ragnarssonauthor=P.+Artursson&title=Determination+of+drug+permeability+and+prediction+of+drug+absorption+in+Caco-2+monolayers&doi=10.1038%2Fnprot.2007.303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers</span></div><div class="casAuthors">Hubatsch, Ina; Ragnarsson, Eva G. E.; Artursson, Per</div><div class="citationInfo"><span class="NLM_cas:title">Nature Protocols</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2111-2119</span>CODEN:
                <span class="NLM_cas:coden">NPARDW</span>;
        ISSN:<span class="NLM_cas:issn">1750-2799</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Permeability coeffs. across monolayers of the human colon carcinoma cell line Caco-2, cultured on permeable supports, are commonly used to predict the absorption of orally administered drugs and other xenobiotics.  This protocol describes our method for the cultivation, characterization and detn. of permeability coeffs. of xenobiotics (which are, typically, drug-like compds.) in the Caco-2 model.  A few modifications that have been introduced over the years are incorporated in the protocol.  The method can be used to trace the permeability of a test compd. in two directions, from the apical to the basolateral side or vice versa, and both passive and active transport processes can be studied.  The permeability assay can be completed within one working day, provided that the Caco-2 monolayers have been cultured and differentiated on the permeable supports 3 wk in advance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX7zGXziU_VLVg90H21EOLACvtfcHk0lhC0ocUQKwu-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFagsb%252FN&md5=85e2f95420919ee61c2d691c305bc1ef</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fnprot.2007.303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnprot.2007.303%26sid%3Dliteratum%253Aachs%26aulast%3DHubatsch%26aufirst%3DI.%26aulast%3DRagnarsson%26aufirst%3DE.%2BG.%2BE.%26aulast%3DArtursson%26aufirst%3DP.%26atitle%3DDetermination%2520of%2520drug%2520permeability%2520and%2520prediction%2520of%2520drug%2520absorption%2520in%2520Caco-2%2520monolayers%26jtitle%3DNat.%2520Protoc.%26date%3D2007%26volume%3D2%26spage%3D2111%26epage%3D2119%26doi%3D10.1038%2Fnprot.2007.303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6','PDB','4JT6'); return false;">PDB: 4JT6</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OAC" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OAC','PDB','6OAC'); return false;">PDB: 6OAC</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i52"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00620">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_48126"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00620?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00620</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Comparison of PQR620 (<b>52</b>) PK profile in mice and cynomolgus monkeys; metabolites analysis of <b>52</b> in cynomolgus monkey; final compounds SAR studies: activity data and standard errors (SEM); TREEspot data visualization of KINOMEScan interactions of compounds PQR626 (<b>8</b>), PQR617 (<b>53</b>), PQR620 (<b>52</b>) and INK128 (<b>50</b>); selectivity profile calculated from KinomeScan data; kinase interactions (KINOMEscan data; <i>in vitro</i> pharmacology I—ligand binding asays with compound <b>8</b> at 10 μM; <i>in vitro</i> pharmacology II—enzyme assays with compound <b>8</b> at 10 μM; stability of compounds <b>8</b> and <b>52</b> in primary mouse, rat, dog, and human hepatocytes; plasma and brain concentration of compound <b>8</b> after a single p.o. dose of 5 mg/kg in rats; plasma insulin and glucose concentration after a single p.o. dose of 5 mg/kg of compound <b>8</b> and after vehicle administration in rats; plasma concentration of compound <b>8</b> after a p.o. single dosing and multiple dosing at 10 mg/kg and of everolimus (<b>56</b>) after a p.o. multiple dosing at 10 mg/kg in mice; brain concentration of compound <b>8</b> after a p.o. single dosing and multiple dosing at 10 mg/kg and of compound <b>56</b> after a p.o. multiple dosing at 10 mg/kg in mice; plasma and brain concentration after a p.o. single dosing of compound <b>8</b> at 25 mg/kg, of compound <b>56</b> at 10 mg/kg, and of AZD2014 (<b>51</b>) at 25 mg/kg in mice; plasma insulin and glucose concentration after a p.o. single dosing of compound <b>8</b> at 25 mg/kg, of compound <b>56</b> at 10 mg/kg, and of compound <b>51</b> at 25 mg/kg in mice; time-course of inhibition of mTOR signaling in murine brain cortex by compound <b>8</b>; body weight changes in nontumor bearing Balb/c mice; body weight of mice as a function of treatments in <i>Tsc1</i><sup>GFAP</sup> knockout mice; statistical reports for survival analysis in <i>Tsc1</i><sup>GFAP</sup> knockout mice; details on <i>Tsc1</i><sup>GFAP</sup> knockout mice used in the experiments; <sup>1</sup>H NMR spectra; <sup>13</sup>C{<sup>1</sup>H} NMR spectra; MALDI spectra; HRMS spectra; HPLC chromatograms; final compounds (chemical structures); intermediates (chemical structures); and reference compounds (chemical structures) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of compounds <b>1</b>–<b>21</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_002.csv">CSV</a>)</p></li><li><p class="inline">3D PDB Files for Figure 2 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_003.pdf">PDF</a>)</p></li><li><p class="inline">Compound <b>8</b>_methyl up-mTOR (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Compound <b>8</b>_methyl down-mTOR (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_005.pdb">PDB</a>)</p></li><li><p class="inline">Compound <b>8</b>_methyl up-PI3Kα (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_006.pdb">PDB</a>)</p></li><li><p class="inline">Compound <b>8</b>_methyl down-PI3Kα (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_007.pdb">PDB</a>)</p></li><li><p class="inline">Compound <b>4</b>_methyl right-mTOR (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_008.pdb">PDB</a>)</p></li><li><p class="inline">Compound <b>4</b>_methyl left-mTOR (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_009.pdb">PDB</a>)</p></li><li><p class="inline">Compound <b>4</b>_methyl right-PI3Kα (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_010.pdb">PDB</a>)</p></li><li><p class="inline">Compound <b>4</b>_methyl left-PI3Kα (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_011.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_001.pdf">jm0c00620_si_001.pdf (9.98 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_002.csv">jm0c00620_si_002.csv (2.93 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_003.pdf">jm0c00620_si_003.pdf (56.63 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_004.pdb">jm0c00620_si_004.pdb (997.48 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_005.pdb">jm0c00620_si_005.pdb (0.98 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_006.pdb">jm0c00620_si_006.pdb (1.7 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_007.pdb">jm0c00620_si_007.pdb (1.7 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_008.pdb">jm0c00620_si_008.pdb (0.98 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_009.pdb">jm0c00620_si_009.pdb (997.49 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_010.pdb">jm0c00620_si_010.pdb (1.7 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00620/suppl_file/jm0c00620_si_011.pdb">jm0c00620_si_011.pdb (1.7 MB)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4JT6">4JT6</a> was used for docking of compounds PQR626 (<b>8</b>) and <b>4</b> into mTOR kinase. PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6OAC">6OAC</a> was used for docking of PQR626 (<b>8</b>) and <b>4</b> into PI3Kα.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00620&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00620%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-22" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00620" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c831aba63d30","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
